

EXHIBIT 30

Ex. No.	Date	Description	BegBates	EndBates
PUR0001	7/11/1996	OxyContin Tablets Package Insert - 1996	PDD1501603661	PDD1501603669
PUR0002	7/18/2001	OxyContin Package Insert - 2001	PDD1501610836	PDD1501610844
PUR0004	7/24/2001	Letter from Christopher Prue to Cynthia McCormick re: Oxy Contin Controlled-Release Tablets, NDA #20-553	PURCHI-000679478	PURCHI-000679484
PUR0005	11/5/2007	OxyContin 2007 Package Insert	PPLPC031000441510	PPLPC031000441520
PUR0006	12/2/2008	Letter from Medical Director/CEO Purdue Pharma to Healthcare Professional	PDD8901578396	PDD8901578398
PUR0007	4/6/2010	Highlights of Prescribing Information and Full Prescribing Information for OxyContin (oxycodone hydrochloride controlled-release) Tablets for oral use, CII	PDD8901035967	PDD8901036004
PUR0008	10/4/2010	Letter from Purdue to Health Professional about Counseling Patients on How To Appropriately Take Reformulated OxyContin	PPLPC031000685835	PPLPC031000685838
PUR0010	4/18/2013	Letter from FDA to Beth Connelly/Purdue Pharma Re: Amendments to New Drug Application About Drug Abuse and Dependence and OxyContin Label revised 04/2013	PPLPC003000060503	PPLPC003000060538
PUR0011	1/11/2013	Letter from Bob A. Rappaport to Beth Connelly re: OxyContin Label - Revised 09/2012	PPLPC001000124576	PPLPC001000124640
PUR0012	4/17/2015	OxyContin Prescribing Information and Medication Guide, revised 2014	PPLP003275296	PPLP003275307
PUR0013	3/31/2017	OxyContin Prescribing Information and Medication Guide, revised 12/2016	PPLPC031001522632	PPLPC031001522649
PUR0015	9/1/2018	OxyContin FPI and Highlights of Prescribing Information - Extended Release NDA # 22-272	PUREX00071649	PUREX00071694
PUR0016	5/8/2007	Corporate Integrity Agreement between the OIG of DHHS, and Purdue Pharma L.P. (Executed 5/8/2007)	PPLP004032394	PPLP004032433
PUR0017	12/1/2006	Purdue Presentation to the Health and Human Services Office of the Inspector General December 1, 2006	PPLP004430028	PPLP004430067
PUR0018	12/18/2006	Purdue Presentation to the Department of Health and Human Services Office of the Inspector General: Purdue Corporate Compliance Program, December 18, 2006	PPLP004430145	PPLP004430225
PUR0019	4/12/2007	Appendix B to CIA for Purdue Pharma, L.P. Promotional and Product Services Engagement (Draft)	PPLPC032000057076	PPLPC032000057091
PUR0021	5/9/2007	US v. Purdue Agreed Statement of Facts (FINAL)	PPLPC030000394184	PPLPC030000394202
PUR0022	5/8/2007	Agreed Entry and Final Judgment Order (judge Lynch) State of Ohio, ex rel. Marc Dann, Atty. General v. Purdue Pharma, Case No. 07CVH-05-6195	PPLPC032000058415	PPLPC032000058436
PUR0023	5/9/2007	Plea Agreement - U.S v. Michael Friedman	PPLP004425223	PPLP004425229
PUR0024	5/10/2007	Plea Agreement - U.S. v. The Purdue Frederick Company, Inc.	PPLP004429758	PPLP004429772
PUR0025	6/21/2007	Purdue Presentation: Purdue Pharma's Corporate Integrity Agreement; June 2007 District Meetings	PPLPC015000030073	PPLPC015000030073
PUR0026	6/20/2007	Letter from Sarah G. Reznek to Michael S. Ziegler re Purdue Pharma Multistate Consent Judgment	PPLPC051000043420	PPLPC051000043421
PUR0027	6/26/2007	Email from Margaret Feltz to Allison Uzar attaching Letter from Sarah Reznek to AG of Ohio re Purdue Pharma Multistate Consent Judgment - with attachments	PPLP004431854	PPLP004431868
PUR0028	10/17/2007	Email from Bert Weinstein to Keshia Thompson, et al. re Purdue Pharma Notification of Government Investigations or Legal Proceedings as of 10/17/07	PPLPC026000035678	PPLPC026000035678
PUR0029	10/17/2007	Purdue Notification to HHS Office of IG: Government Investigations or Legal Proceedings Pursuant to Corporate Integrity Agreement section III.G	PPLPC026000035679	PPLPC026000035683
PUR0030	11/28/2007	Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 1	PPLP004432029	PPLP004432048
PUR0031	11/28/2007	Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 4 - Compliance Officer Certification - Policies and Procedures Distribution	PPLP004432089	PPLP004432253
PUR0032	11/28/2007	Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 5 - Compliance Officer Certification	PPLP004432254	PPLP004432255
PUR0033	10/31/2007	Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 7 - Letter from Timothy Nugent to Bert Weinstein	PPLP004432277	PPLP004432278
PUR0034	11/28/2007	Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 9 - Compliance Officer Certification	PPLP004432301	PPLP004432303
PUR0035	5/2/2008	Email from Bert Weinstein to Keshia Thompson, et al. re FW: Purdue Pharma Notification of Government Investigations or Legal Proceedings as of 5/1/08	PPLPC026000041179	PPLPC026000041179
PUR0036	5/1/2008	Purdue Pharma L.P. Notification to HHS Office of Inspector General: Government Investigations or Legal Proceedings Pursuant to Corporate Integrity Agreement section III.G (as of 05/01/08)	PPLPC026000041180	PPLPC026000041186
PUR0037	5/7/2008	Letter from Sarah G. Reznek to Michael S. Ziegler re: Purdue Pharma Multistate Consent Judgment	PPLPC026000041921	PPLPC026000041928
PUR0038	9/25/2008	First Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement, dated May 8, 2007	PPLPC057000007986	PPLPC057000008457
PUR0040	11/25/2008	Letter from Anthony Santopolo, M.D. to Thomas W. Abrams RPh. Director/FDA with Attachment to DHS OIG compliance letter concerning improper promotion video	PPLPC026000044078	PPLPC026000044079
PUR0041	12/15/2008	Email From Bert Weinstein to LaDonna Steiner, Robin Abrams, et al. re FW: Thompson letter re Purdue CIA and video	PPLPC026000044070	PPLPC026000044070
PUR0042	12/15/2008	Letter from Bert Weinstein to Keshia Thompson, Esq. of DHS OIG regarding improper promotion	PPLPC026000044071	PPLPC026000044071
PUR0043	1/7/2009	MA-MS-SOP 000003: "Creation, Review, and Approval of Standard Responses and Custom Responses"	PPLPC026000045693	PPLPC026000045710

PUR0044	5/7/2009	Email from Bert Weinstein to Guy Schmidt attaching Letter from Sarah Reznek to AG of Ohio re Purdue Pharma Multistate Consent Judgment - with attachments	PPLP004431807	PPLP004431815
PUR0045	5/7/2009	Letter from Sarah G. Reznek to Michael S. Ziegler re Purdue Pharma Multistate Consent Judgment	PPLPC051000115683	PPLPC051000115683
PUR0046	9/25/2009	Second Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement	PPLPC057000007349	PPLPC057000007985
PUR0047	11/16/2009	Letter from bert Weinstein to Keshia B. Thompson, Esq. re Purdue Pharma CIA Supplement to the Reporting Period 1 (RP1) Annual Report and Certification	PPLPC041000009371	PPLPC041000009398
PUR0048	1/18/2010	Purdue Corporate Compliance Series, Integrity Agreement Module Final CIA 20100118	PPLPC022000397947	PPLPC022000398004
PUR0049	9/27/2010	Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement - TOC	PPLP004434300	PPLP004434300
PUR0050	9/27/2010	Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 3 - Compliance Officer Certification - Code of Business Ethics Distribution	PPLP004434454	PPLP004434455
PUR0051	9/27/2010	Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 4	PPLP004434456	PPLP004434789
PUR0052	9/27/2010	Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 10 - Compliance Officer Certification	PPLP004434882	PPLP004434884
PUR0053	10/13/2010	Purdue Presentation: OIG On-site Visit at Purdue, October 13-14, 2010 (cover page)	PPLP004427568	PPLP004427568
PUR0054	12/3/2010	Letter from Keshia Thompson (Office of Inspector General) to Purdue Pharma re Office of Inspector General On-Site Visit	PPLPC044000029777	PPLP044000029781
PUR0055	6/23/2011	Purdue SOP - Communications with the Office of Inspector General	PPLP004385377	PPLP004385380
PUR0056	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement - TOC	PPLP004432374	PPLP004432374
PUR0057	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 1	PPLP004432375	PPLP004432404
PUR0058	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 3 - Compliance Officer Certification - Code of Business Ethics Distribution	PPLP004432557	PPLP004432558
PUR0059	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 4 - Independent Review Organization Promotional and Product Services Transactions Engagement - Reporting Period 4	PPLP004432559	PPLP004432958
PUR0060	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 7 - Forth Reporting Period Disclosures Related to Federal Health Care Programs of FDA Requirements	PPLP004432973	PPLP004433062
PUR0061	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 9 - Notifications to HHS OIG: Government Investigations of Legal Proceedings Pursuant to Corporate Integrity Agreement section III.G (as of 07/18/11)	PPLP004433095	PPLP004433099
PUR0062	9/23/2011	Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 10 - Compliance Officer Certification	PPLP004433100	PPLP004433102
PUR0065	9/23/2011	4th Annual CIA report of Purdue Pharma, September 23, 2011	PPLPC031000833441	PPLPC031000833470
PUR0066	9/27/2012	Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement - TOC	PPLP004434944	PPLP004434944
PUR0067	9/27/2012	Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement Tab 3 - Compliance Officer Certification - Code of Business Ethics Distribution	PPLP004434981	PPLP004434982
PUR0068	9/25/2012	Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement Tab 4 - Independent Review Organization's Promotional and Product Services Transactions Engagement - Reporting Period 5	PPLP004434983	PPLP004435219
PUR0069	9/27/2012	Fifth Annual Report of Purdue Pharma LP, September 27, 2012, Compliance Officer Certification	PPLP004435257	PPLP004435259
PUR0070	11/13/2012	Letter from Bert Weinstein to Keshia Thompson, DHHS, regarding Purdue Pharma CIA - Contract Sales Force District Manager Activities and Promotion Monitoring Program	PPLP004429625	PPLP004429627
PUR0071	12/14/2012	Letter from Bert Weinstein to Keshia Thompson, DHHS, regarding Supplement to 5th Annual Report from Purdue (Contract Sales Force Promotion Monitoring Program Concern)	PPLP004429608	PPLP004429615
PUR0072	10/27/2014	Attorneys General Dear HCP Letter mailing fulfillment package	PPLP003345109	PPLP003345109
PUR0073	10/7/2016	Memorandum from Douglas R. Jensen and Tami Stark to Michael D. Reisman, Esq. and Maria A. Barton, Esq. re: Auditor's First Report on Purdue Pharma's ADD Program	PPLP004473667	PPLP004473708
PUR0074	8/19/2015	New York OAG - In the Matter of Purdue Pharma Assurance No.: 15-151 - Assurance of Discontinuance Under Executive Law Section - inquiry into Purdue business practices	PPLP004035441	PPLP004035464
PUR0075	10/20/2017	Memorandum from Douglas R. Jensen and Tami Stark to Michael D. Reisman, Esq. and Maria A. Barton, Esq. re: Auditor's Second Report on Purdue Pharma's ADD Program	PPLP004473709	PPLP004473737
PUR0076	10/19/2018	Legal memo from Douglas R. Jensen to Lisa Landau, Marc Kesselman, and Danielle Gentin Stock regarding Third Report of Auditor Pursuant to AOD - NYAG Audit Report	PPLP004473738	PPLP004473756
PUR0077	2/18/2000	Letter from Jay P. McCloskey to Medical Rehab Asso Inc. regarding seeking assistance in combating the abuse of "Oxycontin" in Maine.	PKY180270314	PKY180270315
PUR0078	3/9/2001	Email from Robert Reder to Howard Udell, et al., re: DEA Meeting	PPLPC020000010013	PPLPC020000010014

PUR0079	3/27/2001	Email from William Herlihy to Michael Friedman regarding DEA - Summary of March 22, 2001 Meeting with DEA by Michael Friedman	PDD1771000503	PDD1771000507
PUR0080	3/27/2001	Email from Michael Friedman to Robin Hogen, Dr. David Haddox, et al. on 3/27/2001 re: Meeting with DEA on abuse and diversion	PPLPC020000010352	PPLPC020000010355
PUR0081	4/2/2001	Letter from Michael Friedman, Purdue, to Laura Nagel, DEA, re Follow-up letter to March 22, 2001 meeting	PDD1706196175	PDD1706196179
PUR0083	5/25/2001	Letter from Howard Udell to Kenneth Ronals regarding Confirming the Scheduling of a Meeting with Purdue, DEA and FDA to be Held on 5/31/2001	PDD1506250057	PDD1506250059
PUR0084	5/31/2001	Typewritten Notes re: Highlights of Purdue, DEA and FDA meeting	PDD1706196135	PDD1706196136
PUR0085	7/25/2001	Letter from Howard Udell, General Counsel to Laura Nagel, Deputy Assistant Administrator DEA Office of Diversion Control, regarding FDA approval of new package insert and lawsuits concerning OxyContin Tablets	PDD1506250086	PDD1506250087
PUR0086	4/9/2002	Letter from Edward Albright to Michael Smilek (DEA) re: Closing Conference - Administrative Inspection of The P.F. Laboratories, Inc.	PKY180180736	PKY180180753
PUR0087	6/20/2002	Memorandum from Ronald Greenbaum and Sandra Holgerson to DEA Distribution List re: DEA Visit (Ardsley) on June 20, 2002	8833591320	8833591325
PUR0088	6/28/2002	Rough Notes of DEA Closing Meeting, June 28, 2002	PPLPC018000055741	PPLPC018000055745
PUR0089	12/19/2002	Letter from Howard Udell to Alan Marc Soloway re: DEA referral to US Attorney, United States v. The P.F. Laboratories, Inc.	PKY181433013	PKY181433036
PUR0090	5/20/2003	Email from Howard Udell to Jack Crowley et al. re: DEA Inspection of Wilson Inventory for Quota Verification	PPLPC019000033023	PPLPC019000033024
PUR0091	11/29/2005	Email from Robin Abrams to Jack Crowley, Michael Friedman, Howard Udell re: RE: DEA Closing Conference at PF Labs	PPLPC018000070533	PPLPC018000070537
PUR0092	12/18/2007	Email from Jack Crowley to Robin Abrams, Howard Udell re: RE: DEA Update Wilson	PPLPC012000164151	PPLPC012000164155
PUR0093	1/13/2009	Email from Pamela Rose to Stuart Baker, James Dolan, Russell Gasdia, Dr. Craig Landau, David Long, Edward Mahony, William Mallin, Kathleen Schady, John Stewart, Bert Weinstein re: FW: Wilson Site - DEA Inspection	PPLPC012000208866	PPLPC012000208867
PUR0094	1/14/2009	Email from Jack Crowley to Stuart Baker, James Dolan, Russell Gasdia, Dr. Craig Landau, David Long, Edward Mahony, William Mallin, Kathleen Schady, John Stewart, Bert Weinstein re: Wilson Site DEA Inspection - Day 2	PPLPC012000208973	PPLPC012000208974
PUR0095	1/23/2009	Memo by D.I. William Callan re: Scheduled In-Depth Investigation of a Schedule II Manufacturer - Purdue Pharma, DEA Registration diversion audit	PPLPC018000264952	PPLPC018000264953
PUR0096	2/12/2009	Purdue Closing Conference Outline to DEA, February 12, 2009	PPLPC018000265397	PPLPC018000265398
PUR0097	7/15/2009	Email from Jack Crowley to DEA regarding Purdue Pharma Order Monitoring System	PPLPC020000293272	PPLPC020000293274
PUR0098	7/15/2009	DEA Letter to U.S. commercial entities registered with the DEA to distribute controlled substances regarding SOM	PPLPC020000293275	PPLPC020000293278
PUR0099	7/15/2009	Highlighted letter from Joseph Rannazzisi (DEA) to U.S. commercial entities registered with the DEA to distribute controlled substances regarding SOM	PPLPC020000293279	PPLPC020000293282
PUR0100	9/17/2009	Email from Charles Forsaith to Jack Crowley RE: Today's Meeting with DEA	PPLPC019000312690	PPLPC019000312692
PUR0101	8/17/2010	Email from Robin Abrams to Stuart Baker, et al., re: RE: Bi-Weekly Board Call Thursday, August 19, 2010 (Revised)	PPLPC012000283342	PPLPC012000283343
PUR0102	8/17/2010	Summary - Several Recent DEA Inspections at Purdue facilities	PPLPC012000283344	PPLPC012000283345
PUR0103	4/13/2011	Email from Jack Crowley to Beth Evans regarding FW: What happened at DEA - concerning a DEA meeting	PPLPC053000051163	PPLPC053000051167
PUR0104	9/30/2011	List of Slow Pharmacies for DEA	PPLPC018000580121	PPLPC018000580121
PUR0105	10/4/2011	Email from Jack Crowley to Leonard Levin regarding Teleconference of October 4, 2011	PPLPC018000580119	PPLPC018000580120
PUR0106	10/31/2011	Email from James Gardner to Richard Mannion, Jack Crowley, Frank Pedi, Michael Iannaccone, Jenny Kianto, Doug Standley, Rachana Trivedi, Jerry Furtak, Morolake Esi re: FW: DEA Inspection - Cranbury Analytical Registration - Day 1	PPLPC018000592943	PPLPC018000592944
PUR0107	9/21/2017	Email from Rodney Benson to Eric Triana, DEA, regarding DEA Referral, pharmacy of interest	PPLPC023000956283	PPLPC023000956283
PUR0108	10/25/2017	Email from Rodney Benson to Eric Triana, DEA, regarding DEA Referral/Suspicious Order: McKesson	PPLPC023000965824	PPLPC023000965824
PUR0109	1/8/2018	Email from Rodney Benson to Eric Triana, DEA, regarding DEA Referral/Suspicious Orders	PPLPC023000969451	PPLPC023000969451
PUR0110	4/12/2011	DEA Presentation: Effective Controls Against Diversion of Controlled Substances: Meeting with Purdue Pharma, April 12, 2011	US-DEA-00001209	US-DEA-00001241
PUR0111	5/3/2011	DEA Memorandum from Barbara Bockholdt to Joseph Rannazzisi Office of Diversion Control re Distributor Briefing with Purdue Pharma on April 12, 2011	US-DEA-00001242	US-DEA-00001245
PUR0112	5/29/2015	Purdue Advisory Committee Briefing Materials for Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee on July 7-8, 2015	PPLPC001000207098	PPLPC001000207286
PUR0113	2/27/2013	Letter from Dannel Mallory, Governor of Connecticut, to Margaret Hamburg, FDA, regarding addressing opioid crisis	PPLPC012000412862	PPLPC012000412863
PUR0114	4/8/2005	FBI-LEEDA Press Release - "FBI-LEEDA Recognizes Purdue Pharma For Innovative Contributions to Law Enforcement"	PPLPC029000148831	PPLPC029000148831
PUR0115	9/10/2009	Purdue Workbook: LELE activity all years 2001 through 9/9/2009	PPLPC022000277485	PPLPC022000277485
PUR0116	11/6/2009	Email from David Haddox to Mark Geraci, et al. regarding forwarded email from NADDI president John Burke praising Purdue's assistance to law enforcement	PPLPC020000325584	PPLPC020000325585
PUR0117	12/8/2009	Email from NADDI to Michael Mone regarding News from NADDI - Purdue Pharma's LELE Group named educator of the year	CAH_MDL2804_00904876	CAH_MDL2804_00904882

PUR0118	4/4/2011	Email from Brian Rosen to Alan Must regarding Ohio AG's Office Meeting; 4/4/2011 Meeting Summary	PPLPC018000504432	PPLPC018000504433
PUR0119	2/9/2012	Letter from Richard Thomas, FBI-LEEDA, to Purdue Pharma regarding Presentation of the President's Award of Excellence to Purdue in 2012	PPLPC019000644391	PPLPC019000644392
PUR0120	10/6/2014	Letter from Charles Robb, Jr., FBI-LEEDA to Purdue Pharma Lauding the "Platinum Corporate Partnership between Purdue Pharma and FBI-LEEDA	PPLPC023000740830	PPLPC023000740831
PUR0121	10/5/2015	Letter from Charles Robb, Jr., FBI-LEEDA to Purdue Pharma, L.P. - longest running corporate partnership	PPLPC022000903265	PPLPC022000903266
PUR0122	8/18/2015	Nimrit Lotey, MD, Northeast Ohio Medical University Draft Paper: Surveying Ohio Physicians on Opiate Prescribing Behaviors	SUMMIT_000839795	SUMMIT_000839813
PUR0123	7/11/2012	Purdue Pharma BUTRANS Full Prescribing Information - NDA Insert FINAL	PPLPC020000596519	PPLPC020000596557
PUR0124	7/19/2001	Purdue Sales Bulletin: PSD Incentive Bonus Program	7012200150	
PUR0125	10/10/2002	Email from Robin Hogen to David Haddox re: use of Purdue funded NADDI brochure by police officer in Ohio	8833469655	8833469656
PUR0126	5/5/2003	Memorandum from LaDonna Steiner to Michael Friedman regarding the Compliance Committee	8856383976	8856383979
PUR0127	3/21/2001	Email from Howard Udell to Michael Friedman et al. re: DEA Meeting with Ken Ronald (forwarded by William Herlihy to Paulette Peterson)	9100200598	9100200599
PUR0128	9/22/2003	Email from Melissa Brennan to Kathryn Phelps re: Internal Investigations concerning "particular prescribers"	9101439815	9101439815
PUR0129	9/15/2003	Purdue Law Department Report: Internal Investigations regarding Oxycontin prescribers	9101439816	9101439816
PUR0148	1/1/2016	Draft Proposal: Ohio Opioid STR Project	AG-MHA_203822	AG-MHA_203887
PUR0149	9/11/2017	Ohio Department of Health and Human Services - Substance Abuse and Mental Health Services Administration: FY 2017 Mid-Year State Targeted Response to the Opioid Crisis Grants	AG-MHA_205242	AG-MHA_205471
PUR0158	1/31/2015	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2014 - January 2015	AG-MHA_250755	AG-MHA_250774
PUR0163	6/30/2016	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio; January to June 2016	AG-MHA_255566	AG-MHA_255757
PUR0164	6/30/2015	Ohio Substance Abuse Monitoring Network: Drug Abuse Trends in the Athens Region January - June 2015	AG-MHA_256410	AG-MHA_256427
PUR0165	6/30/2015	Ohio Substance Abuse Monitoring Network: Drug Abuse Trends in the Athens Region January - June 2015	AG-MHA_256827	AG-MHA_257004
PUR0166	6/30/2015	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio; January to June 2015	AG-MHA_259299	AG-MHA_259473
PUR0168	1/31/2012	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio; June 2011-January 2012	AG-MHA_297905	AG-MHA_298056
PUR0169	12/1/2017	CVS Health Brochure: Important Update - Opioid Medication Management Strategy; Enhanced Opioid Utilization	AKRON_000004128	AKRON_000004131
PUR0170	9/25/2015	Ohio Homeland Security, Ohio Department of Public Safety Strategic Analysis & Information Center Bulletin: Ohio Daily Briefing	AKRON_000238965	AKRON_000238974
PUR0171	5/20/2015	Summit County Children Services: Citizens Advisory Committee Presentation: The Opiate & Heroin epidemic: Ohio's New Criminal (Produced Natively)	AKRON_000335932	AKRON_000335932
PUR0172	12/13/2012	Ohio State Board of Pharmacy Report of Investigation of Dr. Adolph Harper, Jr.	AKRON_000368463	AKRON_000368463
PUR0173	3/22/2016	Thomas Gilson, MD, Cuyahoga County, Medical Examiner's Office Presentation: Heroin & Fentanyl Related Deaths in Cuyahoga County - March 22, 2016 update	AKRON_000370034	AKRON_000370058
PUR0174	5/1/2012	Office of the Ohio Attorney General, Ohio Bureau of Criminal Investigation Criminal Intelligence Unit Presentation: Heroin In Ohio	AKRON_000374610	AKRON_000374632
PUR0175	1/1/2018	Medical Mutual of Ohio Publication: Prescription Drug Formulary Updates	AKRON_000908347	AKRON_000908362
PUR0176	12/1/2017	Medical Mutual of Ohio Publication: 2018 Prescription Drug Formulary Basic and Basis Plus Formulary; non-ACA plans	AKRON_000908852	AKRON_000909021
PUR0177	9/19/2013	Amended and Restated Prescription Benefit Services Agreement between CaremarkPCS Health, L.L.C. and Employers Health Purchasing Corporation	AKRON_001050561	AKRON_001050693
PUR0178	1/1/2014	CVS Caremark Publication: Medications Requiring Prior Authorization for Medical Necessity	AKRON_001064294	AKRON_001064297
PUR0179	1/31/2011	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2010-January 2011	AKRON_001095133	AKRON_001095238
PUR0180	12/1/2016	Medical Mutual of Ohio Publication: 2017 Comprehensive Basic and Basic Plus Formulary; commercial group plans	AKRON_001143334	AKRON_001143490
PUR0182	3/1/2016	National Center for Injury Prevention and Control Centers for Disease Control and Prevention, Report: Undetermined Risk Factors for Fentanyl-Related Overdose Deaths Ohio, 2015 (EpiAid 2016-003) Trip Report - Epi2	AKRON_001212069	AKRON_001212121
PUR0183	5/25/2010	Joe Gay & Orman Hall, Crafting an Effective Response to the Increasing Number of Opioid Overdose Deaths	AKRON_001257821	AKRON_001257853
PUR0187	12/20/2017	CVS Caremark Clinical Plan Management - Prescription Benefit Services Agreement	AKRON_001384131	AKRON_001384166
PUR0188	1/1/2009	CVS Caremark Slide Deck: RxInsights City of Akron Prescription Benefit Review, Jan 2008-Dec 2008	AKRON_001818558	AKRON_001818615
PUR0189	1/1/2009	CVS Caremark Slide Deck: High Performance Formulary Plan Designs	AKRON_001818644	AKRON_001818651
PUR0190	1/1/2010	Caremark Plan Service Contract excerpt	AKRON_001818807	AKRON_001818808
PUR0191	1/1/2010	Caremark Plan Service Contract excerpt	AKRON_001818839	AKRON_001818840
PUR0192	4/10/2003	Caremark Presentation: City of Akron - 2002 RxInsights	AKRON_001819111	AKRON_001819153
PUR0193	4/30/2008	CVS Caremark Presentation: RxInsights - City of Akron - Prescription Benefit Review Jan 2007 - Dec 2007, and Handwritten notes	AKRON_001819307	AKRON_001819356

PUR0194	4/24/2007	Caremark Presentation: RxInsights - City of Akron: Prescription Benefit Review, Jan 2006 - Dec 2006	AKRON_001819612	AKRON_001819666
PUR0195	4/14/2004	Caremark Presentation: 2003 RxInsights - City of Akron: Prescription Benefit Annual Review for 2003	AKRON_001820047	AKRON_001820066
PUR0196	5/15/2013	Email from Jeffrey Cotone to Tammy Denton about prior authorization process for City of Akron	AKRON_001820444	AKRON_001820452
PUR0197	1/1/2014	CVS Caremark EHPC Restated Agreement, Exhibit A Financial Terms	AKRON_001820622	AKRON_001820623
PUR0198	1/1/2014	CVS Caremark EHPC Restated Agreement, Exhibit A Financial Terms excerpt	AKRON_001820624	AKRON_001820625
PUR0199	1/1/2014	CVS/Caremark EHPC Restated Agreement, Exhibit A Financial Terms	AKRON_001820626	AKRON_001820627
PUR0200	8/28/2014	Memorandum from Matthew D. Harman, Pharm.D., MPH, to Employers Health Members	AKRON_001822568	AKRON_001822570
PUR0201	12/19/2011	Email from Cathy DiEgidio to Diane Miller-Dawson et al. regarding Caremark Formulary; Attaching Caremark Formulary Documents	AKRON_001823977	AKRON_001823987
PUR0202	2/14/2012	Memorandum from Tammy Kalail to Tammy Denton regarding Caremark's Formulary Prior Authorization Option	AKRON_001823992	AKRON_001823996
PUR0203	1/18/2012	Memorandum from Tammy M. Denton to Cheri Cunningham regarding CVS Caremark 2012 preferred drug list	AKRON_001824024	AKRON_001824028
PUR0204	5/24/2012	City of Akron Plan Design Report	AKRON_001824555	AKRON_001824579
PUR0205	2/1/2019	IQVIA Specialty List Report February-2019	ALLERGAN_MDL_04449164	ALLERGAN_MDL_04449164
PUR0206	1/1/2017	Ohio Department of Mental Health and Addiction Services Office of Quality, Planning and Research Ohio Substance Abuse Monitoring Network Surveillance of Drug Abuse Trends Report; June 2016-January 2017, State of Ohio	AOHC 000117	AOHC 000312
PUR0207	12/31/2013	American Pain Society - Detailed account of all payments/transfers	APS-MDL00000001	APS-MDL00000047
PUR0208	5/2/2018	State of Ohio Board of Pharmacy Summary Suspension letter	BOP_MDL 1st Production_000115	BOP_MDL 1st Production_000119
PUR0209; PUR4920	11/2/1998	Ohio State Board of Pharmacy Order re: C. Hanifin	BOP_MDL 1st Production_000843	BOP_MDL 1st Production_000856
PUR0210; PUR4929	6/14/2000	Ohio State Board of Pharmacy Order, Thomas William Foti, Docket Number D-991005-024, June 2000	BOP_MDL 1st Production_001228	BOP_MDL 1st Production_001233
PUR0211; PUR4924	11/2/2010	Ohio State Board of Pharmacy Order, Henry Kozik, Docket Number D- 100621-134, November 2, 2010	BOP_MDL 1st Production_001250	BOP_MDL 1st Production_001257
PUR0212; PUR4925	11/4/2009	Ohio State Board of Pharmacy Order, John Joseph Perry, Docket Number D-09724-003, November 4, 2009	BOP_MDL 1st Production_001877	BOP_MDL 1st Production_001899
PUR0213; PUR4927	3/7/2007	Ohio State Board of Pharmacy Order, Michael Esber, Docket Number D-060724-002, March 7 2007	BOP_MDL 1st Production_001914	BOP_MDL 1st Production_001928
PUR0214; PUR4930	1/13/1998	Ohio State Board of Pharmacy Order, William Cody, Docket Number, D-970918-006, January 13, 1998	BOP_MDL 1st Production_002391	BOP_MDL 1st Production_002400
PUR0215; PUR4934	1/7/2003	Ohio State Board of Pharmacy Order, Todd Jaros, Docket Number, D-021127-041, January 7, 2003	BOP_MDL 1st Production_002682	BOP_MDL 1st Production_002694
PUR0216; PUR4931	4/6/1999	Ohio State Board of Pharmacy Order, Matthew Earl Fisher, Docket Number D-980820008, April 6, 1999	BOP_MDL 1st Production_004897	BOP_MDL 1st Production_004909
PUR0217; PUR4928	6/29/1989	Ohio State Board of Pharmacy Order, Stephen Deitsch, Docket Number D-890316-104, June 29, 1989	BOP_MDL 1st Production_007921	BOP_MDL 1st Production_007925
PUR0218; PUR4926	10/7/1997	Ohio State Board of Pharmacy Order, Joseph Claire Salmen, Docket Number D-970909-005, October 7, 1997	BOP_MDL 1st Production_008888	BOP_MDL 1st Production_008896
PUR0219; PUR4933	9/8/1998	Ohio State Board of Pharmacy, Robert Dougherty, Docket Number D-980818-007, September 8, 1998	BOP_MDL 1st Production_008929	BOP_MDL 1st Production_008938
PUR0220	1/1/2017	Report, unintentional Opioid Deaths in Ohio	BOP_MDL001759	BOP_MDL001776
PUR0224	10/1/2014	Ohio Board of Pharmacy Meeting Minutes, October 2014	BOP_MDL098390	BOP_MDL098432
PUR0225	6/14/2017	Email from Jason Gable to Homer Chapa regarding Sam Club's effort to comply with the DEA	BOP_MDL105095	BOP_MDL105096
PUR0226	7/11/2017	Email from Jason Gable to Homer Chapa regarding an DEA form	BOP_MDL105097	BOP_MDL105097
PUR0227	7/11/2017	Walmart Compliance Notification of Controlled Substance Losses	BOP_MDL105098	BOP_MDL105098
PUR0228	4/5/2013	Ohio State Board of Pharmacy, Record of the Proceedings for April 04 and 05 of 2013	BOP_MDL1062184	BOP_MDL1062222
PUR0229	9/14/2012	Ohio Board of Pharmacy Order re: K. F. Higgins	BOP_MDL1063472	BOP_MDL1063497
PUR0230	11/5/2013	Summary Suspension Order from the Ohio Board of Pharmacy regarding Kelly Anne Schmid	BOP_MDL1085959	BOP_MDL1085973
PUR0231	2/13/2015	Memorandum from Agent Thomas Miksch to Jesse Wimberly regarding Doctor Adolph Harper's hearing	BOP_MDL1087650	BOP_MDL1087650
PUR0232	6/27/2018	Ohio State Board of Pharmacy Report and Recommendation regarding Carrie Allen	BOP_MDL1109879	BOP_MDL1109884
PUR0233	5/2/2018	Suspension Order from the Ohio Board of Pharmacy regarding Carrie Allen	BOP_MDL1109901	BOP_MDL1109938
PUR0234	11/11/2015	Email from Caroline Riogi to Michael Poe regarding a communication with the DEA	BOP_MDL111819	BOP_MDL111819
PUR0235	10/30/2015	DEA; Theft or Loss of Controlled Substances; State of Ohio	BOP_MDL111820	BOP_MDL111821
PUR0236	10/20/2015	Letter from Walmart practice compliance to DEA	BOP_MDL111822	BOP_MDL111822
PUR0237	11/17/2014	Report of Investigation, Ohio State Board of Pharmacy, regarding Kelley Anne Schmid.	BOP_MDL1200188	BOP_MDL1200212
PUR0238	2/10/2010	Ohio State Board of Pharmacy: Order finding that J. Thomas, R.Ph., is abusing controlled substances and admitted to stealing drugs while a practicing pharmacist	BOP_MDL122386	BOP_MDL122394
PUR0239	3/1/2015	Ohio State Pharmacy Board meeting minutes, 2015	BOP_MDL177101	BOP_MDL177135
PUR0240	3/2/2015	Pharmacy Board meeting minutes; create a record in accordance with Ohio Revised code chapter 110 and 4729	BOP_MDL178752	BOP_MDL178785
PUR0241	9/10/2012	Pharmacy Board; minutes; order finding M. Mastramico, intern, stole drugs from his employer for personal use	BOP_MDL208345	BOP_MDL208351

PUR0242	9/10/2012	Pharmacy Board; Meeting Minutes; regarding investigation of complaints about licensees and registrants.	BOP_MDL208353	BOP_MDL208392
PUR0243	9/10/2012	Draft pharmacy board meeting minutes; purpose of investigation of complaints regarding licensees and registrants	BOP_MDL208405	BOP_MDL208442
PUR0244	9/10/2012	Ohio Pharmacy Board meeting minutes; September 10-12, 2012	BOP_MDL208443	BOP_MDL208476
PUR0245	9/10/2012	Ohio State Board of Pharmacy Meeting Minutes September 10-12, 2012	BOP_MDL208707	BOP_MDL208737
PUR0246	1/7/2013	Ohio State Board of Pharmacy meeting minutes January 7-8, 2013	BOP_MDL208873	BOP_MDL208886
PUR0247	9/12/2012	Meeting Minutes of the Ohio State Board of Pharmacy September 10-12, 2012	BOP_MDL208943	BOP_MDL208978
PUR0248	9/10/2012	OHBOP order re pharmacist intern M. Mastramico, diversion and drug abuse	BOP_MDL211299	BOP_MDL211304
PUR0249	7/6/1998	Ohio State Board of Pharmacy, Record of the Proceedings for July 06, 07, and 08 1998	BOP_MDL211669	BOP_MDL212072
PUR0250	9/12/2012	Minutes of the September 10-12, 2012 Meeting of the Ohio State Board of Pharmacy	BOP_MDL212128	BOP_MDL212161
PUR0252	12/8/2004	Ohio State Board of Pharmacy-Minutes of the Meeting on December 6, 7, 8, 2004	BOP_MDL212377	BOP_MDL212400
PUR0253	12/31/2014	DEA Report: itemization of lost prescription drugs reported between 10/01/2014 through 12/31/2014	BOP_MDL417382	BOP_MDL417382
PUR0254	3/4/2015	Minutes of the March 2-4, 2015 Meeting of the Ohio State Board of Pharmacy	BOP_MDL450035	BOP_MDL450068
PUR0255	8/15/2012	Ohio State Board of Pharmacy- Notice of Hearing and Board Orders	BOP_MDL465725	BOP_MDL465790
PUR0256	3/7/2001	Ohio State Board of Pharmacy, Record of the Proceedings for March 05, 06, and 07, 2001	BOP_MDL465897	BOP_MDL465935
PUR0257	5/7/2002	Ohio State Board of Pharmacy, Record of the Proceedings for April 08, 09, and 10, 2002.	BOP_MDL465936	BOP_MDL465962
PUR0258	3/5/2008	Minutes of the March 3-5, 2008 Meeting of the Ohio State Board of Pharmacy	BOP_MDL466034	BOP_MDL466070
PUR0259	8/3/2010	Ohio State Board of Pharmacy-Minutes from the meeting on August 2 and 3, 2010	BOP_MDL466071	BOP_MDL466103
PUR0260	4/14/1999	Ohio State Board of Pharmacy, Record of the Proceedings for March 08 and 09 of 1999	BOP_MDL466151	BOP_MDL466181
PUR0261	5/24/2012	Ohio State Board of Pharmacy-Notice of Hearings and Orders imposing Sanctions on various Pharmacists	BOP_MDL466266	BOP_MDL466298
PUR0262	7/8/2013	Minutes of the January 7-8, 2013 Meeting of the Ohio State Board of Pharmacy	BOP_MDL466673	BOP_MDL466686
PUR0263	7/11/2012	Ohio State Board of Pharmacy Re: Order revoking the pharmacist card of H. W. Ridgeway	BOP_MDL467172	BOP_MDL467181
PUR0264	5/24/2012	Ohio State Board of Pharmacy re: Orders imposing sanctions upon various Pharmacists	BOP_MDL470328	BOP_MDL470360
PUR0265	2/5/2013	Minutes of the February 4-5, 2013 Meeting of the Ohio State Board of Pharmacy	BOP_MDL470428	BOP_MDL470468
PUR0266	4/19/2012	Ohio State Board of Pharmacy-Summary Suspension Order/Notice of Opportunity for Hearing.	BOP_MDL470482	BOP_MDL470490
PUR0268	10/13/2017	OHBOP DEA Prescriptions written between Jan. 2017-Oct. 2017	BOP_MDL763501	BOP_MDL763501
PUR0269	12/31/2017	OHBOP DEA 106 Forms Jan. 2017-Dec 2017	BOP_MDL764778	BOP_MDL764778
PUR0270	1/1/2017	Prescriptions filled through Buckeye Health Plan	Buckeye_000001	Buckeye_000001
PUR0271	5/18/1993	DEA Diversion Investigators Manual	CAH_MDL_PRIORPROD_DEA07_011 76247-R	CAH_MDL_PRIORPROD_DEA07_011 76558-R
PUR0272	10/1/2017	The 2017-2018 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors	CAH_MDL2804_00124512	CAH_MDL2804_00124743
PUR0273	4/25/2011	Email from Jennifer Lobb to Micke Brown, BSN RN re: edited version of the opioid statement	CHI_000748209	CHI_000748217
PUR0274	4/16/2012	Email from Mark Maginn to Samantha Libby-Cap and Micke Brown re: Complaint filed by Dr. Andrew Kolodny about 2 chronic pain webcasts on Pri-Med.	CHI_000895522	CHI_000895526
PUR0275	10/3/2011	Ohio Substance Abuse Monitoring Network-Drug Abuse Trends in the Cleveland Region between January-June 2011	CLEVE_000116241	CLEVE_000116260
PUR0276	10/5/2015	2010-2014 City of Cleveland Opioid Death Report	CLEVE_000164168	CLEVE_000164184
PUR0285	2/1/2013	Ohio Emergency and Acute Care Facility-Opioids and Other Controlled Substances (OOCs) Prescribing Guidelines	CLEVE_000220808	CLEVE_000220816
PUR0286	6/19/2017	Heroin Involved Death Investigations: H.I.D.I.	CLEVE_000274280	CLEVE_000274320
PUR0287	3/10/2015	Agreement between the City of Cleveland on behalf of The Cleveland Municipal Court and Moore Counseling and Mediation Services, Inc.	CLEVE_000367902	CLEVE_000367948
PUR0288	4/1/2018	CVS Caremark Value Formulary effective 04-01-2018	CLEVE_001480241	CLEVE_001480297
PUR0289	2/5/2015	Cuyahoga County Overdose Deaths 2006-2015 Most Common Drugs	CLEVE_001483812	CLEVE_001483822
PUR0290	5/2/2016	Undetermined risk factors for fentanyl-related overdose deaths - Ohio, 2015 trip Report -Epi2 Handwritten notes on Opiate Task Force	CLEVE_001483864	CLEVE_001483924
PUR0291	5/7/2012	2011 Narcotics Unit Compliance Enforcement Stats	CLEVE_001485354	CLEVE_001485356
PUR0292	2/18/2014	Article by Tome Meyer: For a certain kind of drug trafficker, blank prescription pads are the way to gain pills - with a little help from their friends, who they use to get them filled	CLEVE_001485599	CLEVE_001485603
PUR0293	10/2/2018	2017 Ohio Drug Overdose Data: General Findings	CLEVE_002216732	CLEVE_002216744
PUR0294	11/25/2013	January 2014 CVS Caremark Performance Drug List	CLEVE_002226920	CLEVE_002226927
PUR0295	1/1/2018	CVS Caremark "Medications Requiring Prior Authorization for Medical Necessity"	CLEVE_002227702	CLEVE_002227710
PUR0296	5/19/2016	2016 NADDI Application - Cleveland	CLEVE_002373068	CLEVE_002373085
PUR0298	11/28/2017	OH Overdose Initiative-Cuyahoga Co.	CLEVE_002404458	CLEVE_002404458
PUR0299	12/31/2017	Annual Report Non-Fatal Heroin Invests	CLEVE_002404493	CLEVE_002404602

PUR0302	12/31/2013	Cleveland Police Narcotics Unit Compliance Case Tracker	CLEVE_003231271	CLEVE_003231271
PUR0303	12/31/2014	Cleveland Police Narcotics Unit Compliance Case Tracker	CLEVE_003231272	CLEVE_003231272
PUR0304	12/31/2016	Cleveland Police Narcotics Unit Compliance Case Tracker	CLEVE_003231274	CLEVE_003231274
PUR0305	12/31/2017	Cleveland Police Narcotics Unit Compliance Case Tracker	CLEVE_003231275	CLEVE_003231275
PUR0306	7/21/2016	City of Cleveland Employees: PPO Network Major Medical Health Care Benefit Book	CLEVE_003622874	CLEVE_003622946
PUR0307	1/19/2016	CVS Caremark Clinical Plan Management	CLEVE_003624670	CLEVE_003624674
PUR0308	1/1/2016	2016 Standard Formulary List of Drugs Requiring Prior Authorization for Medical Necessity	CLEVE_003638292	CLEVE_003638298
PUR0309	1/1/2014	CVS Caremark Performance Drug List	CLEVE_003639822	CLEVE_003639829
PUR0311	2/5/2014	City of Cleveland Employees: HMO Health Ohio Health Care	CLEVE_003640512	CLEVE_003640576
PUR0312	1/1/2015	CVS/ Caremark Formulary Drug Removals	CLEVE_003651759	CLEVE_003651763
PUR0313	4/17/2015	CVS Caremark Clinical Plan Management	CLEVE_003651810	CLEVE_003651814
PUR0315	4/13/2016	Cleveland Division of Police; Various Case Reports; 11/23/2011 to 04/13/2016; State of Ohio	CLEVE_004084759	CLEVE_004084858
PUR0317	2/26/2013	Cleveland, Ohio Police Department, Report 02/26/2013 re: illegal prescriptions	CLEVE_004293491_1_0001	CLEVE_004293491_1_0001
PUR0318	2/26/2013	Cleveland, Ohio Police Department Report 02/26/2013 re: suspicious prescription writing practices.	CLEVE_004293492_1_0001	CLEVE_004293492_1_0001
PUR0327	9/18/2008	Indictments for Robert Sepkovich	CUYAH_000039780	CUYAH_000039784
PUR0331	8/7/2011	Cuyahoga County Medical Examiner, Joan L. Tressler Vital Statistics Report	CUYAH_000943379	CUYAH_000943431
PUR0332	6/22/2018	Opioid Bookings Data since 2006	CUYAH_001355728	CUYAH_001355728
PUR0333	6/22/2018	Opioid: All Drug Charge Bookings Since 2006	CUYAH_001355729	CUYAH_001355729
PUR0334	6/20/2018	Opioid: All Bookings Since 2006	CUYAH_001355730	CUYAH_001355730
PUR0335	6/20/2018	Opioid: All Drug Charge Bookings Since 2006	CUYAH_001355731	CUYAH_001355731
PUR0336	5/27/2014	Email from Patricia Rideout RE: Studt released by JAMA this week	CUYAH_001364147	CUYAH_001364148
PUR0337	1/31/2013	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio	CUYAH_001432497	CUYAH_001432660
PUR0338	3/18/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news	CUYAH_001552658	CUYAH_001552659
PUR0343	8/20/2013	Presentation: The Cuyahoga County Heroin Epidemic by Thomas Gilson	CUYAH_001637996	CUYAH_001637996
PUR0347	4/27/2017	Email from Erin Reed to Eric S Lavins re: SOFT abstract	CUYAH_001649318	CUYAH_001649318
PUR0348	4/15/2017	SOFT/TIAFT 2017 Annual Meeting Abstract Submission Form	CUYAH_001649319	CUYAH_001649320
PUR0350	11/8/2014	Cuyahoga County Medical Examiner (Thomas Gilson, MD) Presentation: By the Numbers: The Opiate Epidemic in Cuyahoga County	CUYAH_001655635	CUYAH_001655635
PUR0351	4/1/2014	Ohio Governor's Cabinet Opiate Action Team, Epidemiological Report, No. 3 (April 2014): Increasing Heroin Overdoes in Ohio: Understanding the Issue	CUYAH_001656795	CUYAH_001656806
PUR0354	5/9/2016	Email from Steven Schierholt to Thomas Gilson regarding drug anomaly for Cuyahoga and Lake Counties, May 7, 2016	CUYAH_001700390	CUYAH_001700391
PUR0355	6/6/2016	Email from Steven Schierholt to Thomas Gilson regarding drug anomaly for Cuyahoga and Lake Counties, June 4, 2016	CUYAH_001701162	CUYAH_001701164
PUR0356	6/10/2016	Email from Steven Schierholt to Thomas Gilson regarding drug anomaly for Cuyahoga and Lake Counties, June 9, 2016	CUYAH_001701693	CUYAH_001701694
PUR0357	9/13/2016	Email from Trey Edwards to Thomas Gilson regarding interview request for family friend	CUYAH_001704841	CUYAH_001704841
PUR0358	9/13/2016	Email from Trey Edwards to Thomas Gilson regarding interview request for family friend	CUYAH_001704850	CUYAH_001704851
PUR0359	8/26/2016	Email from Trey Edwards to Thomas Gilson regarding hydrocodone question	CUYAH_001704865	CUYAH_001704867
PUR0360	8/25/2016	Email from Trey Edwards to Thomas Gilson regarding hydrocodone question	CUYAH_001705238	CUYAH_001705238
PUR0424	3/3/2016	Email from Edwards Trey to Jena Suhadolnik et al.; RE: Heroin and Opioid weekly news 3/3/16	CUYAH_001837372	CUYAH_001837373
PUR0426	6/30/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news 6-30-2016	CUYAH_001837852	CUYAH_001837853
PUR0427	7/8/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news 7-7-2016	CUYAH_001837854	CUYAH_001837855
PUR0428	6/23/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news 6-16-16 and 6-23-2016	CUYAH_001837856	CUYAH_001837857
PUR0429	10/7/2013	Email from Christina M. Delos reyes to Thomas P Gilson; RE 10.7.13: Governor's Office realse new prescriber-focused website, and Opioid Prescribing Guidelines	CUYAH_001899383	CUYAH_001899383
PUR0430	10/7/2013	State of Ohio Communication Department; Ohio Opens New Front In the Fight Against Opiate Abuse	CUYAH_001899384	CUYAH_001899385
PUR0431	10/7/2013	Opiate Action Team; Fighting Prescription Drug Abse Rx Prescribing Guidelines	CUYAH_001899386	CUYAH_001899387
PUR0438	8/24/2017	Email from Trey Edwards to Hugh Shannon, RE: opiate death 3-23-2013	CUYAH_002115922	CUYAH_002115923
PUR0439	8/16/2017	Email from Trey Edwards to Hugh Shannon re: opiate death of a Doctor on 3-23-2013	CUYAH_002116277	CUYAH_002116277
PUR0440	4/5/2016	Email from Lynn Mudra to Hugh Shannon re: Overdose Deaths	CUYAH_002121772	CUYAH_002121772
PUR0441	4/15/2016	Email from Chad Garner to Hugh Shannon re: Heroin and Opioid Action Plan Committee Meeting on Friday, April 15 at 2:00 p.m.	CUYAH_002121944	CUYAH_002121944
PUR0442	6/10/2016	Email from Lisa Dietsche to Hugh Shannon re: Heroin and Opioid Action Plan Committee Meeting on Friday, June 10 at 2:00 p.m.	CUYAH_002122659	CUYAH_002122659
PUR0443	8/5/2016	Email from David Gallagher to Hugh Shannon re: Heroin and Opioid Action Plan Committee Meeting on Friday, June 10 at 2:00 p.m.	CUYAH_002123053	CUYAH_002123053
PUR0444	2/12/2018	Email from Trey Edwards to Hugh Shannon, RE: Loperamide, the active ingredient in anti-diarrhea medication, is sought by opioid addicts	CUYAH_002131692	CUYAH_002131694
PUR0445	10/3/2017	Email from Trey Edwards to Hugh Shannon, RE: opiate death 3-23-2013	CUYAH_002133963	CUYAH_002133965
PUR0446	10/3/2017	Email from Trey Edwards to Hugh Shannon, RE: opiate death 3-23-2013	CUYAH_002133976	CUYAH_002133977

PUR0455	10/19/2012	Cuyahoga County Major Medical Health Care Benefit Book	CUYAH_002329456	CUYAH_002329509
PUR0458	1/1/2017	Cuyahoga County Major Medical Health Care Benefit Book Cert MetroSelect HSA 060217	CUYAH_002368691	CUYAH_002368762
PUR0459	5/1/2016	Medical Mutual Service Presentation: Cuyahoga County Major Medical Health Care Benefit Book MHS	CUYAH_002371448	CUYAH_002371514
PUR0460	8/8/2016	Medical Mutual Services Presentation: MetroHealth select Health Care Benefit Book Hearing Rider	CUYAH_002371515	CUYAH_002371583
PUR0461	2/19/2016	Cuyahoga County Choice Plus Summary Plan Description; 2016 January 1 - December 31; State of Ohio	CUYAH_002372604	CUYAH_002372726
PUR0462	4/14/2016	Cuyahoga County - Client Opportunity Report	CUYAH_002373114	CUYAH_002373114
PUR0466	8/14/2016	Formulary Client Opportunity Report - Cuyahoga County	CUYAH_002385095	CUYAH_002385095
PUR0468	8/8/2016	Medical Mutual Services Presentation: MetroHealth Select Health Care Benefit Book Hearing Rider	CUYAH_002388927	CUYAH_002388993
PUR0469	6/2/2017	Medical Mutual Services Presentation: EPO Network Comprehensive Major Medical Health Care Benefit Book	CUYAH_002391610	CUYAH_002391682
PUR0470	9/15/2016	CVS Caremark Clinical Plan Management for the Prescription Benefit Services Agreement for Cuyahoga County	CUYAH_002394325	CUYAH_002394333
PUR0473	5/1/2016	Cuyahoga County Corrections Center Drug Formulary	CUYAH_003465875	CUYAH_003465877
PUR0474	5/1/2016	Cuyahoga County Corrections Center Drug Formulary	CUYAH_003484903	CUYAH_003484905
PUR0475	5/1/2016	Cuyahoga County Corrections Center Drug Formulary	CUYAH_003516915	CUYAH_003516917
PUR0479	7/3/2018	GAL/Assigned Counsel Tracking System Navigation Pane	CUYAH_007086312	CUYAH_007086312
PUR0480	3/2/2014	Thomas Gilson MD et al, The Cuyahoga County Heroin Epidemic, Academic Forensic Pathology Inc., 2014 4 (1) 109-113.	CUYAH_009397824	CUYAH_009397828
PUR0486	4/23/2014	Cuyahoga County Heroin related Overdose deaths 2007-2013	CUYAH_009600370	CUYAH_009600370
PUR0503	5/13/2014	2006-2013 Cuyahoga Overdose Deaths, Most Common Drugs	CUYAH_010384455	CUYAH_010384478
PUR0508	7/1/2015	□Metro Health Select Comprehensive Major Medical Health Care Benefit Book: Hearing Rider	CUYAH_011202580	CUYAH_011202639
PUR0572	3/15/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news	CUYAH_012492968	CUYAH_012492969
PUR0573	3/3/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news	CUYAH_012493905	CUYAH_012493906
PUR0574	2/25/2016	Email from Edwards Trey to Jena Suhadolnik et al.; re: Heroin and Opioid weekly news	CUYAH_012494619	CUYAH_012494621
PUR0602	9/2/2015	Proceedings from the 9/2/2015 Ohio Behavioral Health Benefit Design Discussion	CUYAH_012578294	CUYAH_012578310
PUR0646	2/23/2011	Alcohol, Drug Addiction and Mental Health Services Board of Cuyahoga County Policy Statement, re Medicaid Assurance Policy	CUYAH_012676591	CUYAH_012676591
PUR0658	10/23/2014	ADAMHS Presentation Herion, Cocaine & Prescription Drugs - An Epidemic Among Us	CUYAH_012777374	CUYAH_012777374
PUR0666	8/16/2012	William Denihan Interview; Faces of Addiction	CUYAH_012795771	CUYAH_012795779
PUR0673, PUR4986	4/17/2012	Email from Scott Osiecki to Rachel Dissell: RERE: Quick Question	CUYAH_012799505	CUYAH_012799506
PUR0719	1/1/2014	Charter of Metro Health Physician Peer Review for Prescribing of Controlled Substances	CUYAH_013472581	CUYAH_013472582
PUR0720	1/1/2014	MetroHealth Physician Peer Review for Prescribing Controlled Substances Charter	CUYAH_013472584	CUYAH_013472585
PUR0721	7/25/2013	Cuyahoga County Opiate Task Force Minutes Meetings: Task Force Meeting	CUYAH_013478954	CUYAH_013478955
PUR0722	1/1/2015	CVS/Caremark Performance Drug List	CUYAH_013609039	CUYAH_013609047
PUR0723	1/1/2010	Medical Mutual, Carolina Care Plan, Consumers Life Insurance Company Presentation Provider Manual	CUYAH_013803075	CUYAH_013803315
PUR0724	10/1/2005	Cuyahoga County District Board of Health Presentation UnitedHealthcare Choice Plus	CUYAH_013888678	CUYAH_013888825
PUR0725	1/1/2011	Cuyahoga County District Board of Health Presentation Anthem Health Certificate of Coverage	CUYAH_013889200	CUYAH_013889314
PUR0726	2/1/2011	Oxford Health Plans, Drug Coverage Guidelines for Commercial	CUYAH_013924286	CUYAH_013924321
PUR0727	12/1/2017	Anthem BlueCross BlueShield Ohio Provider Manual	CUYAH_013931330	CUYAH_013931420
PUR0728	10/1/2017	Ambetter Presentation 2017 Prescription Drug List	CUYAH_013933224	CUYAH_013933394
PUR0729	10/1/2017	CareSource Ohio Medicaid Formulary List	CUYAH_013934591	CUYAH_013934665
PUR0730	1/25/2017	CareSource Ohio Health Partner Manual	CUYAH_013934843	CUYAH_013934988
PUR0731	3/16/2012	CareSource Presentation 2012 Ohio Provider Manual	CUYAH_013935005	CUYAH_013935147
PUR0732	11/1/2017	MedMutual Advantage HMO and PPO plans 2017 Formulary	CUYAH_013938006	CUYAH_013938123
PUR0733	12/1/2017	Medical Mutual 2017 National Preferred Formulary	CUYAH_013938124	CUYAH_013938403
PUR0734	7/1/2012	Medical Mutual Presentation 2012 Provider Manual	CUYAH_013938719	CUYAH_013938890
PUR0735	9/1/2013	Medical Mutual Presentation 2013 Provider Manual	CUYAH_013938891	CUYAH_013939064
PUR0736	7/1/2016	Medical Mutual Presentation 2017 Prescription Drug Formulary	CUYAH_013939328	CUYAH_013939444
PUR0737	6/1/2016	Medical Mutual 2016 Provider Manual	CUYAH_013939456	CUYAH_013939671
PUR0738	7/1/2015	UnitedHealthcare Presentation Network Bulletin	CUYAH_013965947	CUYAH_013965987
PUR0739	6/1/2015	United Healthcare Medical and Administrative Policy Updates	CUYAH_013966019	CUYAH_013966187
PUR0740	1/1/2015	United Healthcare Ohio Provider Manual	CUYAH_013966217	CUYAH_013966288
PUR0741	1/1/2011	Anthem 2011 certificate of coverage	CUYAH_013981693	CUYAH_013981807
PUR0742	2/28/2000	United Healthcare of Ohio, Inc. and United Healthcare Insurance Company of Ohio Report: United Healthcare Plus Certificate of Coverage	CUYAH_013982236	CUYAH_013982278
PUR0743	1/1/2013	United Healthcare Choice Plus Certificate of Coverage 2013	CUYAH_013982602	CUYAH_013982771
PUR0749	9/1/2015	Controlled Substance Prescribing Policy	CUYAH_014194125	CUYAH_014194133
PUR0762	1/1/2012	Summary Plan Description-Choice Plus 90/70 Plan for Cuyahoga County of Ohio	CUYAH_014388306	CUYAH_014388417
PUR0779	4/2/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076452	CUYAH_016076453

PUR0780	3/29/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076454	CUYAH_016076455
PUR0781	4/8/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076483	CUYAH_016076484
PUR0782	4/28/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076526	CUYAH_016076527
PUR0783	5/5/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076531	CUYAH_016076532
PUR0784	4/25/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076533	CUYAH_016076534
PUR0785	5/12/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076535	CUYAH_016076536
PUR0786	5/23/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076537	CUYAH_016076538
PUR0787	5/27/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076557	CUYAH_016076558
PUR0788	6/10/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076566	CUYAH_016076567
PUR0789	8/30/2016	Email from Trey Edwards to Jena Suhadolnik et al., regarding Heroin and Opioid weekly news	CUYAH_016076749	CUYAH_016076750
PUR0790	11/15/2017	Email from Trey Edwards to Hugh Shannon regarding compliance investigation (Joseph Hammond DOD 7/27/2017)	CUYAH_016091077	CUYAH_016091077
PUR0791	11/16/2017	Email from Trey Edwards to Hugh Shannon regarding compliance investigation (Joseph Hammond DOD 7/27/2017)	CUYAH_016091636	CUYAH_016091637
PUR0792	11/6/2017	Email from Trey Edwards to Hugh Shannon regarding compliance investigation (Stephen Zbiegien)	CUYAH_016092143	CUYAH_016092143
PUR0793	10/16/2017	Email from Trey Edwards to Hugh Shannon regarding compliance investigation (Joseph Hammond DOD 7/27/2017)	CUYAH_016093291	CUYAH_016093291
PUR0794	12/1/2013	The Heroin Epidemic in Northeast Ohio - Our Community's Action Plan	CUYAH_016115377	CUYAH_016115385
PUR0795	3/9/2015	Board of Cuyahoga County - Alcohol, Drug Addiction & Mental Health Services (ADAMHS); Cleveland Metropolitan School District Teachers Presentation: Heroin, Prescription Drugs & Alcohol - An Epidemic Among Us	CUYAH_016425330	CUYAH_016425330
PUR0796	7/18/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502469	CUYAH_016502490
PUR0797	5/20/2014	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502491	CUYAH_016502543
PUR0799	7/8/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502545	CUYAH_016502566
PUR0800	7/3/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502567	CUYAH_016502587
PUR0801	9/14/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502588	CUYAH_016502631
PUR0802	6/14/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502632	CUYAH_016502669
PUR0803	8/16/2013	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502670	CUYAH_016502693
PUR0804	5/20/2014	Ohio Automated Rx Reporting System (OARRS) - Patient Rx History Reports	CUYAH_016502694	CUYAH_016502696
PUR0807	5/8/2007	Consent Judgment, State of Illinois v. Pudue Pharma L.P.	PUREX0000001	PUREX00000024
PUR0808	5/8/2007	Press Release, Government of the District of Columbia, Office of the AG	PUREX00000025	PUREX00000026
PUR0809	4/5/2007	Email from Bennett Rushkoff to Wayne Witkowski regarding consumer protection fund	PUREX00000027	PUREX00000028
PUR0810	4/9/2007	Email from Grant Moy to Linda Singer re: consumer protection fund - OxyContin Multistate Investigation	PUREX00000029	PUREX00000031
PUR0811	5/4/2007	Email from Grant Moy to Bennett Rushkoff regarding Press Release	PUREX00000032	PUREX00000034
PUR0812	5/7/2014	Email from Linda Singer to Bennett Rushkoff	PUREX00000035	PUREX00000035
PUR0813	5/8/2007	Joint Motion for entry of consent judgment, District of Columbia v. Purdue Pharma LP	PUREX00000036	PUREX00000060
PUR0814	4/8/2013	Letter from City of Chicago, Department of Law to Linda Singer	PUREX00000061	PUREX00000063
PUR0815	8/21/2014	Professional Biography of Linda Singer	PUREX00000064	PUREX00000066
PUR0816	1/1/2017	All Purdue Opioid-Related Calls, 2006-2016	PUREX00000423	PUREX00000423
PUR0817	6/1/2018	MME Calculation by Explanatory Variable, Jan 1996-May 2018	PUREX00000424	PUREX00000424
PUR0818	1/1/2017	All Opioid Mortality Rate 2006-2016 - section_v_indirect-regression	PUREX00000425	PUREX00000425
PUR0819	1/1/2018	NSDUH Ohio Juvenile instructions	PUREX00000426	PUREX00000426
PUR0820	9/14/2018	Dahlhamer et al. (2018) prevalence estimates, 2016	PUREX00000427	PUREX00000427
PUR0821	1/1/2018	Workbook with tabs re: Opioid-Related Percent of Criminal Activity, Cuyahoga County and Summit County, Percent of Harms Attributable to All Shipments	PUREX00000428	PUREX00000428
PUR0822	1/1/2018	Workbook with tabs re: Opioid-Related Percent of Criminal Activity, Cuyahoga County and Summit County, Percent of Harms Attributable to All Shipments	PUREX00000429	PUREX00000429
PUR0823	1/1/2018	Purdue Opioid Calls Variables	PUREX00000430	PUREX00000431
PUR0824	1/1/2018	Purdue Opioid Calls Variables	PUREX00000432	PUREX00000432
PUR0825	1/1/2018	Section v direct-regression	PUREX00000433	PUREX00000433
PUR0826	5/11/2019	section v direct-regression	PUREX00000434	PUREX00000434
PUR0827	1/1/2018	section v indirect-regression, all opioid	PUREX00000435	PUREX00000435
PUR0828	1/1/2017	section indirect regression ilicid	PUREX00000436	PUREX00000436
PUR0829	1/1/2017	section v mortality-to-misuse-adjustment	PUREX00000437	PUREX00000437
PUR0830	5/11/2019	section iv bellwether-claims-analysis	PUREX00000438	PUREX00000438
PUR0831	5/11/2019	Variables - Purdue Opioid Calls	PUREX00000439	PUREX00000440
PUR0832	5/11/2019	Variables - Purdue Opioid Calls	PUREX00000441	PUREX00000441
PUR0833	1/1/2018	section iv direct-c-y-oh-mme	PUREX00000442	PUREX00000442
PUR0834	5/11/2019	section iv: iqvia-common-dose	PUREX00000443	PUREX00000443
PUR0835	5/11/2019	section iv: namcs-statistics	PUREX00000444	PUREX00000444
PUR0836	1/1/2017	section iv: rosenthal-indirect-regression	PUREX00000445	PUREX00000445
PUR0837	5/11/2019	section v crime-regression	PUREX00000446	PUREX00000446

PUR0838	5/11/2019	section_v_crime-regression	PUREX00000447	PUREX00000447
PUR0839	5/11/2019	section_v_indirect-regression-allopioid	PUREX00000448	PUREX00000448
PUR0840	5/11/2019	section_v_mortality-to-misuse-adjustment	PUREX00000449	PUREX00000449
PUR0841	5/11/2019	section_v_nsduh-age-of-pmr-misusers	PUREX00000450	PUREX00000450
PUR0842	5/11/2019	section_v_nsduh-nm-use-pre-heroin	PUREX00000451	PUREX00000451
PUR0843	5/11/2019	section_v_nsduh-other-subs-before-heroin-and-pr	PUREX00000452	PUREX00000452
PUR0844	5/11/2019	section_v_nsduh-oud-and-mortality	PUREX00000453	PUREX00000453
PUR0845	5/11/2019	section_v_nsduh-pmr-sources	PUREX00000454	PUREX00000454
PUR0846	5/11/2019	section_v_teds-age-of-first-use	PUREX00000455	PUREX00000455
PUR0847	5/11/2019	section_vi_iqvia-hydrocodone-share	PUREX00000456	PUREX00000456
PUR0848	5/11/2019	section_vi_iqvia-purdue-oxy-share	PUREX00000457	PUREX00000457
PUR0849	5/11/2019	section_vi_nsduh-hycd-nm-mu	PUREX00000458	PUREX00000458
PUR0850	5/11/2019	section_vi_patient-count-statistics	PUREX00000459	PUREX00000459
PUR0851	5/11/2019	section_vii_iqvia-nsduh-oxycontin-patient-comparison	PUREX00000460	PUREX00000460
PUR0852	5/11/2019	section_vii_nsduh-oud-with-other-sud	PUREX00000461	PUREX00000461
PUR0853	5/11/2019	section_viii_teds-oud-hud-statistics	PUREX00000462	PUREX00000462
PUR0854	5/11/2019	Aggregate Percent Harm Including Selected Defendants in But-For 2006-2017	PUREX00000463	PUREX00000464
PUR0855	5/11/2019	But For baseline data	PUREX00000465	PUREX00000465
PUR0856	5/11/2019	But For data	PUREX00000466	PUREX00000466
PUR0857	5/11/2019	But For data	PUREX00000467	PUREX00000467
PUR0858	5/11/2019	Comparison of Model Estimates	PUREX00000468	PUREX00000468
PUR0859	5/11/2019	Comparison of Model Estimates	PUREX00000469	PUREX00000469
PUR0860	5/11/2019	Model MME data	PUREX00000470	PUREX00000470
PUR0861	5/11/2019	Model MME data	PUREX00000471	PUREX00000471
PUR0862	5/11/2019	Model MME data	PUREX00000472	PUREX00000472
PUR0863	5/11/2019	But For MME data	PUREX00000473	PUREX00000473
PUR0864	5/11/2019	But For MME data	PUREX00000474	PUREX00000474
PUR0865	5/11/2019	But For MME data	PUREX00000475	PUREX00000475
PUR0866	5/11/2019	Comparison of Model Estimates	PUREX00000476	PUREX00000476
PUR0867	5/11/2019	Comparison of Model Estimates with price indices	PUREX00000477	PUREX00000477
PUR0868	5/11/2019	Model MME Data	PUREX00000478	PUREX00000478
PUR0869	5/11/2019	Model MME data	PUREX00000479	PUREX00000479
PUR0870	5/11/2019	Model MME data	PUREX00000480	PUREX00000480
PUR0871	5/11/2019	Comparison of Model Estimates Table	PUREX00000481	PUREX00000481
PUR0872	5/11/2019	Comparison of Model Estimates Table	PUREX00000482	PUREX00000482
PUR0873	5/11/2019	Comparison of Model Estimates data	PUREX00000483	PUREX00000483
PUR0874	5/11/2019	Comparison of Model Estimates data	PUREX00000484	PUREX00000484
PUR0875	5/11/2019	Comparison of Model Estimates data	PUREX00000485	PUREX00000485
PUR0876	5/11/2019	Comparison of Model Estimates Table	PUREX00000486	PUREX00000486
PUR0877	5/11/2019	Comparison of Model Estimates Table	PUREX00000487	PUREX00000487
PUR0878	5/11/2019	Comparison of Model Estimates data	PUREX00000488	PUREX00000488
PUR0879	5/11/2019	Comparison of Model Estimates data	PUREX00000489	PUREX00000489
PUR0880	5/11/2019	Comparison of Model Estimates data	PUREX00000490	PUREX00000490
PUR0881	5/11/2019	Comparison of Model Estimates Table	PUREX00000491	PUREX00000491
PUR0882	5/11/2019	Comparison of Model Estimates Table	PUREX00000492	PUREX00000492
PUR0883	5/11/2019	Comparison of Model Estimates data	PUREX00000493	PUREX00000493
PUR0884	5/11/2019	Comparison of Model Estimates data	PUREX00000494	PUREX00000494
PUR0885	5/11/2019	Comparison of Model Estimates data	PUREX00000495	PUREX00000495
PUR0886	5/10/2019	CDC NAMCS Medication Counts Data	PUREX00000496	PUREX00000496
PUR0887	5/10/2019	CDC Oral Morphine Milligram Equivalents Data, Sept 2017	PUREX00000497	PUREX00000497
PUR0888	5/3/2019	Excel spreadsheet titled "Death of Despair: 2005-2016," showing deaths/County-State	PUREX00000498	PUREX00000498
PUR0889	5/3/2019	Computer code file for "Death of Despair"	PUREX00000499	PUREX00000503
PUR0890	4/9/2019	NSDUH 2002-2017 Data	PUREX00000504	PUREX00000504
PUR0891	5/10/2019	nsduh_ohio_juvenile_sud	PUREX00000505	PUREX00000505
PUR0892	5/10/2019	raw_cleveland_sports_wins	PUREX00000506	PUREX00000506
PUR0893	5/10/2019	raw_precipitation_national	PUREX00000507	PUREX00000507
PUR0894	5/10/2019	raw_precipitation_ohio	PUREX00000508	PUREX00000508
PUR0895	4/15/2019	2019-04-10 - 2018-11-21 Order - Akron - Medical - CONFIDENTIAL HEALTH CARE CLAIMS DATA ACCESS RESTRICTED TO ATTORNEYS AND EXPERTS	PUREX00000509	PUREX00000509
PUR0896	4/15/2019	2019-04-10 - 2018-11-21 Order - Akron - Medical - Part2 - CONFIDENTIAL HEALTH CARE CLAIMS DATA_ACCESS RESTRICTED TO ATTORNEYS AND EXPERTS	PUREX00000510	PUREX00000510
PUR0897	4/13/2019	2019-04-10 - 2018-11-21 Order - Cleveland - Medical	PUREX00000511	PUREX00000511
PUR0898	4/13/2019	2019-04-10 - 2018-11-21 Order - Cleveland - Medical - Part2	PUREX00000512	PUREX00000512
PUR0899	4/15/2019	2019-04-10 - 2018-11-21 Order - Cuyahoga - Medical	PUREX00000513	PUREX00000513
PUR0900	4/15/2019	2019-04-10 - 2018-11-21 Order - Cuyahoga - Medical - Part2	PUREX00000514	PUREX00000514
PUR0901	4/10/2019	2019-04-10 - 2018-11-21 Order - Summit - Medical	PUREX00000515	PUREX00000515
PUR0902	4/10/2019	2019-04-10 - 2018-11-21 Order - Summit - Medical - Part2	PUREX00000516	PUREX00000516
PUR0903	4/15/2019	2019-04-10 - 2018-11-21 Order - Akron - Pharmacy	PUREX00000517	PUREX00000517
PUR0904	4/15/2019	2019-04-10 - 2018-11-21 Order - Akron - Pharmacy - Part2	PUREX00000518	PUREX00000518
PUR0905	4/13/2019	2019-04-10 - 2018-11-21 Order - Cleveland - Pharmacy	PUREX00000519	PUREX00000519
PUR0906	4/13/2019	2019-04-10 - 2018-11-21 Order - Cleveland - Pharmacy - Part2	PUREX00000520	PUREX00000520
PUR0907	4/15/2019	2019-04-10 - 2018-11-21 Order - Cuyahoga - Pharmacy	PUREX00000521	PUREX00000521
PUR0908	4/15/2019	2019-04-10 - 2018-11-21 Order - Cuyahoga - Pharmacy - Part2	PUREX00000522	PUREX00000522
PUR0909	4/10/2019	2019-04-10 - 2018-11-21 Order - Summit - Pharmacy	PUREX00000523	PUREX00000523
PUR0910	4/10/2019	2019-04-10 - 2018-11-21 Order - Summit - Pharmacy - Part2	PUREX00000524	PUREX00000524

PUR0911	5/11/2019	OH_AllFields_2007-2018	PUREX00000525	PUREX00000525
PUR0913	9/13/2018	Ohio Call Notes 1994-2005	PUREX00000527	PUREX00000527
PUR0914	5/11/2019	Purdue Pharma Report, Opioids Patient Counts	PUREX00000528	PUREX00000528
PUR0915	4/18/2019	Narne data	PUREX00000529	PUREX00000529
PUR0916	4/20/2019	Final 1980-1995 data	PUREX00000530	PUREX00000530
PUR0917	4/19/2019	Account Details data	PUREX00000531	PUREX00000531
PUR0918	4/19/2019	drug_status_classification data	PUREX00000532	PUREX00000532
PUR0919	4/19/2019	drug_status_classification_data	PUREX00000533	PUREX00000533
PUR0920	4/18/2019	narme_def_manu_drug_v10 data	PUREX00000534	PUREX00000534
PUR0921	4/19/2019	Aggregate MME data	PUREX00000535	PUREX00000535
PUR0922	4/15/2019	Model MME data	PUREX00000536	PUREX00000536
PUR0923	5/1/2019	Reg data	PUREX00000537	PUREX00000537
PUR0924	7/11/2017	TEDSA_2015	PUREX00000538	PUREX00000538
PUR0925	9/26/2018	TEDSA 2016	PUREX00000539	PUREX00000539
PUR0926	5/3/2016	TEDSA 1992 data	PUREX00000540	PUREX00000540
PUR0927	5/3/2016	TEDSA 1993 data	PUREX00000541	PUREX00000541
PUR0928	5/3/2016	TEDS-A-1994 data	PUREX00000542	PUREX00000542
PUR0929	5/3/2016	TEDS-A-1995-DS0001-data-excel	PUREX00000543	PUREX00000543
PUR0930	5/3/2016	TEDS-A-1996-DS0001-data-excel	PUREX00000544	PUREX00000544
PUR0931	5/3/2016	TEDS-A-1997-DS0001-data-excel	PUREX00000545	PUREX00000545
PUR0932	5/3/2016	TEDS-A-1998-DS0001-data-excel	PUREX00000546	PUREX00000546
PUR0933	5/3/2016	TEDS-A-1999-DS0001-data-excel	PUREX00000547	PUREX00000547
PUR0934	5/3/2016	TEDS-A-2000-data	PUREX00000548	PUREX00000548
PUR0935	5/3/2016	TEDS-A-2001-data	PUREX00000549	PUREX00000549
PUR0936	5/3/2016	TEDS-A-2002-Data	PUREX00000550	PUREX00000550
PUR0937	5/3/2016	TEDS-A-2003 data	PUREX00000551	PUREX00000551
PUR0938	5/3/2016	TEDS-A-2004 data	PUREX00000552	PUREX00000552
PUR0939	5/3/2016	TEDS-A-2005 data	PUREX00000553	PUREX00000553
PUR0940	5/3/2016	TEDS-A-2006 data	PUREX00000554	PUREX00000554
PUR0941	5/3/2016	TEDS-A-2007 data	PUREX00000555	PUREX00000555
PUR0942	5/3/2016	TEDS-A-2008 data	PUREX00000556	PUREX00000556
PUR0943	5/3/2016	TEDS-A-2009-Data	PUREX00000557	PUREX00000557
PUR0944	5/3/2016	TEDS-A-2010 data	PUREX00000558	PUREX00000558
PUR0945	5/3/2016	TEDS-A-2011 data	PUREX00000559	PUREX00000559
PUR0946	5/4/2016	TEDS-A-2012 data	PUREX00000560	PUREX00000560
PUR0947	4/29/2016	TEDS-A-2013 data	PUREX00000561	PUREX00000561
PUR0948	12/1/2016	TEDS-A-2014 data	PUREX00000562	PUREX00000562
PUR0949	5/11/2019	zip code database county overlay	PUREX00000563	PUREX00000563
PUR0950	5/31/2018	Title 21 U.S.C. 352	PUREX00000564	PUREX00000570
PUR0951	10/1/1973	Blinder, Alan S., Wage Discrimination: Reduced Form and Structural Estimates, University of Wisconsin Press, Vol. 8, No. 4 (Autumn 1973), pp. 436-455.	PUREX00000571	PUREX00000591
PUR0952	10/1/1973	Oaxaca, Ronald, Male-Female Wage Differentials in Urban Labor Markets, Wiley for the Economics Department of the University of Pennsylvania and Institute of Social and Economic Research, Osaka University, Vol. 14, No. 3, pp. 693-709 (October 1973).	PUREX00000592	PUREX00000609
PUR0953	6/1/1976	Lucas, Jr., Robert E., Econometric Policy Evaluation: A Critique, pp. 19-46, (1976).	PUREX00000610	PUREX00000637
PUR0954	1/1/1992	Anderson, Simon P., and de Palma, Andre, The Logit as A Model of Product Differentiation, Oxford University Press, Vol 44, No. 1, pp. 51-67 (Jan. 1992).	PUREX00000638	PUREX00000655
PUR0955	6/1/1993	Abramovitz, Moses, The Search for Sources of Growth: Areas of Ignorance, Old and New, Journal of Economic History, Vol. 53, Issue 2, pp. 217-243, (June 1993).	PUREX00000656	PUREX00000683
PUR0956	1/1/1993	Miller, Ted R., Cohen Mark A., and Rossman, Shelli B., Data Watch: Victim Costs of Violent Crime and Resulting Injuries, Health Affairs, Winter 1993, pp. 186- 197, (1993).	PUREX00000684	PUREX00000695
PUR0957	7/1/1994	Berry, Steven T., Estimating Discrete-Choice Models of Product Differentiation, The RAND Journal of Economics, Vol. 25, No. 2, pp. 242-262, (Summer1994).	PUREX00000696	PUREX00000717
PUR0958	10/1/1994	Kelleher, Kelly, Chaffin, Mark, Hollenberg, Janice, and Fischer, Ellen, Alcohol and Drug Disorders among Physically Abusive and Neglectful Parents in A Community Based Sample, American Journal of Public Health, Vol. 84, No. 10, pp. 1586-1590, (October 1994).	PUREX00000718	PUREX00000732
PUR0959	11/12/1995	James Campbell APS 1995 Presidential Address	PUREX00000733	PUREX00000736
PUR0960	1/1/1996	Miller, Ted R., Cohen Mark A, Wiersema, Brian, Victim Costs and Consequences: A New Look, U.S.Department of Justice, pp. 1-35, (January 1996).	PUREX00000737	PUREX00000771
PUR0961	1/1/1996	Wolock, Isabel and Magura, Stephen, Parental Substance Abuse As A Predictor of Child Maltreatment Re-Reports, Child Abuse and Neglect, Vol. 20, no. 12, pp. 1183-1193, (1996).	PUREX00000772	PUREX00000782
PUR0962	1/11/1996	Letter from Lee Ann Storey, RN, MPH to Diane Schnitzler, FDA; response to promotional questions	PUREX00000783	PUREX00000891
PUR0968	3/8/1996	Letter from Lee Ann Storey, RN, MPH to Diane Schnitzler, FDA regarding response to promotional questions	PUREX00000958	PUREX00000981
PUR0973	1/1/1998	Purdue Presentation: 1998 Budget Presentation-Marketing and Sales Department	PUREX00001013	PUREX00001468
PUR0974	1/1/1998	Purdue Presentation: 1998 OxyContin Budget Plan	PUREX00001469	PUREX00001520

PUR0975	4/28/1998	Greenfield, Lawrence A., Alcohol and Crime An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime, U.S. Department of Justice pp. 1-36, (1998)	PUREX00001521	PUREX00001566
PUR0976	1/1/1999	Purdue Presentation: 1999 Budget Presentation Marketing and Sales Department	PUREX00001567	PUREX00001976
PUR0977	1/1/2000	Purdue Presentation: 2000 Budget Presentation Marketing and Sales Department	PUREX00001977	PUREX00002239
PUR0978	1/1/2001	Purdue Presentation: 2001 OxyContin Budget Plan	PUREX00002240	PUREX00002293
PUR0979	4/25/2001	2001 OxyContin Package Insert	PUREX00002294	PUREX00002315
PUR0980	7/18/2001	Dear Healthcare Professional Letter from Robert F. Reder, M.D.	PUREX00002316	PUREX00002318
PUR0981	12/24/2002	Faxed letter from Tom Abrams, R.Ph., MBA, Director DDMAC to Michael Friedman	PUREX00002319	PUREX00002328
PUR0982	1/1/2002	Purdue Presentation: 2002 OxyContin Budget Plan	PUREX00002329	PUREX00002386
PUR0983	5/7/2002	Letter from Eleanor Hill, King & Spalding, to John C. Hansen	PUREX00002387	PUREX00002393
PUR0984	1/1/2002	Azoulay, Pierre, Do Pharmaceutical Sales Respond to Scientific Evidence?, Journal of Economics & Management Strategy, Vol. 11, No. 4, pp. 551-594, (Winter 2002).	PUREX00002394	PUREX00002437
PUR0985	1/15/2003	Letter to Healthcare Practitioner from Robert F. Reder, M.D.	PUREX00002438	PUREX00002439
PUR0986	1/14/2003	Letter from Kleinfeld, Kaplan and Becker, LLP to Thomas Abrams, R.PH., MBA, and Daniel E. Troy, Esq.	PUREX00002440	PUREX00002447
PUR0988	11/1/2004	Purdue Presentation: 2004 Financial Year-In-Review 2005 Budget Proposal November 1, 2004	PUREX00002453	PUREX00002453
PUR0989	7/1/2005	Crawford, Gregory S., and Shum, Matthew, Uncertainty and Learning in Pharmaceutical Demand, Econometrica, Vol. 73, No. 4, pp. 1137-1173, (July 2005).	PUREX00002454	PUREX00002490
PUR0990	7/1/2005	Li, Quan, and Wen, Ming, The Immediate and Lingering Effects of Armed Conflict on Adult Mortality: A Time-Series Cross-National Analysis, Journal of Peace Research, Vol. 42, No. 4, Special Issue on the Demography of Conflict and Violence, pp. 471-492, (July 2005).	PUREX00002491	PUREX00002513
PUR0991	5/22/2006	Verispan Report: OxyContin Protect and Defend Summary Report of Qualitative Research with Physicians and Retail Pharmacists, May 22, 2006	PUREX00002514	PUREX00002581
PUR0992	7/15/2006	Miller, Ted R., Levy, David T., Cohen, Mark A., and Cox, Kenya L.C., Costs of Alcohol and Drug-Involved Crime, Preventive Science, Vol. 7, pp. 333-342, (2006).	PUREX00002582	PUREX00002591
PUR0994	3/23/2007	Synovate Healthcare Report: OxyContin Issues Analysis Qual Final Report	PUREX00002592	PUREX00002635
PUR0995	5/10/2007	Statement of US Attorney John Brownle on the Guilty Plea of the Purdue Frederick Company and its Executives for Illegally Branding OxyContin	PUREX00002636	PUREX00002724
PUR0996	5/21/2007	Psyma International Inc., Report: OxyContin Patient Copay Study Final Report	PUREX00002725	PUREX00002768
PUR0997	9/5/2007	Synovate Healthcare Report: OxyContin Positioning Qualitative	PUREX00002769	PUREX00002813
PUR0998	12/14/2007	Synovate Healthcare Report: OxyContin Qualitative Positioning Project #2	PUREX00002814	PUREX00002859
PUR0999	12/15/2006	Blondel, Serge, Loheac, Youenn, Rinaudo, Stephane, Rationality and Drug Use: An Experimental Approach, Journal of Health Economics, Vol. 26, pp. 643-658, (2007)	PUREX00002860	PUREX00002875
PUR1000	9/1/2007	Ching, Andrew, and Ishihara, Masakazu, The Effects of Detailing on Prescribing Decisions Under Quality Uncertainty, Munich Personal RePEc Archive, Vol. 10 pp. 1-43, (September 2007)	PUREX00002876	PUREX00002921
PUR1001	3/1/2007	Goldin, Claudia, and Katz, Lawrence F., The Race Between Education and Technology: The Evolution of US Educational Wage Differentials, 1890-2005, NBER Working Paper No. 12984, pp. 1-43 (March 2007)	PUREX00002922	PUREX00002969
PUR1002	6/1/2007	Viscusi, W. Kip, The Flawed Hedonic Damages Measure of Compensation for Wrongful Death and Personal Injury, Journal of Forensic Economics, Vol.20, No. 2, pp. 113-135, (2007).	PUREX00002970	PUREX00002992
PUR1003	11/5/2007	OxyContin Prescribing Information	PUREX00002993	PUREX00003003
PUR1004	1/31/2008	Harris Interactive Report: OxyContin New Strengths Detail Aide Qualitative-1/31/08	PUREX00003004	PUREX00003013
PUR1005	1/31/2008	Harris Interactive Report: OxyContin New Strengths Detail Aide Qualitative 1/31/08	PUREX00003014	PUREX00003052
PUR1006	3/26/2008	Synovate Report: OxyContin OTR Tamper Language	PUREX00003053	PUREX00003147
PUR1007	4/4/2008	Harris Interactive OTR Concept Concept Test #2 4/4/08	PUREX00003148	PUREX00003245
PUR1008	4/28/2008	Target Rx Report: OxyContin OTR Messaging Test 4/28/08	PUREX00003246	PUREX00003305
PUR1009	10/13/2008	Synovate Healthcare Presentation (Prepared for Purdue): A Strategic Market Study to Aid in the Development of Compelling Messaging for OxyContin.	PUREX00003306	PUREX00003373
PUR1010	10/13/2008	Synovate Healthcare Presentation (Prepared for Purdue): OxyContin Journal Ad Test	PUREX00003374	PUREX00003415
PUR1011	12/8/2008	Harris Interactive Report: OIC and OXN Qualitative Market Research	PUREX00003416	PUREX00003425
PUR1012	12/2/2008	Letter from Medical Director/CEO Purdue Pharma to Healthcare Professional	PUREX00003426	PUREX00003428
PUR1013	9/3/2008	Purdue Presentation: 2009 OxyContin Marketing Plan	PUREX00003429	PUREX00003586
PUR1014	7/23/2010	Purdue Presentation: 2010 OxyContin Incremental eMarketing Plan	PUREX00003587	PUREX00003602
PUR1015	11/1/2009	2010 OxyContin Tablet Budget Presentation	PUREX00003603	PUREX00003632
PUR1017	5/7/2010	DellaVigna and Gentzkow, Persuasion: Empirical Evidence, Annu. Rev. Econ. 2010, 2:643-69	PUREX00003633	PUREX00003660
PUR1018	1/14/2010	Hammit & Haninger, Valuing fatal risks to children and adults: Effects of disease, latency, and risk aversion, Springer Science-Business Media, LLC,	PUREX00003661	PUREX00003687
PUR1019	4/1/2010	Jayachandran et al, Modern Medicine and the Twentieth Century Decline in Mortality, American Economic Journal: Applied Economics 2(April 2010): 118-146	PUREX00003688	PUREX00003718

PUR1020	12/1/2010	2010 Viscusi Hersch Tobacco Regulation through Litigation: The Master Settlement Agreement, University of Chicago Press	PUREX00003719	PUREX00003750
PUR1021	1/1/2011	2010 Viscusi Policy Challenges of the Heterogeneity of the Value of Statistical Life	PUREX00003751	PUREX00003826
PUR1022	4/1/2010	2010-04-00 Oxycontin Label	PUREX00003827	PUREX00003864
PUR1023	4/5/2010	2010-04-05 NDA Approval for OxyContin Tablets	PUREX00003865	PUREX00003949
PUR1025	8/23/2010	2011 OxyContin eMarketing Plan	PUREX00003950	PUREX00003950
PUR1026	11/1/2010	2011 Oxycontin Tablets Budget Submission	PUREX00003951	PUREX00004034
PUR1027	1/1/2011	Clinical Message Development for Pain Molecule Prepared by GIK	PUREX00004035	PUREX00004077
PUR1030	3/29/2011	Purdue Pharmaceuticals OxyContin Concept Test: Qualitative Research Prepared by Harris Interactive	PUREX00004078	PUREX00004122
PUR1031	7/1/2011	A Strategic Market Study to Understand the Position of OxyContin in the Continuous Pain Universe Prepared by Synovate Healthcare on 7/1/2011	PUREX00004123	PUREX00004200
PUR1032	8/25/2011	OxyContin Reformulation Prepared by Kantar Health on 8/25/2011	PUREX00004201	PUREX00004244
PUR1035	4/1/2011	2011, Cropper Hammitt Robinson, Valuing Mortality Risk Reductions	PUREX00004245	PUREX00004280
PUR1036	4/6/2011	Volkow et al, Characteristics of Opioid Prescriptions in 2009 Available at https://jamanetwork.com/ on 04/29/2019	PUREX00004281	PUREX00004283
PUR1037	1/17/2012	OxyContin Pri-Med (West) Conference Impact-Jan thru Oct 2011	PUREX00004284	PUREX00004296
PUR1038	1/17/2012	OxyContin Pri-Med (West) Conference Impact-Jan thru Oct 2011	PUREX00004297	PUREX00004308
PUR1039	1/24/2012	Conference ROI-Pri-Med (OxyContin), AAPM (Butrans), AAFP (Butrans)	PUREX00004309	PUREX00004349
PUR1040	1/26/2012	Conference ROI-Pri-Med (OxyContin), AAPM (Butrans), AAFP (Butrans)	PUREX00004350	PUREX00004424
PUR1041	1/31/2012	Conference ROI-Pri-Med (OxyContin), AAPM (Butrans), AAFP (Butrans)	PUREX00004425	PUREX00004464
PUR1042	2/7/2012	Conference ROI-Pri-Med (OxyContin), AAPM (OxyContin), AAFP (OxyContin)	PUREX00004465	PUREX00004503
PUR1043	2/8/2012	Conference ROI-AAPM (Butrans), AAFP (Butrans), Pri-Med (OxyContin)	PUREX00004504	PUREX00004542
PUR1044	2/28/2012	Conference Attendee Profile: AAPM, AAFP, Pri-Med	PUREX00004543	PUREX00004562
PUR1045	7/12/2012	OxyContin-Marketing Mix Modeling Result-July 2012	PUREX00004563	PUREX00004599
PUR1046	8/22/2012	2012.08.22 OxyContin e-Voucher Program Analysis	PUREX00004600	PUREX00004658
PUR1047	12/8/2012	Conference ROI-AAPM (Feb)-Butrans, OxyContin Nov 2011 thru Jul 2012	PUREX00004659	PUREX00004684
PUR1048	12/9/2016	Conference ROI-AAPA (May)-Butrans, OxyContin, Intermezzo Nov 2011 thru Aug 2012	PUREX00004685	PUREX00004717
PUR1049	12/10/2012	Conference ROI-PriMed West (Apr)-Butrans, OxyContin, Intermezzo Nov 2011 thru Aug 2012	PUREX00004718	PUREX00004747
PUR1050	12/11/2012	Conference ROI-AAPM (May), AAPA (May), ACOFP (Mar), PriMed West (Apr)	PUREX00004748	PUREX00004837
PUR1051	1/1/2012	2012 Bhattacherjee Social Sciences Research: Principles, Methods, and Practices	PUREX00004838	PUREX00004996
PUR1052	7/1/2012	2012-07-00 OxyContin Label	PUREX00004997	PUREX00005027
PUR1053	9/1/2012	2012-09-00 OxyContin Label	PUREX00005028	PUREX00005058
PUR1055	1/25/2013	2013.01.25 - FDA-Testimony-on-hydrocodone-combo-upscheduling from III to II	PUREX00005059	PUREX00005089
PUR1056	4/30/2013	Conference ROI-ACP (April)-Butrans, OxyContin, Intermezzo Oct 2011 thru Oct 2012	PUREX00005090	PUREX00005118
PUR1057	4/30/2013	Conference ROI-APA (May)-Butrans, OxyContin Nov 2011 thru Nov 2012	PUREX00005119	PUREX00005138
PUR1058	4/30/2013	Conference ROI-ACP, APS, SLEEP	PUREX00005139	PUREX00005196
PUR1060	7/24/2013	OxyContin e-Voucher and Savings Card Program ROI Analysis: Updated Executive Summary	PUREX00005197	PUREX00005293
PUR1064	10/30/2013	Sales Trend Analysis of Kentucky, Vermont and Washington	PUREX00005294	PUREX00005317
PUR1067	11/1/2013	Brand Writers Summary	PUREX00005318	PUREX00005328
PUR1069	11/8/2013	Nov 4-8, 2013 Exploring Professional Campaign Concepts for OxyContin: What Stands Out?	PUREX00005329	PUREX00005395
PUR1070	11/18/2013	E2E: Workload Targeting OxyContin & Butrans Coverage Review	PUREX00005396	PUREX00005483
PUR1073	12/2/2013	Current Market Share (total and branded)	PUREX00005484	PUREX00005491
PUR1074	12/19/2013	OxyContin Quantitative Message Testing: Top Line	PUREX00005492	PUREX00005541
PUR1076	10/16/2015	CDC Controlled Substance Prescribing Patterns-Prescription Behavior Surveillance System , 8 states., 2013	PUREX00005542	PUREX00005561
PUR1077	3/28/2013	2013_Miller, Bhattacharya_Incidence and Cost of Carbon Monoxide Poisoning for All Ages, Pool and Spa Submersions for Ages 0-4, and Lead Poisoning for Ages 0-4	PUREX00005562	PUREX00005563
PUR1078	4/1/2013	2013-04 Oxycontin Label	PUREX00005564	PUREX00005596
PUR1080	1/27/2014	FAMR Prescriber Analysis	PUREX00005597	PUREX00005599
PUR1082	4/21/2014	FAMR Q1 2014 OxyContin and Butrans Called on HCPs performance	PUREX00005600	PUREX00005616
PUR1084	3/4/2014	FAMR Prescriber Analysis	PUREX00005617	PUREX00005619
PUR1085	3/7/2014	FAMR OxyContin Abuse Deterrent Messaging Program - Topline	PUREX00005620	PUREX00005631
PUR1086	3/10/2014	FAMR Manage Care Plan Models and NPV for UHC and Caremark	PUREX00005632	PUREX00005686
PUR1087	3/19/2014	FAMR OxyContin Caremark Commercial Model and NPV Analysis	PUREX00005687	PUREX00005693
PUR1088	4/11/2014	FAMR Rebate Program Value Assessment	PUREX00005694	PUREX00005700
PUR1089	4/24/2014	Evolve to Excellence - Update on Implementation	PUREX00005701	PUREX00005719
PUR1090	4/24/2014	FAMR OxyContin ESI/Medco Commercial Model and NPV	PUREX00005720	PUREX00005732
PUR1091	5/1/2014	FAMR Pain Week Convention Program OxyContin and Butrans for September 2013	PUREX00005733	PUREX00005758
PUR1092	5/4/2014	FAMR OxyContin Patient Essential Kit (Feb 2013 - May 2013 Cohorts)	PUREX00005759	PUREX00005777
PUR1093	5/30/2014	Purdue Final Report on Nurse Practitioner and Physician Assistant Exploratory Research	PUREX00005778	PUREX00005815
PUR1094	6/6/2014	FAMR OxyContin Patient Essential Kit	PUREX00005816	PUREX00005841
PUR1095	6/18/2014	FAMR NP/PA Study with Strategic Business Research	PUREX00005842	PUREX00005887
PUR1096	7/23/2014	2014 FAMR HCP call analysis	PUREX00005888	PUREX00005907
PUR1097	11/24/2014	Cobbs Creek Healthcare Budget Analysis	PUREX00005908	PUREX00005914

PUR1099	12/7/2014	FAMR High Decile HCP analysis	PUREX00005915	PUREX00005916
PUR1100	12/8/2014	FAMR OxyContin Prescriber Analysis	PUREX00005917	PUREX00005918
PUR1101	12/9/2014	Cobb's Creek Healthcare: OxyContin RM Analysis	PUREX00005919	PUREX00005977
PUR1102	6/1/2014	Cassidy et al_Changes in prevalence of prescription opioid abuse after introduction of ADF	PUREX00005978	PUREX00005989
PUR1103; PUR4989	5/28/2014	Cicero et al_The Changing Face of Heroin Use in the United States a Retrospective Analysis of the Past 50 Years	PUREX00005990	PUREX00005995
PUR1104	5/14/2014	2014 Kolodny Testimony to Senate	PUREX00005996	PUREX00006001
PUR1105	6/1/2014	Zgierska, Rabago, and Miller_Impact of patient satisfaction ratings on physicians and clinical care	PUREX00006002	PUREX00006011
PUR1106	4/1/2014	4/2014 OxyContin FPI	PUREX00006012	PUREX00006023
PUR1107	1/1/2015	Cobbs Creek Healthcare: FAMR Regional Analysis of Butrans and OxyContin Prescribing Volume, January 2015	PUREX00006024	PUREX00006064
PUR1108	2/2/2015	FAMR Vacant Territory and Floater Representative Concept Analysis	PUREX00006065	PUREX00006072
PUR1109	2/18/2015	FAMR Vacant Territory Analysis	PUREX00006073	PUREX00006073
PUR1110	3/1/2014	ADT Awareness Quantitative Research, Final Report Prepared for Purdue Pharma	PUREX00006074	PUREX00006099
PUR1111	3/29/2015	Cobbs Creek FAMR OxyContin RM Analysis	PUREX00006100	PUREX00006123
PUR1112	4/2/2015	Cobbs Creek FAMR Long Term Care Analysis	PUREX00006124	PUREX00006130
PUR1113	4/2/2015	Cobbs Creek FAMR Analysis of the Impact of Moving OxyContin Primary Calls to Butrans	PUREX00006131	PUREX00006134
PUR1114	8/1/2015	2015.08 OxyContin Label	PUREX00006135	PUREX00006173
PUR1115	8/17/2015	Report on OxyContin Promotional Concept Qualitative Testing	PUREX00006174	PUREX00006224
PUR1117	9/24/2015	Sommer Consulting: OxyContin Message Testing Research Final Report	PUREX00006225	PUREX00006276
PUR1119	12/8/2015	2015_Case and Deaton Rising morbidity and mortality in midlife among white non-Hispanic Americans	PUREX00006277	PUREX00006282
PUR1120	10/27/2015	2015 Miller and Hendrie Nurse Family Partnership, Comparing Costs per Family	PUREX00006283	PUREX00006289
PUR1121	6/16/2015	2015 Miller Projected Outcomes of Nurse-Family Partnership Home Visitation During 1996-2013, USA	PUREX00006290	PUREX00006302
PUR1122	5/2/2015	2015 Nahin Estimates of Pain Prevalence and Severity in Adults United States 2012	PUREX00006303	PUREX00006330
PUR1124	5/5/2015	2016 OxyContin Strategy Plan	PUREX00006331	PUREX00006353
PUR1125	4/1/2016	Purdue Xtampza Impact Study Final Report	PUREX00006354	PUREX00006404
PUR1126	3/25/2016	FAMR Speaker Program Analysis	PUREX00006405	PUREX00006406
PUR1127	4/6/2016	FAMR Employer Group Potential Upside Analysis	PUREX00006407	PUREX00006415
PUR1128	9/23/2016	Aptus Health Purdue Campaign Measurement Results through June 2016	PUREX00006416	PUREX00006467
PUR1129	11/14/2016	Cobbs Creek Healthcare OxyContin Experience Program Analysis	PUREX00006468	PUREX00006495
PUR1130	11/16/2016	Cobbs Creek Healthcare: OxyContin RM Analysis	PUREX00006496	PUREX00006525
PUR1131	12/2/2016	Cobbs Creek Healthcare: OxyContin Marketing Mic Modeling Report	PUREX00006526	PUREX00006550
PUR1132	6/1/2016	2016 Adams, Bledsoe, and Armstrong Are Pain Management Questions in Patient Satisfaction Surveys Driving the Opioid Epidemic	PUREX00006551	PUREX00006552
PUR1133	12/1/2016	12/2016 OxyContin FPI	PUREX00006553	PUREX00006570
PUR1136	12/1/2017	Ruhm, Christopher J., Geographic Variation in Opioid and Heroin Involved Drug Poisoning Mortality Rates, American Journal of Preventative Medicine, 53, 745-753, 2017	PUREX00006571	PUREX00006579
PUR1138	3/14/2017	Yin, Peng, et al., Particulate Air Pollution and Mortality in 38 of China's Largest Cities Time Series Analysis, BMJ, 2017	PUREX00006580	PUREX00006591
PUR1139	7/12/2018	July 11/12, 2018 Cuyahoga Onsite Meeting Notes	PUREX00006592	PUREX00006603
PUR1140	10/12/2017	Purdue Pharma Presentation: 2018 Budget Proporal Sales and Promotion	PUREX00006604	PUREX00006642
PUR1141	9/14/2018	Dahlhamer, James, Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults, Morbidity and Mortality Weekly Report, 67, 2018	PUREX00006643	PUREX00006648
PUR1142	3/1/2018	Currie, Janet, et al., US Employment and Opioids: Is There a Connection?, Princeton University, 2018	PUREX00006649	PUREX00006686
PUR1143	6/15/2016	Demanet, et al., Personal Use, Social Supply or Redistribution? cryptomarket demand on Silk Road 2 and Agora, Springer Science+Business Media, 2016	PUREX00006687	PUREX00006706
PUR1144	7/31/2018	2018 Fierce Healthcare CMS proposes nixing pain-management questions from HCAHPS	PUREX00006707	PUREX00006710
PUR1146	12/31/2016	Cox, Cynthia, et al., A look at how opioid addiction treatment has cost large employers	PUREX00006711	PUREX00006716
PUR1147	1/1/2018	Patient Satisfaction Surveys, NEJM Catalyst, 2018	PUREX00006717	PUREX00006725
PUR1148	10/1/2018	Pitt, Alison L., et al., Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic, 2018	PUREX00006726	PUREX00006732
PUR1149	1/1/2018	Ruhm, Christopher J. Deaths of Despair or Drug Problems, National Bureau of Economic Research, 2018	PUREX00006733	PUREX00006802
PUR1150	4/1/2017	Tompkins, Hobelmann, and Compton Providing chronic pain management in the 'Fifth Vital Sign' Era	PUREX00006803	PUREX00006828
PUR1151	9/1/2018	9/2018 OxyContin Prescribing Information	PUREX00006829	PUREX00006874
PUR1152	8/6/2018	Moyle, Leah, et al., Drugs for sale - an exploration of the use of social media and encrypted messaging apps to supply and access drugs	PUREX00006875	PUREX00006884
PUR1153	9/9/2010	Cuyahoga County's Corruption Investigation: A Comprehensive Guide, www.cleveland.com	PUREX00006885	PUREX00006888
PUR1154	5/10/2019	TND Project towards no drug abuse overview, Univ. of Southern California Institute for Prevention Research	PUREX00006889	PUREX00006889
PUR1156; PUR4988	5/11/2019	G Caleb Alexander Supplemental Expert Witness Report	PUREX00006890	PUREX00007004
PUR1157	5/1/2018	Dionissi Aliprantis, Opioids and the Labor Market (Federal Reserve Bank of Cleveland)	PUREX00007005	PUREX00007037

PUR1158	5/10/2019	All Stars Prevention - Building Bright Futures overview	PUREX00007038	PUREX00007038
PUR1159	11/1/2018	Abby Alpert et al "Supply Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids" (American Economic Journal)	PUREX00007039	PUREX00007074
PUR1160	12/31/2016	US Census Bureau, American FactFinder Total US population and Total Cuyahoga & Summit County OH population 2016	PUREX00007075	PUREX00007076
PUR1161	8/1/2009	Britta Anderson et al. "Factors Associated With Physicians Reliance on Pharm Sales Reps" (Physician Industry Relations - Academic Medicine, Vol 84, No. 8 Aug 2009)	PUREX00007077	PUREX00007085
PUR1162	1/1/2001	Badi Baltagi and Dan Levin "Estimating Dynamic Demand for Cigarettes Using Panel Data: The Effects of Bootlegging, Taxation and Advertising Reconsidered" (the Review of Economics and Statistics 2001)	PUREX00007086	PUREX00007094
PUR1164	5/1/1995	Ernst Berndt et al., Information, Marketing, and Pricing in the US Antiulcer Drug Market, American Economic Review, 1995, Vol. 85(2); 100-105	PUREX00007095	PUREX00007101
PUR1165	12/1/2001	Patricia Berry, et al, Pain Current Understanding of Assessment Management and Treatments, Nat'l Pharm. Council, 2001	PUREX00007102	PUREX00007202
PUR1166	8/7/2012	Cameron, TA and DeShazo, J.R., Demand for Health Risk Reductions, Journal of Environmental Economics and Management, Vol 65, pp. 87-109, 2013	PUREX00007203	PUREX00007225
PUR1167; PUR4982	3/15/2016	Deborah Dowell MD et al. CDC Morbidity and Mortality Weekly Report, March 15, 2016	PUREX00007226	PUREX00007284
PUR1168	12/31/2018	CDC - Opioid Data Analysis and Resources, 2018 Annual Surveillance Report of Drug Related Risks and Outcomes	PUREX00007285	PUREX00007290
PUR1169	11/1/2017	Council of Economic Advisers, Executive Office of the President of the United States - The Underestimated Cost of the Opioid Crisis, November 2017	PUREX00007291	PUREX00007304
PUR1170	6/18/2010	Center for Drug Evaluation and Research, NDA No. 22-272 (Purdue Pharma): Risk Assessment and Risk Mitigation Review(s) Prior Approval of REMS Modification	PUREX00007305	PUREX00007357
PUR1171	4/1/2018	Food and Drug Administration, HHS, 21 CFR, Ch. I (4-1-18 Edition), Section 202.1 - Prescription Drug Advertising	PUREX00007358	PUREX00007367
PUR1172	12/31/2016	US Dept of Health and Human Services website: Concept and History of Permanency in U.S. Child Welfare, available at https://www.acf.hhs.gov/programs/cb	PUREX00007368	PUREX00007370
PUR1173	8/11/2009	Pradeep Chintagunta et al; Information, Learning, and Drug Diffusion: The case of Cox 2 inhibitors (Quant Mark Econ, Vol 7, pp.399-443; 2009)	PUREX00007371	PUREX00007415
PUR1174	3/2/1994	Mary Margaret Chren and Seth Landefeld; Physicians' Behavior and Their Interactions With Drug Companies - A Controlled Study of Physicians Who Requested Additions to a Hospital Drug Formulary, JAMA, Vol. 271, No. 9, pp. 684-688; March 1994	PUREX00007416	PUREX00007421
PUR1176	5/1/2015	Theodore Cicero PHD et al; Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States Lessons Learned From OxyContin (JAMA Psychiatry, Vol 75, No. 5, pp. 424-429; 2015)	PUREX00007422	PUREX00007427
PUR1177	11/2/2018	Article: CMS finalizes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019 (CMS News and Media Group)	PUREX00007428	PUREX00007440
PUR1178	9/26/2003	Federal Register Vol 68, No. 187 Department of Health and Human Services, Centers for Medicare and Medicaid Services, Medicare Program, Revised Process for making Medicare National Coverage Determinations 2003	PUREX00007441	PUREX00007448
PUR1179	12/20/2017	Community Assessment of the Opioid Crisis in Lorain County OH, The Nord Family Foundation 2017	PUREX00007449	PUREX00007454
PUR1180	11/1/1998	David Cutler, et al. - Are Medical Prices Declining? Evidence from Heart Attack Treatments, The Quarterly Journal of Economics, Vol 113, No. 4, pp. 991-1024	PUREX00007455	PUREX00007490
PUR1181	1/1/2000	David Cutler and Ellen Meara - The Technology of Birth: Is It Worth It? National Bureau of Economic Research, Vol 3, Jan 2000	PUREX00007491	PUREX00007527
PUR1184	7/1/2018	US Census Bureau, Cuyahoga County Population 2018	PUREX00007528	PUREX00007528
PUR1185	12/31/2017	Richard Dart, MD, RADARS System Presentation: Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids.	PUREX00007529	PUREX00007558
PUR1186	12/31/2017	Richard Dart MD, RADARS System Presentation: Interventions in Prescription Opioid Abuse – Do (or can) Prescription Monitoring Programs Make a Difference	PUREX00007559	PUREX00007576
PUR1187	10/1/2018	Karyn Kai Anderson, et al., Data Analysis Brief: National Trends in High-dose Chronic Opioid Utilization among Dually Eligible and Medicare-only Beneficiaries (2006-2015), Oct. 2018.	PUREX00007577	PUREX00007599
PUR1188	2/19/2016	Anusua Datta, et al., "Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence, Health Economics, Vol. 26, pp. 450-68, Feb. 19, 2016	PUREX00007600	PUREX00007618
PUR1189	7/1/2013	Dhavel Dave and Henry Saffer, Demand for Smokeless Tobacco: Role of Advertising, National Institute of Health 2013	PUREX00007619	PUREX00007651
PUR1190	1/1/2010	Jessica De Maeyer et al, Quality of life among opiate dependent individuals: A review of the literature, International Journal of Drug Policy 21 (2010)	PUREX00007652	PUREX00007668
PUR1191	8/21/2014	Article - DEA To Publish Final Rule Rescheduling Hydrocodone Combination Products, 2014	PUREX00007669	PUREX00007670
PUR1192	6/20/2016	Colette Ddejong, et al., "Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries," available at https://jamanetwork.com/on04/07/2019 , JAMA, 2016	PUREX00007671	PUREX00007679

PUR1193	8/16/2007	Julie Donohue, et. at., A Decade of Direct-to-Consumer Advertising of Prescription Drugs, The New England Journal of Medicine, Vol. 357, pp 673-681 (Aug. 16, 2007)	PUREX00007680	PUREX00007688
PUR1194	12/1/2004	Julie Donohue, Julie, et al., Effects of Pharmaceutical Promotion of Adherence to the Treatment Guidelines for Depression, Medical Care, Vol 42, pp 1176-1195 (Dec. 2004)	PUREX00007689	PUREX00007698
PUR1196	3/1/2019	Evans WN, Lieber EM & Power P, How the Reformulation of Oxycontin Ignited the Heroin Epidemic, The Review of Economics and Statistics, Vol. CI, pp. 1-15 (March 2019)	PUREX00007707	PUREX00007721
PUR1197	5/10/2019	Factiva Public Press Search results - Oxycontin - 1990 to 2016	PUREX00007722	PUREX00007722
PUR1198	5/10/2019	Factiva Public Press Search results - OxyContin - 1990 to 2010	PUREX00007723	PUREX00007723
PUR1199	1/25/2013	FDA Drug Safety and Risk Management Advisory Committee January 25, 2013 Meeting Transcript	PUREX00007724	PUREX00008075
PUR1200	4/5/2010	Letter from Bob Rappaport (FDA) to Purdue Pharma L.P. re: NDA Approval for OxyContin Tablets.	PUREX00008076	PUREX00008082
PUR1201	5/10/2019	FDA Fundamentals, available at https://www.fda.gov/about-fda/fda-basics/fda-fundamentals	PUREX00008083	PUREX00008086
PUR1202	9/18/2018	Approved Risk Mitigation and Mitigation Strategies (REMS): Opioid Analgesic REMS - Update History, www.fda.gov	PUREX00008087	PUREX00008090
PUR1204	2/24/2019	FDA's Drug Review Process: Continued, available at https://www.fda.gov/drugs/resourcesforyou/consumers/ucum289601.htm	PUREX00008091	PUREX00008095
PUR1205	5/1/2009	Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical Device Promotion - Draft Guidance, FDA (May 2009)	PUREX00008096	PUREX00008122
PUR1206	6/1/2010	Fortin N, Lemieux T & Firpo S, Decomposition Methods in Economics, National Bureau of Economic Research Working Paper Series (June 2010)	PUREX00008123	PUREX00008240
PUR1207	10/1/2016	Florence, CS, et. al. The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013	PUREX00008241	PUREX00008246
PUR1208	5/1/2004	Federation of State Medical Boards, Model Policy for the Use of Controlled Substances for the Treatment of Pain, 2004	PUREX00008247	PUREX00008251
PUR1209	1/1/2011	Forti, N., et. al., Decomposition Methods in Economics, Handbook of Labor Economics, Volume 4a, 2011, 1- 101	PUREX00008252	PUREX00008353
PUR1210	12/1/2003	GAO Report to Congressional Requesters: Prescription Drugs - OxyContin Abuse and Diversion and Efforts to Address the Problem, December 2003	PUREX00008354	PUREX00008416
PUR1211	6/1/2018	Hadland, Assoc of Pharm Industry Marketing of Opioid, JAMA Internal Medicine, Vo 178 No. 6, June, 2018	PUREX00008417	PUREX00008419
PUR1212	9/1/2017	Hadland - industry Payments to Physicians for Opioid Products 2013-2015	PUREX00008420	PUREX00008422
PUR1213	1/18/2019	Hadland SE, et. al., Association of Pharmaceutical Industry Marketing of Opioid Products with Mortality from Opioid-Related Overdoses, JAMA Network Open, Vol. 2 (Jan. 18, 2019)	PUREX00008423	PUREX00008434
PUR1214	6/1/2018	Hadland, Assoc of Pharm Industry Marketing of Opioid, JAMA Internal Medicine, Vo 178 No. 6, June, 2018	PUREX00008435	PUREX00008437
PUR1215	7/1/1986	Robert E. Hall, Oliver Jean Blanchard, and R. Glenn Hubbard, Market Structure and Macroeconomic Fluctuations, Brookings Institution Press, Vol. 1986, No. 2, pp. 285-338.	PUREX00008438	PUREX00008492
PUR1216	11/1/1972	Hamilton, James L, 1972. "The Demand for Cigarettes: Advertising, the Health Scare, and the Cigarette Advertising Ban," The Review of Economics and Statistics, MIT Press, vol. 54(4), pages 401-411, November.	PUREX00008493	PUREX00008504
PUR1217	3/28/2018	Harris, Matthew and Kessler, Lawrence and Murray, Matthew N. and Glenn, M. Elizabeth, Prescription Opioids and Labor Market Pains: The Effect of Schedule II Opioids on Labor Force Participation and Unemployment (March 28, 2018).	PUREX00008505	PUREX00008574
PUR1218	1/1/2011	IIOM (Institute of Medicine) Committee on Advancing Pain Research, Care, and Education, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press.2011	PUREX00008575	PUREX00008957
PUR1219	8/10/2016	Harison Jacobs, "Pain doctors: Insurance companies won't cover the alternatives to opioids" Business Insider	PUREX00008958	PUREX00008969
PUR1221	5/5/2017	Baker DW, The Joint Commission's Pain Standards: Origins and Evolution, The Joint Commission (May 5, 2017)	PUREX00008970	PUREX00008979
PUR1224	9/7/2017	Krueger AB, Where Have All the Workers Gone? An Inquiry into the Decline of the U.S. Labor Force Participation Rate, Brookings Papers on Economic Activity Conference Drafts (Sept. 7-8, 2017)	PUREX00009029	PUREX00009109
PUR1225	6/1/2014	Larkin - Health Affairs: Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children	PUREX00009110	PUREX00009119
PUR1227	5/1/2019	Botvin Life Skill Training pamphlet re substance abuse prevention program overview, available at https://www.lifeskilltraining.com/1st-overview/	PUREX00009125	PUREX00009127
PUR1228	3/1/1997	A. Craig MacKinlay, Event Studies in Economics and Finance, Journal of Economic Literature, 1997, Vol. 35, issue 1, pp. 13-39.	PUREX00009128	PUREX00009154
PUR1229	3/2/2013	Manchanda P & Honka E, The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review, Yale J. Health Policy, Law & Ethics, Vol. 5, pp. 785-822 (March 2, 2013)	PUREX00009155	PUREX00009193
PUR1231	12/1/1990	Max, M.B., Improving Outcomes of Analgesic Treatment: Is Education Enough?, Ann Intern Med. 1990 Dec 1; 113(11):885-889.	PUREX00009194	PUREX00009198
PUR1232	12/1/2004	May, et al, Drug Markets and Distribution Addiction Research & Theory Volume 12, 2004 - Issue 6	PUREX00009199	PUREX00009214
PUR1233	4/1/2010	McCollister et al; The cost of crime to society, Drug Alcohol Depend. 2010 April 1; 108(1-2): 98-109.	PUREX00009215	PUREX00009240

PUR1234	10/3/1990	McKinney WP, et al., Attitudes of Internal Medicine Faculty and Residents Toward Professional Interaction With Pharmaceutical Sales Representatives, JAMA, Vol. 264, pp. 1693-1697 (Oct. 3, 1990)	PUREX00009241	PUREX00009246
PUR1235	12/1/2015	CMS Pamphlet: Medicaid Documentation for Medical Professionals (Dec. 2015)	PUREX00009247	PUREX00009249
PUR1236; PUR4979	12/1/2004	Mizik N & Jacobson R, Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions, Management Science, Vol. 50, pp. 1704-1715 (Dec. 2004)	PUREX00009250	PUREX00009261
PUR1238	7/31/2017	National Forensic Laboratory Information System Questions and Answers (Q&A)	PUREX00009274	PUREX00009280
PUR1239	11/1/2014	DEA Report: National Drug Threat Assessment 2014 (Unclassified), DEA-DCT-DIR-002-15	PUREX00009281	PUREX00009342
PUR1240	10/1/2017	DEA Report: 2017 National Drug Threat Assessment (Unclassified), DEA-DCT-DIR-040-17	PUREX00009343	PUREX00009524
PUR1241	10/1/2018	DEA Report: 2018 National Drug Threat Assessment (Unclassified), DEA-DCT-DIR-032-18	PUREX00009525	PUREX00009688
PUR1242	7/1/1992	Newhouse JP, Medical Care Costs: How Much Welfare Loss?, J. Econ. Perspectives, Vol. 6, pp. 3-21 (Summer 1992)	PUREX00009689	PUREX00009709
PUR1244	1/1/2019	Nguyen TD, et al., Pharmaceutical payments to physicians may Increase prescribing for opioids, Addiction (2019)	PUREX00009710	PUREX00009718
PUR1245	7/10/2018	Handwritten and typewritten notes, titled "Meeting with Summit County and Akron in Akron 10 July 2018"	PUREX00009719	PUREX00009723
PUR1246	6/1/2018	NYS Health Foundation Report: Follow the Money: Pharmaceutical Manufacturer Payments and Opioid Prescribing Patterns in New York State (June 2018)	PUREX00009724	PUREX00009753
PUR1247	3/22/2015	Ohio Admin. Code Chapter 5160-1 (General Provisions - Medicaid)	PUREX00009754	PUREX00009864
PUR1248	8/1/2016	Ohio Admin. Code § 5160-1-02 (General reimbursement principles - Medicaid)	PUREX00009865	PUREX00009866
PUR1249	3/4/2002	OxyContin Tablets Risk Management Plan (3/4/2002 Draft)	PUREX00009867	PUREX00009894
PUR1250	1/1/1988	Peay MY & Peay ER, The Role of Commercial Sources in the Adoption of a New Drug, Soc. Sci. Med., Vol. 26, pp. 1183-1189 (1988)	PUREX00009895	PUREX00009901
PUR1252	9/1/2006	DEA Practitioner's Manual: An Informational Outline of the Controlled Substances Act (2006 Ed.)	PUREX00009912	PUREX00009973
PUR1253	10/1/2018	Project ALERT Adds Opioid Lessons to Core Curriculum, www.projectalert.com (Fall 2018)	PUREX00009974	PUREX00009976
PUR1254	5/1/2019	Project Northland overview, www.youth.gov	PUREX00009977	PUREX00009981
PUR1255	5/1/2019	Project Towards No Drug Abuse, tnd.usc.edu	PUREX00009982	PUREX00009982
PUR1256	5/10/2019	Table of Oxycontin search results - No. of published medical articles (1963 to 2019)	PUREX00009983	PUREX00009983
PUR1257	2/1/2014	Rand Corporation Report to the Office of National Drug Control Policy: What America's Users Spend on Illegal Drugs: 2000-2010 (Feb. 2014)	PUREX00009984	PUREX00010107
PUR1258	5/10/2019	Real Prevention Presentation: Drug Education Programs Just Got Easier	PUREX00010108	PUREX00010109
PUR1259	12/1/1973	Miller RA, Book Review: The economics of advertising by R. Schmalensee, published in J. Econ. Lit., Vol. 11, pp. 1400-1402 (Dec. 1973)	PUREX00010110	PUREX00010113
PUR1261	4/1/1999	Rizzo J, Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs, J. Law & Econ., Vol. XLII, pp. 89-116 (April 1999)	PUREX00010114	PUREX00010141
PUR1262	6/30/2015	Robinson LA & Hammitt JK, - Valuing Reductions in Fatal Illness Risks: Implications of Recent Research, Health Econ., Vol. 25, pp. 1039-1052 (2016)	PUREX00010142	PUREX00010155
PUR1263	1/1/2003	Rosenthal et al., Demand Effects of Recent Changes in Prescription Drug Promotion, NBER Frontiers in Health Policy Research 6, pp. 1-26 (2003)	PUREX00010156	PUREX00010171
PUR1264	2/14/2002	Rosenthal MB, et al., Promotion of prescription drugs to consumers, New Eng. J. Med., Vol. 346, pp. 498-505 (Feb. 14, 2002)	PUREX00010172	PUREX00010179
PUR1265	1/31/2018	SAMHSA Clinical Guidance Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants, HHS Publication No. (SMA) 18-5054	PUREX00010180	PUREX00010344
PUR1266	4/1/2018	Savych B, et al Do Opioids Help Injured Workers Recover and Get Back to Work?: The Impact of Opioid Prescriptions on Duration of Temporary Disability, NBER Working Paper Series, No. 24528 (April 2018)	PUREX00010345	PUREX00010393
PUR1267	1/1/1972	Schmalensee R., The Economics of Advertising, Contributions to Economic Analysis, pp. 1-125 (1972)	PUREX00010394	PUREX00010519
PUR1268	1/1/1972	Schnabel M, An Oligopoly Model of the Cigarette Industry, South. Econ. J., Vol. 38, pp. 325-335 (Jan. 1972)	PUREX00010520	PUREX00010531
PUR1270	1/1/1991	Seldon BJ & Boyd R, The stability of cigarette demand, Applied Econ., Vol. 23, pp. 319-326 (1991)	PUREX00010537	PUREX00010545
PUR1271	1/19/2018	Shapiro BT, Informational Shocks, Off-labe Prescribing, and the Effects of Physician Detailing, Management Science - Articles in Advance, pp. 1-21 (Jan. 19, 2018)	PUREX00010546	PUREX00010567
PUR1272	10/1/2012	Shill J, et al., Factors Associated with High Levels of Patient Satisfaction with Pain Management, Academic Emergency Medicine, Vol. 19, pp. 1212-1215 (Oct. 2012)	PUREX00010568	PUREX00010572
PUR1273	8/1/1957	Solow RM, Technical Change and the Aggregate Production Function, The Review of Econ. & Statistics, Vol. 39, pp. 312-320 (Aug. 1957)	PUREX00010573	PUREX00010582
PUR1275	10/19/2010	Spurling GK, et al., Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review, PLoS Medicine, Vol. 7, pp. 1- 22 (Oct. 2010)	PUREX00010583	PUREX00010604
PUR1276	1/4/2012	Start Taking Alcohol Risks Seriously (STARS) for Families - Program Overview, www.childtrends.org	PUREX00010605	PUREX00010615

PUR1277	1/1/2007	Stock JH & Watson MW, Introduction to Econometrics, Addison-Wesley Series in Economics, pp. 315-325 (2007)	PUREX00010616	PUREX00010629
PUR1278	7/1/2018	Summit County, Ohio 2018 Population Estimate, www.census.gov	PUREX00010630	PUREX00010630
PUR1279	10/23/2017	Taking Measure of Ohio's Opioid Crisis, www.aede.osu.edu	PUREX00010631	PUREX00010632
PUR1280	4/1/2011	U.S. Dept. of Justice, Nat'l Drug Intelligence Center Report: The Economic Impact of Illicit Drug Use on American Society 2011, Product No. 2011-Q0317-002 (April 2011)	PUREX00010633	PUREX00010755
PUR1281	9/17/2017	Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers, The New York Times.	PUREX00010756	PUREX00010763
PUR1282	10/1/2000	Pain as the 5th Vital Sign Toolkit, Veterans Health Administration (Oct. 2000, Rev. Ed.)	PUREX00010764	PUREX00010820
PUR1283	2/1/2009	Van Zee A, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy, Am. J. Pub. Health, Vol. 99 (2), pp. 221-227 (Feb. 2009)	PUREX00010821	PUREX00010827
PUR1285	1/1/2014	Wetherington S, et al., Pain Quality of Life as Measured by Utilities, Pain Medicine, Vol. 15, pp. 865-870 (2014)	PUREX00010849	PUREX00010854
PUR1286	1/1/2016	Wooldridge JM, Introductory Econometrics: A Modern Approach, pp. 372-412 (6th Ed. 2016)	PUREX00010855	PUREX00010905
PUR1287	1/1/2013	Zimlichman E, Rozenblum R & Millenson ML, The road to patient experience of care measurement: lessons from the United States, Israel Journal of Health Policy Research, Vol. 2, pp. 1-6 (2013)	PUREX00010906	PUREX00010911
PUR1288	5/10/2019	Exhibit 1: Ohio County - Level Direct Model of Prescription Opioid Shipments (Excel Workbook)	PUREX00010912	PUREX00010912
PUR1289	5/11/2019	Cutler Direct Regression Model Accounting for Despair Proxy and Variables 1993-2010	PUREX00010913	PUREX00010913
PUR1290	5/11/2019	Cockburn rebuttal exhibits 3-6, 8: Cutler table III 10-14; Direct Mortality, Direct Mortality Sensitivities, Indirect Sensitivities, Illicit Supply Adjustment, Indirect AnyOp Sensitivities	PUREX00010914	PUREX00010914
PUR1291	5/11/2019	Cockburn Rebuttal Exhibit 7, Cutler Figure II.6 with Adjustments to Mortality Prediction	PUREX00010915	PUREX00010915
PUR1292	3/1/2019	Netezza Interaction Standards	PUREX00010916	PUREX00010916
PUR1294	3/1/2019	Data	PUREX00010917	PUREX00010918
PUR1295	3/1/2019	Data	PUREX00010919	PUREX00010922
PUR1296	3/1/2019	Data	PUREX00010923	PUREX00010924
PUR1297	3/1/2019	Data	PUREX00010925	PUREX00010925
PUR1298	3/1/2019	Data	PUREX00010926	PUREX00010939
PUR1299	3/1/2019	Data	PUREX00010940	PUREX00010945
PUR1300	3/1/2019	Data	PUREX00010946	PUREX00010948
PUR1301	3/1/2019	Data	PUREX00010949	PUREX00010951
PUR1302	3/1/2019	Data	PUREX00010952	PUREX00010952
PUR1303	5/10/2019	Stata Header	PUREX00010953	PUREX00010953
PUR1304	5/11/2019	Code for data analysis	PUREX00010954	PUREX00010955
PUR1305	5/11/2019	SAS computer code	PUREX00010956	PUREX00010956
PUR1306	5/11/2019	SAS computer code	PUREX00010957	PUREX00010959
PUR1307	5/6/2019	SAS macro code - Mortality and Census	PUREX00010960	PUREX00010960
PUR1308	5/10/2019	Computer Code - Section IV - Calculate OxyContin episode distribution based on Bellwether claims	PUREX00010961	PUREX00010963
PUR1309	5/11/2019	SAS computer code	PUREX00010964	PUREX00010964
PUR1310	5/11/2019	SAS computer code - County/Year Direct Model	PUREX00010965	PUREX00010965
PUR1311	5/10/2019	Computer Code - Section IV - Calculate the most common dose and average prescription length for OxyContin/generic	PUREX00010966	PUREX00010966
PUR1312	5/10/2019	Computer Code - Section IV - Calculate statistics from the CDC National Ambulatory Medical Care Survey	PUREX00010967	PUREX00010968
PUR1313	5/10/2019	Computer Code - Section IV - Run Rosenthal's indirect regression at the county-level	PUREX00010969	PUREX00010978
PUR1314	5/11/2019	SAS computer code	PUREX00010979	PUREX00010979
PUR1315	5/11/2019	SAS computer code	PUREX00010980	PUREX00010999
PUR1316	5/10/2019	Computer Code - Section IV - Rosenthal preferred model, two turning point	PUREX00011000	PUREX00011015
PUR1317	5/10/2019	Computer Code - Section V - Crime Regression	PUREX00011016	PUREX00011017
PUR1318	5/10/2019	Computer Code - Section V - Cutler direct regression, adding deaths of despair as control (Exhibit 2)	PUREX00011018	PUREX00011019
PUR1319	5/10/2019	Computer Code - Section V - Generate input for update Table III.14 and Figure 6 (Exhibits 7 & 8)	PUREX00011020	PUREX00011021
PUR1320	5/11/2019	SAS computer code - modify Cutler's indirect illicit mortality regression	PUREX00011022	PUREX00011023
PUR1321	5/10/2019	Computer Code - Section V - Calculates mortality to misuse factor by using misuse and CDC wonder mortality (Exhibit 5)	PUREX00011024	PUREX00011025
PUR1322	5/10/2019	Computer Code - Section V - Calculates share of pain reliever misusing population and proper use population under 35 and 50 or older	PUREX00011026	PUREX00011026
PUR1323	5/10/2019	Computer Code - Section V - Calculates share of individuals who used both heroin and pain relievers nonmedically	PUREX00011027	PUREX00011027
PUR1324	5/10/2019	Computer Code - Section V - Uses NSDUH to calculate the percent of individuals who used an illicit substance, excluding nonmedical use of pain relievers, before first using heroin	PUREX00011028	PUREX00011029
PUR1325	5/10/2019	Computer Code - Section V - Uses NSDUH and CDC opioid mortality data to calculate the ratio of OUD to opioid mortality	PUREX00011030	PUREX00011031
PUR1326	5/10/2019	Computer Code - Section V - Uses NSDUH to calculate share of nonmedical users/misusers of pain relievers by source of pain relievers used nonmedically/misused	PUREX00011032	PUREX00011032

PUR1327	5/10/2019	Computer Code - Section V - Statistics calculation for first use of prescription opioids by admitees to OUD treatment clinics	PUREX00011033	PUREX00011033
PUR1328	5/10/2019	Computer Code - Section VI - Calculate national hydrocodone shares of Trx and MME from Rosenthal's IQVIA data	PUREX00011034	PUREX00011034
PUR1329	5/10/2019	Computer Code - Section VI - Calculate national Purdue and OxyContin/generic Oxy shares of Trx and MME from Rosenthal's IQVIA data	PUREX00011035	PUREX00011035
PUR1330	5/10/2019	Computer Code - Section VI - Calculates share of pain reliever nonmedical use/misuse accounted for by hydrocodone nonmedical users/misusers	PUREX00011036	PUREX00011036
PUR1331	5/10/2019	Computer Code - Section VI - Calculate statistics from IQVIA patient count data on shares of patients with certain prescriptions	PUREX00011037	PUREX00011037
PUR1332	5/10/2019	Computer Code - Section VII - Compares IQVIA OxyContin patient counts to estimates	PUREX00011038	PUREX00011038
PUR1333	5/11/2019	SAS computer code - calculate share of individuals with OUD who have another SUD	PUREX00011039	PUREX00011039
PUR1334	5/10/2019	Computer Code - Section VIII - Calculate Ohio OUD/HUD admissions statistics from TEDS-A data	PUREX00011040	PUREX00011041
PUR1335	5/10/2019	Computer Code - Cutler's mortality data set for all counties	PUREX00011042	PUREX00011046
PUR1336	5/9/2019	Computer Code - Aggregate Cleveland Sports Wins	PUREX00011047	PUREX00011047
PUR1337	5/10/2019	Computer Code - Construction of deaths of despair mortality rate based on Case and Deaton (2015, 2017)	PUREX00011048	PUREX00011052
PUR1338	5/10/2019	Computer Code - Builds NSDUH data, 2002-2017	PUREX00011053	PUREX00011053
PUR1339	5/10/2019	Computer Code - Purpose: Join US precipitation, Ohio precipitation, and Cleveland sports wins onto Rosenthal's data	PUREX00011054	PUREX00011055
PUR1340	5/10/2019	Computer Code - Prepares Ohio Purdue call notes data for analysis; flags opioid-related calls (Rosenthal Direct Ex. 1)	PUREX00011056	PUREX00011057
PUR1341	5/10/2019	Computer Code - Rosenthal county year and county quarter data for direct model analysis	PUREX00011058	PUREX00011058
PUR1342	5/9/2019	Computer Code - Bellwether Claims	PUREX00011059	PUREX00011060
PUR1343	5/9/2019	Computer Code - CDC National Ambulatory Medical Survey medication counts	PUREX00011061	PUREX00011061
PUR1344	5/10/2019	Computer Code - CDC Oral MME List	PUREX00011062	PUREX00011062
PUR1345	5/10/2019	Computer Code - Imports NSDUH dataset, 2002-2017	PUREX00011063	PUREX00011064
PUR1346	5/10/2019	Computer Code - Import IQVIA Patient Count Data	PUREX00011065	PUREX00011065
PUR1347	5/10/2019	Computer Code - Import Purdue call notes for Ohio	PUREX00011066	PUREX00011066
PUR1348	5/10/2019	Computer Code - turn Rosenthal datasets into SAS readable files	PUREX00011067	PUREX00011067
PUR1349	4/22/2019	Computer Code - Rosenthal's Cancer Deaths data from 4/22/2019	PUREX00011068	PUREX00011068
PUR1350	5/9/2019	Computer Code - Import TEDS A data into Netezza	PUREX00011069	PUREX00011069
PUR1351	5/9/2019	Computer Code - Import US Zip Codes	PUREX00011070	PUREX00011070
PUR1352	5/8/2019	SAS cancel/abort report message	PUREX00011071	PUREX00011071
PUR1353	5/8/2019	SAS macro code - Assign Def Status (Manufacturers and drug names)	PUREX00011072	PUREX00011072
PUR1354	5/8/2019	SAS macro code - Delete MVars	PUREX00011073	PUREX00011073
PUR1355	5/8/2019	SAS macro code - Filters for Janssen, Codeine, Buprenorphine, and Butrans	PUREX00011074	PUREX00011074
PUR1356	5/8/2019	SAS macro code - Number of Observations	PUREX00011075	PUREX00011075
PUR1357	5/8/2019	SAS macro code - Delete dataset	PUREX00011076	PUREX00011076
PUR1358	5/8/2019	SAS macro code - Model Macros	PUREX00011077	PUREX00011077
PUR1359	5/11/2019	SAS Model Macro Code	PUREX00011078	PUREX00011078
PUR1360	5/8/2019	SAS macro code - New Drug Names	PUREX00011079	PUREX00011079
PUR1361	5/8/2019	SAS macro code - New Manufacturer	PUREX00011080	PUREX00011080
PUR1362	5/8/2019	SAS macro code - New Strength	PUREX00011081	PUREX00011081
PUR1363	5/8/2019	SAS macro code - Price Index	PUREX00011082	PUREX00011082
PUR1364	5/8/2019	SAS macro code - Runquit	PUREX00011083	PUREX00011083
PUR1365	5/8/2019	SAS macro code - Show Data/Info	PUREX00011084	PUREX00011084
PUR1366	5/8/2019	SAS macro code - Vexist	PUREX00011085	PUREX00011085
PUR1368	5/31/2019	MME Calculation by Explanatory Variable, Jan 1996-May 2018 - section_iv_rosenthal-preferred-model-standalone-nearfinal.xlsx	PUREX00011086	PUREX00011086
PUR1369	5/31/2019	Purdue Call Notes	PUREX00011087	PUREX00011087
PUR1370	5/31/2019	section_iv_direct-c-y-oh.xls	PUREX00011088	PUREX00011088
PUR1371	5/31/2019	fn-6.xlsx (Excel spreadsheet "oh share of hydrocodone")	PUREX00011089	PUREX00011089
PUR1372	5/31/2019	fn-69a.xlsx (Excel spreadsheet with shares)	PUREX00011090	PUREX00011090
PUR1373	5/31/2019	fn-69b.xlsx (Excel spreadsheet with episodes & daily doses)	PUREX00011091	PUREX00011091
PUR1374	5/31/2019	section_iv_direct-c-q-oh.xls	PUREX00011092	PUREX00011092
PUR1375	1/1/2017	section_iv_direct-c-y-oh-mme.xls	PUREX00011093	PUREX00011093
PUR1376	1/1/2018	Excel attachment Call-notes analysis	PUREX00011094	PUREX00011094
PUR1377	5/31/2019	Excel attachment, pdmp patient share	PUREX00011095	PUREX00011095
PUR1378	1/1/2018	Excel Attachment, exhibit-7-top, Decile Purdue	PUREX00011096	PUREX00011096
PUR1379	1/1/2018	Excel attachment, exhibits-3-4 Purdue Oxy-shares, Summit County and Cuyahoga County, 2018	PUREX00011097	PUREX00011097
PUR1380	1/1/2018	Excel Attachment, exhibits-5 and 6, Annual-prescribes, Cuyahoga County and Summit County	PUREX00011098	PUREX00011098
PUR1381	1/1/2018	Excel Attachment ,exhibits 5 and 6, annual-prescribes-Purdue, Summit County and Cuyahoga County	PUREX00011099	PUREX00011099
PUR1382	1/1/2019	Excel Attachment, Exhibits8 9 min-max-Purdue. Summit County and Cuyahoga County	PUREX00011100	PUREX00011100
PUR1383	5/31/2019	paragraph-3-claims-opioid-naive	PUREX00011101	PUREX00011101
PUR1384	5/31/2019	Excel Sheet: Bellwether County Manual Mapping	PUREX00011102	PUREX00011102
PUR1385	5/29/2019	Kessler call notes	PUREX00011103	PUREX00011103
PUR1386	5/31/2019	OH_AllFields_2007-2018_03232019	PUREX00011104	PUREX00011104

PUR1387	5/31/2019	Ohio Call Notes 2006-2018 PPINV0011618001 (native of PPLPMDL002000001)	PUREX00011105	PUREX00011105
PUR1388	5/31/2019	Ohio_CallNotes_1994-2005_09122018	PUREX00011106	PUREX00011106
PUR1389	5/28/2019	sum_cuy_fips_manual_matching.xlsx	PUREX00011107	PUREX00011107
PUR1390	5/20/2019	overlap.sas7bdat	PUREX00011108	PUREX00011108
PUR1391	5/31/2019	drug_flagging	PUREX00011109	PUREX00011109
PUR1392	2/5/2018	Comparison of the Number of People Receiving OxyContin Prescriptions IQVIA vs. NSDUH 2014-2017	PUREX00011110	PUREX00011110
PUR1393	5/31/2019	Specialty List	PUREX00011111	PUREX00011111
PUR1394	5/31/2019	ndc_nhric_labeler_codes_05_17_2019	PUREX00011112	PUREX00011112
PUR1395	4/4/2019	BOP MDL 5th Production	PUREX00011113	PUREX00011113
PUR1396	4/4/2019	BOP MDL 5th Production	PUREX00011114	PUREX00011114
PUR1397	4/4/2019	BOP MDL 5th Production	PUREX00011115	PUREX00011115
PUR1398	4/4/2019	BOP MDL 5th Production	PUREX00011116	PUREX00011116
PUR1399	4/4/2019	BOP MDL 5th Production	PUREX00011117	PUREX00011117
PUR1400	4/4/2019	BOP MDL 5th Production	PUREX00011118	PUREX00011118
PUR1401	4/4/2019	BOP MDL 5th Production	PUREX00011119	PUREX00011119
PUR1402	4/4/2019	BOP MDL 5th Production	PUREX00011120	PUREX00011120
PUR1403	3/31/2010	List of prescriptions filled during the period 1/1/2010 to 3/31/2010 with prescription, drug, pharmacy, prescriber and patient information	PUREX00011121	PUREX00011121
PUR1404	6/30/2010	List of prescriptions filled during the period 4/1/2010 to 6/30/2010 with prescription, drug, pharmacy, prescriber and patient information	PUREX00011122	PUREX00011122
PUR1405	9/30/2010	List of prescriptions filled during the period 7/1/2010 to 9/30/2010 with prescription, drug, pharmacy, prescriber and patient information	PUREX00011123	PUREX00011123
PUR1406	10/1/2010	PMP data from 10-1-2010 for BOP MDL 5th Production	PUREX00011124	PUREX00011124
PUR1407	1/1/2011	PMP data for 1/1/2011 for BOP MDL 5th Production	PUREX00011125	PUREX00011125
PUR1408	4/1/2011	PMP data for 4/1/2011 for BOP MDL 5th Production	PUREX00011126	PUREX00011126
PUR1409	7/1/2011	PMP data for 7/1/2011 for BOP MDL 5th Production	PUREX00011127	PUREX00011127
PUR1410	10/1/2011	BOP MDL 5th Production	PUREX00011128	PUREX00011128
PUR1411	1/1/2012	BOP MDL 5th Production	PUREX00011129	PUREX00011129
PUR1412	4/1/2012	PMP Data for 4/1/2012 BOP MDL 5th Production	PUREX00011130	PUREX00011130
PUR1413	7/1/2012	BOP MDL 5th Production	PUREX00011131	PUREX00011131
PUR1414	10/1/2012	PMP data for 10/1/2012 for BOP MDL 5th Production	PUREX00011132	PUREX00011132
PUR1415	1/1/2013	PMP data for 1/1/2013 for BOP MDL 5th Production	PUREX00011133	PUREX00011133
PUR1416	4/1/2013	PMP data for 4/1/2013 for BOP MDL 5th Production	PUREX00011134	PUREX00011134
PUR1417	7/1/2013	PMP data for 7/1/2013 for BOP MDL 5th Production	PUREX00011135	PUREX00011135
PUR1418	10/1/2013	PMP data for 10/1/2013 for BOP MDL 5th Production	PUREX00011136	PUREX00011136
PUR1419	1/1/2014	PMP data for 1/1/2014 for BOP MDL 5th Production	PUREX00011137	PUREX00011137
PUR1420	4/1/2014	PMP data for 4/1/2014 for BOP MDL 5th Production	PUREX00011138	PUREX00011138
PUR1421	7/1/2014	PMP data for 7/1/2014 for BOP MDL 5th Production	PUREX00011139	PUREX00011139
PUR1422	10/1/2014	PMP data for 10/1/2014 for BOP MDL 5th Production	PUREX00011140	PUREX00011140
PUR1423	1/1/2015	PMP data for 1/1/2015 for BOP MDL 5th Production	PUREX00011141	PUREX00011141
PUR1424	4/1/2015	PMP data for 4/1/2015 for BOP MDL 5th Production	PUREX00011142	PUREX00011142
PUR1425	7/1/2015	PMP data for 7/1/2015 for BOP MDL 5th Production	PUREX00011143	PUREX00011143
PUR1426	10/1/2015	PMP data for 10/1/2015	PUREX00011144	PUREX00011144
PUR1427	1/1/2016	PMP data for 1/1/2016	PUREX00011145	PUREX00011145
PUR1428	4/1/2016	PMP data for 4/1/2016	PUREX00011146	PUREX00011146
PUR1429	7/1/2016	PMP data for 7/1/2016	PUREX00011147	PUREX00011147
PUR1430	10/1/2016	PMP data for 10/1/2016	PUREX00011148	PUREX00011148
PUR1431	1/1/2017	PMP data for 1/1/2017	PUREX00011149	PUREX00011149
PUR1432	4/1/2017	PMP data for 4/1/2017	PUREX00011150	PUREX00011150
PUR1433	7/1/2017	PMP data for 7/1/2017	PUREX00011151	PUREX00011151
PUR1434	10/1/2017	PMP data for 10/1/2017	PUREX00011152	PUREX00011152
PUR1435	1/1/2018	PMP data for 1/1/2018	PUREX00011153	PUREX00011153
PUR1436	4/1/2018	PMP data for 4/1/2018	PUREX00011154	PUREX00011154
PUR1437	7/1/2018	PMP data for 7/1/2018	PUREX00011155	PUREX00011155
PUR1438	10/1/2018	PMP data for 10/1/2018	PUREX00011156	PUREX00011156
PUR1439	3/31/2017	1/1/2017-3/31/2017 PMP data narne_spec_clean_v10.sas7bdat	PUREX00011157	PUREX00011157
PUR1440	9/1/2017	CDC National Center for Injury Prevention and Control: CDC Oral Morphine Milligram Equivalents Data, Sept 2017	PUREX00011158	PUREX00011158
PUR1441	5/17/2019	Drugs@FDA: FDA Approved Drug Products: Hydrocodone NDA, New Drug Application NDA: 005213 Company: Genus Lifesciences	PUREX00011159	PUREX00011162
PUR1443	3/19/2019	DailyMed Label: IMPAX Generics New Drug Application Generic: OxyCodone Hydrochloride Tablet, Film Coated, Extended Release	PUREX00011163	PUREX00011224
PUR1444	4/26/2013	Pharmaceutical & Healthcare News from Purdue re: Purdue Announces Resolution of OxyContin Tablets CII Patent Lawsuit with Actavis, Inc.	PUREX00011225	PUREX00011226
PUR1445	12/2/2013	Pharmaceutical & Healthcare News from Purdue re: Purdue Announces Resolution of OxyContin Tablets CII Lawsuit with Impax Laboratories	PUREX00011227	PUREX00011228
PUR1447	4/1/2017	DailyMed: Teva Pharmaceuticals USA, Inc. Authorized Generic Label for oxycodone hydrochloride - oxycodone hydrochloride tablet, film coated, extended release	PUREX00011229	PUREX00011286
PUR1448	2/1/2005	Virabhak, S., et al.: Physicians' Prescribing Responses to a Restricted Formulary: The Impact of Medicaid Preferred Drug Lists in Illinois and LouisianaThe American Journal of Managed Care 11 Spec No(Spec No):SP14-20 · February 2005	PUREX00011287	PUREX00011294
PUR1449	1/1/2005	Wang, YR and Pualy, MV, Spillover Effects of Restrictive Drug Formularies on Physician Prescribing Behavior: Evidence from Medicaid, Journal of Economics & Management Strategy, 14;755-773	PUREX00011295	PUREX00011313

PUR1453	11/1/2011	Kalra, A. et al., Understanding Responses to Contradictory Information About Products, Marketing Science, Vol 30 (6), p 1098-1114, 2011	PUREX00011314	PUREX00011331
PUR1454	11/1/2004	Manchanda, P., et al.: Response Modeling with Nonrandom Marketing-Mix Variables, Journal of Marketing Research 46:478-478 (2004)	PUREX00011332	PUREX00011344
PUR1455	1/1/2003	Rector, T., et al.: Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medication, Medical Care, 41(3); 398-406 2003	PUREX00011345	PUREX00011353
PUR1456	8/1/2005	Narayanan, S., et al.: Temporal Differences in the Role of Marketing Communication in new Product Categories, Journal of Marketing Research, Vol. XLII; 278-290 (August 2005)	PUREX00011354	PUREX00011366
PUR1457	10/1/2010	Nair, H., et al.: Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders, Journal of Marketing Research Vol. XLVII; 883-895 (2010)	PUREX00011367	PUREX00011380
PUR1458	11/1/2007	Venkataraman, Sriram and Stremersch, Stefan, The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link? Management Science Vol. 53(11);1688-1701, 2007	PUREX00011381	PUREX00011395
PUR1459	6/1/2013	Xie, Ying et al., Treatment Effectiveness and Side Effects: A Model of Physician Learning, Management Science 59(6) 1309-1325, 2013	PUREX00011396	PUREX00011414
PUR1461	1/1/1999	Allenby, G. and Rossi, PE, Marketing Models of Consumer Heterogeneity, Journal of Econometrics 89:57-78, 1999	PUREX00011415	PUREX00011436
PUR1462	2/1/1990	Melzack, R.: The tragedy of needless pain. Scientific American, Vol. 262(2) (1990)	PUREX00011437	PUREX00011443
PUR1463	1/1/1982	Perry, S. and Heidrich, G., Management of Pain during Debridement: a Survey of U.S. Burn Units, Pain, 13 (1982) 267-280	PUREX00011444	PUREX00011457
PUR1466	11/1/1989	Art. 4495c Intractable Pain Treatment Act, Vernon's Ann. Texas Civ. St. Art. 4495c, Vernon's Texas Statutes and Codes Annotated, Civil Statutes, Title 71- Health - Public Chapter Six - Medicine	PUREX00011458	PUREX00011459
PUR1467	5/17/2019	Drugs@FDA: FDA Approved Drug Products Dolophine HCL Therapeutic Equivalents Chart	PUREX00011460	PUREX00011461
PUR1468	9/1/2018	Highlights of Prescribing Information: Dolophine Tablets Label (methadone hydrochloride), Full Prescribing Information and Medication Guide, Reference ID: 4320667, revised 9/2018	PUREX00011462	PUREX00011495
PUR1469	5/16/2019	Drugs@FDA: FDA Approved Drug Products, Fentanyl ER classification	PUREX00011496	PUREX00011499
PUR1470	5/16/2019	FDA List of Extended-Release and Long-Acting Opioid Products Required to Have an Opioid REMS	PUREX00011500	PUREX00011501
PUR1471	5/8/2015	FDA Extended-Release and Long-Acting Opioid Analgesics shared system Risk Evaluation and Mitigation Strategy (REMS)	PUREX00011502	PUREX00011505
PUR1472	5/16/2019	Drugs@FDA: FDA Approved Drug Products Report - Morphine Sulfate Classification May 16, 2019, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process	PUREX00011506	PUREX00011510
PUR1473	12/1/2016	Mylan Methadone HCL Injection prescribing information, revised 12/2016, Reference ID: 4028221	PUREX00011511	PUREX00011544
PUR1474	2/1/2018	Mallinckrodt Methadone HCL Powder prescribing information, Rev 2/2018, Reference ID: 4215172	PUREX00011545	PUREX00011577
PUR1475	2/1/2018	Highlights of Prescribing Information: West-Ward Methadone HCL Tablet for Suspension prescribing information, Revised: 2/2018, Reference ID: 4215342	PUREX00011578	PUREX00011605
PUR1476	4/1/2014	VistaPharm Methadone HCL Solution Full Prescribing Information, Revised April 2014, Reference ID: 3488686	PUREX00011606	PUREX00011629
PUR1477	4/4/2014	West-Ward Methadone HCL Solution Full Prescribing Information, revised April, 2014	PUREX00011630	PUREX00011631
PUR1478	5/18/2019	Drugs@FDA: FDA Approved Drug Products, West-Ward Pharms, Abrevauated Abbreviated New Drug Application: Methadone Hydrochloride Intensol; Methadone HCL Therapeutic Equivalents, ANDA: 089897	PUREX00011632	PUREX00011633
PUR1479	12/30/2008	Purdue Pharma Ryzolt (tramadol hydrochloride extended-release tablets) Information Label, 12/30/2008	PUREX00011634	PUREX00011655
PUR1480	5/17/2019	Drugs@FDA: FDA Approved Drug Products West-Ward Methadone HCL Tablet Therapeutic Equivalents	PUREX00011656	PUREX00011657
PUR1481	6/10/2003	Center For Drug Evaluation and Research Approval Package for Application Number: 18-401/S-015; Buprenex (buprenorphine), Reckitt Benkiser Pharmaceuticals, Inc., June 10, 2003	PUREX00011658	PUREX00011679
PUR1482	11/20/2018	Letter from Vincent Sansone, FDA to Watson Laboratories Inc re FDA ANDA 204937 Approval Letter, Buprenorphine Hydrochloride Patch Transdermal System, 11/20/2018	PUREX00011680	PUREX00011685
PUR1483	10/1/2018	Highlights of Prescribing Information Hikma Pharmaceuticals Buprenorphine Hydrochloride Sublingual Tablet , Full Prescribing Information , revised 10/2018	PUREX00011686	PUREX00011719
PUR1484	1/1/2018	Highlights of Prescribing Information and Full Prescribing Information for Buprenorphine Naloxone Sublingual Tablets, revised 09/2017 and 01/2018 Reference ID: 4276171	PUREX00011720	PUREX00011755
PUR1485	5/30/2019	Department of Justice, Diversion Control Division Advisory - Methadone Hydrochloride Tablets 40 mg (Dispersible)	PUREX00011756	PUREX00011757
PUR1486	2/1/2018	Highlights of Prescribing Information - Full Prescribing Information for Methadone Hydrochloride_Disket, Dispersible Tablet, Tablet for Suspension, revised 02/2018 Reference ID: 4215342	PUREX00011758	PUREX00011785
PUR1487	2/12/2004	Center For Drug Evaluation And Research Approval Package for: Dolophine Hydrochloride (Methadone Hydrochloride Injectable)	PUREX00011786	PUREX00011863
PUR1488	4/1/2014	Floxane Laboratories Medication Guide - Methadone Hydrochloride Oral Solution, revised April 2014	PUREX00011864	PUREX00011865

PUR1489	4/16/1998	ANDA Letter to Eon Labs Manufacturing for Methadone Hydrochloride Tablets, USP 5 mg and 10 mg. (1998)	PUREX00011866	PUREX00011867
PUR1490	4/1/2014	Roxane Laboratories Medication Guide for Methadone Hydrochloride Tablets, Oral Solution, Oral Concentrate, revised April 2014	PUREX00011868	PUREX00011870
PUR1491	2/1/2018	Mallinckrodt Pharmaceuticals presentation: Methadose Oral Concentrate and Methadose Sugar-Free Oral Concentrate Reference ID: 4215175	PUREX00011871	PUREX00011902
PUR1492	5/16/2019	FDA List of Extended Release and Long-Acting Opioid Products Required to Have an Opioid REMS, 5/16/2019, https://www.fda.gov/drugs/information-drug-class/list-extended-release-and-long-acting-opioid-products-required-have-opioid-rems	PUREX00011903	PUREX00011904
PUR1493	5/8/2015	FDA List of Extended - Release and Long-Acting Opioids Analgesics shared system Risk Evaluation and Mitigation Strategy (REMS)	PUREX00011905	PUREX00011908
PUR1494	12/1/2018	FDA Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse	PUREX00011909	PUREX00011944
PUR1496	4/26/2013	Pharmaceutical & Healthcare News from Purdue Pharma L.P., Purdue Pharma L.P. Announces Resolution of OxyContin (oxycodone HCL controlled-release) Tablets CII Patent Lawsuit with Actavis, Inc., 4/26/2013	PUREX00012024	PUREX00012025
PUR1498	9/2/2008	Pharmaceutical & Healthcare News from Purdue Pharma L.P., Purdue Pharma L.P. Announces Resolution of OxyContin (oxycodone HCL controlled-release) Tablets CII Patent Lawsuit with Mallinckrodt Inc., 9/2/2008	PUREX00012028	PUREX00012028
PUR1499	11/21/2018	U.S. Marshals: Cuyahoga County deprives inmates of food, water and Constitutional Rights amid string of seven deaths, Cleveland.com	PUREX00012029	PUREX00012034
PUR1500	1/14/2019	Cuyahoga County law director resigns, Cleveland.com	PUREX00012035	PUREX00012038
PUR1501	1/18/2019	3 Cuyahoga County officials indicted in corruption probe, www.cleveland19.com	PUREX00012039	PUREX00012046
PUR1502	1/18/2019	Three Cuyahoga County administrators indicted in corruption probe, www.cleveland.com	PUREX00012047	PUREX00012055
PUR1503	2/15/2019	Warrant shows search of Cuyahoga County Executive Armond Budish's office related to troubled jail operations, cites possible extortion, www.cleveland.com	PUREX00012056	PUREX00012062
PUR1504	2/28/2019	Who's who of Cuyahoga County investigation, www.cleveland.com	PUREX00012063	PUREX00012068
PUR1505	12/19/2017	DailyMed News, Announcements for December 19, 2017	PUREX00012069	PUREX00012070
PUR1506	5/30/2019	Drugs@FDA: FDA Approved Drug Products Home Page	PUREX00012071	PUREX00012073
PUR1507	5/30/2019	RxList - The Internet Drug Index for Prescription Drug Information, Interactions and Side Effects (landing page)	PUREX00012074	PUREX00012078
PUR1508	5/30/2019	WebMD landing page	PUREX00012079	PUREX00012084
PUR1510	1/1/2019	OxyContin Butrans and Hysingla Annual Patient Counts OH MA and RI highlighted for OH	PUREX00012085	PUREX00012085
PUR1511	1/1/2015	2015 Ohio Rx Reporting System report	PUREX00012086	PUREX00012094
PUR1512	1/1/2016	2016 Ohio Rx Reporting System Report	PUREX00012095	PUREX00012108
PUR1513	5/12/2011	Ohio Legislative Service Commission Report: Bill Analysis for Sub. H.B. 93, Ohio 129th General Assembly	PUREX00012109	PUREX00012132
PUR1514	11/21/2011	Ohio State Board of Pharmacy Report: Ohio's Dangerous Drug Database Past, Present, and Future House Bill 93 Report	PUREX00012133	PUREX00012143
PUR1515	1/1/2014	Am. Sub. H.B. No. 341, 2014 Ohio 130th General Assembly	PUREX00012144	PUREX00012161
PUR1516	4/24/2019	CDC Newsroom Media Statement; CDC Advises Against Misapplication of the Guideline For Prescribing Opioids For Chronic Pain Some policies, practices attributed to the Guideline are inconsistent with its recommendations	PUREX00012162	PUREX00012163
PUR1517	1/1/2016	Excel Attachment, Ohio County, Level Direct Model of Prescription Opioid Shipments	PUREX00012164	PUREX00012164
PUR1518	1/1/2018	Excel Attachment, Purdue Sales Representatives who made calls in Ohio Flagged by Doctor Kessler, 1995- 2018	PUREX00012165	PUREX00012165
PUR1519	1/1/2018	Excel attachment Share of Prescription Drug Monitoring Program Opioid Patients who filled a Purdue Opioid Prescription, Cuyahoga and Summit Counties 2012- 2018	PUREX00012166	PUREX00012166
PUR1520	1/1/2018	Excel attachment, Plaintiff County Prescribes in the National Decile of Purdue Prescriptions, Exhibit 7, 1997-2018	PUREX00012167	PUREX00012167
PUR1521	1/1/2018	Excel Attachments, Exhibit 3-4, All Purdue Products Share of Opioid Prescriptions in Ohio and Plaintiff Counties, 1997- 2018	PUREX00012168	PUREX00012168
PUR1522	1/1/2018	Excel Attachment, Exhibits 5-6, 8-9., Number of Prescribes from Cuyahoga County in each national Prescribing decile, 1997- 2018	PUREX00012169	PUREX00012169
PUR1524	5/31/2019	Code for statistical analysis	PUREX00012171	PUREX00012172
PUR1525	5/31/2019	Production Instructions	PUREX00012173	PUREX00012174
PUR1526	5/30/2019	Code to calculate stats in FN 6 that rely on Allergan IQVIA data	PUREX00012175	PUREX00012175
PUR1527	5/30/2019	fn-69a.R (calculate stats in FN 69 that rely on Allergan IQVIA data)	PUREX00012176	PUREX00012176
PUR1528	5/30/2019	fn-69b.R (calculate OxyContin episode distribution based on Bellwether claims)	PUREX00012177	PUREX00012179
PUR1529	5/31/2019	County Quarter Direct Model	PUREX00012180	PUREX00012180
PUR1530	5/30/2019	County Year Direct Model	PUREX00012181	PUREX00012181
PUR1531	5/30/2019	exhibit 1, Call-notes-analysis	PUREX00012182	PUREX00012182
PUR1532	5/31/2019	Excel attachment, pdmp patient-share	PUREX00012183	PUREX00012183
PUR1533	5/31/2019	Excel Attachment, exhibits-3-4, Purdue Oxy shares	PUREX00012184	PUREX00012187
PUR1534	5/31/2019	Excel attachment, exhibits 5-6, All Opioids panel	PUREX00012188	PUREX00012190
PUR1535	5/31/2019	Excel Attachment, Exhibits-5 and 9, Purdue Panel.	PUREX00012191	PUREX00012199
PUR1536	5/30/2019	paragraph-3-claims-opioid-naive.R	PUREX00012200	PUREX00012204
PUR1537	5/31/2019	Ohio Purdue Call Notes Data analysis	PUREX00012205	PUREX00012205
PUR1538	5/31/2019	IQVIA national data	PUREX00012206	PUREX00012206

PUR1539	5/31/2019	IQVIA specialties	PUREX00012207	PUREX00012207
PUR1540	5/30/2019	Rosenthal direct model data analysis	PUREX00012208	PUREX00012208
PUR1541	5/29/2019	Allergan Iqvia Rx Data	PUREX00012209	PUREX00012209
PUR1542	5/30/2019	Allergan Iqvia Specialties.Rx data	PUREX00012210	PUREX00012210
PUR1543	5/30/2019	Bellwether county manual mapping	PUREX00012211	PUREX00012211
PUR1544	5/31/2019	Call Notes Data analysis	PUREX00012212	PUREX00012213
PUR1545	5/31/2019	Import Cutler zip code - County mapping Data	PUREX00012214	PUREX00012214
PUR1546	5/31/2019	pdmp.R	PUREX00012215	PUREX00012215
PUR1547	5/29/2019	pg-nfr-crosswalk.R	PUREX00012216	PUREX00012216
PUR1550	12/1/2001	Section II: Assessment of Pain, National Pharmaceutical Council, Pain: Current Understanding of Assessment, Management, and Treatments, pp. 20-29, (2001)	PUREX00012217	PUREX00012226
PUR1552	6/3/2015	AAMC. 2014 Physician Specialty databook, updated 6/3/2015	PUREX00012227	PUREX00012268
PUR1553	5/1/2006	Adams EH, et al., A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain, Journal of Pain & Symptom Management, Vol. 31, pp. 465-476 (May 2006)	PUREX00012269	PUREX00012280
PUR1555	10/1/2011	Primary Care Workforce Facts and Stats No 1: The Number of Practicing Primary Care Physicians in the United States; Agency for Healthcare Research and Quality Prevention and Chronic Care Program, October 2011	PUREX00012281	PUREX00012282
PUR1556	1/1/2005	Allan, Laurie, et al., Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain, Spine, Vol 30, 22, 2484-90, 2005	PUREX00012283	PUREX00012289
PUR1557	1/1/2017	Alpert et al. Supply-Side Drug Policy in the Presence of Substitutes: evidence from abuse-deterrent opioids, Rand Bing Center for Health Economics, Jan 2017	PUREX00012290	PUREX00012349
PUR1558	8/1/2005	Altier, Nadege, et al., Management of chronic neuropathic pain with methadone: A review of 13 cases, Clin Pain, Vol 21, 4, 364-69, 2005	PUREX00012350	PUREX00012355
PUR1559	1/1/2010	Atli, Aysel, et al., Intrathecal opioid therapy for chronic nonmalignant pain: A retrospective cohort study with 3-year follow-up, Pain Medicine 2010, Vol 11, 1010-16, 2010	PUREX00012356	PUREX00012362
PUR1560	1/1/1997	Am. Academy Pain Med. & Am. Pain Society consensus statement, The use of opioids for the treatment of chronic pain, The Clinical Journal of Pain, Lippincott-Raven Publisher, 13(1):6-8, 1997	PUREX00012363	PUREX00012365
PUR1561	11/13/2018	AMA Delegates Back Physician Freedom in Opioid Prescribing - CDC guidelines are well-intentioned but shouldn't restrict prescribing, they say, MEDPAGE Today, available at https://www.medpagetoday.com/meetingcoverage/ama/6322	PUREX00012366	PUREX00012368
PUR1562	11/13/2018	AMA, Report of Reference Committee, Resolution 235 - Inappropriate Use of CDC Guidelines for Prescribing	PUREX00012369	PUREX00012408
PUR1563	2/1/1999	Anderson, VC and Burchiel, KJ, A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain, Neurosurgery, Vol 44, 2, 289-301, 1999	PUREX00012409	PUREX00012422
PUR1564	1/1/1998	Angel, Ian F., et al., Intrathecal morphine pump as a treatment option in chronic pain of nonmalignant origin, Surg Neurol, Vol 49, 92-99, 1998	PUREX00012423	PUREX00012430
PUR1565	7/1/2004	BABUL et al., Efficacy and safety of extended-release, once-daily tramadol in chronic pain-Journal of Pain and Symptom Management, Vol.28, 2004	PUREX00012431	PUREX00012443
PUR1566	3/21/2017	Baker D, History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic, JAMA, Vol. 317, pp. 117-118, March 21, 2017	PUREX00012444	PUREX00012445
PUR1567	3/10/1979	Behar M, et al., Epidural Morphine in Treatment of Pain, The Lancet, pp. 527-529 (March 10, 1979)	PUREX00012446	PUREX00012448
PUR1568	1/1/2012	BRADEN-Predictors of change in pain and physical functioning among post-menopausal women, Amer. Pain Society, Vol. 13, 2012	PUREX00012449	PUREX00012457
PUR1569	7/1/2007	Brennan et al., Pain Management - A Fundamental Human Right, Int. Anaesthesia Research Society, Vol. 105, 2007	PUREX00012458	PUREX00012474
PUR1570	12/1/1993	Brookoff, Abuse Potential of Various Opioid Medications, Journal of General Medicine, Vol. 8:688-690, 1993	PUREX00012475	PUREX00012477
PUR1571	4/4/2002	Caldwell, J. et al, Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to Severe Osteoarthritis Pain: Results from a Randomized, Placebo-Controlled, Double-Blind Trail and Open-Label Extension Trial, Journal of Pain and Symptom Management, Vol 23, No. 4, pp. 278-291, April 2002	PUREX00012478	PUREX00012491
PUR1572	11/1/2014	Medical Board of California - Guidelines for Prescribing Controlled Substances for Pain	PUREX00012492	PUREX00012581
PUR1573	11/1/2007	Carise, D., et al, Prescription OxyContin Abuse Among Patients Entering Addiction Treatment, Am J Psychiatry, Vol. 164, No. 11, pp. 1750-1756, November 2007	PUREX00012582	PUREX00012588
PUR1574	11/1/2017	Cassidy T et al, Abuse of Reformulated OxyContin: Updated Findings from a Sentinel Surveillance Sample of Individuals Assessed for Substance Use Disorder, Journal of Opioid Management, Vol. 13, No. 6, pp. 425-440, November/ December 2017	PUREX00012589	PUREX00012606
PUR1576	6/1/1997	Chabal C, et al., Prescription Opiate Abuse in Chronic Pain Patients: Clinical Criteria, Incidence, and Predictors, The Clinical Journal of Pain, Vol. 13, pp. 150-155 (June 1997)	PUREX00012607	PUREX00012613
PUR1577	1/1/2005	Chao J, Retrospective Analysis of Kadian (Morphine Sulfate SustainedRelease Capsules) in Patients with Chronic, Nonmalignant Pain, PAIN MEDICINE Vol 6, No 3, 2005	PUREX00012614	PUREX00012617

PUR1578	4/1/2014	Chaparro LE; Opioids Compared With Placebo or Other Treatments for Chronic Low Back Pain: An Update of the Cochrane Review; SPINE Vol 39, No 7, pp 556-563; 2014	PUREX00012618	PUREX00012625
PUR1579	2/1/2009	Chou R et al; Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain; The Journal of Pain, Vol 10, No 2 , pp. 113-130; February 2009	PUREX00012626	PUREX00012665
PUR1580	2/17/2015	Chou R et al; The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop; Annals of Internal Medicine, Vol 162, No. 4, pp. 276-295; Feb 2015.	PUREX00012666	PUREX00012685
PUR1581	11/16/2017	Cicero TJ and Ellis MS; Prescription Opioid Epidemic: a review of qualitative studies on the progression from initial use to abuse; Dialogues in Clinical Neuroscience; Vol 19, No. 3, pp. 259-270; 2017	PUREX00012686	PUREX00012697
PUR1582	1/1/2007	Cicero (2007) Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban , and urban locations in the US	PUREX00012698	PUREX00012711
PUR1583; PUR4959	5/28/2014	Cicero (2014) The Changing Face of Heroin Use in the United States; A Retrospective Analysis of the Past 50 Years	PUREX00012712	PUREX00012717
PUR1584; PUR4999	5/31/2018	Cicero et al. Increased use of heroin as an initiating opioid of abuse. Addictive Behaviors, 87:267-271, May 2018	PUREX00012718	PUREX00012722
PUR1585	8/1/2017	Cicero et al. Increases-in-self-reported-fentanyl-use-among-a-population-entering-drug treatment. Aug 2017	PUREX00012723	PUREX00012725
PUR1586	1/26/2009	CICERO-Co-morbidity and utilization of medical services by pain patients-2009	PUREX00012726	PUREX00012733
PUR1588	11/1/2010	Clark, MR & Galati, SA, Opioids and Psychological Issues, European Journal of Pain Supplements, Vol 4:4, pp. 261-267	PUREX00012738	PUREX00012745
PUR1589	4/27/2016	Cleveland Clinic, Non-Steroidal Anti-Inflammatory Medicines (NSAIDs), NSAIDS: What You Need to Know, https://my.clevelandclinic.org/health/drugs/11086-non-steroidal-anti-inflammatory-medicines , 4/27/2016	PUREX00012746	PUREX00012756
PUR1590	6/12/2018	Collins et al.: Helping to end addiction over the long-term; JAMA	PUREX00012757	PUREX00012758
PUR1591	7/1/2007	Crocq; Historical and cultural aspects of man's relationship with addictive drugs, Dialogues in Clinical Neuroscience, Vol 9, No. 4, 355-361, 2007	PUREX00012759	PUREX00012765
PUR1592	9/14/2018	James Dahlhamer: Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults; MMWE, 67:1001-1006, 2018	PUREX00012766	PUREX00012771
PUR1593	1/15/2015	Dart et al. (2015) Trends in Opioid Analgesic Abuse-NEJM	PUREX00012772	PUREX00012779
PUR1596	12/1/2014	Dasgupta et al., Observed transition from opioid analgesic deaths toward heroin, Drug and Alcohol Dependence, Vol. 145, pp. 238-241, Dec. 2014	PUREX00012780	PUREX00012784
PUR1597	1/22/1957	Annotated Report to the Committee on Drug Addiction and Narcotics, Minutes of the 18th Meeting (Jan. 21-22, 1957) - Appendix N: Annual Report on Studies in the Monkey (Macaca Mulatta) Designed to Determine the Value of this Animal for Predicting Addiction Liability to the Newer Synthetic Analgesics	PUREX00012785	PUREX00012792
PUR1598	1/1/1987	Donovan, Marilee, et al., Incidence and characteristics of pain in a sample of medical-surgical inpatients, Rush University and Joliet Junior College, Pain, 30(1987) pp 69-79	PUREX00012793	PUREX00012802
PUR1599	5/1/1983	Donovan BD, Patient Attitudes to Postoperative Pain Relief, Anaesth Intens Care, Vol 11, pp 125-129 (May 1983)	PUREX00012803	PUREX00012807
PUR1600	4/25/2019	Dowell et al. (CDC) No shortcuts to safer opioid prescribing. 04-24-2019	PUREX00012808	PUREX00012810
PUR1601	8/24/1973	DuPont & Greene. Dynamics of a Heroin Addiction Epidemic, Science, 181: 716-722	PUREX00012811	PUREX00012818
PUR1602	1/1/1957	Eddy, NB et. al., Synthetic Substances with Morphine-like Effect, Bulletin of World Health Organization (1957), pp. 567-836	PUREX00012819	PUREX00012968
PUR1603	1/1/1957	Eddy, NB et. al., Synthetic Substances with Morphine-like Effect, Bulletin of World Health Organization (1957), pp. 567-836 (Part 2)	PUREX00012969	PUREX00013113
PUR1604	3/1/2007	Edlund, MJ, et al., Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain, Pain, Vol. 129, pp. 355-362 (2007)	PUREX00013114	PUREX00013121
PUR1605	11/1/2018	Eid et al. Variation of Opioid Prescribing Patterns among Patients undergoing Similar Surgery on the Same Acute Care Surgery Service. Surgery 164:926-930, Nov 2018.	PUREX00013122	PUREX00013126
PUR1606	1/1/2003	Elander J, et al., Pain management and symptoms of substance dependence among patients with sickle cell disease, Social Science & Medicine, Vol. 57, pp. 1683-1696 (2003)	PUREX00013127	PUREX00013140
PUR1607	2/1/2004	Elander J, et al., Understanding the Causes of Problematic Pain Management in Sickle Cell Disease: Evidence That Pseudoaddiction Plays a More Important Role Than Genuine Analgesic Dependence, Journal of Pain & Symptom Management, Vol. 27, pp. 156-169 (Feb. 2004)	PUREX00013141	PUREX00013154
PUR1608	2/14/2018	Abstract: William Evans ,Feb 2018, How the Reformulation of OxyContin Ignited the Heroin Epidemic; JEL: I12, I18, K42	PUREX00013155	PUREX00013204
PUR1609	12/8/1995	FDA communications & material re: oxycodone IR capsules (1995); FDA FOIA Response - May 1994 imbedded document pp 2-30/37	PUREX00013205	PUREX00013241
PUR1610	5/4/2018	Fendrich & Becker; Prior prescription opioid use in cohort of heroin users; Elsevier, 8:8-10 May 2018.	PUREX00013242	PUREX00013244
PUR1611	6/1/1993	Michael Ferrante; Opioids - Postoperative Pain Management; Churchill Livingstone, pp 145- 209, 1993	PUREX00013245	PUREX00013311
PUR1612	11/17/1989	The Medical Letter: Patient-Controlled Analgesia. Vol. 31(805);p. 104.	PUREX00013312	PUREX00013313

PUR1613	5/1/1988	Ferrante FM, et al., A Statistical Model for Pain in Patient-Controlled Analgesia and Conventional Intramuscular Opioid Regimens, Anesth Analg., 1988 May; 67(5): pp. 457-61.	PUREX00013314	PUREX00013318
PUR1614	9/1/2003	Ferrante FM-The Pharmacologic Management of Neuropathic Pain-2003.	PUREX00013319	PUREX00013325
PUR1615	11/1/1996	Ferrante, Review of "Interventional PAin Managment" by S.D. Waldman and A.P. Winnie. Anesth ANALG 1996;83: 1136-8	PUREX00013326	PUREX00013328
PUR1616	4/1/2001	Ferrante review of Practical Managment of Pain, 3rd Edition by P. Prithvi Raj, MD. Regional Anesthesia and Pain Medicine Vol. 26 No. 2 March-April 2001.	PUREX00013329	PUREX00013331
PUR1617	1/1/1989	Review of Pain (1987) by Howard L. Fields by Arthur Asbury, Copyright 1989 by the American Neurological Association	PUREX00013332	PUREX00013332
PUR1618	7/1/2011	Fine, PG, Long-Term Consequences of Chronic Pain Mounting Evidence for Pain as a Neurological Disease and Parallels with Other Chronic Disease States, Pain Medicine 2011, pp. 996-1004	PUREX00013333	PUREX00013341
PUR1619	1/1/1979	Foley, KF, Pain Syndromes in Patients with Cancer, Advances in Pain Research and Therapy, Vol. 2, pp. 59-75	PUREX00013342	PUREX00013359
PUR1620	1/1/1979	Foley, KF, The Management of Pain of Malignant Origin, Current Neurology, Vol. 2, pp. 279-302	PUREX00013360	PUREX00013385
PUR1621	7/11/1985	Foley, KF, The Treatment of Cancer Pain, New England Journal of Medicine, Vol. 313, pp. 84-95	PUREX00013386	PUREX00013397
PUR1623	2/13/2015	FSMB Pain Management Policies, Board-by-Board Review	PUREX00013398	PUREX00013410
PUR1624	10/17/2011	Furlan, AD, et. al., A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain, Pain Res Manage, Vol. 16, No. 5, pp. 337-351	PUREX00013411	PUREX00013425
PUR1625	6/1/2010	A. Gatti et al, Transdermal buprenorphine in non-oncological Moderate-to-Severe Chronic Pain, Clin. Drug Invesig. 2010; 30 Suppl. 2: 31-38.	PUREX00013426	PUREX00013434
PUR1626	3/1/2008	Geller, AK, Commentary: The Sickle Cell Crisis: A Dilemma in Pain Relief, <ay>J Clin Proc., March 2008;83(3): 320-323.	PUREX00013435	PUREX00013438
PUR1627	4/21/2010	GORDON, et al., Buprenorphine transdermal system in adults with chronic low back pain, Clinical Therapeutics, Vol. 32, Number 5, 2010.	PUREX00013439	PUREX00013455
PUR1628	3/1/2005	Gourlay, et al., Commentary: Universal Precautions in Pain Medicine, Pain Medicine Vol. 6, Number 2, 2005; pp. 107-112	PUREX00013456	PUREX00013461
PUR1629	8/1/2012	GRATTAN-Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substances abuse, Ann Fam Med 2012; 10; 304-311.	PUREX00013462	PUREX00013469
PUR1630; PUR491	10/1/2015	Greene & Chambers. Pseudoaddiction - Fact or Fiction, Curr Addict Rep. 2015; 2(4): 310-317.	PUREX00013470	PUREX00013477
PUR1631	5/1/1991	Grichnik - The difference between acute and chronic pain, The Mount Sinai Journal of Medicine Vol 58, No 3, May 1991.	PUREX00013478	PUREX00013481
PUR1633	4/1/1997	Hagen & Babul (1997) Comparative clinical efficacy and safety, Cancer, April 1, 1997 Volume 79, Number 7.	PUREX00013482	PUREX00013491
PUR1634	6/1/2009	HAILE-The Potential of Pharmacogenomics to treat drug addiction, Pharmacogenomics (2009)10 (12), 1883-1886.	PUREX00013492	PUREX00013495
PUR1635	9/1/1999	Hale et al. (1999) Efficacy and safety of controlled-release versus immediate-release oxycodone, Clincial Journal of Pain, Volume 15, Number 3, September 1999.	PUREX00013496	PUREX00013503
PUR1637	4/23/2010	M Hale, A. Khan, M. Kutch, S. Li; Once-daily OROS hydromophone ER compared with placebo in opioid-tolerant patients with chronic low back pain; CMRO; Vol. 26 No. 6, 1505-1516, 2010	PUREX00013504	PUREX00013517
PUR1639	8/7/2018	Han et al. Correlates of Prescription Opioid Use, Misuse, Use Disorders and Motivations for Misuse Among US Adults, J. Clin Psychiatry 2018; 79 (5).	PUREX00013518	PUREX00013528
PUR1640	8/1/2017	Han et al.; Prescription Opioid Use, Misuse and Use Disorders in U.S.Adults; NSDUH; Vol 167 No. 5; Sept. 2017	PUREX00013529	PUREX00013539
PUR1642	5/10/2016	Alex Harocopoulos and Bennett Allen; Routes Into Opioid Analgesic Misuse; Journal of Drug Issues, Vol. 45(4) 385-395, 2015	PUREX00013540	PUREX00013550
PUR1644	12/11/2018	Hedegaard (CDC). Drugs Most Frequently Involved in Drug Overdose Deaths, 2011-2016; Volume 67, No. 9; 2018	PUREX00013551	PUREX00013564
PUR1645	6/1/1997	Tarja Heiskanen and Eija Kalso; Controlled-release oxycodone and morphine in cancer related pain; Pain 73, 37-45, 1997	PUREX00013565	PUREX00013573
PUR1646; PUR5018	4/21/2018	C Higgins, B.H. smith, and k. Matthews, Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. BJA, 120(6): 1335-1344, 2018	PUREX00013574	PUREX00013583
PUR1647	7/1/1994	Laura S. Hitchcock et al.; The Experience of Chronic Nonmalignant Pain; Journal of Pain and symptom Management; Vol 9 No. 5; 1994	PUREX00013584	PUREX00013590
PUR1648	1/1/1974	John J. Bonica; International Symposium on Pain; Raven Press, Vol. 4; 1974	PUREX00013591	PUREX00013604
PUR1649	2/1/2015	Kelly L. Huffman et al.; Nonopiod substance use disorders & opioid dose predict therapeutic opioid addiction; American Pain Society, vol. 16 Np. 2 pp 126-134; 2015	PUREX00013605	PUREX00013613
PUR1650	1/1/1975	John Hughes; Isolation of an endogenous compound from the brain with pharmacological; Brain Research, 88 295-308; 1975	PUREX00013614	PUREX00013627
PUR1651	1/1/1972	Patrick Hughes et al.; The natural histroy of a heroin epidemic, Vol. 62, No. 7; 1972	PUREX00013628	PUREX00013634
PUR1652	1/1/2001	Ellena Huse et al.; he effect of opioids on phantom limb pain and cortical reorganization; ELSEViER Pain 90 47-55; 2001	PUREX00013635	PUREX00013643
PUR1653	1/1/2011	IASP (2011) Declaration of Montreal Declaration that Access to Pain Management is a Fundamental Human Right	PUREX00013644	PUREX00013646

PUR1655; PUR4956	9/20/2018	Jalal et al. Changing dynamics of the drug overdose epidemic 1979-2016	PUREX00013647	PUREX00013654
PUR1656	1/1/1993	Jamison 1993. Clinical measurement of pain	PUREX00013655	PUREX00013670
PUR1657	4/15/1994	Jamison-Survey of opioid use in chronic non-malignant cancer pain. 1994	PUREX00013671	PUREX00013676
PUR1658	12/9/2010	Jones 2010. Neonatal abstinence syndrome after methadone or buprenorphine	PUREX00013677	PUREX00013688
PUR1659	5/1/2017	Jones et al. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. Clin J Pain. 2017 May;33(5):452-461.	PUREX00013689	PUREX00013698
PUR1660	8/14/2013	Jones. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers.	PUREX00013699	PUREX00013704
PUR1661	1/1/1993	Katz 1993. Nociception - Part 1	PUREX00013705	PUREX00013749
PUR1662	1/1/1993	Katz 1993. Nociception - Part 2	PUREX00013750	PUREX00013757
PUR1663	1/1/2007	Journal of Substance Abuse Treatment:-A Stepped Care for reducing cannabis use in opioid-dependent outpatients	PUREX00013758	PUREX00013764
PUR1664	8/1/2014	Kocherlakota 2014. Neonatal abstinence syndrome	PUREX00013765	PUREX00013781
PUR1665	1/1/2000	KUMAR-Surg Neurol: Continuous intrathecal morphine treatment for chronic pain- 2001	PUREX00013782	PUREX00013789
PUR1666	6/1/2018	Ladapo et al. Physician_Prescribing_of_Opioids_to_Patients_at_Increased_Risk_of_Overdose_Fro_m_Benzodiazepine_Use_in_the_US. Jun 2018	PUREX00013790	PUREX00013797
PUR1667; PUR4991	11/29/2011	Lankenau et al. International Journal of Drug Policy: Initiation into prescription opioid misuse amongst young injection drug users.	PUREX00013798	PUREX00013805
PUR1668	8/11/2014	Layout et al. Drug Saf: Indicators of drug-seeking aberrant behaviours: The feasibility of use in observational post-marketing cohort studies for risk management	PUREX00013806	PUREX00013817
PUR1669	6/1/1993	LEOW. Determination of the serum protein binding of oxycodone.	PUREX00013818	PUREX00013825
PUR1670	8/29/2018	Lin et al. (2018) Prescription Drug Coverage for Treatment of Low Back Pain - Supp Mat	PUREX00013826	PUREX00013840
PUR1671	6/22/2018	Lin et al. Prescription Drug Coverage for Treatment of Low Back Pain among US insurers	PUREX00013841	PUREX00013853
PUR1673	2/6/1915	David Macht, The history of opium and some of its preparations and alkaloids, The Journal of the American Medical Association VOL LXIV, No. 6 (February 6, 1915)	PUREX00013854	PUREX00013858
PUR1674	1/1/2015	Mackesy-Amiti: Prescription opioid misuse and mental health among young injection drug users, 2015	PUREX00013859	PUREX00013866
PUR1678; PUR4963	9/3/2010	Manchikanti MD, et al., Therapeutic Use, Abuse, and Nonmedical Use of Opioids: A Ten-Year Perspective, Pain Physician Journal 2010, 13, 401-435	PUREX00013875	PUREX00013910
PUR1679	7/1/2012	Manchikanti L1, Helm S 2nd, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV., Opioid epidemic in the United States. Pain Physician. 2012 Jul;15(3 Suppl):ES9-38.	PUREX00013911	PUREX00013940
PUR1680	3/1/2011	Manchikanti et al: A Systematic Review of Randomized Trials of Long-Term Opioid Management for Chronic Non-Cancer Pain; Pain Physicians, March/ April 2011	PUREX00013941	PUREX00013972
PUR1681	7/1/2018	Manchikanti L, Sanapati J, Benyamin RM, Atluri S, Kaye AD, Hirsch JA. Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic. Pain Physician. 2018 Jul;21(4):309-326.	PUREX00013973	PUREX00013990
PUR1685	11/9/1996	Mandema, J.W. et al. (1996) Characterization and validation of a pharmacokinetic model for controlled-release oxycodone, Br J Clin Pharmacol 1996, 42: 747-756.	PUREX00013997	PUREX00014006
PUR1686	9/26/2018	Markman et al. Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone, J Pain Res. 2018; 11: 2051-2059.	PUREX00014007	PUREX00014015
PUR1688	10/19/2013	Mars et al. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting., Int J Drug Policy. 2014 Mar;25(2):257-66. doi: 10.1016/j.drugpo.2013.10.004. Epub 2013 Oct 19.	PUREX00014016	PUREX00014025
PUR1689	1/16/2007	Martell BA, Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007 Jan 16;146(2):116-27.	PUREX00014026	PUREX00014042
PUR1691	2/11/1966	Martin, W.R. et al. (1996), "Dependence Assessment Studies of Narcotic Analgesics," Committee on Problems of Drug Dependence.	PUREX00014071	PUREX00014085
PUR1692	7/13/2011	Martin et al. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011 Dec;26(12):1450-7.	PUREX00014086	PUREX00014093
PUR1693	7/1/1966	MARTIN, W.R. et al., An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther. 1966 Jul-Aug; 7(4): 455-65.	PUREX00014094	PUREX00014105
PUR1695	4/1/1979	Maruta, T. et al., Drug Abuse and Dependency in Patients with Chronic Pain, Mayo Clin Proc. 1979 Apr; 54(4): 241-244.	PUREX00014106	PUREX00014110
PUR1696	12/24/1971	Mayer, D. et al., Analgesia from Electrical Stimulation in the Brainstem of the Rat, Science. 1971 Dec 24; Vol. 174 (1971): 1351-4.	PUREX00014111	PUREX00014114
PUR1698	12/1/2013	McCarberg; NSAIDs in the Older Patient: Balancing Benefits and Harms, Pain Med. 2013 Dec;14 Suppl 1:S43-4. doi: 10.1111/pme.12253	PUREX00014115	PUREX00014116
PUR1700	4/18/2015	Meiman et al., Trends and characteristics of heroin overdoses in Wisconsin, 2003-2012. Drug Alcohol Depend. 2015 Jul 1;152:177-84. doi: 10.1016/j.drugalcdep.2015.04.002. Epub 2015 Apr 18.	PUREX00014117	PUREX00014124
PUR1701	11/12/2003	Meldrum, M.L., A capsule history of pain management. JAMA 2003 Nov 12;290(18):2470-5.	PUREX00014125	PUREX00014130
PUR1702	11/19/1965	Melznick, R and Wall, P.D., Pain Mechanisms: A New Theory, Science, Vol. 150, No 3699, pp. 971-979.	PUREX00014131	PUREX00014139

PUR1703	6/29/2012	Merrill JO, Von Korff M, Banta-Green CJ, et al. Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. <i>Gen Hosp Psychiatry.</i> 2012;34(6):581–587. doi:10.1016/j.genhosppsych.2012.06.018	PUREX00014140	PUREX00014146
PUR1704	1/1/1994	Merskey, H. 1994. CLASSIFICATION OF CHRONIC PAIN: DESCRIPTIONS OF CHRONIC PAIN SYNDROMES AND DEFINITIONS OF PAIN TERMS Second Edition, prepared by the Task Force on Taxonomy of the International Association for the Study of Pain.	PUREX00014147	PUREX00014384
PUR1706	4/1/2015	Miller et al. Prescription opioid duration of action and the risk of unintentional overdose. <i>JAMA Intern Med.</i> 2015 Apr;175(4):608-15. doi: 10.1001/jamainternmed.2014.8071.	PUREX00014385	PUREX00014392
PUR1707	2/1/2004	Miller et al. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. <i>Am J Ther.</i> 2004 Jan-Feb;11(1):26-32.	PUREX00014393	PUREX00014399
PUR1708	8/1/2001	MILLIGAN et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. <i>J Pain.</i> 2001 Aug;2(4):197-204.	PUREX00014400	PUREX00014407
PUR1712	11/3/2017	Julie O'Donnell et al.;Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700; MMWR, 66:1197-1202, Nov. 3 2017	PUREX00014408	PUREX00014413
PUR1713	3/30/2018	Puja Seth, et al.; Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016; MMWR, 67:349-374, March 30, 2018	PUREX00014414	PUREX00014441
PUR1714	8/31/2018	MMWR Mattson. Opportunities to Prevent ODs Involving Prescription and Illicit Drugs, 11 states, July 2016-June 2017	PUREX00014442	PUREX00014448
PUR1716	8/2/2018	Mohamadi et al. Risk Factors and Pooled Rate of Prolonged Opioid Use Following Trauma or Surgery: A Systematic Review and Meta-(Regression) Analysis. <i>J Bone Joint Surg Am.</i> 2018 Aug 1;100(15):1332-1340.	PUREX00014449	PUREX00014457
PUR1719	6/1/2017	Moreley (2017) - Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. <i>Pain.</i> 2017 Jun;158(6):1138-1144.	PUREX00014458	PUREX00014464
PUR1720	11/1/2013	Morone, Weiner; Pain as the fifth vital sign: exposing the vital need for pain education <i>Clin Ther.</i> 2013 Nov;35(11):1728-32. doi: 10.1016/j.clinthera.2013.10.001. Epub 2013 Oct 18.	PUREX00014465	PUREX00014469
PUR1721	6/1/1998	Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. <i>European J Pain.</i> 1998; 2:239–49.	PUREX00014470	PUREX00014480
PUR1722	8/1/2013	Muhuri et al; Associations of nonmedical pain reliever use and heroin initiation. CBHSQ Data Review, Substance Abuse and Mental Health Services Administration (2013)	PUREX00014481	PUREX00014497
PUR1723	6/1/2006	Mularski (2005) Measuring Pain as 5th Vital Sign Does Not Improve Quality of Pain Mgmt, <i>J Gen Intern Med.</i> 2006 Jun; 21(6): 607–612.	PUREX00014498	PUREX00014503
PUR1725	3/1/1995	Mumford, G. et al., (1995) Alprazolam absorption kinetics affects abuse liability. <i>Clin Pharmacol Ther.</i> 1995 Mar;57(3):356-65.	PUREX00014504	PUREX00014514
PUR1726	8/1/2003	Mystakidou, K. et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl, <i>The Journal of Pain,</i> August 2003 Vol. 4 (6):298–306.	PUREX00014515	PUREX00014523
PUR1729	8/1/2016	NASHP. Chronic Pain Management Therapies in Medicaid. A PUBLICATION OF THE NATIONAL ACADEMY FOR STATE HEALTH POLICY Aug 2016	PUREX00014524	PUREX00014534
PUR1730	1/1/2008	Karin J. Neufeld, M.D et al, A BEHAVIORAL TREATMENT FOR OPIOID DEPENDENT PATIENTS WITH ANTI SOCIAL PERSONALITY, <i>J Subst Abuse Treat.</i> 2008 Jan; 34(1): 101–111.	PUREX00014535	PUREX00014545
PUR1733	12/1/2001	National Pharmaceutical Council, Inc. and Joint Commission on Accreditation of Healthcare Organizations Monograph: Pain: Current Understanding of Assessment, Management, and Treatments	PUREX00014549	PUREX00014649
PUR1734	9/1/2017	O'Donnell JK, et al., Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region -- United States, 2006 - 2015, <i>Morb. Mortal. Wkly. Rep.</i> 66(34) pp. 897-903.	PUREX00014650	PUREX00014656
PUR1735	1/3/2018	OSBP Data File Format	PUREX00014657	PUREX00014659
PUR1736	4/26/2018	Oquendo MA and Volkow ND, Suicide: A Silent Contributor to Opioid-Overdose Deaths, <i>N Engl J Med.</i> 2018 Apr 26;378(17):1567-1569.	PUREX00014660	PUREX00014662
PUR1738	4/1/2004	Reid C, Davies A, The World Health Organization three-step analgesic ladder comes of age. <i>Palliat Med.</i> 2004 Apr;18(3):175-6.	PUREX00014663	PUREX00014664
PUR1740	7/1/1994	Pappagallo, M., Campbell, JN. Chronic opioid therapy as alternative treatment for post-herpetic neuralgia. <i>Ann Neurol.</i> 1994; 35 Suppl:S54-S56.	PUREX00014665	PUREX00014667
PUR1741	10/9/1998	Pariss, W. et al., (1998) The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. <i>J Pain Symptom Manage.</i> 1998 Oct;16(4):205-11.	PUREX00014668	PUREX00014674
PUR1742	10/1/2007	PASCUAL- Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. <i>Curr Med Res Opin.</i> 2007 Oct;23(10):2531-42.	PUREX00014675	PUREX00014686
PUR1744	1/1/2011	PASSIK-Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. <i>J Pain Symptom Manage.</i> 2011 Jan;41(1):116-25. doi: 10.1016/j.jpainsymman.2010.03.012. Epub 2010 Jul 1.	PUREX00014687	PUREX00014696

PUR1745	2/1/2001	Gavril W. Pasternak, 2001. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001 Feb; 22(2):67-70.	PUREX00014697	PUREX00014700
PUR1747	6/23/2004	Peloso, P., et al.: Analgesic Efficacy and Safety of Tramadol/Acetaminophen Combination Tablets (Ultracet) in Treatment of Chronic Low Back Pain: A Multicenter, Outpatients, Randomized, Double Blind, Placebo Controlled Trial, 2004	PUREX00014701	PUREX00014710
PUR1748	3/24/2017	Pergolizzi et al., The Basic Pharmacology of Opioids 2017	PUREX00014711	PUREX00014726
PUR1749	3/9/1973	Pert CB & Snyder SH, Opiate Receptor: Demonstration in Nervous Tissue, Science, Vol. 179, pp. 1011-1014 (March 9, 1973)	PUREX00014727	PUREX00014730
PUR1750	11/1/2016	Pew. Medication-Assisted Treatment Improves Outcomes for Patients with OUD. Nov 2016	PUREX00014731	PUREX00014738
PUR1751	7/26/2000	Phillips DM, JCAHO Pain Management Standards Are Unveiled, JAMA, Vol. 284, pp 428-429 (July 26, 2000)	PUREX00014739	PUREX00014740
PUR1752	12/1/1989	Pickworth, WB et al., Opiate-induced pupillary effects in humans, Methods & Findings in Experimental & Clinical Pharmacology, Vol. 11, No. 12 , pp. 759-763	PUREX00014741	PUREX00014746
PUR1753	1/1/1986	Portenoy and Foley (1986) Chronic Use of Opioid Analgesics in Non-Malignant pain: Report of 38 Cases, Pain, 25(1986) 171-186	PUREX00014747	PUREX00014762
PUR1755	2/1/1990	Portenoy RK, Chronic Opioid Therapy in Nonmalignant Pain, J. Pain & Symptom Management, Vol. 5, pp. S46-S62 (Feb. 1990)	PUREX00014763	PUREX00014780
PUR1756	4/1/1996	Portenoy. Opioid Therapy for CNCP - a review of the critical issues. Apr 1996	PUREX00014781	PUREX00014795
PUR1757	1/10/1980	Porter & Jick; Addiction Rare in Patients Treated With Narcotics; The New England Journal of Medicine, Vol. 302:123-124, Jan. 10, 1980	PUREX00014796	PUREX00014798
PUR1759	1/1/1994	Poyhia, R et al., Liposolubility and protein binding of oxycodone in vitro, Pharmacology & Toxicology, 74, pp. 23-27	PUREX00014804	PUREX00014808
PUR1760	10/1/2001	Article: Nikolai RAINOV-Long-term intrathecal infusion of drug combinations for chronic back and leg pain	PUREX00014809	PUREX00014818
PUR1761	1/1/1994	Judith A. Ralphs et al., Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods, Pain, 56 (1994) 279-288.	PUREX00014819	PUREX00014828
PUR1763	11/1/2006	Richard RAUCK-A Randomized, Open-Label Study of once a day Avinza	PUREX00014829	PUREX00014835
PUR1764	7/1/2010	Reid et al. Characteristics of older adults receiving opioids. 2010	PUREX00014836	PUREX00014844
PUR1765	3/1/2002	Reid MC, et al., Use of Opioid Medications for Chronic Noncancer Pain Syndromes in Primary Care, J. Gen. Intern. Med., Vol. 17, pp. 173-179 (March 2002)	PUREX00014845	PUREX00014851
PUR1766	5/4/2010	RHODIN et al; Opioid Endocrinopathy: A clinical Problem in Patients With Chronic Pain and Long-term Oral Opioid Treatment; Clinical Pain, Volume 6, Number 5	PUREX00014852	PUREX00014858
PUR1769	8/1/1999	Article, , ROMACH, Journal of Clinical Psychopharmacology, Long-term codeine use is Associated with Depressive Symptoms-1999	PUREX00014859	PUREX00014863
PUR1770	9/20/2018	Article Substance Abuse and Rehabilitation Ronquest et al. Relationship-between-buprenorphine-adherence-and-relapse, health care utilization, pp59-78, 9/2018	PUREX00014864	PUREX00014883
PUR1771	9/18/2018	Rose et al. Potentially Inappropriate Opioid Prescribing, Overdose and Mortality in Massachusetts 2011–2015. Sep 2018	PUREX00014884	PUREX00014891
PUR1772	3/27/2000	Article, Roth, Arch Intern Med (2000) Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis Related Pain	PUREX00014892	PUREX00014899
PUR1773	12/30/2016	Rudd (2016) - Increase_in_Drug_and_Opioid-Involved_Overdose_Deaths	PUREX00014900	PUREX00014907
PUR1774	1/13/2017	Rudd (2016) - Increase_in_Drug_and_Opioid-Involved_Overdose_Deaths_(Erratum)	PUREX00014908	PUREX00014908
PUR1776	1/1/2012	R. Rychlik, et al.(2012). Pain Management and Costs of aCombination of Oxycodone + Naloxone in Low Back Pain Patients, Pain Management - Current Issues andOpinions, Dr. Gabor Racz (Ed.), ISBN: 978-953-307-813-7	PUREX00014909	PUREX00014924
PUR1777	1/1/2007	Saffier, Kenneth, et al., Addiction Severity Index in a chronic pain sample, Journal of Substance Abuse Treatment 33:303-311, Dec 2006	PUREX00014925	PUREX00014933
PUR1778	8/17/2018	Saloner et al. Changes in OPR prescriptions following Affordable Care Act Medicaid expansion; JAMA Network;	PUREX00014934	PUREX00014946
PUR1779	12/18/2014	SAMHSA (2014), The DAWN Report: Benzodiazepines in Combination with Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes	PUREX00014947	PUREX00014951
PUR1780	9/1/2018	Substance Abuse & Mental Health Services Administration Report: Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health	PUREX00014952	PUREX00015075
PUR1781	9/28/2015	SAMHSA. Medication and Counseling Treatment; https://www.samhsa.gov/medication-assisted-treatment/treatment	PUREX00015076	PUREX00015082
PUR1782	1/1/2006	SAMHSA. National All Schedules Prescription Electronic Reporting Act of 2005: A review of Implementation of Existing State Controlled Substance Monitoring Programs	PUREX00015083	PUREX00015087
PUR1783	1/1/2017	Samuels et al. Medicare Formulary Coverage Restrictions for Prescription Opioids; American College of Physicians, pp 895-896	PUREX00015088	PUREX00015089
PUR1785	5/1/2004	Saper, J.R., et al., Daily scheduled opioids for intractable head pain, CME, pp. 1687-1694, May. 2004	PUREX00015090	PUREX00015097
PUR1786	4/27/2014	Sartor et al. Rate_of_progression_from_first_use_to_dependence. 2014	PUREX00015098	PUREX00015104
PUR1787	2/21/2018	Satel (2018) The Myth of What's Driving the Opioid Crisis	PUREX00015105	PUREX00015112
PUR1788	1/5/2010	Saunders (2010) Relationship of Opioid Use and Dosage Levels to fractures in older chronic pain patients	PUREX00015113	PUREX00015118

PUR1789	7/1/2003	Savage et al. (2003) Definitions related to the medical use of opioids: Evolution Towards Universal Agreement, Journal of Pain and Symptom Management; 26(1):655-667	PUREX00015119	PUREX00015131
PUR1790	2/1/2006	Ambulatory Care Visits to Physician Offices, Hospital Outpatient Departments, and Emergency Departments: United States, 2001-02, CDC's Vital and Health Statistics, Series 13, Number 159 (Feb. 2006)	PUREX00015132	PUREX00015204
PUR1791	6/1/2011	Michael E. Schatzman; Role of the health insurance industry in perpetuating suboptimal pain management; Pain Medicine, 12:415-426, 2011	PUREX00015205	PUREX00015216
PUR1794	5/1/2013	Schwartz et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.	PUREX00015217	PUREX00015222
PUR1796	2/1/1971	Sechzer PH, Studies in Pain with the Analgesic-demand System, Anesthesia & Analgesia, Vol. 50, pp. 1-10 (Jan.-Feb. 1971)	PUREX00015223	PUREX00015232
PUR1797	4/23/2018	Amie Severino; Pain Therapy Guided by Purpose & Perspective Opioid Epidemic; frontiers in Psychiatry, 9, April, 2018	PUREX00015233	PUREX00015245
PUR1798	10/22/2016	Severtson (2016) Sustained Reduction of Diversion and Abuse after AD Formulation of ER Oxy	PUREX00015246	PUREX00015256
PUR1800	2/18/2011	Skurtweit, Svetlana, et al., To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use?, PAIN 152:1555-1561, 2011	PUREX00015257	PUREX00015263
PUR1801	7/24/2013	Sostres C, et al.: Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research & Therapy 2013, 15(Suppl 3):S3.	PUREX00015264	PUREX00015271
PUR1802	3/21/2019	Spencer (CDC). Drug Overdose Deaths Involving Fentanyl 2011-2016. 03-21-2019	PUREX00015272	PUREX00015290
PUR1803	3/1/2001	Stafford K, et al., u-Opioid receptor downregulation contributes to opioid tolerance in vivo, Pharmacology, Biochemistry & Behavior, Vol. 69, pp. 233-237 (2001)	PUREX00015291	PUREX00015295
PUR1805	10/12/2008	Geetha A Subramaniam et al, Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder; Drug and Alcohol Dependence	PUREX00015296	PUREX00015302
PUR1806	9/4/2013	Mark Sullivan & Catherine Howe, Opioid therapy for chronic pain in the United States promises and perils, Pain. 2013 Dec;154 Suppl 1:S94-100.	PUREX00015303	PUREX00015309
PUR1808	3/1/2017	Sullivan et al. Prescription Opioid Taper Support for Outpatients With Chronic Pain. Mar 2017	PUREX00015310	PUREX00015320
PUR1811	1/1/1996	Abraham Sunshine et al., Analgesic efficacy of controlled-release oxycodone in postoperative pain; J Clin Pharmacol 36:595-603, 1996	PUREX00015321	PUREX00015329
PUR1814	1/13/2014	Thomas et al., Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence, Psychiatric Services, Vol. 65 No. 2, February 2014, pp. 158-170	PUREX00015330	PUREX00015342
PUR1816	1/1/1948	Tainter ML, Pain, Annals: New York Academy of Sciences (1948)	PUREX00015343	PUREX00015351
PUR1818	1/1/2019	Treede RD, et al., Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11), www.painjournalonline.com, Vol. 160, pp. 19-27 (Jan. 2019)	PUREX00015352	PUREX00015360
PUR1819	1/4/2018	Trickey E, Inside the Story of America's 19th-Century Opiate Addiction, available at https://www.smithsonianmag.com/history/inside-story-americas-19th-century-opiate-addiction-180967673/ (Jan. 4, 2018)	PUREX00015361	PUREX00015363
PUR1820	8/1/1984	Trzepacz, PT et al., Response to opioids in three patients with restless legs syndrome, Am J Psychiatry 141:8, August 1984, pp. 993-995	PUREX00015364	PUREX00015366
PUR1821	6/7/2016	Uncovering Coverage Gaps - A Review of Addiction Benefits in ACA Plans. June 2016	PUREX00015367	PUREX00015427
PUR1824	8/15/2017	Voon et al. Chronic pain and opioid misuse: a review of reviews	PUREX00015428	PUREX00015436
PUR1826	8/21/2018	Votaw et al. Nonmedical prescription sedative, tranquilizer use in alcohol and opioid use; Elsevier, 88:48-55, 2019	PUREX00015437	PUREX00015444
PUR1828	4/1/2017	Waljee (2017) Iatrogenic Opioid Dependence in the US - Are Surgeons the Gatekeepers	PUREX00015445	PUREX00015447
PUR1829	4/1/2009	Mark Wallace, Long-term safety, tolerability, and efficacy of OROS®hydromorphone in patients with chronic pain; Journal of Opioid Management 5:2; March/April 2009	PUREX00015448	PUREX00015456
PUR1831	2/1/1993	Arthur Walters et al., Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep, 16(4):327-332, 1993	PUREX00015457	PUREX00015462
PUR1832	2/1/1979	Wang JK, et al., Pain Relief by Intrathecally Applied Morphine in Man, Anesthesiology, Vol. 50, pp. 149-151 (Feb. 1979)	PUREX00015463	PUREX00015465
PUR1833	1/1/2006	Wasan et al. Iatrogenic addiction in patients treated for acute or subacute pain a systematic review	PUREX00015466	PUREX00015472
PUR1834	3/1/2004	WATSON Chronic noncancer pain and the long term utility of opioids-2004	PUREX00015473	PUREX00015479
PUR1840	1/1/1983	Weiss OF, et al., Attitudes of Patients, Housestaff, and Nurses Toward Postoperative Analgesic Care, Vol. 62, pp. 70-74 (1983)	PUREX00015480	PUREX00015484
PUR1841	3/1/1989	Weissman & Haddox; Opioid pseudoaddiction - an iatrogenic syndrome; Elsevier, Pain 36:363-366, 1989	PUREX00015485	PUREX00015489
PUR1842	9/28/2018	Hefei Wen et al.; Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use.JAMANetworkOpen.2018;1(5):e182943	PUREX00015490	PUREX00015502
PUR1843	4/24/2017	Wong A & Graudins A, Risk prediction of hepatotoxicity in paracetamol poisoning, Clinical Toxicology, Vol. 55, pp. 879-892 (April 24, 2017)	PUREX00015503	PUREX00015516
PUR1845	10/4/2006	Wu, Stephen M., et al., The addiction behaviors checklist, Journal of Pain and Symptom Management, 32(4):342-351, Oct. 2006	PUREX00015517	PUREX00015526
PUR1846	9/1/1998	Steven Ytterberg et al. Codeine and oxycodone use in chronic rheumatic pain.	PUREX00015527	PUREX00015536

PUR1848	2/1/1992	Long-term oral opioid therapy in patients with chronic nonmalignant pain Zenz, Michael et al. Journal of Pain and Symptom Management, Volume 7, Issue 2, 69 - 77	PUREX00015537	PUREX00015545
PUR1849	8/1/1990	American Pain Society, Principles of analgesic use in the treatment of acute pain and chronic cancer pain, 2nd edition, Clin Pharm, 1990, 9(8):601-11	PUREX00015546	PUREX00015558
PUR1850	2/14/2001	ASAM: Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addictive Medicine	PUREX00015559	PUREX00015562
PUR1851	1/1/2001	ASAM (2001) Definitions Related to the Use of Opioids for the Treatment of Pain	PUREX00015563	PUREX00015566
PUR1852	7/11/2011	Boscarino et al. (2011) Prevelence of Prescription Opioid Abuse Disorder	PUREX00015567	PUREX00015577
PUR1853	12/18/2018	Bussee, JW, et al., Opioids for Chronic Non-cancer Pain: A Systemic Review and Meta-Analysis, JAMA volume Vol. 320 (23), pp. 2448-2460, December 2018.	PUREX00015578	PUREX00015590
PUR1854; PUR4975	8/15/2017	Case A and Deaton A, Mortality and Morbidity in the 21st Century, Brookings Papers on Economic Activity, pp. 397-476, Spring 2017	PUREX00015591	PUREX00015670
PUR1855	11/27/2018	Cheatle M et al.; Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain; Pain medicine, Vol 19, pp. 764-773, April 2018	PUREX00015671	PUREX00015680
PUR1856	3/1/1995	Chen, I, Why Doctors Are Stingy with Morphine, Hippocrates, pp. 69-72, March 1995	PUREX00015681	PUREX00015684
PUR1857	2/19/2019	Chua K, et al., Opioid Prescribing Limits for Acute Pain: Potential Problems With Design and Implementation, JAMA, Vol 321, No. 7, pp. 643-644 (Feb. 19, 2019)	PUREX00015685	PUREX00015686
PUR1858	7/13/2017	Cicero TJ et al; Increased Use of Heroin as Initiating Opioid of Abuse; Addictive Behaviors, Vol 74, pp. 63-66; 2017	PUREX00015687	PUREX00015690
PUR1860	1/14/2016	Compton et al. Relationship between nonmedical prescription opioid and heroin use. 2016	PUREX00015694	PUREX00015703
PUR1861	6/21/2017	RADARS System Presentation: Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids.	PUREX00015704	PUREX00015733
PUR1863	3/15/2016	Deborah Dowell et al. CDC guideline for prescribing opioids for chronic pain. Clinical Review & Education 2016	PUREX00015734	PUREX00015755
PUR1864	4/24/2013	The Medical Letter Treatment Guidelines, Drugs_for_Pain. 1993 revised 4/24/2013	PUREX00015756	PUREX00015768
PUR1865	1/1/2013	DSM-V (2013)	PUREX00015769	PUREX00016738
PUR1866	1/1/2013	DSM-V. Opioid Use Disorder. 2013	PUREX00016739	PUREX00016746
PUR1867	7/14/2010	Edlund, MJ, et al., Risks for opioid abuse and dependence among recipients of chronic opioid therapy: Results from the TROUP Study, Drug and Alcohol Dependence, Vol. 112, pp. 90-98 (July 14, 2010)	PUREX00016747	PUREX00016755
PUR1869	1/1/1992	Fishbain, DA, et al., Drug Abuse, Dependence, and Addiction in Chronic Pain Management, The Clinical Journal of Pain, Vol. 8, pp. 77-85	PUREX00016756	PUREX00016765
PUR1870	1/1/2007	Fishman, SM, Responsible Opioid Prescribing: A Physician's Guide, Published by Waterford Life Sciences, Washington, DC	PUREX00016766	PUREX00016911
PUR1871	11/1/2008	Fleming, MF, et al., Reported Lifetime Aberrant Drug-Taking Behaviors Are Predictive of Current Substance Use and Mental Health Problems in Primary Care Patients, Pain Medicine, Vol. 9, pp. 1098-1106	PUREX00016912	PUREX00016920
PUR1873	5/2/1998	FSMB Model Guidelines for the use of controlled substances for treatment of pain	PUREX00016921	PUREX00016924
PUR1874	5/9/2006	Furlan, AD, et. al., Opioids for chronic noncancer pain a meta-analysis of effectiveness and side effects, CMAJ, 174(11), pp. 1589-1594	PUREX00016925	PUREX00016930
PUR1876	3/6/2019	Health Professionals for Patients in Pain; Professionals Call on the CFC to Address Misapplication of its Guideline on Opioids for Chronic Pain through Public Clarification and Impact Evaluation	PUREX00016935	PUREX00016973
PUR1878	3/1/2010	Jamison, RN, et al., Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial, PAIN, Vol. 150, pp. 390-400 (2010)	PUREX00016974	PUREX00016984
PUR1879	9/9/2004	Kalso (2004) Opioids in chronic non-cancer pain - systematic review of efficacy and safety	PUREX00016985	PUREX00016993
PUR1880	1/1/2017	Alan Kaye, et al. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1, Pain Physician, 20: S93-S109, 2017	PUREX00016994	PUREX00017011
PUR1881	1/1/2009	Kroenke, Krebs. Pharmacotherapy for chronic pain: a synthesis of recommendations from systemic reviews; General Hospital Psychiatry	PUREX00017012	PUREX00017025
PUR1882	3/1/2000	LAMBERT, Harvard magazine: Deep Cravings. New research on the brain and behavior clarifies the mysteries of addiction, 3/1/2000	PUREX00017026	PUREX00017033
PUR1883	8/1/1990	Arthur G. Lipman, Clinically relevant differences among the opioid analgesics, American Journal of Hospital Pharmacy, Vol 47, No. 8, Aug 1990 Suppl 1, S7-S13.	PUREX00017034	PUREX00017041
PUR1884	1/1/2006	Manchikanti L, et al., Does Adherence Monitoring Reduce Controlled Substance Abuse in Chronic Pain Patients?, Pain Physician, Vol. 9, pp. 57-60 (2006)	PUREX00017042	PUREX00017045
PUR1885	2/1/1973	Marks & Sachar, Undertreatment of Medical Inpatients with Narcotic Analgesics, Ann Intern Med. 1973 Feb; 78(2): 173-81.	PUREX00017046	PUREX00017055
PUR1886	1/1/2007	Briget Martell; Systematic review - opioid treatment for chronic back pain - prevalence, efficacy, and association with addiction; Annals of Internal Medicine, 146: 116-127, 2007	PUREX00017056	PUREX00017072
PUR1887	7/1/2012	Minozzi et al. Development of dependence following treatment with opioid analgesics for pain relief. Addiction, 108:688-698, 2012	PUREX00017073	PUREX00017083

PUR1889	11/1/2015	Mowbray (2015) Prescription Pain Reliever Misuse Prevalence, Correlates, and Origin of Possession Throughout the Life Course	PUREX00017084	PUREX00017086
PUR1890	8/29/2018	Tanner Nissly, Buprenorphine to treat opioid use disorder: A practical guide; The Journal of Family Practice, Vol. 67 No.9; 2018	PUREX00017087	PUREX00017091
PUR1891	1/1/2010	The Cochrane Collaboration - Review: Noble et al. Long-term opioid management for CNCP	PUREX00017092	PUREX00017163
PUR1894	7/1/2009	Passik; Issues in long-term opioid therapy: Unmet Needs, Risk, and Solutions; Mayo Clinic Proc	PUREX00017167	PUREX00017175
PUR1895; PUR4964	5/5/2011	Passik et al, Pseudoaddiction revisited: a commentary on clinical and historical considerations. Pain Manage. 1(3), 239-248, 2011	PUREX00017176	PUREX00017185
PUR1896	7/31/2018	Pergolizzi Jr., Abuse-deterrent opioidsL an update on current approaches and considerations; Taylor and Financial Group, Vol. 34, pp 711-723, 2018	PUREX00017186	PUREX00017198
PUR1897	4/29/2019	Rubin R, Limits on Opioid Prescribing Leave Patients With Chronic Pain Vulnerable, JAMA (published online April 29, 2019)	PUREX00017199	PUREX00017201
PUR1898; PUR4965	12/1/2017	Teresa Rummans et al; How Good Intentions Contributed to Bad Outcomes; Mayo Clinic, pp 344-350	PUREX00017202	PUREX00017208
PUR1899	12/20/2011	SCHNEIDER, J., et al., Patients Who Require Ultra-high Opioid Doses, Practical Pain Management, Vol 9, Issue 7, last updated December 20, 2011	PUREX00017209	PUREX00017216
PUR1900	12/21/2018	Scholl (CDC). Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. 12-21-2018	PUREX00017217	PUREX00017225
PUR1901	3/31/2016	Volkow & McLellan 2016, Opioid Abuse in Chronic Pain	PUREX00017226	PUREX00017236
PUR1902; PUR4968	4/1/2015	Vowles (2015) Rates of Opioid Misuse, Abuse, and Addiction in Chronic Pain	PUREX00017237	PUREX00017244
PUR1903	11/19/2018	Sunali Wadehra, et al., Opioid Use Disorder on the Rise in Pregnant Women, Practical Pain Management, updated 11/19/2018	PUREX00017245	PUREX00017249
PUR1904	11/1/2017	Lynn Webster. Risk Factors for Opioid-Use Disorder and Overdose.; Narrative Review Article, 125:1741-1748, Nov. 2017	PUREX00017250	PUREX00017257
PUR1907	9/27/2018	Purdue Pharma Presentation: OxyContin Prescribing Information	PUREX00017258	PUREX00017303
PUR1908	5/2/2019	Controlled Substances - Alphabetical Order	PUREX00017304	PUREX00017320
PUR1911	5/10/2019	DEA Drug Scheduling, available at https://www.dea.gov/drug-scheduling	PUREX00017321	PUREX00017322
PUR1913	10/4/2016	DEA Reduces Amount Of Opioid Controlled Substances To Be Manufactured In 2017 (10-4-2016), available at https://www.dea.gov/press-releases/2016/10/04/dea-reduces-amount-opioid-controlled-substances-be-manufactured-2017	PUREX00017323	PUREX00017324
PUR1914	12/15/2004	DOJ/DEA Diversion Control Division website article - "Turn In Pharmaceutical Pill Pushers Confidentially (12-15-2004)" available at https://www.deadiversion.usdoj.gov/pubs/advisories/report_rx_press.htm	PUREX00017325	PUREX00017326
PUR1915	10/1/2000	DEA National Drug Threat Assessment 2001: The Domestic Perspective (Oct. 2000)	PUREX00017327	PUREX00017422
PUR1916	1/9/2002	DEA National Drug Threat Assessment 2002 (Dec. 2001)	PUREX00017423	PUREX00017542
PUR1918; PUR4994	11/7/2013	National Drug Threat Assessment Summary 2013	PUREX00017543	PUREX00017570
PUR1919	2/1/2005	DEA National Drug Threat Assessment 2005 (Feb. 2005)	PUREX00017571	PUREX00017796
PUR1920	1/1/2007	National Drug Threat Assessment 2007	PUREX00017797	PUREX00017863
PUR1922; PUR5002	2/9/2001	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2000 - January 2001	PUREX00017864	PUREX00017993
PUR1923	6/29/2000	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, January 2000 - June 2000	PUREX00017994	PUREX00018136
PUR1924	1/28/2000	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 1999 - January 2000	PUREX00018137	PUREX00018267
PUR1925	7/31/2001	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, January 2001 - June 2001	PUREX00018268	PUREX00018409
PUR1926	1/18/2002	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2001 - January 2002	PUREX00018410	PUREX00018533
PUR1927	6/7/2002	Surveillance of Drug Abuse Trends in the State of Ohio, January 2002 - June 2002: A Report Prepared for the Ohio Alcohol and Drug Addiction Services, Ohio Substance Abuse Monitoring Network, et al. (June 7, 2002)	PUREX00018534	PUREX00018659
PUR1928; PUR5003	1/31/2003	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2002 - January 2003	PUREX00018660	PUREX00018781
PUR1929	1/28/2005	Executive Summary; The Ohio Substance Abuse Monitoring Network (OSAM) January 2005 Meeting, Ohio Department of Alcohol and Drug Addiction Services	PUREX00018782	PUREX00018784
PUR1930	6/27/2003	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, January 2003 - June 2003	PUREX00018785	PUREX00018909
PUR1931; PUR5004	6/4/2004	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, January 2004 - June 2004	PUREX00018910	PUREX00018991
PUR1932	6/24/2005	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, January 2005 - June 2005	PUREX00018992	PUREX00019075
PUR1933	1/31/2004	Patterns and Trends of Drug Use in Summit and Stark Counties, Ohio A report prepared for Ohio Substance Abuse Monitoring Network - July 2003-January 2004	PUREX00019076	PUREX00019195
PUR1934	2/3/2006	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio, June 2005- January 2006	PUREX00019196	PUREX00019299
PUR1935	6/16/2006	Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio January 2006 - June 2006	PUREX00019300	PUREX00019383
PUR1936	1/26/2007	Executive Summary; The Ohio Substance Abuse Monitoring Network (OSAM) January 2007 Meeting, Ohio Department of Alcohol and Drug Addiction Services	PUREX00019384	PUREX00019387

PUR1937	6/8/2007	Executive Summary; The Ohio Substance Abuse Monitoring Network (OSAM) June 2007 Meeting, Ohio Department of Alcohol and Drug Addiction Services	PUREX00019388	PUREX00019391
PUR1938	3/21/2008	The Ohio Substance Abuse Monitoring Network: Surveillance of Drug Abuse Trends in the State of Ohio	PUREX00019392	PUREX00019491
PUR1939	6/18/2008	Ohio Substance Abuse Monitoring Network; Surveillance of Drug Abuse Trends in the State of Ohio	PUREX00019492	PUREX00019566
PUR1940	1/23/2009	Ohio Substance Abuse Monitoring Network, Surveillance of Drug Abuse Trends in the State of Ohio	PUREX00019567	PUREX00019647
PUR1941	1/31/2011	Ohio Substance Abuse Monitoring Network: surveillance of Drug Abuse Trends in the State of Ohio	PUREX00019648	PUREX00019753
PUR1942; PUR5005	6/30/2011	OSAM Reports.zip\OSAM Reports\2011-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00019754	PUREX00019896
PUR1943	1/31/2012	OSAM Reports.zip\OSAM Reports\2012-01 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00019897	PUREX00020048
PUR1944; PUR5006	6/30/2012	OSAM Reports.zip\OSAM Reports\2012-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00020049	PUREX00020209
PUR1945	1/31/2014	OSAM Reports.zip\OSAM Reports\2014-01 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00020210	PUREX00020378
PUR1946; PUR5007	1/31/2013	OSAM Reports.zip\OSAM Reports\2013-01 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00020379	PUREX00020542
PUR1947	6/30/2013	Ohio Substance Abuse Monitoring Network Reports, Surveillance of Drug Abuse Trends in the State of Ohio January-June 2013	PUREX00020543	PUREX00020706
PUR1948	6/30/2014	OSAM Reports.zip\OSAM Reports\2014-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00020707	PUREX00020879
PUR1949	1/31/2015	OSAM Reports.zip\OSAM Reports\2015-01 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00020880	PUREX00021046
PUR1950; PUR5008	6/30/2015	OSAM Reports.zip\OSAM Reports\2015-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00021047	PUREX00021224
PUR1951	1/31/2016	OSAM Reports.zip\OSAM Reports\2016-01 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00021225	PUREX00021406
PUR1952	6/30/2016	OSAM Reports.zip\OSAM Reports\2016-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00021407	PUREX00021598
PUR1953; PUR5009	1/31/2017	OSAM Reports: Surveillance of Drug Abuse Trends in the State of OH (June 2016-January 2017); State of Ohio	PUREX00021599	PUREX00021794
PUR1954	6/30/2017	OSAM Report- Surveillance of Drug Abuse Trends in the State of OH	PUREX00021795	PUREX00022004
PUR1955	1/31/2018	OSAM Reports - Surveillance of Drug Abuse Trends in the State of OH	PUREX00022005	PUREX00022230
PUR1956	6/30/2018	OSAM Reports.zip\OSAM Reports\2018-06 OSAM - Surveillance of Drug Abuse Trends in the State of OH	PUREX00022231	PUREX00022440
PUR1957	5/8/2018	Robert W. Patterson Testimony Before the House Judiciary Committee for a Hearing Entitled "Challenges and Solutions in the Opioid Abuse Crisis"; https://www.dea.gov/documents/2018/05/08/robert-w-patterson-house-judiciary-committee-us-house-representatives-hearing	PUREX00022441	PUREX00022441
PUR1958	4/8/2006	Compton-Abuse of Prescription Drugs 2006	PUREX00022442	PUREX00022445
PUR1959	1/1/2013	Fox, PD and Kongstvedt, PR, Chapter 1: A History of Managed Health Care and Health Insurance in the United States, in Essentials of Managed Health Care, pp. 3-20, 2013	PUREX00022446	PUREX00022465
PUR1961	8/29/2018	Lin et al.: Supplementary Online Content for Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and commercial insurers	PUREX00022466	PUREX00022480
PUR1962	1/1/2019	Mojatabai R, Amin-Esmaeili M, Nejat E, Olfson M. Misuse of prescribed opioids in the United States. <i>Pharmacoepidemiol Drug Saf.</i> 2019;1-9	PUREX00022481	PUREX00022489
PUR1963	1/1/2009	Navarro and Hailey, Overview of Prescription Drug Benefits, Managed Care Pharmacy Practice, Chapter 2, pp. 17-50, 2009	PUREX00022490	PUREX00022524
PUR1964	1/1/2009	Navarro, et al., Pharmacy & Therapeutics Committees in Managed Care Organizations, Managed Care Pharmacy Practice, Chapter 13, pp.323-340, 2009	PUREX00022525	PUREX00022542
PUR1965	1/1/2009	Navarro, et al., Pharmacy Benefit Management Companies, Chapter 4, Managed Care Pharmacy Practice, pp.95-114, 2009	PUREX00022543	PUREX00022562
PUR1966	1/1/2013	Navarro, et al., Prescription Drug Benefits in Managed Care, Chapter 11, Essentials of Managed Health Care, pp. 257-282, 2013	PUREX00022563	PUREX00022590
PUR1967	1/1/2009	Navarro, et al., Role of Drug Formularies in Managed Care Organizations, Managed Care Pharmacy Practice, Chapter 9, pp. 233-252, 2009	PUREX00022591	PUREX00022610
PUR1968	1/1/2009	Peterson, et al., Drug Utilization Review Strategies, Managed Care Pharmacy Practice, Chapter 8, pp. 215-231, 2009	PUREX00022611	PUREX00022626
PUR1969	12/1/2003	OxyContin Abuse and Diversion and Efforts to Address the Problem, United States General Accounting Office, GAO-04-110, pp. 1-57, (December 2003).	PUREX00022627	PUREX00022689
PUR1971	5/1/1998	Ainslie & Rossi (1998). Similarities in Choice Behavior Across Product Categories, Marketing Science 1998, Vol. 17:2, pp. 91-106.	PUREX00022690	PUREX00022706
PUR1972	2/1/2009	Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy; American Journal of Public Health	PUREX00022707	PUREX00022713
PUR1973	8/1/2009	Anderson, B., et al. Factors Associated With Physicians' Reliance on Pharmaceutical Sales Representatives, Academic Medicine, Vol. 84, No. 8, August 2009, pp. 994-1002	PUREX00022714	PUREX00022722
PUR1974	7/1/1982	Jerry Avorn, Milton Chen, Richard Hartley; Scientific vs Commercial Sources of Influence on the Prescribing Behavior of Physicians; Medicine, Science, and Society, Vol. 73, pp. 4-8, July 1982	PUREX00022723	PUREX00022727

PUR1975	10/1/2002	Pierre Azoulay, (2002) Do Pharmaceutical Sales Respond to Scientific Evidence?, Journal of Economics & Management Strategy Winter 2002, 11(4);551-594.	PUREX00022728	PUREX00022771
PUR1976	12/1/1992	Beltramini, R. & Sirsi, A. (1992), Physician Information Acquisition and Believability: A Field Experiment on Source and Type of Information, Journal of Health Care Marketing, December 1992, pp. 52-59	PUREX00022772	PUREX00022780
PUR1977	5/1/2007	Benson EB & Alfors SN, Prescription Drug Advertising and Promotion: Learnings from Recent Food and Drug Administration Warning Letters, Drug Info. J., Vol. 41, pp. 281-289 (May 2007)	PUREX00022781	PUREX00022789
PUR1978	6/11/2002	Ernst Berndt, et. al., An Analysis of the Diffusion of New Antidepressants Variety Quality and Marketing Efforts, J MENT Health Policy Econ 5, 3-19 (2002)	PUREX00022790	PUREX00022806
PUR1979	6/26/2014	Tat Chan, et al; Treatment Effectiveness and Side Effects: A Model of Physician Learning; Management Science Vol 59, No 6, pp. 1309-1325, (2013)	PUREX00022807	PUREX00022825
PUR1980	5/12/2009	Chimonas S and Kassirer J; No More Free Drug Samples; PLOS Medicine, available at https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000074	PUREX00022826	PUREX00022831
PUR1981	2/11/2010	Ching A and & Ishihara M; The Effects of Detailing on Prescribing Decisions Under Quality Uncertainty; Quant Mark Econ, Vol 8, pp. 123-165; 2010	PUREX00022832	PUREX00022874
PUR1982	3/30/2012	Chintagunta P et al; New Drug Diffusion when Forward-Looking Physicians Learn from Patient Feedback & Detailing; March 30, 2012	PUREX00022875	PUREX00022917
PUR1983	8/1/1997	Christen M et al; Using Market-Level Data to Understand Promotion Effects in a Nonlinear Model; Journal of Marketing Research, Vol. XXXIV, pp. 322-334, Aug 1997	PUREX00022918	PUREX00022931
PUR1984	3/1/1990	Donald P Connelly (1990), Knowledge Resource Preferences of Family Physicians, the Journal of Family Practice, Vol. 30 (3); pp. 353-360.	PUREX00022932	PUREX00022940
PUR1985	9/1/2003	Coscelli, Andrea & Shum, Matthew. 2004. "An empirical model of learning and patient spillovers in new drug entry," Journal of Econometrics, Elsevier, vol. 122(2), pages 213-246, October.	PUREX00022941	PUREX00022974
PUR1986	9/1/2000	Coscelli, A. (2000), The Importance of Doctors' and Patients' Preferences in the Prescription Decision. The Journal of Industrial Economics, 48 (3): 349-369.	PUREX00022975	PUREX00022995
PUR1987	7/1/2005	Crawford & Shum (2005) Uncertainty and Learning in Pharmaceutical Demand	PUREX00022996	PUREX00023032
PUR1988	6/21/2017	Dart Presentation. Effect of Abuse-Deterrent Formulations and IR Opioids.	PUREX00023033	PUREX00023062
PUR1989	6/21/2017	RADARS System Presentation: Interventions in Prescription Opioid Abuse – Do (or can) Prescription Monitoring Programs Make a Difference	PUREX00023063	PUREX00023080
PUR1990	12/3/1997	FDA 1997 Guidance on Industry-Supported Scientific and Educational Activities.	PUREX00023081	PUREX00023088
PUR1991	2/1/2010	Fischer, M. & Albers, S, Patient- or Physician-Oriented Marketing: What Drives Primary Demand for Prescription Drugs?, Journal of Marketing Research, Vol. XLVII, pp. 103-121	PUREX00023089	PUREX00023108
PUR1992	7/1/2001	Gonul, et al., Promotion of Prescription Drugs and Its Impact on Physician's Choice Behavior, Journal of Marketing, Vol. 65, pp. 79-90	PUREX00023109	PUREX00023121
PUR1994	6/1/2008	Janakiraman R, et al.. Physicians' Persistence and Its Implications for Their Response to Promotion of Prescription Drugs, Management Science, Vol. 54, pp. 1080-1093 (June 2008)	PUREX00023122	PUREX00023136
PUR1995	11/1/2011	Ajay Kalra, et a.; Understanding Responses to Contradictory Information About Products; informs, 30:1098-1114, Nov.-Dec. 2011	PUREX00023137	PUREX00023154
PUR1996	11/1/1989	Kamakura & Russell (1989). A Probabilistic Choice Model for Market Segmentation and Elasticity Structure, Journal of Marketing Research, Vol. 26, No. 4 (Nov., 1989), pp. 379-390.	PUREX00023155	PUREX00023167
PUR1997	9/16/2002	Charles KING, Marketing, Product Differentiation, and Competition in the Market for Antiulcer Drugs, Abstract 2002	PUREX00023168	PUREX00023216
PUR1998	3/4/2013	Kornfield et al; Promtion of Prescription Drugs to Consumers and Providers, 2001-2010; PLOS ONE. Volume 8, Issue 3	PUREX00023217	PUREX00023223
PUR2000	5/1/1992	Peter Lichstein et al., Impact of Pharmaceutical Company Representatives on Internal Medicine Residency Programs: A Survey of Residency Program Directors, Arch Intern Med, Vol 152, May 1992, pp. 1009-1013	PUREX00023224	PUREX00023228
PUR2001	1/1/2005	Machanda & Honka: The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review, 2005 Vol. 5(2)	PUREX00023229	PUREX00023267
PUR2002	12/16/2004	Manchanda & Chintagunta Marketing Letters, Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis (2004)	PUREX00023268	PUREX00023284
PUR2003	11/1/2004	Puneet Manchanda, et al.; Response Modeling with Nonrandom Marketing-Mix Variables; American Marketing Association, 41:467-478, Nov. 2004	PUREX00023285	PUREX00023297
PUR2004	10/3/1990	W. Paul McKinney, et al., Attitudes of Internal Medicine Faculty and Residents Toward Professional Interaction With Pharmaceutical Sales Representatives, JAMA, October 3, 1990 - Vol 264, No. 13, pp. 1693-1697	PUREX00023298	PUREX00023302
PUR2006	10/1/2010	Harikesh S. Nair, et al; Asymmetric Social Interactions in Physician Prescription Behavior, American Marketing Association, 47:883-895, Oct. 2010	PUREX00023303	PUREX00023316
PUR2008	10/1/2004	Narayanan S, Desiraju R & Chintagunta PK, Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions, Journal of Marketing, Vol. 68, pp. 90-105 (Oct. 2004)	PUREX00023317	PUREX00023333

PUR2010	1/1/1990	Marilyn Peay, & Edmund Peay, Patterns of Preference for Information Sources in the Adoption of New Drugs by Specialists, Soc. Sci. Med. Vol. 31, No. 4, pp. 467-476, 1990	PUREX00023334	PUREX00023343
PUR2011	7/1/2002	PhRMA Code on Interactions with Healthcare Professionals	PUREX00023344	PUREX00023352
PUR2012	1/1/2004	PhRMA Code 2004	PUREX00023353	PUREX00023408
PUR2013	7/1/2008	PhRMA Code of Interactions with Healthcare Professionals	PUREX00023409	PUREX00023444
PUR2015	1/1/2004	Richard & Van Horn, Persistence in Prescriptions of Branded Drugs, Intl. J. Ind. Organ. 22 (2004), 523-540	PUREX00023445	PUREX00023462
PUR2016	1/1/2007	Everett Rogers, Diffusion of Innovations, Knowledge and Innovation Management, January 2007	PUREX00023463	PUREX00023477
PUR2017	1/1/2008	Salas et al: Analysis of US Food and Drug Administration Warning Letters; Pharm Med 2008	PUREX00023478	PUREX00023484
PUR2018	12/1/2018	Bradley SHAPIRO, Informational Shocks, Off-Label Prescribing, and the Effects of Physician Detailing, Management Science, Vol. 64, No. 12, December 2018, pp. 5925-5945	PUREX00023485	PUREX00023505
PUR2019	1/18/2019	Treki J, A Perspective Regarding the Current State of the Opioid Epidemic, JAMA Network Open, Vol. 2 (Jan. 18, 2019)	PUREX00023506	PUREX00023507
PUR2023	9/1/2005	Wang and Pauly, Spillover Effects of Restrictive Drug Formularies on Physician Prescribing Behavior: Evidence from Medicaid, Journal Economics & Management Strategy, 14(3); 755-773 Fall 2005	PUREX00023508	PUREX00023526
PUR2024	9/1/1991	Williams JR & Hensel PJ, Changes in Physicians' Sources of Pharmaceutical Information: A Review and Analysis, J. Health Care Marketing, Vol. 11, pp. 46-60 (Sept. 1991)	PUREX00023527	PUREX00023541
PUR2025	1/1/1992	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Smoking, Drinking, and Illicit Drug Use Among American Secondary School Students, College Students, and Young Adults, 1975-1991, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 93-3481, pp. 1-176, (1992).	PUREX00023542	PUREX00023723
PUR2029	7/22/2010	FDA Joint Meeting of the Anesthetic and Life Support Drugs Advisory and Drug Safety and Risk Management Advisory Committees presentation; Covidien: Our Experience in EXALGO Risk Management	PUREX00023724	PUREX00023734
PUR2030	8/4/2010	Transcript, Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM), July 22, 2010	PUREX00023735	PUREX00024097
PUR2032	7/22/2010	Rollin M. Gallagher MD, MPH Presentation: Improving functional Outcomes In Chronic Pain: The Importance of Appropriate, Safe Opioid Analgesia in Pain Management	PUREX00024098	PUREX00024294
PUR2033	7/22/2010	Presentation: Joint Meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees July 22-23, 2010; Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Products, Industry Working Group	PUREX00024295	PUREX00024341
PUR2034	7/22/2010	FDA Ad Com Chart: Annual U.S. Oxycontin Prescriptions (Millions) and Annual U.S. Oxycontin Retail Sales (Billions) 2000-2009	PUREX00024342	PUREX00024344
PUR2035	7/23/2010	Transcript, Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk Management Advisory Committee (DSaRM), July 23, 2010	PUREX00024345	PUREX00024667
PUR2040	9/29/2016	Ayanda, D. et al., Update on pharmacotherapy for treatment of opioid use disorder, Expert Opinion on Pharmacotherapy, Vol. 17:17, pp. 2307-2318	PUREX00024682	PUREX00024693
PUR2041	7/1/2008	Ballantyne, Efficacy of Opioids for Chronic Pain, A Revie, Clin J Pain, Vol 24, 2008	PUREX00024694	PUREX00024703
PUR2042	9/24/2012	Ballantyne, Opioid Dependence vs. Addiction, A Distinction, Amer. Med. Assoc., 2012	PUREX00024704	PUREX00024705
PUR2043	5/26/2009	BANTA-GREEN, et al., Opioid use behaviors, mental health and pain-Drug and Alcohol Dependence, 104:34-42, 2009	PUREX00024706	PUREX00024714
PUR2044	7/1/2017	Bartelson BB, et al., Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy, Pharmacoeconomics Drug Saf., Vol. 26, pp. 1061-1070 (2017)	PUREX00024715	PUREX00024724
PUR2045	3/9/2017	Barth, et al., Review of Guidelines, Training and Policy in Pain Management, Drug and Alcohol Dependence, Vol. 173, pp. s22-s30, 2017	PUREX00024725	PUREX00024733
PUR2046	2/1/1997	David Benziger et al., A Pharmacokinetic/pharmacodynamic study of controlled-release oxycodone, Jounal of Pain and Symptom Management, Vol. 13 (2); 75-82.	PUREX00024734	PUREX00024741
PUR2047	5/22/2015	Berna et al., Tapering Long-term Opioid Therapy in CNCP, Mayo Clinic, 2015	PUREX00024742	PUREX00024756
PUR2048	1/1/2010	BINSFELD, et al, A randomized study to demonstrate noninferiority, 2010	PUREX00024757	PUREX00024768
PUR2049	4/6/2010	Boscarino (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US health care system	PUREX00024769	PUREX00024776
PUR2050	4/1/1959	BOYD, RH, A clinical trial of dihydro-hydroxycodeinone pectinate, Anaesthesia, Vol. 14, No. 2, pp. 144-47	PUREX00024777	PUREX00024780
PUR2051	1/1/2006	Boyd et al., Medical and Nonmedical Use of Prescription Pain Medication by Youth, Drug and Alcohol Dependence, 2006	PUREX00024781	PUREX00024789
PUR2053	9/13/2010	Braden, ER visits among patients on chronic opioid therapy, Amer. Med. Assoc., Vol. 170, 9/13/2010	PUREX00024790	PUREX00024797
PUR2054	5/21/2016	Brandeis (2016) PDMP Prescriber Use Mandates	PUREX00024798	PUREX00024807
PUR2055	12/1/2017	Gabriel Brat, et al., Postsurgical Prescriptions for Opioid Naive Patients and Association with Overdose and Misuse; BMJ, 360:j5790, 2018	PUREX00024808	PUREX00024816

PUR2058	6/1/2006	BROWN, et al, Adverse Effects and Cognitive Function Among Primary Care Patients Taking Opioids, Journal of Opioid Management, pp 137-146, May/June 2006	PUREX00024820	PUREX00024829
PUR2059	10/1/1998	Eduardo Bruera et al., Randomized, Double-Blind, Cross-Over Trial Comparing Safety and Efficacy of Oral Controlled-Release Oxycodone With Controlled-Release Morphine in Patients With Cancer Pain, Amer. Society of Clinical Oncology, Journal of Clinical Oncology, 16(10)3222-3229, 1998	PUREX00024830	PUREX00024837
PUR2060	2/7/1986	F. Peter Buckley, et al., Medication Management in Patients With Chronic Non-Malignant Pain; Elsevier, Pain 26: 153-165	PUREX00024838	PUREX00024850
PUR2061	3/1/1986	Busto, U and Sellers, E., Pharmacokinetic Determinants of Drug Abuse and Dependence - A Conceptual Perspective, Clinical Pharmacokinetics, ADIS, Vol. 11, No. 2, pp.87-175, March/April 1986	PUREX00024851	PUREX00024861
PUR2062	4/1/2013	Butler et al., Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment, The Journal of Pain, Vol 14, No 4, pp. 351-358, April 2013	PUREX00024862	PUREX00024869
PUR2063	4/1/1999	Caldwell et al, Treatment of Osteoarthritis Pain with Controlled Release Oxycodone or Fixed Combination Oxycodone Plus Acetaminophen, Journal of Rheumatology, Vol 26, No. 4, pp. 862-869, April 1999	PUREX00024870	PUREX00024879
PUR2065	1/1/2014	Cassidy T et al. Changes in Prevalence of Prescription Opioid Abuse After Abuse-Deterrent Opioid Formulation, American Academy of Pain Medicine, Vol 15, pp. 440-451, 2014	PUREX00024880	PUREX00024891
PUR2066	12/21/2018	CDC News Release - New Data Show Growing Complexity of Drug Overdose Deaths in America	PUREX00024892	PUREX00024894
PUR2067	1/13/2005	Chelminski P, et al; A Primary Care, Multi-disciplinary Disease Management Program for Opioid-treated Patients with Chronic Non-cancer Pain and a High Burden of Psychiatric Co-morbidity, BMC Health Series Research, Vol. 5, No 3; 2005	PUREX00024895	PUREX00024907
PUR2069	8/15/2016	Cicero et al. Psychoactive substance use prior to development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers, Addictive Behaviors Elsevier, 65 (2017) 242-244.	PUREX00024908	PUREX00024910
PUR2072	9/1/2018	Cochran et al.; Prescription opioid quality measures applied among PA Medicaid Enrollees; Journal of Manager Care & Specialty Pharmacy, Vol. 24 No. 9; Sept. 2018	PUREX00024915	PUREX00024925
PUR2073	3/1/2008	Collado and Torres, Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain, J Opioid Management 4(2); 111-115	PUREX00024926	PUREX00024930
PUR2074	1/14/2016	Compton et al.; 2016 NEJM Rel Btwn Nonmed Opioid Use & Heroin Use; New England Journal of Medicine, 374:2, Jan. 14 2016	PUREX00024931	PUREX00024940
PUR2075	3/1/2003	Cone, E., et al.: Oxycodone Involvement in Drug Abuse Deaths: A DAWN-Based Classification Scheme Applied to an Oxycodone Postmortem Database Containing over 1000 cases (2003)	PUREX00024941	PUREX00024951
PUR2076	3/1/2015	Hilary Connery. Medication-Assisted Treatment of Opioid Use Disorder; Harvard College, Vol. 23:63-75	PUREX00024952	PUREX00024964
PUR2077	7/1/2004	Contet et al. (2004). Mu opioid receptor a gateway to drug addiction	PUREX00024965	PUREX00024974
PUR2078	9/1/2016	Coplan et al. Effect of Abuse-Deterrent OxyContin on Opioid Abuse related outcomes in the postmarketing setting, Clin Pharm & Therapies 100(3)	PUREX00024975	PUREX00024986
PUR2079	12/31/2018	OxyContin Butrans and Hysingla Annual MME Dispensed in Ohio 2001 - 2018	PUREX00024987	PUREX00024988
PUR2080	12/31/2018	OxyContin, Hysingla ER and Butrans TRx in Ohio, IQVIA xponent, and retail pharmacies and mail order 1998 - 2018	PUREX00024989	PUREX00024989
PUR2081	11/30/2015	Courtwright: Preventing and Treating Narcotic Addiction-A Century of Federal Drug Control.	PUREX00024990	PUREX00024992
PUR2082	1/1/2005	David T. Cowan et al., A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of Long-Term Opioid Drug Consumption and Subsequent Abstinence in Chronic Noncancer Pain Patients Receiving Controlled-Release Morphine, Pain Medicine, Vol. 5 Number 2, 2005	PUREX00024993	PUREX00025001
PUR2083	1/1/2003	Cowan, David T., et al., A survey of chronic non cancer pain patients prescribed opioid analgesics, Pain Medicine, 4(4): 340-351, 2003	PUREX00025002	PUREX00025014
PUR2084	1/1/1999	G. B. Curtis, et al.; Relative potency of controlled-release oxycodone and controlled-release morphine; J Clin Pharmacol, 55:425-429 , 1999	PUREX00025015	PUREX00025019
PUR2085	1/1/2000	Cuyahoga County 1999 Coroner Statistic Report	PUREX00025020	PUREX00025257
PUR2092	2/1/2018	Dasgupta et al., Opioid Crisis - No Easy Fix to Its Social and Economic Determinants, AJPH, Vol. 108, pp. 182-186, Feb. 2018	PUREX00025258	PUREX00025262
PUR2093	1/1/2006	Dasgupta, N., et al., Association between nonmedical and prescriptive usage of opioids and Alcohol Dependence, Vol. 82, pp. 135-142, 2006	PUREX00025263	PUREX00025270
PUR2094; PUR4990	7/1/2017	Davis et al. Prescription Opioid Use among Adults with Mental Health Disorders in the United States. 2017	PUREX00025271	PUREX00025281
PUR2095	7/1/2001	Drug Abuse Warning Network, The Dawn Report: Major Drugs of Abuse in ED Visits 2000, SAMHSA	PUREX00025282	PUREX00025284
PUR2096	10/1/2002	Drug Abuse Warning Network, The Dawn Report: Major Drugs of Abuse in ED Visits 2001 Update, SAMHSA	PUREX00025285	PUREX00025287
PUR2097	5/18/2004	The DAWN Report: Major Drugs of Abuse in ED Visits, 2002 Update	PUREX00025288	PUREX00025290
PUR2098	12/1/2004	"Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-related Emergency Department Visits," published by the U.S. Department of Health and Human Services, at http://DAWNinfo.samhsa.gov/	PUREX00025291	PUREX00025394

PUR2099	4/1/2006	"Drug Abuse Warning Network, 2004: Interim National Estimates of Drug-related Emergency Department Visits," published by the U.S. Department of Health and Human Services, at http://DAWNinfo.samhsa.gov/	PUREX00025395	PUREX00025474
PUR2100	2/1/2007	"Drug Abuse Warning Network, 2005: National Estimates of Drug-related Emergency Department Visits," published by the U.S. Department of Health and Human Services, at http://DAWNinfo.samhsa.gov/	PUREX00025475	PUREX00025568
PUR2101	1/1/2006	Drug Abuse Warning Network, DAWN Codebook (2006)	PUREX00025569	PUREX00025880
PUR2102	1/1/2007	Drug Abuse Warning Network, DAWN Codebook (2007)	PUREX00025881	PUREX00026192
PUR2103	2/1/2011	HHS SAMHSA, Drug Abuse Warning of Network, 2008: National Estimates of Drug-Related Emergency Department Visits	PUREX00026193	PUREX00026290
PUR2104	1/1/2009	Drug Abuse Warning Network, DAWN Codebook (2009)	PUREX00026291	PUREX00026687
PUR2105	7/2/2012	The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network Findings on Drug-Related Emergency Department Visits	PUREX00026688	PUREX00026695
PUR2106	11/1/2012	Drug Abuse Warning Network, 2010: National Estimates of Drug-Related Emergency Department Visits	PUREX00026696	PUREX00026878
PUR2107	2/22/2013	DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits	PUREX00026879	PUREX00026886
PUR2108	5/1/2013	Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits	PUREX00026887	PUREX00026986
PUR2109	8/29/2013	The CBHSQ Report: A Day in the Life of American Adolescents - Substance Use Fact Update; SAMHSA	PUREX00026987	PUREX00026994
PUR2110	5/11/2017	The CBHSQ Report A Day in the Life of Older Adults - Substance Use Facts.	PUREX00026995	PUREX00027001
PUR2111	6/10/2014	The CBHSQ Report A Day in the Life of Young Adults - Substance Use Facts. Jun 2014	PUREX00027002	PUREX00027008
PUR2112	12/18/2014	The DAWN Report: BenzoCombos with Opioids. Dec 2014.	PUREX00027009	PUREX00027014
PUR2113	4/16/2004	The DAWN Report: Benzodiazepines in Drug Abuse-Related Emergency Department Visits 1995-2002	PUREX00027015	PUREX00027018
PUR2114	1/29/2013	The DAWN Report ED visits involving buprenorphine, SAMHSA	PUREX00027019	PUREX00027025
PUR2115	8/7/2014	The DAWN Report: Emergency Department Visits for Drug-Related Suicide Attempts Have Increased. Aug 2014.	PUREX00027026	PUREX00027026
PUR2116	6/19/2014	The DAWN Report: Emergency Department Visits Involving Methamphetamine 2007 to 2011.	PUREX00027027	PUREX00027031
PUR2117	11/5/2015	The DAWN Report: Emergency Department Visits Involving Narcotic Pain Relievers. Nov 2015.	PUREX00027032	PUREX00027046
PUR2118	6/1/2003	Drug Abuse Warning Network, The Dawn Report: Trends in Drug-Related Emergency Department Visits, 1994-2001 at a Glance, SAMHSA June 2003	PUREX00027047	PUREX00027054
PUR2119	1/1/1991	US Dept of Health and Human Services, National Institute on Drug Abuse 1991: Annual Emergency Room Data 1990, Series I, No. 10-A	PUREX00027055	PUREX00027178
PUR2120	3/1/1994	Excerpt from DAWN Report: Annual Emergency Room Data 1991, Series I, Number 11-A, pp.76-144 (1992); Excerpt from DAWN Report: Annual Emergency Room Data 1992, Series I, Number 12-A, pp.1-59 (March 1994)	PUREX00027179	PUREX00027302
PUR2121	3/1/1994	Excerpt from DAWN Report: Annual Emergency Room Data 1992, Series I, Number 12-A, pp. 61-End (March 1994)	PUREX00027303	PUREX00027422
PUR2122	1/1/1992	DAWN Report: Annual Emergency Room Data 1991, Series I, Number 11-A (1992)	PUREX00027423	PUREX00027581
PUR2123	3/1/1994	DAWN Report: Annual Emergency Room Data 1992, Series I, Number 12-A, pp. 1-84 (March 1994) (Part 1 of 2)	PUREX00027582	PUREX00027681
PUR2124	3/1/1994	DAWN Report: Annual Emergency Room Data 1992, Series I, Number 12-A, pp. 85-End (March 1994) (Part 2 of 2)	PUREX00027682	PUREX00027779
PUR2125	7/1/1998	DAWN Report: Annual Medical Examiner Data 1996, pp. 1-33 (July 1998) (Part 1 of 2)	PUREX00027780	PUREX00027829
PUR2126	7/1/1998	DAWN Report: Annual Medical Examiner Data 1996, pp. 34-End (July 1998) (Part 2 of 2)	PUREX00027830	PUREX00027888
PUR2127	8/1/1999	DAWN Report: Annual Emergency Department Data 1997, pp. 1-62 (August 1999) (Part 1 of 2)	PUREX00027889	PUREX00027968
PUR2128	8/1/1999	DAWN Report: Annual Emergency Department Data 1997, pp. 63-End (August 1999) (Part 2 of 2)	PUREX00027969	PUREX00028064
PUR2129	8/1/2000	DAWN Report: Year-end 1999 Emergency Department Data (August 2000)	PUREX00028065	PUREX00028202
PUR2130	7/1/2001	DAWN Report: Year-End 2000 Emergency Department Data (July 2001)	PUREX00028203	PUREX00028335
PUR2131	3/24/2017	DEA 2016 National Drug Threat Assessment Summary (November 2016)	PUREX00028336	PUREX00028529
PUR2132	12/1/2008	National Drug Threat Assessment 2009	PUREX00028530	PUREX00028623
PUR2133	11/26/2014	DEA National Drug Threat Assessment Summary 2014	PUREX00028624	PUREX00028685
PUR2134	10/1/2017	2017 DEA National Drug Threat Assessment 2017 (Oct. 2017)	PUREX00028686	PUREX00028867
PUR2135	10/2/2018	2018 DEA National Drug Threat Assessment (Oct. 2018)	PUREX00028868	PUREX00029031
PUR2136	11/9/2015	DEA 2015 National Drug threat Assessment Summary	PUREX00029032	PUREX00029179
PUR2137	1/1/2003	National Drug Threat Assessment 2003	PUREX00029180	PUREX00029317
PUR2138	2/9/2006	DEA National Drug Threat Assessment 2006 (Jan. 2006)	PUREX00029318	PUREX00029374
PUR2140; PUR4993	10/1/2007	National Drug Threat Assessment 2008 (Oct. 2007)	PUREX00029375	PUREX00029463
PUR2141	6/22/2010	National Drug Threat Assessment 2010	PUREX00029464	PUREX00029547
PUR2142	8/1/2011	USDOJ National Drug Intelligence Center, National Drug Threat Assessment 2011	PUREX00029548	PUREX00029619
PUR2143	8/6/2018	DeGrandpre, The Cult of Pharmacology: How America Became the World's Most Troubled Drug Culture (2006)	PUREX00029620	PUREX00029623
PUR2144	10/4/1998	Delleijn, et al., "Prolonged treatment with transdermal fentanyl in Neuropathic Pain," Journal of Pain and Symptom Management, Vol. 16, Oct. 1998	PUREX00029624	PUREX00029633

PUR2145	7/27/2018	Deborah Dowell et al. CDC guideline for prescribing opioids for chronic pain. 2016	PUREX00029634	PUREX00029655
PUR2146	7/1/1994	DRUMMER, OH et al., A study of deaths involving oxycodone, Journal of Forensic Sciences, 39:4, pp. 1069-1075	PUREX00029656	PUREX00029662
PUR2148	4/1/1998	Ferrante - The Pharmacologic Management of Chronic Orthopaedic Pain; U.P.O.J. Volume 11 Spring 1998, pgs. 73-78	PUREX00029663	PUREX00029673
PUR2150	1/1/1990	Ferrante, MF, Patient Characteristics Influencing Effective Use of Patient-Controlled Analgesia, Patient-Controlled Analgesia, Chapter 5, pp. 51- 60	PUREX00029674	PUREX00029685
PUR2151	9/21/2018	Renata Ferrari Effectiveness of Opioid Analgesics in Chronic Noncancer Pain; Pain Practice 15:272-278; 2015	PUREX00029686	PUREX00029692
PUR2152	11/1/2010	Fine, PG, Long-Term Safety and Tolerability of Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain: An 18-Month Study, Journal of Pain and Symptom Management, Vol 40 No. 5, pp.747-760	PUREX00029693	PUREX00029706
PUR2153	5/30/2016	Finestone, et al., Opioid prescribing is a surrogate for inadequate pain management resources, Canadian Family Physician, Vol. 62, pp. 465-468	PUREX00029707	PUREX00029710
PUR2154	4/1/2008	Fishbain DA, et. al., What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review, Pain Medicine, Vol. 9, No. 4, pp. 444-459 (2008)	PUREX00029711	PUREX00029727
PUR2155	7/27/2018	Fishman, SM, et al. Core Competencies for Pain Management: Results of an Interprofessional Consensus Summit, Pain Medicine, Vol. 14, pp. 971-981	PUREX00029728	PUREX00029738
PUR2156	11/9/1995	Reder, RF, Fitzmartin, RD, Stigma Associated with Opioid Therapy for Pain: Results of a Health Care Provider Survey (abstract)	PUREX00029739	PUREX00029740
PUR2158	7/1/2007	Fleming, MF, Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy, The Journal of Pain Medicine, Vol. 8, pp. 573-582	PUREX00029741	PUREX00029750
PUR2159	2/1/2002	Franco, M., et al.: Usefulness of transdermal fentanyl in the management of nonmalignant chronic pain: A prospective, observational, multicenter study, The Pain Clinic, 2002	PUREX00029751	PUREX00029766
PUR2160	8/1/2018	Frank, JW, et. al., Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy, Annals of Internal Medicine, Vol. 167, Aug. 2017	PUREX00029767	PUREX00029795
PUR2161	9/30/2014	Franklin, GM, Opioids for chronic noncancer pain: A position paper of the American Academy of Neurology; American academy of Neurology; 83:1277-1284	PUREX00029796	PUREX00029804
PUR2162	1/1/2006	Fredheim, OM, Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study, Palliative Medicine 20:35-41, 2006	PUREX00029805	PUREX00029811
PUR2163	9/16/2003	Fudin, J, et al., Chronic Pain Management With Opioids in Patients With Past or Current Substance Abuse Problems, Journal of Pharmacy Practice 2003, Vol. 16(4), pp. 291-308	PUREX00029812	PUREX00029829
PUR2165	12/28/2018	Gaither, JR, et. al., US National Trends in Pediatric Deaths From Opioids, JAMA Network Open	PUREX00029830	PUREX00029843
PUR2166	3/1/2000	Galski et.al., Effects of Opioids on Driving Ability, Journal of Pain and Symptom Management, Vol, 19 No. 3, pp. 200 - 208	PUREX00029844	PUREX00029852
PUR2167	12/5/2010	Gatti, A., et al.: Long-Term Controlled-Release Oxycodone and Pregabalin in the Treatment of Non-cancer Pain: An Observational Study, European Neurology, 65:317-322, 2011	PUREX00029853	PUREX00029858
PUR2168	1/1/2010	Gatti, A., et al.: Transdermal Buprenorphine in Non-Oncological Moderate-to-Severe Chronic Pain	PUREX00029859	PUREX00029867
PUR2169	2/28/2003	Gimbel, JS, et al., Controlled-release oxycodone for pain in diabetic neuropathy, Neurology 2003;60:927-934.	PUREX00029868	PUREX00029875
PUR2170	1/1/2010	Giuggioli, D, et al.: Oxycodone in the Long-Term Treatment of Chronic Pain Related to Scleroderma Skin Ulcers, Pain Medicine 2010, pp. 1500-1503	PUREX00029876	PUREX00029879
PUR2171	10/6/2018	Goertz & George commentary on Heyward, Insurer Coverage of Nonpharmacological Treatments for Low Back Pain, JAMANetworkOpen.2018;1(5):e182943	PUREX00029880	PUREX00029882
PUR2172	2/17/2018	Gomes, et al. Burden of opioid-related mortality in the US, JAMA Network Open, June 1, 2018	PUREX00029883	PUREX00029888
PUR2175	9/21/2018	Gudin, Long-term Analgesic Effectiveness of Opioid Therapy in noncancer pain, 2016	PUREX00029889	PUREX00029890
PUR2176	9/12/2018	Hadland et al. Receipt of Timely Addiction Treatment in Adolescents. JAMA Pediatrics.	PUREX00029891	PUREX00029899
PUR2178	11/4/2015	Martin E. Hale, Thomas R. Zimmerman, Jr., Yuju Ma, and Richard Malamut; Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain; Journal of Opioid Management; 11:4, Sept/Oct 2015	PUREX00029908	PUREX00029917
PUR2180	6/1/2012	Meaged Hamza et al.: Prospective Study of 3-Year Follow-Up of Low-Dose Intrathecal Opioids in the Management of Chronic Nonmalignant Pain; Pain Medicine; 13; 1305-1313, 2012	PUREX00029918	PUREX00029927
PUR2181	8/7/2018	Beth Han et al.; Correlates of Prescription Opioid Use, Misuse, Use Disorders and Motivations for Misuse Among US Adults; Physicians Postgraduate Press; J cli Psychiatry 79:5, Sept/Oct 2018	PUREX00029928	PUREX00029938
PUR2182	2/22/2000	Yadollah Harati et al.: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy; Journal of Diabetes and Its complications	PUREX00029939	PUREX00029944

PUR2183	10/1/1995	Samuel J. Hassenbusch et al.: Long-Term Intraspinal Infusions of Opioids in the Treatment of Neuropathic Pain, Journal of Pain and Symptom Management, Vol 10 No. 7, Oct. 1995	PUREX00029945	PUREX00029961
PUR2185	10/6/2018	James Heyward et al.; Coverage of non-pharmacologic treatments for low back pain among us public and private insurers; JAMANetworkOpen.2018;1(5):e182943	PUREX00029962	PUREX00029975
PUR2186	7/25/2013	Jette Hojsted; Addictive behaviors related to opioid use for chronic pain: A population-based study; IASP; 154, 2677-2683; 2013	PUREX00029976	PUREX00029982
PUR2189	8/1/2017	Butrans total prescriptions by HCP product and strength	PUREX00029997	PUREX00029997
PUR2190	8/1/2017	Butrans total prescriptions by HCP product and strength	PUREX00029998	PUREX00029998
PUR2191	12/13/2018	IMS Data.zip?Hysingla TRx.xlsx	PUREX00029999	PUREX00029999
PUR2192	12/13/2018	IMS Data.zip?Hysingla Units Dispensed.xlsx	PUREX00030000	PUREX00030000
PUR2193	12/31/2017	Comparison of People Receiving OxyContin Prescriptions - IQVIA vs. NSDUH (2014-2017)	PUREX00030001	PUREX00030001
PUR2194	8/1/2017	Butrans total prescriptions by HCP product and strength	PUREX00030002	PUREX00030002
PUR2195	8/1/2017	Butrans total prescriptions by HCP product and strength	PUREX00030003	PUREX00030003
PUR2196	12/13/2018	IMS Data: ER Opioid Monthly Sales and IR Opioid Monthly Sales (Jan. 1992 - Sept. 2017)	PUREX00030004	PUREX00030004
PUR2197	12/13/2018	IMS Data: ER Opioid Monthly TRx and IR Opioid Monthly TRx (Jan. 1992 - Sept. 2017)	PUREX00030005	PUREX00030005
PUR2198	12/13/2018	IMS Data: ER Opioid Monthly Units Dispensed and IR Opioid Monthly Units Dispensed (Jan. 1992 - Sept. 2017)	PUREX00030006	PUREX00030006
PUR2199	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030007	PUREX00030007
PUR2200	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030008	PUREX00030008
PUR2201	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030009	PUREX00030009
PUR2202	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030010	PUREX00030010
PUR2203	8/1/2017	Oxycontin total prescriptions by HCP product and strength	PUREX00030011	PUREX00030011
PUR2204	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030012	PUREX00030012
PUR2205	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030013	PUREX00030013
PUR2206	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030014	PUREX00030014
PUR2207	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030015	PUREX00030015
PUR2208	8/1/2017	OxyContin total prescriptions by HCP product and strength	PUREX00030016	PUREX00030016
PUR2209	8/1/2017	OxyContin Units Dispensed by HCP, Product and Strengths (5 of 6): Retail Pharmacies and Mail Order (Source: QuintilesIMS exponent)	PUREX00030017	PUREX00030017
PUR2210	8/1/2017	OxyContin Units Dispensed by HCP, Product and Strengths (6 of 6): Retail Pharmacies and Mail Order (Source: QuintilesIMS exponent)	PUREX00030018	PUREX00030018
PUR2212	6/1/2014	Islam & McRae. Inevitable wave of PDMPs in the context of prescription opioids. 2014	PUREX00030019	PUREX00030025
PUR2213	9/21/2018	STAT, Why there is an opioid epidemic. 09-20-2018; https://www.statnews.com/2018/09/20/overdose-epidemic-multiple-threads/	PUREX00030026	PUREX00030028
PUR2215	9/21/2018	Hawre Jalal, Supplementary Materials for changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016; AAAS, 2018	PUREX00030029	PUREX00030040
PUR2216	10/27/2015	Abuse-Deterrent Opioid Formulations, Clincial Review & Education	PUREX00030041	PUREX00030042
PUR2217	5/15/2018	Abuse-Deterrent Opioids, JAMA, Vol 319, May 15, 2018	PUREX00030043	PUREX00030044
PUR2218	10/1/2003	Jamison, R., et al.: Neuropsychological Effects of Long-Term Opioid Use in Chronic Pain Patients- Journal of Pain and Symptom Management, Oct. 2003	PUREX00030045	PUREX00030053
PUR2219	1/1/1998	Jamison, R., et al., Opioid Therapy for Chronic Noncancer Back Pain: A Randomized Prospective Study, SPINE, Vol. 23(23), p.2591-2600.	PUREX00030054	PUREX00030063
PUR2221	1/1/1977	JASINSKI, D.R., Assessment of the Abuse Potentiality of Morphinelike Drugs, Drug Addiction I (1977), pp. 197-258	PUREX00030064	PUREX00030127
PUR2222	7/9/1977	JASINSKI, D.R., Progress Report from the Clinical Pharmacology Section of the NIDA Addiction Research Section, Problems of Drug Dependence 1977, pp. 133-168	PUREX00030128	PUREX00030165
PUR2223	7/28/2005	Jensen, M., et al.: 10-year follow-up of chronic non-malignant pain patients: Opioid use, health related quality of life and health care utilization, 2005	PUREX00030166	PUREX00030176
PUR2224	11/26/2018	John, WS, et al. Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco, Drug & Alcohol Dependence, Vol. 194, pp. 468-475 (Nov. 26, 2018)	PUREX00030177	PUREX00030184
PUR2225	5/1/2017	Christopher Jones, Pradip Muhuri, and Peer Lurie, Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013, Wolters Kluwer Health, Vol. 33, May, 2017	PUREX00030185	PUREX00030194
PUR2227	1/1/1999	Kaiko RF & Beczkowska IW, Comparative review of daily dose requirements of OxyContin and MS Contin in patients with non-malignant and malignant pain (1999)	PUREX00030195	PUREX00030195
PUR2228	10/1/1998	Ronald Kaplan, Comparison of controlled-release and immediate-release oxycodone tablets, Journal of Clinical Oncology 16(10):3230-3237, 1998	PUREX00030196	PUREX00030203
PUR2229	4/1/2013	Katz NP, et al., Prescription Opioid Abuse: Challenges and Opportunities for Payers, Journal of Managed Care, Vol. 19, pp. 295-302 (April 2013)	PUREX00030204	PUREX00030214
PUR2230	9/12/2006	Kidorf, MK et al., A stepped care for reducing cannabis use in opioid-dependent outpatients, Journal of Substance Abuse & Treatment 32 (2007), pp. 341-347	PUREX00030215	PUREX00030221
PUR2231	1/1/1991	Liebeskind, JC, Guest Editorial: Pain can kill, Pain, 44 (1991), pp. 3-4	PUREX00030222	PUREX00030223
PUR2234	8/26/2010	Lin, T., et al.: Chronic opioid therapy in patients with chronic noncancer pain in Taiwan, J Anesth, 2010, 24:882-887	PUREX00030224	PUREX00030230
PUR2236	7/29/2013	Mafi (2013) Worsening Trends in the Mgmt and Treatment of Back Pain	PUREX00030231	PUREX00030239
PUR2237	1/1/2005	Mahowald, M., et al.: Opioid Use by Patients in an Orthopedics Spine Clinic, 2005	PUREX00030240	PUREX00030249

PUR2238	1/1/2005	Malone, H., et al.: Long-term tolerability of tramadol LP, a new once-daily formulation in patients with osteoarthritis or low back pain, 2005	PUREX00030250	PUREX00030257
PUR2240	7/1/2012	Manchikanti (2012) Opioid epidemic in the US	PUREX00030258	PUREX00030287
PUR2244	6/26/2005	Manchikanti, Laxmaiah, et al., Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (Hydrocodone) or Long-Lasting (Methadone) Opioids, Pain Physician, Vol 8, 257-61, 2005	PUREX00030288	PUREX00030293
PUR2245	5/28/2004	Manchikanti, Laxmaiah, et al., Prospective evaluation of patients with increasing opioid needs: Prescription Opiate Abuse and Illicit Drug Use, Pain Physician, Vol 7, 339-44, 2004	PUREX00030294	PUREX00030299
PUR2247	9/25/2018	John Markman, Analgesic efficacy, safety, and tolerability of a longacting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone; Journal of Pain Resrch pp. 2051-2059; 2018	PUREX00030300	PUREX00030308
PUR2249; PUR4992	10/8/2013	Mars et al. Every never I ever said came true transitions from opioid pills to heroin injecting. International Journal of Drug Policy 25:257-266, 2014	PUREX00030309	PUREX00030318
PUR2250	10/30/2018	Bridget Martell et al.; Systematic review - opioid treatment for chronic back pain - prevalence, efficacy, and association with addiction; Ann Intern Med, 146:116-127, 2007	PUREX00030319	PUREX00030335
PUR2251	1/1/1966	William R. Martin, Assessment of the dependence-producing potentiality of narcotic Chapter 9, Pergamon Press, 1:155-180, 1966	PUREX00030336	PUREX00030363
PUR2255	12/1/1981	MARUTA, T, Problems with the use of oxycodone compound in patients with chronic pain, Pain, Vol. 11, No. 3, pp. 389-396	PUREX00030379	PUREX00030387
PUR2257	3/29/2013	Beneciuk et al; Opioid wear does not increase chronic pain; The Journal of Pain	PUREX00030388	PUREX00030388
PUR2258	3/29/2013	Matsuno et al. Purdue Abstract 408. Within patient vs. between patient designs to evaluate effects of long-term opioid therapy; The Journal of Pain	PUREX00030389	PUREX00030389
PUR2259	1/1/2005	McIlwain, H. and Ahdieh, H.: Safety, Tolerability, and Effectiveness of Oxymorphone Extended Release for Moderate to Severe Osteoarthritis Pain, 2005	PUREX00030390	PUREX00030396
PUR2260	4/18/2015	Jon Meiman et al.; Trends and characteristics of heroin overdoses in Wisconsin; Elsevier, 152:177-184	PUREX00030397	PUREX00030404
PUR2262	8/21/2004	Michna et al. Predicting aberrant drug behavior. Journal of Pain and Symptom Management Vol. 28 No. 3 September 2004	PUREX00030405	PUREX00030413
PUR2264	1/1/2004	Miller. Patient Characteristics and Risks Factors for oxycodone dependence. 2004	PUREX00030414	PUREX00030420
PUR2267	1/1/2001	Mironer, Y. E., et al.: Methadone in the Intrathecal Treatment of Chronic NonMalignant Pain Resistant to Other Neuroaxial Agents: The First Experience, 2001	PUREX00030421	PUREX00030428
PUR2268	11/4/2011	Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, Vol. 60, No. 43, November 4, 2011	PUREX00030429	PUREX00030464
PUR2272	9/1/2017	MMWR O'Donnell (2017) Trends in Deaths Involving Heroin & Synthetic Opioids Excluding Methadone and Law Enforcement, 2006-15	PUREX00030465	PUREX00030471
PUR2273	8/2/2018	Amin Mohamadi, Risk Factors and Pooled Rate of Prolonged Opioid Use Following Traumaor Surgery. Journal of Bone and Joint Surgery, 100:1332-40, 2018	PUREX00030472	PUREX00030480
PUR2274	8/2/2010	Morasco, B., et al.: Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain, 2010	PUREX00030481	PUREX00030488
PUR2275	1/1/2008	Morasco, Benjamin J., Dobscha, Steven K., Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain, General Hospital Psychiatry, Vol 30, 93-99, 2008	PUREX00030489	PUREX00030495
PUR2278	11/20/2018	Patricia Mucci-LoRusso et al., CR oxycodone compared with controlled-release morphine in the treatment of cancer pain., European Journal of Pain (1998) 2:239-249, 1998	PUREX00030496	PUREX00030506
PUR2283	2/1/2011	Naliboff, B., et al.: A Randomized Trial of 2 Prescription Strategies for Opioid Treatment of Chronic Nonmalignant Pain, Journal of Pain, Vol 12, No. 2, 2011	PUREX00030507	PUREX00030515
PUR2286	2/13/2007	Neufield, KJ et al., A behavioral treatment for opioid-dependent patients with antisocial personality, Journal of Substance Abuse Treatment 34 (2008); pp.101-111	PUREX00030516	PUREX00030526
PUR2288	6/27/2006	Nicholson, B>, et al.: Randomized trial comparing polymer coated extended release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain, 2006	PUREX00030527	PUREX00030538
PUR2291	4/1/1995	Substance Abuse & Mental Health Services Administration Data Archive (SAMHDA) National Household Survey on Drug Abuse: Public Release Codebook 1979 (April 1995)	PUREX00030539	PUREX00030738
PUR2292	4/1/1995	Substance Abuse & Mental Health Data Archive (SAMHDA): National Household Survey on Drug Abuse: Public Release Codebook 1982 (April 1995)	PUREX00030739	PUREX00030898
PUR2293	7/1/1994	Substance Abuse & Mental Health Data Archive (SAMHDA): National Household Survey on Drug Abuse: Public Release Codebook 1985 (July 1994)	PUREX00030899	PUREX00031146
PUR2294	1/1/1991	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1988	PUREX00031147	PUREX00031387

PUR2295	12/31/1990	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1990	PUREX00031388	PUREX00031579
PUR2296	12/31/1991	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Data Archive, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1991	PUREX00031580	PUREX00032059
PUR2297	3/1/1995	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1993	PUREX00032060	PUREX00032568
PUR2298	6/1/1996	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1994-A	PUREX00032569	PUREX00032983
PUR2299	6/1/1996	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1994-B	PUREX00032984	PUREX00033458
PUR2300	4/1/1997	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1995	PUREX00033459	PUREX00033923
PUR2301	2/1/1998	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1996	PUREX00033924	PUREX00034496
PUR2302	3/1/1999	US Dept of Health and Human Services, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Household Survey on Drug Abuse, Public Release Codebook 1997	PUREX00034497	PUREX00035179
PUR2303	12/31/1998	National Household Survey on Drug Abuse, 1998 - US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, 1998	PUREX00035180	PUREX00035674
PUR2304	12/31/1999	National Household Survey on Drug Abuse, 1999 - US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, 1999	PUREX00035675	PUREX00036269
PUR2305	12/31/2000	National Household Survey on Drug Abuse, 2000 - US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2000	PUREX00036270	PUREX00037094
PUR2306	12/31/2001	National Household Survey on Drug Abuse, 2001 - US Dept of Health and Human Services, Substance Abuse and Mental Health Services Administration, 2001	PUREX00037095	PUREX00038073
PUR2307	9/1/2003	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Results from the 2002 National Survey on Drug Use and Health: National Findings	PUREX00038074	PUREX00038175
PUR2308	3/23/2018	Substance Abuse and Mental Health Services and Administration: 2002 National Survey on Drug Use and Health	PUREX00038176	PUREX00038840
PUR2309	8/23/2004	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Results from the 2003 National Survey on Drug Use and Health: National Findings	PUREX00038841	PUREX00039112
PUR2310	3/23/2018	Substance Abuse and Mental Health Services and Administration: 2003 National Survey on Drug Use and Health	PUREX00039113	PUREX00039758
PUR2311	9/2/2005	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Results from the 2004 National Survey on Drug Use and Health: National Findings	PUREX00039759	PUREX00040068
PUR2312	5/21/2004	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Nonmedical Use of Prescription Pain Relievers	PUREX00040069	PUREX00040071
PUR2313	9/1/2006	Results from the 2005 National Survey on Drug Use and Health: National Findings	PUREX00040072	PUREX00040355
PUR2314	1/21/2005	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Nonmedical Oxycodone Users: A Comparison with Heroin Users	PUREX00040356	PUREX00040358
PUR2315	6/8/2006	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Nonmedical Users of Pain Relievers: Characteristics of Recent Initiates	PUREX00040359	PUREX00040362
PUR2316	9/10/2007	Department of Health & Human Services, Substance Abuse & Mental Health Services Administration, Office of Applied Studies Report: Results from the 2006 National Survey on Drug Use and Health: National Findings	PUREX00040363	PUREX00040644
PUR2317	9/1/2008	Department of Health & Human Services, Results from the 2007 National Survey on Drug Use and Health: National Findings	PUREX00040645	PUREX00040950
PUR2318	3/23/2018	Substance Abuse and Mental Health Services and Administration: 2007 National Survey on Drug Use and Health	PUREX00040951	PUREX00041786
PUR2319	9/1/2009	Results from the 2008 National Survey on Drug Use and Health: National Findings; U.S. Department of Health and Human Services	PUREX00041787	PUREX00042090

PUR2320	3/23/2018	2008 National Survey on Drug Use and Health, Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	PUREX00042091	PUREX00042955
PUR2321	3/23/2018	2009 National Survey on Drug Use and Health, Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	PUREX00042956	PUREX00043822
PUR2322	2/5/2009	The NSDUH Report, Trends in Nonmedical Use of Prescription Pain Relievers: 2002-2007	PUREX00043823	PUREX00043826
PUR2323	9/1/2011	HHS SAMHSA, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings	PUREX00043827	PUREX00043982
PUR2324	3/23/2018	2011 National Survey on Drug Use and Health, Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	PUREX00043983	PUREX00044842
PUR2325	3/23/2018	2012 National Survey on Drug Use and Health, Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	PUREX00044843	PUREX00045712
PUR2326	9/1/2014	Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality Report: Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings	PUREX00045713	PUREX00045791
PUR2327	3/23/2018	2013 National Survey on Drug Use and Health, Substance Abuse & Mental Health Services Administration, Center for Behavioral Health Statistics and Quality	PUREX00045792	PUREX00046669
PUR2328	8/20/2015	Substance Abuse & Mental Health Services Administration Report: Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health	PUREX00046670	PUREX00046733
PUR2329	8/22/2016	Substance Abuse & Mental Health Services Administration Report: Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health	PUREX00046734	PUREX00046805
PUR2330	1/17/2017	Substance Abuse & Mental Health Services Administration Report: Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health	PUREX00046806	PUREX00046879
PUR2331	8/11/2017	Substance Abuse & Mental Health Services Administration Report: Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health	PUREX00046880	PUREX00046965
PUR2336	12/1/2005	P&T Digest (2005) Pain Management - A Peer Reviewed Compendium of Formulary Considerations	PUREX00046969	PUREX00047031
PUR2337	8/30/2017	Palliative Medicine (2004) The WHO Three-Step Analgesic Ladder comes of age	PUREX00047032	PUREX00047033
PUR2338	1/1/2017	Pappagallo and Heinberg, Ethnical Issues in the Management of Chronic Nonmalignant Pain, Seminars in Neurology, Vol 17, Number 3, 1997	PUREX00047034	PUREX00047042
PUR2343	1/1/2011	Paaik, Steven D., et al., Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and Fentanyl buccal tablet for breakthrough pain, Journal of Pain and Symptom Management, Vol 41, 1, 116-25, 2011	PUREX00047043	PUREX00047052
PUR2344	6/1/2006	Pellino et al. Review of Wisconsin Managed Care Climate for Pain Management. 2006	PUREX00047053	PUREX00047059
PUR2348	2/14/2017	Pezzala (2017) Secular Trends in Prescribing	PUREX00047060	PUREX00047064
PUR2349	8/1/2018	Pham, T., et al.: Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016. Aug 2018	PUREX00047065	PUREX00047073
PUR2353	5/4/2007	Portenoy (2007) Long-term use of controlled-release oxycodone for noncancer pain	PUREX00047074	PUREX00047086
PUR2356	2/1/1993	Poyhia, R et al., A review of oxycodone's clinical pharmacokinetics and pharmacodynamics, Journal of Pain & Symptom Management, Vol. 8, No. 2, pp. 63-67	PUREX00047087	PUREX00047091
PUR2359	1/1/2008	Rauck (2008) Titration with oxymorphone extended release to achieve effective long term pain relief	PUREX00047092	PUREX00047100
PUR2361	7/25/2018	M. Carrington Reid et al.; Reid et al. Preliminary Research Article Characteristics of Older Adults Receiving Opioids in Primary Care: Treatment Duration and Outcomes; Wiley Periodicals, 1063-1071, 2010	PUREX00047101	PUREX00047109
PUR2364	1/1/2013	Richartz, U., et al.: Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended Release (OROS hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain, 2013	PUREX00047110	PUREX00047120
PUR2365	1/1/1999	Seymour Diamond, Oxycodone CR, a long-acting opioid, for severe chronic daily headache, Headache Quarterly, 19:305-309, 1999	PUREX00047121	PUREX00047126
PUR2367	9/20/2018	NaokoRonquest, Substance Abuse and Rehabilitation , Ronquest et al. Relationship-between-buprenorphine-adherence-and-relapse, health care utilization; 59-78, 2018	PUREX00047132	PUREX00047151
PUR2369	3/27/2000	Roth, S. et al., Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain, Arch Intern Med (2000)	PUREX00047152	PUREX00047159
PUR2373	12/18/2012	Rychlik, R., et al.: Pain Management and Costs of a Combination of Oxycodone + Naloxone in Low Back Pain Patients, 2012	PUREX00047160	PUREX00047175
PUR2376	12/18/2014	SAMHSA, The DAWN Report: Benzodiazepines in Combination with Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes (2014)	PUREX00047176	PUREX00047180
PUR2378	10/29/2018	Substance Abuse and Mental Health Services Administration, Medication and Counseling Treatment (2018)	PUREX00047181	PUREX00047187

PUR2380	5/1/2010	Sander-Kiesling, A., et al.: Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain, 2010	PUREX00047188	PUREX00047199
PUR2387	10/30/2018	Schatman, M.: Role of the Health Insurance Industry in Perpetuating Suboptimal Pain Management, Pain Medicine, 12:415-426, 2011	PUREX00047200	PUREX00047211
PUR2388	6/1/1999	Schofferman, J.,: Long-Term Opioid Analgesic Therapy for Severe Refractory Lumbar Spine Pain, 1999	PUREX00047212	PUREX00047217
PUR2391	11/2/2010	Schwartz, S., et al.: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial, Current Medical Research & Opinion v.27, No.1, 2011, 151-162	PUREX00047218	PUREX00047229
PUR2392	2/1/2015	Secades-Villa, R. et al.: Probability and predictors of the cannabis gateway effect. (2015)	PUREX00047230	PUREX00047250
PUR2393	4/23/2018	Severino, A., et al.; Pain Therapy Guided by Purpose & Perspective Opioid Epidemic; frontiers in Psychiatry (2018)	PUREX00047251	PUREX00047263
PUR2395	8/1/2007	Shaladi, A., et al.:Continuous Intrathecal Morphine Infusion in Patients With Vertebral Fractures Due to Osteoporosis, 2007	PUREX00047264	PUREX00047270
PUR2397	6/6/2017	Health and Human Services Public Access: Smith, S. , et al.: Classification and Definition of Misuse, Abuse, and Related Events in Clinical Trials: ACTTION systemic review and recommendations	PUREX00047271	PUREX00047293
PUR2399	6/1/1963	Stathers, D. , et al.: Oxycodone Suppositories in the Relief of Intractable Pain. May & Baker LTD, 190:779 - 781 (1963)	PUREX00047294	PUREX00047297
PUR2401	9/4/2013	Sullivan, M. & Howe, C.: Opioid therapy for chronic pain in the United States: Promises and perils, IASP, Vol 154 S94-S100, 2013	PUREX00047305	PUREX00047311
PUR2402	10/23/2006	Sullivan, M., et al.: Association Between Mental Health Disorders, Problem Drug Use, and Regular Prescription Opioid Use (2006)	PUREX00047312	PUREX00047318
PUR2404	2/19/2010	Sullivan, M., et al.: Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain, 2010	PUREX00047319	PUREX00047327
PUR2405	5/20/2010	Sullivan, Mark D., et al.: Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP study, Pain, Vol 50, 332-39, 2010	PUREX00047328	PUREX00047335
PUR2407	1/27/2003	Tassain, V., et al.: Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain, 2003	PUREX00047345	PUREX00047356
PUR2408	4/19/2019	S1 Appendix: One-time cost methods and sources	PUREX00047357	PUREX00047359
PUR2409	4/19/2019	S2 Appendix: Personnel Cost Methods and Sources	PUREX00047360	PUREX00047362
PUR2410	4/19/2019	S3 Appendix: Operational Cost Methods and Sources	PUREX00047363	PUREX00047365
PUR2411	4/19/2019	S4 Appendix: Prevention/Medical Services Cost Methods and Sources	PUREX00047366	PUREX00047368
PUR2412	4/19/2019	S5 Appendix: Onsite Medical/Testing Services Cost Methods and Sources	PUREX00047369	PUREX00047369
PUR2413	4/19/2019	S6 Appendix: Mobile Van Cost Methods and Sources	PUREX00047370	PUREX00047370
PUR2414	4/22/2019	Teshale EH, Asher A, Aslam MV, Augustine R, Duncan E, Rose-Wood A, et al., Estimated Cost of Comprehensive Syringe Service Program in the United States, PLoS ONE, 14(4), pp. 1-10.	PUREX00047371	PUREX00047380
PUR2415	1/5/2004	Thimineur, M., et al.: Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study, 2004	PUREX00047381	PUREX00047388
PUR2417	4/1/2008	Thorne, C., et al.: A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with osteoarthritis, 2008	PUREX00047389	PUREX00047398
PUR2421	4/19/2011	Vojtassak, J., et al.: A phase 111b, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee, Pain Research and Treatment, Vol 2011	PUREX00047402	PUREX00047410
PUR2424	8/1/2011	Vorsanger, G., et al.: Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients, Pain Res Manage Vol 16 No 4 July/August 2011, pp. 245-251	PUREX00047411	PUREX00047417
PUR2429	1/1/2011	Wallace, M., et al.: Open-Label Study on the Long-Term Efficacy, Safety, and Impact on Quality of Life of OROS Hydromorphone ER in Patients with Chronic Low Back Pain,	PUREX00047418	PUREX00047429
PUR2433	8/1/2010	Watson, CPN, et al.: The long-term safety and efficacy of opioids: A survey of 84 selected patients with intractable chronic noncancer pain, 2010	PUREX00047436	PUREX00047440
PUR2435	11/1/2010	Webster, L., et al.: Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain, 2010	PUREX00047441	PUREX00047453
PUR2436	12/1/2006	Webster, L. et al.: Oxytrex Minimizes Physical Dependence While Providing Effective Analgesia: A Randomized Controlled Trial in Low Back Pain, 2006	PUREX00047454	PUREX00047463
PUR2437	5/7/2009	Weisner, Constance M., et al., Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders, Pain, Vol 145, 287-93, 2009	PUREX00047464	PUREX00047470
PUR2439	9/28/2018	Wen et al. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use, JAMANetworkOpen.2018;1(5):e182943	PUREX00047471	PUREX00047483
PUR2440	4/29/2010	Wild, J., et al.: Long-Term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain, 2010	PUREX00047484	PUREX00047495

PUR2441	3/1/2011	Article: Li-Tzy Wu et al. How do prescription opioid users differ from users of heroin or other drugs in psychopathology.	PUREX00047496	PUREX00047503
PUR2443	9/7/2007	Murat Yucel et al. . Understanding drug addiction: a neuropsychological perspective, The Royal Australian and New Zealand College of Psychiatrists	PUREX00047504	PUREX00047516
PUR2444	7/31/2018	Barbara Zedler. Risk Factors for Serious Prescription Opioid Related Toxicity or Overdose among Veterans Health Administration Patients; Pain Medicine: 15: 1911-1929, 2014	PUREX00047517	PUREX00047535
PUR2446	11/27/2018	Johnston, Lloyd D., Bachman, Jerald G., O'Malley, Patrick, Highlights from Drug Use Among High School Students 1975-77, U.S. Government Printing Office,pp. 1-43, (1978)	PUREX00047545	PUREX00047594
PUR2447	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drugs and The Class of 1978: Behaviors, Attitudes, and Recent National Trends, U.S. Government Printing Office, pp. 1-353, (1979).	PUREX00047595	PUREX00047948
PUR2448	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drugs and The Nation's High School Students Five Year National Trends, U.S. Government Printing Office, DHEW Publication No. (ADM) 80-930, pp. 1-80, (1980).	PUREX00047949	PUREX00048033
PUR2449	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Highlights From Drugs and The Class of '78: Behaviors, Attitudes, and Recent National Trends, U.S. Government Printing Office, DHEW Publication No. (ADM) 79-878, pp. 1-57, (1979).	PUREX00048034	PUREX00048097
PUR2450	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Highlights from Student Drug Use in America, U.S. Government Printing Office, DHEW Publication No. (ADM) 81-1066, pp. 1-113, (1980).	PUREX00048098	PUREX00048213
PUR2451	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Highlights from Student Drug Use in America 1975-1981, U.S. Government Printing Office, DHHS Publication No. (ADM) 82-1208, pp. 1-124, (1982).	PUREX00048214	PUREX00048341
PUR2452	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Student Drug Use In America, U.S. Government Printing Office, DHEW Publication No. (ADM) 80-930, pp. 1-433, (1982).	PUREX00048342	PUREX00048775
PUR2453	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Student Drug Use, Attitudes and Beliefs National Trends 1975-1982, U.S. Government Printing Office, DHHS Publication No. (ADM) 83-1260, pp. 1-134, (1983).	PUREX00048776	PUREX00048914
PUR2454	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drugs and American High School Students 1975-1983, U.S. Government Printing Office, DHHS Publication No. (ADM) 84-1317, pp. 1-135, (1984).	PUREX00048915	PUREX00049053
PUR2455	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Use of Licit and Illicit Drugs by America's High School Students, U.S. Government Printing Office, DHHS Publication No. (ADM) 85-1394, pp. 1-159, (1985).	PUREX00049054	PUREX00049217
PUR2456	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drug Use Among American High School Students, College Students, and Other Young Adults, U.S. Government Printing Office, DHHS Publication No. (ADM) 86-1450, pp. 1-237, (1986).	PUREX00049218	PUREX00049465
PUR2457	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Trends in Drug Use and Related Factors Among American High School, U.S. Government Printing Office, DHHS Publication No. (ADM) 87-1535, pp. 1-8265, (1987).	PUREX00049466	PUREX00049741
PUR2458	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Illicit Drug Use, Smoking and Drinking by America's High School Students, College Students, and Young Adults 1975-1987, U.S. Government Printing Office, DHHS Publication No. (ADM) 89-1602, pp. 1-307, (1988).	PUREX00049742	PUREX00050051
PUR2459	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drug Use, Drinking, and Smoking: National Survey Results from High School, College, and Young Adult Populations, U.S. Government Printing Office, DHHS Publication No. (ADM) 89-1638, pp. 1-339, (1989).	PUREX00050052	PUREX00050397
PUR2460	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Trends in Drug Use and Associated Factors Among American High School Students, College Students, and Young Adults 1975-1989, U.S. Government Printing Office, pp. 1-331, (1991).	PUREX00050398	PUREX00050742
PUR2461	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drug Use Among American High School Seniors, College Students and Young Adults 1975-1990, Volume I High School Seniors, U.S. Government Printing Office, DHHS Publication No. (ADM) 91-1813, pp. 1-199, (1991).	PUREX00050743	PUREX00050944
PUR2462	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Drug Use Among American High School Seniors, College Students and Young Adults, 1975-1990, U.S. Government Printing Office, DHHS Publication No. (ADM) 91-1835, pp. 1-168, (1991).	PUREX00050945	PUREX00051121
PUR2463	11/27/2018	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Smoking, Drinking, and Illicit Drug Use Among American Secondary School Students, College Students, and Young Adults Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 93-3480, pp. 1-231, (1992).	PUREX00051122	PUREX00051356
PUR2464	1/1/1993	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring the Future Study, 1975-1992, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 93-3598, pp. 1-190, (1993).	PUREX00051357	PUREX00051554

PUR2465	1/1/1993	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1992, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 93-3597, pp. 1-269, (1993).	PUREX00051555	PUREX00051838
PUR2466	1/1/1994	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1993, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 94-3810, pp. 1-189, (1994).	PUREX00051839	PUREX00052037
PUR2467	1/1/1994	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, U.S. Government Printing Office, NIH Publication No. 94-3809, pp. 1-281, (1994).	PUREX00052038	PUREX00052331
PUR2468	1/1/1995	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results On Drug Use from The Monitoring The Future Study, 1975-1994, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 95-4026, pp. 1-327, (1995).	PUREX00052332	PUREX00052674
PUR2469	1/1/1996	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1994, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 96-4027, pp. 1-189, (1996).	PUREX00052675	PUREX00052874
PUR2470	1/1/1997	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1995, Volume I College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 98-4140, pp. 1-188, (December 1987).	PUREX00052875	PUREX00053073
PUR2471	1/1/1996	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1995, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 96-4139, pp. 1-381, (1996).	PUREX00053074	PUREX00053461
PUR2472	1/1/1998	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1997, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 94345, pp. 1-433, (1998).	PUREX00053462	PUREX00053907
PUR2473	1/1/1998	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1997, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 98-4346, pp. 1-206, (1998).	PUREX00053908	PUREX00054124
PUR2474	1/1/1999	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1998, Volume II College Students and Young Adults, U.S. Government Printing Office, NIH Publication No. 99-4661, pp. 1-218, (1999).	PUREX00054125	PUREX00054352
PUR2475	1/1/1999	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1998, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 99-4660, pp. 1-420, (1999).	PUREX00054353	PUREX00054788
PUR2476	1/1/2000	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., The Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings, 1999, U.S. Government Printing Office, NIH Publication No. 00-4690, pp. 1-37, (2000).	PUREX00054789	PUREX00054842
PUR2477	8/1/2000	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Monitoring The Future National Survey Results on Drug Use, 1975-1999, Volume I Secondary School Students, U.S. Government Printing Office, NIH Publication No. 00-4802, pp. 1-480, (August 2000).	PUREX00054843	PUREX00055338
PUR2478	1/1/2002	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings, 2001, U.S. Government Printing Office, National Institutes of Health pp. 1-39, (2002).	PUREX00055339	PUREX00055399
PUR2479	1/1/2003	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Monitoring The Future National Results on Adolescent Drug Use, Overview of Key Findings, National Institute of Health, www.monitoringthefuture.org, pp. 1-56, (2003).	PUREX00055400	PUREX00055460
PUR2480	6/1/2004	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings, U.S. Government Printing Office, NIH Publication No. 04-5506, pp. 1-59, (2004).	PUREX00055461	PUREX00055523
PUR2481	4/1/2005	Johnston, Lloyd, Bachman, Jerald G., O'Malley, Patrick M., Schulenberg, John E., Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings, U.S. Government Printing Office, NIH Publication No. 05-5726, pp. 1-66, (2005).	PUREX00055524	PUREX00055595
PUR2482	4/1/2006	Johnston, Lloyd D., Bachman, Jerald G., O'Malley, Patrick M., Schulenberg, John E., Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings 2005, U.S. Government Printing Office, NIH Publication No. 06-5882, pp. 1-67, (2006).	PUREX00055596	PUREX00055668
PUR2483	5/1/2007	Johnston, Lloyd D., Bachman, Jerald G., O'Malley, Patrick M., Schulenberg, John E., Monitoring The Future National Results on Adolescent Drug Use Overview of Key Findings 2006, U.S. Government Printing Office, NIH Publication No. 07-6202, pp. 1-71, (2007).	PUREX00055669	PUREX00055744
PUR2484	4/1/2008	Johnston LD, O'Malley PM, Bachman JG & Schulenberg JE, Monitoring The Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2007, U.S. Government Printing Office, NIH Publication No. 08-6418, pp. 1-70 (April 2008).	PUREX00055745	PUREX00055820

PUR2485	5/1/2009	Johnston LD, Bachman JG, O'Malley PM & Schulenberg JE, Monitoring The Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2008, U.S. Government Printing Office, NIH Publication No. 09-7401, pp. 1-73 (May 2009).	PUREX00055821	PUREX00055899
PUR2486	5/1/2010	Johnston LD, Bachman JG, O'Malley PM & Schulenberg JE, Monitoring The Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2009, U.S. Government Printing Office, NIH Publication No. 10-7583, pp. 1-77 (May 2010).	PUREX00055900	PUREX00055982
PUR2487	2/1/2011	Johnston LD, Bachman JG, O'Malley PM & Schulenberg JE, Monitoring The Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2010, Institute for Social Research, The University of Michigan pp. 1-77 (February 2011).	PUREX00055983	PUREX00056066
PUR2488	2/1/2012	Johnston LD, O'Malley PM, Bachman JG & Schulenberg JE, Monitoring the Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2011, Institute for Social Research, The University of Michigan, pp. 1-83 (Feb. 2012)	PUREX00056067	PUREX00056151
PUR2489	2/1/2013	Johnston LD, O'Malley PM, Bachman JG & Schulenberg JE, Monitoring the Future: National Results on Drug Use - 2012 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-83 (Feb. 2013)	PUREX00056152	PUREX00056241
PUR2490	2/1/2014	Johnston LD, O'Malley PM, Miech RA, Bachman, JG & Schulenberg JE, Monitoring the Future: National Results on Drug Use - 2013 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-84 (Feb. 2014)	PUREX00056242	PUREX00056331
PUR2491	2/1/2015	Johnston LD, O'Malley PM, Miech RA, Bachman JG & Schulenberg JE, Monitoring the Future: National Survey Results on Drug Use - 2014 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-90 (Feb. 2015)	PUREX00056332	PUREX00056429
PUR2492	2/1/2016	Johnston LD, O'Malley PM, Miech RA, Bachman JG & Schulenberg JE, Monitoring the Future: National Survey Results on Drug Use - 2015 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-97 (Feb. 2016)	PUREX00056430	PUREX00056533
PUR2493	1/1/2017	Johnston LD, O'Malley PM, Miech RA, Bachman JG & Schulenberg JE, Monitoring the Future: National Survey Results on Drug Use - 2016 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-113 (Jan. 2017)	PUREX00056534	PUREX00056653
PUR2494	1/1/2018	Johnston LD, O'Malley et al.; Monitoring the Future: National Survey Results on Drug Use - 2017 Overview of Key Findings on Adolescent Drug Use, Institute for Social Research, The University of Michigan, pp. 1-97 (Jan. 2018)	PUREX00056654	PUREX00056776
PUR2495	8/1/2018	John E Schulenberg, National Survey Result on Drug Use: College Students & Adults, 1975-2017	PUREX00056777	PUREX00057252
PUR2500	6/25/2015	U.S. Government Accountability Office Report to Congressional Requestors; Prescription Drugs More DEA Information about Registrants' Controlled Substances Roles Could Improve Their Understanding and Help Ensure Access; June 2015	HDA_MDL_000000374	HDA_MDL_000000464
PUR2527	8/13/2009	Email from Jack Crowley to George Euson regarding Pharmacy Inquiry	HDS_MDL_00086406	HDS_MDL_00086407
PUR2528; PUR4918	10/20/2014	U.S. Attorney's Office Northern District of Ohio Press Release, re: Akron doctor pleads guilty to illegally prescribing painkillers	MCKPUB00000001	MCKPUB00000003
PUR2536; PUR4919	3/12/2015	U.S. Attorney's Office Northern District of Ohio online publication re Akron Doctor Pleads Guilty to Illegal Prescribing Painkillers	MCKPUB00004921	MCKPUB00004922
PUR2543	11/1/2017	The President's Commission on Combating Drug Addiction and the Opioid Crisis - Recommendations	MCKPUB00030241	MCKPUB00030378
PUR2554	4/1/2003	Agreement between The City of Cleveland and Medical Mutual of Ohio for medical insurance coverage	MMO_000269	MMO_000431
PUR2555	1/14/2019	County of Cuyahoga EPO Network Comprehensive Major Medical Health Care Benefit Book, Hearing Rider	MMO_007040	MMO_007290
PUR2565	1/21/2014	Ohio Board of Nursing - Compliance Unit Letter regarding disciplinary records	OBN_MDL 1st Production 043085	OBN_MDL 1st Production 040844
PUR2566	9/26/2012	Letter from the Ohio Board of Nursing - Compliance Unit regarding disciplinary records	OBN_MDL 1st Production 047750	OBN_MDL 1st Production 045533
PUR2567	9/20/2013	Ohio Board of Nursing Consent Agreements with various individuals	OBN_MDL 1st Production 062106	OBN_MDL 1st Production 059516
PUR2568	1/26/2017	Ohio Board of Nursing - Consent Agreement Between B. Adamski, L.P.N. and Ohio Board of Nursing	OBN_MDL 1st Production 116045	OBN_MDL 1st Production 119051
PUR2571	6/15/2017	Threat Assessment & Strategy Program Year 2017: Ohio High Intensity Drug Trafficking Area prepared for Office of National Drug Control Policy High Intensity Drug Trafficking Area Program	OH-HIDTA-00011475	OH-HIDTA-00011546
PUR2572	11/1/2017	Letter from Ohio State Board of Pharmacy to Amy Wildermuth Re: summary suspension order/notice of opportunity for hearing	Ohio BOP 00003054	Ohio BOP 00003057
PUR2573	9/14/2012	Ohio State Board of Pharmacy Order re In the Matter of Dave Wayne Blackwell	Ohio BOP 00003247	Ohio BOP 00003258
PUR2574	7/9/2008	Ohio State Board of Pharmacy Order re In the Matter of Dave Wayne Blackwell	Ohio BOP 00003259	Ohio BOP 00003266
PUR2575	6/10/2014	Ohio State Board of Pharmacy Settlement Agreement re In the Matter of Christopher Tolliver	Ohio BOP 00005186	Ohio BOP 00005188
PUR2576	3/15/2018	Ohio State Board of Pharmacy Order re In the Matter of Kristine King	Ohio BOP 00005576	Ohio BOP 00005581
PUR2577	6/17/1997	Ohio Board of Pharmacy Orders re In the Matter of Kent W. Schindler (6/17/1997 and 4/25/1995)	Ohio BOP 00007630	Ohio BOP 00007639

PUR2578	1/17/2013	Order of the State of Ohio Board of Pharmacy	Ohio BOP 00008636	Ohio BOP 00008641
PUR2579	1/11/2007	Order of the Ohio State Board of Pharmacy re In the Matter of Michael T. Dennis	Ohio BOP 00009642	Ohio BOP 00009647
PUR2580	11/8/2006	Orders of the Ohio State Board of Pharmacy re In the Matter of John Paul Tekulve (11/10/2004 and 11/8/2006)	Ohio BOP 00009776	Ohio BOP 00009796
PUR2581	4/9/2015	Order of the Ohio State Board of Pharmacy re In the Matter of Kelley Anne Schmid	Ohio BOP 00009811	Ohio BOP 00009815
PUR2582	9/17/2009	Order of the Ohio State Board of Pharmacy re In the Matter of David Enoch Milhous	Ohio BOP 00010295	Ohio BOP 00010299
PUR2583	8/9/2013	Settlement Agreement with the Ohio State Board of Pharmacy re In the Matter of Wal-Mart Pharmacy #10-2350 c/o Rick Irby	Ohio BOP 00011581	Ohio BOP 00011583
PUR2584	1/11/2007	Order of the State Board of Pharmacy re In the Matter of Strasburg Pharmacy c/o Michael Dennis	Ohio BOP 00011889	Ohio BOP 00011893
PUR2585	7/9/2008	State Medical Board of Ohio Assigned Committees (including Executive Committee, Licensure Committee, and Impairment Committee) Agenda and Minutes	Ohio_State_Medical_Board_00007729	Ohio_State_Medical_Board_00009059
PUR2586	4/8/2009	State Medical Board of Ohio Assigned Committees (Including Executive Committee, Licensure Committee, Impairment Committee, Legislative Liaison and Rules Committee) Agenda and Minutes	Ohio_State_Medical_Board_00023025	Ohio_State_Medical_Board_00024273
PUR2587	12/14/2011	State Medical Board of Ohio Assigned Committees Meeting Agendas and Minutes	Ohio_State_Medical_Board_00053026	Ohio_State_Medical_Board_00053913
PUR2588	7/10/2013	State Medical Board of Ohio Meeting Agendas and Minutes	Ohio_State_Medical_Board_00064842	Ohio_State_Medical_Board_00065318
PUR2589	1/8/2014	State Medical Board of Ohio Assigned Committees Agenda and Minutes	Ohio_State_Medical_Board_00067975	Ohio_State_Medical_Board_00068510
PUR2590	8/13/2014	State Medical Board of Ohio Assigned Committees Agenda and Minutes	Ohio_State_Medical_Board_00071371	Ohio_State_Medical_Board_00072096
PUR2591	11/9/2016	State Medical Board of Ohio Assigned Committees Agenda and Minutes	Ohio_State_Medical_Board_00083377	Ohio_State_Medical_Board_00083740
PUR2592	1/11/2017	State Medical Board of Ohio Assigned Committees (including Licensure Committee and Policy Committee) Agenda and Minutes	Ohio_State_Medical_Board_00084019	Ohio_State_Medical_Board_00084508
PUR2594; PUR5000	9/9/2016	Violence and Injury Prevention Program-Prescription Drug Overdose Managers meeting presentation	OhioDOH_00000641	
PUR2595	3/5/2008	Ohio Board of Pharmacy; Minutes of the March 3-5, 2008 Meeting	OhioPharmMins_0000004	OhioPharmMins_0000004
PUR2596	2/3/2009	Ohio State Board of Pharmacy; Minutes of the January 5-6, 2009 Meeting	OhioPharmMins_0000017	OhioPharmMins_0000017
PUR2597	9/15/2009	Ohio State Board of Pharmacy; Minutes of the August 3-5, 2009 Meeting	OhioPharmMins_0000028	OhioPharmMins_0000028
PUR2598	1/12/2011	Ohio State Board of Pharmacy; Minutes of the December 6-8, 2010 Meeting	OhioPharmMins_0000047	OhioPharmMins_0000047
PUR2599	2/9/2011	Ohio State Board of Pharmacy; Minutes of the February 7-9, 2011 Meeting	OhioPharmMins_0000051	OhioPharmMins_0000051
PUR2600	5/3/2011	Ohio State Board of Pharmacy; Minutes of the April 4-6, 2011 Meeting	OhioPharmMins_0000054	OhioPharmMins_0000054
PUR2601	1/7/2013	Ohio State Board of Pharmacy; Minutes of the September 10-12, 2012 Meeting	OhioPharmMins_0000074	OhioPharmMins_0000074
PUR2602	2/5/2013	Ohio State Board of Pharmacy; Minutes of the December 3-4, 2012 Meeting	OhioPharmMins_0000078	OhioPharmMins_0000078
PUR2603	2/5/2013	Ohio State Board of Pharmacy; Minutes of the January 7-8, 2013 Meeting	OhioPharmMins_0000081	OhioPharmMins_0000081
PUR2604	5/7/2013	Ohio State Board of Pharmacy; Minutes of the April 8-9, 2013 Meeting	OhioPharmMins_0000085	OhioPharmMins_0000085
PUR2605	11/5/2013	Ohio State Board of Pharmacy; Minutes of the October 7-9, 2013 Meeting	OhioPharmMins_0000090	OhioPharmMins_0000090
PUR2606	1/8/2014	Ohio State Board of Pharmacy; Minutes of the December 2-4, 2013 Meeting	OhioPharmMins_0000094	OhioPharmMins_0000094
PUR2607	7/10/2014	Ohio State Board of Pharmacy; Minutes of the June 9-10, 2014 Meeting	OhioPharmMins_0000106	OhioPharmMins_0000106
PUR2608	11/4/2014	Ohio State Board of Pharmacy; Minutes of the October 6-8, 2014 Meeting	OhioPharmMins_0000113	OhioPharmMins_0000113
PUR2609	1/8/2015	Ohio State Board of Pharmacy; Minutes of the December 1-3, 2014 Meeting	OhioPharmMins_0000117	OhioPharmMins_0000117
PUR2610	4/29/2015	Ohio State Board of Pharmacy; Minutes of the March 2-4, 2015 Meeting	OhioPharmMins_0000121	OhioPharmMins_0000121
PUR2612	1/1/1997	Purdue 1997 Budget and Promotional Plan for OxyContin	PDD1501030062	PDD1501030117
PUR2613	1/1/1998	Purdue 1998 Budget and Promotional Plan for OxyContin	PDD1501030118	PDD1501030169
PUR2614	1/1/1999	Purdue 1999 Budget and Promotional Plan for OxyContin	PDD1501030170	PDD1501030218
PUR2615	1/1/2000	Purdue 2000 Budget and Promotional Plan for OxyContin	PDD1501030219	PDD1501030264
PUR2616	1/1/2002	Purdue 2002 Budget and Promotional Plan for OxyContin	PDD1501030328	PDD1501030385
PUR2617	1/1/2003	Purdue Presentation: 2003 OxyContin Marketing Plan	PDD1501030386	PDD1501030430
PUR2618	5/19/1995	Medical Officer Review: Integrated Summary of Safety OxyCodone Controlled Release	PDD1501090033	PDD1501090042
PUR2619	1/1/1996	"24 Hours of Oxycodone Pain Control" Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600072	PDD1501600088
PUR2620	1/1/1996	"24 Hours of Oxycodone Pain Control" The One to Start With" Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600105	PDD1501600119
PUR2621	1/1/2003	Titration Guide - Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600133	PDD1501600134
PUR2622	1/1/2003	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600137	PDD1501600147
PUR2623	1/1/1998	"Dear Dr." New Product Announcement for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600165	PDD1501600165
PUR2624	12/1/1996	Promotional Materials for OxyContin (Oxycodone HCl Controlled Release) Tablets; "Home Care Of The Hospice Patient" Booklet	PDD1501600194	PDD1501600247
PUR2625	12/1/1997	Promotional Materials for OxyContin (Oxycodone HCl Controlled Release) Tablets, and OxyIR	PDD1501600277	PDD1501600310
PUR2626	12/1/1997	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets, OxyIR	PDD1501600311	PDD1501600338
PUR2627	1/1/1998	1998 Pain Management Prescribing Guide Class II & Class III Opioid Analgesics - Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600352	PDD1501600372

PUR2628	1/1/1999	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600373	PDD1501600375
PUR2629	1/1/1998	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600376	PDD1501600397
PUR2630	1/1/1998	Prescribing materials for OxyContin HCl Controlled Release Tablets	PDD1501600407	PDD1501600408
PUR2631	11/12/1998	Symposium for New Directions for the Use of Opioids in Pain Management , November 12, 1998 (sponsored by PurduePharma)	PDD1501600414	PDD1501600416
PUR2632	1/1/1998	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets in Current Thinking in Treatment of: Chronic Pain, Drug-Induced Constipation, Asthma, and COPD	PDD1501600420	PDD1501600423
PUR2633	1/1/1996	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600448	PDD1501600463
PUR2634	1/1/1996	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600464	PDD1501600466
PUR2635	1/1/1996	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600469	PDD1501600470
PUR2636	1/1/1997	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600472	PDD1501600476
PUR2637	1/7/1998	Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets and OxyIR	PDD1501600481	PDD1501600493
PUR2638	1/1/1998	Partners Against Pain Long-Term Care Pain Assessment Tool	PDD1501600494	PDD1501600496
PUR2639	1/1/1996	"OxyContin Patient Profile - Cancer Pain" Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets, OxyIR	PDD1501600506	PDD1501600507
PUR2640	1/1/1998	"Understanding Key Terms In Pain Management" Promotional Material for OxyContin (Oxycodone HCl Controlled Release) Tablets	PDD1501600508	PDD1501600509
PUR2641	1/1/1998	Partners Against Pain "Effective Pain Management Utilizing Opioids an audio review"	PDD1501600513	PDD1501600516
PUR2642	1/11/1999	Hill C Jr.; Chronic Opioid Therapy for Non-Cancer Pain; Partners Against Pain, Vol 3, No. 4, Winter 1999	PDD1501600520	PDD1501600523
PUR2643	8/1/1996	Clinical Backgrounder: OxyContin in the treatment of back pain	PDD1501600524	PDD1501600527
PUR2644	1/1/1999	Purdue OxyContin Marketing Pamphlet: Proven Effective in Post Op Pain	PDD1501600528	PDD1501600529
PUR2645	1/1/1997	New OxyContin CII Controlled Release Tablet Marketing Pamphlet - For pain as bad as it gets...Oxycodone as strong as it gets	PDD1501600533	PDD1501600534
PUR2646	1/1/1996	OxyContin Marketing Pamphlet titled "Pain - Don't Complicate Pain Relief . . . Keep It Simple"	PDD1501600536	PDD1501600539
PUR2647	1/1/1995	Partners Against Pain Comfort Kit Promotional Material	PDD1501600540	PDD1501600544
PUR2648	3/1/1994	Agency for Health Care Policy and Research pamphlet "Managing Cancer Pain"	PDD1501600549	PDD1501600560
PUR2649	1/1/1998	Marketing Letter Template from Robert Lima to providers with "Opioids: Separating myths from facts"	PDD1501600561	PDD1501600562
PUR2650	1/1/1999	OxyContin Promotional material "When Pain Strikes. . . Strike Back with Simplicity"	PDD1501600563	PDD1501600571
PUR2651	1/1/1990	Partners Against Pain; Pain Assessment Questions, Pain Assessment Scales	PDD1501600572	PDD1501600575
PUR2652	1/1/1999	Partners Against Pain pamphlet for OxyContin: Converting to OxyContin From Other Opioids	PDD1501600599	PDD1501600600
PUR2653	8/18/1999	Promotional material "Dispelling the Myths About Opioids" including invitation to Pain Management presentation by Dr. Barry Cole sponsored by The Purdue Frederick Company	PDD1501600604	PDD1501600616
PUR2654	6/14/1999	Promotional material "Enclosed Please Find Your Free Gift, Compliments of OxyContin CII"	PDD1501600617	PDD1501600618
PUR2655	8/1/1998	Promotional material - "The Role of Opioids in Chronic Pain: A Case for OxyContin" Gregory Holmquist, Oncology & Pain Management Pharmacist Specialist	PDD1501600619	PDD1501600628
PUR2656	1/1/1999	Promotional pamphlet for OxyContin, co-promoted by Purdue Pharma LP. and Abbott Laboratories	PDD1501600629	PDD1501600632
PUR2657	1/1/1999	Partners Against Pain Presentation by Dr. Michael Levy: Management or Prevention of Common Opioid Side Effects	PDD1501600633	PDD1501600641
PUR2658	1/1/1999	OxyContin Marketing Pamphlet: Pain in the Long-Term Care Setting	PDD1501600642	PDD1501600650
PUR2659	1/1/1999	OxyContin Marketing Material - "At this point, your patient feels no pain"	PDD1501600651	PDD1501600654
PUR2660	1/1/1999	Abbott Pain Management; OxyContin Marketing Pamphlet - "The tools of your trade have changed"	PDD1501600659	PDD1501600661
PUR2661	1/1/1999	OxyContin CII Marketing Pamphlet - "Proven Effective in Arthritis Pain"	PDD1501600677	PDD1501600682
PUR2662	1/1/1999	Abbott Pain Management: OxyContin CII Marketing Pamphlet - "During surgery, your patients are the focus of your deep concentration"	PDD1501600714	PDD1501600716
PUR2663	1/1/1999	OxyContin CII Titration Guide	PDD1501600791	PDD1501600792
PUR2664	1/1/2000	Promotional material pamphlet: "Effective in Low Back Pain"	PDD1501600879	PDD1501600880
PUR2665	1/1/1999	OxyContin Marketing Pamphlet: "Pain Is A Complex Experience Relief Can Be So Simple" -	PDD1501600890	PDD1501600913
PUR2666	1/23/1996	OxyContin Package Insert	PDD1501602953	PDD1501602960
PUR2668	9/18/1996	Promotional Letter OxyContin Tablets NDA #20-553	PDD1501603788	PDD1501603789
PUR2669	2/27/1997	OxyContin Tablets NDA #20-553 80 mg Patient Visual Aid	PDD1501603873	PDD1501603893
PUR2670	1/1/1997	Marketing Pamphlet; OxyContin CII - Cancer Pain (Including Patient Profile)	PDD1501605048	PDD1501605050
PUR2671	11/4/1998	OxyContin Tablets NDA #20-553 Conversion Reference	PDD1501605927	PDD1501605931
PUR2672	11/23/1998	OxyContin Tablets NDA #20-553 OxyContin Slim Jim	PDD1501605933	PDD1501605942
PUR2673	1/1/1993	Don't Complicate Pain Relief Keep It Simple - OxyContin Marketing Pamphlet	PDD1501606339	PDD1501606368
PUR2674	3/26/2001	OxyContin Tablets NDA #20-553 Professional Sales Aid ("PSA"): OxyContin Titration Guideline Card	PDD1501609961	PDD1501609964

PUR2675	6/13/2001	Promotional material art layout; "A message from the Makers of OxyContin Purdue Pharma's 10-Point Plan to Prevent Prescription Drug Abuse Without Compromising Patient Access to Proper Pain Control"	PDD1501610103	PDD1501610105
PUR2676	5/7/2001	OxyContin Tablets NDA #20-553 Professional Print - Other ("PPO") OxyContin "Stand-By" Anti-Diversion Statement	PDD1501610153	PDD1501610155
PUR2677	8/15/2001	OxyContin Tablets NDA #20-553 Other Referenced Products: Attachment: MS Contin PI	PDD1501612257	PDD1501612261
PUR2678	5/23/2003	Fax from Brenda Marques to Christopher Prue re NDA #20-553	PDD1501615670	PDD1501615673
PUR2679	1/15/2007	Promotional material - OxyContin "For moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time"	PDD1501616873	PDD1501616879
PUR2680	6/1/2001	Dear Physician Letter from Michael Friedman re Purdue's commitment to maintaining the highest standards of marketing practices	PDD1501724751	PDD1501724751
PUR2681	6/1/2001	Promotional material Purdue and Partners Against Pain "Purdue Pharma's 10-Point Plan to Reduce Prescription Drug Abuse Without Compromising Patient Access to Proper Pain Control"	PDD1501724752	PDD1501724755
PUR2682	6/27/2001	Dear HCP letter re revisions to prescribing information WARNINGS Section for OxyContin.	PDD1501726360	PDD1501726361
PUR2684	5/4/2001	Purdue Pharma L.P. Press Release re: Statement on DEA Program to Reduce Diversion of OxyContin Tablets	PDD1501920079	PDD1501920081
PUR2686	1/1/1997	Partners Against Pain pamphlet; "Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain"	PDD1502303733	PDD1502303741
PUR2687	1/3/1997	Scientific Communications Document Review re OxyContin Formulary Kit Update	PDD1502304581	PDD1502304749
PUR2688	1/1/2001	Purdue Pharma's 10 Point Plan to Prevent Prescription Drug Abuse Without Compromising Patient Access to Proper Pain Control	PDD1502325936	PDD1502325939
PUR2689	2/1/2001	Letter from Dr. Robert Reder to Physician re Partners Against Pain brochures	PDD1502330109	PDD1502330110
PUR2690	2/23/2001	Marketing Tips Memorandum from Gary Lewandowski to Purdue Sales Force re Nationwide Anti-Diversion Mailing	PDD1502331520	PDD1502331521
PUR2691	9/1/2000	Purdue Training and Development September 2000 "Guidelines in Rx Promotions"	PDD1502502647	PDD1502502684
PUR2692	1/1/1991	The Purdue Frederick Company Direct Purchasing Accounts, Representative SOP Manual (RSOP 4.7.1)	PDD1503410001	PDD1503410026
PUR2693	1/1/1991	The Purdue Frederick Company Medical Questions, Representative SOP Manual (RSOP 4.7.11)	PDD1503410027	PDD1503410028
PUR2694	1/1/1991	The Purdue Frederick Company Salary, Representative SOP Manual (RSOP 2.1)	PDD1503410029	PDD1503410030
PUR2695	1/1/1991	The Purdue Frederick Company Customer Account Cards, Representative SOP Manual (RSOP 3.8)	PDD1503410031	PDD1503410035
PUR2696	1/1/1991	The Purdue Frederick Company Medicare/Medicaid, Representative SOP Manual (RSOP 4.7.7)	PDD1503410036	PDD1503410043
PUR2697	1/1/1991	The Purdue Frederick Company Medical No-Charge, Representative SOP Manual (RSOP 4.7.10)	PDD1503410044	PDD1503410044
PUR2698	1/1/1991	The Purdue Frederick Company Speaking Engagements for Medical Department Members, Representative SOP Manual (RSOP 4.7.9/ PFRC 009)	PDD1503410045	PDD1503410047
PUR2699	1/1/1991	Purdue Representatives SOP Manual - Representative's Itinerary. January 1, 1991	PDD1503410048	PDD1503410051
PUR2700	1/1/1991	Purdue Report re: DDD Reports, Representative SOP Manual , January 1, 1991	PDD1503410052	PDD1503410060
PUR2701	1/1/1991	Purdue Representative Manual: January 1, 1991	PDD1503410061	PDD1503410073
PUR2702	1/1/1991	Representative SOP Manual - VA & Military, January 1, 1991	PDD1503410074	PDD1503410074
PUR2703	8/1/1991	Representative SOP Manual - Speaker's Bureau Program, August 1, 1991	PDD1503410075	PDD1503410079
PUR2704	1/1/1990	Representative SOP Manual - Career Development	PDD1503410080	PDD1503410089
PUR2705	1/1/1990	Representative SOP Manual - Turnover Order Forms	PDD1503410090	PDD1503410093
PUR2706	1/1/1991	Representative SOP Manual - Standards of Performance, January 1, 1991	PDD1503410094	PDD1503410097
PUR2707	1/1/1991	Representative SOP Manual - Fleet Vehicle, January 1, 1991	PDD1503410104	PDD1503410115
PUR2708	5/7/1992	Representative SOP Manual - Audiotape Rental Library. May 7, 1992	PDD1503410116	PDD1503410118
PUR2709	1/1/1990	Representative SOP Manual - Sales Training & Development. January 1, 1990	PDD1503410119	PDD1503410127
PUR2710	1/1/1991	Representative SOP Manual - Conventions, January 1, 1991	PDD1503410128	PDD1503410140
PUR2711	1/1/1991	Representative SOP Manual - Representative's Home Office. January 1, 1991	PDD1503410144	PDD1503410146
PUR2712	1/1/1991	Representative SOP Manual - Car Organization, January 1, 1991	PDD1503410147	PDD1503410148
PUR2713	1/1/1991	Representative SOP Manual - Traveling Office (Briefcase) January 1, 1991	PDD1503410149	PDD1503410150
PUR2714	1/1/1991	Representative SOP Manual - Job Description for Purdue Representatives, January 1, 1991	PDD1503410151	PDD1503410154
PUR2715	1/1/1991	Representative SOP Manual - Conditions of Employment	PDD1503410155	PDD1503410158
PUR2716	1/1/1992	Representative SOP Manual - Handling Outdated Schedule II/III Product Returns, January 1, 1992	PDD1503410161	PDD1503410165
PUR2717	1/1/1994	Representative SOP Manual - Physician Sample Request, January 1, 1994	PDD1503410166	PDD1503410167
PUR2718	7/1/1991	Purdue Frederick Company Memorandum 1991 Representative SOP Manual 1.7 Legal Guidelines in Prescription Product Promotion	PDD1503410168	PDD1503410169
PUR2719	10/1/1991	Representative SOP Manual - Government Inspections of a representative's home or car. October 1, 1991	PDD1503410170	PDD1503410171
PUR2720	1/1/1994	Representative SOP Manual - Return of Expired Samples. January 1, 1994	PDD1503410172	PDD1503410172
PUR2721	1/1/1992	Representative SOP Manual - Visa Card & Gelco Traveletter Direct Split Pay January 1, 1992	PDD1503410177	PDD1503410196
PUR2722	1/1/1994	Representative SOP Manual - MS Contin/DHCplus Capsules Physician Letter Program, 1994	PDD1503410197	PDD1503410211

PUR2723	1/1/1991	Representative SOP Manual - Required Physician Data, Trade Account Records, Hospital Records, January 1, 1991	PDD1503410214	PDD1503410215
PUR2724	9/14/1994	Representative SOP Manual - Reporting Errors on Reports. January 1, 1991	PDD1503410216	PDD1503410216
PUR2725	1/1/1991	Representative SOP Manual - Home Office Correspondence January 1, 1991	PDD1503410217	PDD1503410217
PUR2726	9/14/1994	Representative SOP Manual - Customer Correspondence	PDD1503410218	PDD1503410218
PUR2727	9/14/1994	Representative SOP Manual - BRC Sampling to Physicians	PDD1503410219	PDD1503410221
PUR2728	9/14/1994	Representative SOP Manual - Physician Transfer Form	PDD1503410222	PDD1503410223
PUR2729	2/28/1995	Memorandum/Sales Bulletin from Jim Lang to Entire Field Force re: New E-Mail Literature Request Procedure	PDD1503410224	PDD1503410235
PUR2730	11/11/1997	Representative SOP Manual - New Representative Development Program	PDD1503410236	PDD1503410257
PUR2731	2/3/1998	Representative SOP Manual - Job Description for Health Systems Specialists	PDD1503410258	PDD1503410260
PUR2732	2/1/1999	SOP for Entire Field Force - Communication with Director, Medical Liaisons	PDD1503410261	PDD1503410265
PUR2733	3/31/1999	Representative SOP Manual - Tuition Aid	PDD1503410266	PDD1503410268
PUR2734	12/1/1999	The Purdue Frederick Company Representative SOP Manual: RSOP 4.2.1 Proper Physician Ratings - Prescription and Hospital Specialty Division Representatives	PDD1503410271	PDD1503410271
PUR2735	1/1/2000	Purdue Representative SOP Manual: RSOP 2.3. Awards Program	PDD1503410272	PDD1503410274
PUR2736	2/1/2000	The Purdue Frederick Company Representative SOP Manual: RSOP 4.7.2. Purchasing Groups	PDD1503410277	PDD1503410290
PUR2737	2/1/2000	The Purdue Frederick Company Representative SOP Manual: RSOP 4.7.4. Vendor Chargeback Program	PDD1503410291	PDD1503410294
PUR2738	5/1/2001	Purdue Pharma Representative SOP Manual: RSOP 4.10 Adverse Event (Experience) Reporting	PDD1503410310	PDD1503410314
PUR2739	1/1/2002	Purdue Pharma Representative SOP Manual: RSOP 2.2. Incentive Bonus Program	PDD1503410315	PDD1503410333
PUR2740	1/1/2002	Purdue Pharma Representative SOP Manual: RSOP 4.9 Thought Leader List - PSD, HSD, and Puerto Rico Representatives	PDD1503410334	PDD1503410336
PUR2741	2/1/2002	Purdue Pharma Representative SOP Manual: RSOP 4.4. Travel Policy	PDD1503410337	PDD1503410341
PUR2742	10/6/2003	Purdue Pharma Representative SOP Manual: RSOP 1.7.1 Indicators of Possible Diversion - Field Sales Organization and Medical Liaisons	PDD1503410342	PDD1503410344
PUR2743	1/1/1991	The Purdue Frederick Company Managers SOP Manual: MSOP 2.1. Benefits	PDD1503420007	PDD1503420007
PUR2744	7/1/1991	The Purdue Frederick Company Managers SOP Manual: MSOP 1.1. Job Description	PDD1503420008	PDD1503420011
PUR2745	7/1/1991	The Purdue Frederick Company Managers SOP Manual: MSOP 4.4.4. Home Office Personnel Who Desire Sales Position	PDD1503420012	PDD1503420013
PUR2746	1/1/1991	The Purdue Frederick Company Managers SOP Manual: MSOP 4.1. Business Conditions Report - BCR; Attaching Sample	PDD1503420014	PDD1503420021
PUR2747	1/1/1992	The Purdue Frederick Company Managers SOP Manual: MSOP 3.2.1. Setting Up Office At Home - District Managers	PDD1503420022	PDD1503420027
PUR2748	7/1/1991	The Purdue Frederick Company Managers SOP Manual: MSOP 1.4. Career Development	PDD1503420028	PDD1503420030
PUR2749	1/1/1991	The Purdue Frederick Company Representative SOP Manual: MSOP 3.4.5. Field Contact Reports, M-2/M-2B	PDD1503420031	PDD1503420035
PUR2750	7/1/1991	Managers SOP Manual - Field Representative Probation	PDD1503420036	PDD1503420037
PUR2751	7/1/1991	Managers SOP Manual - Individualized Development Program	PDD1503420038	PDD1503420041
PUR2753	1/1/1991	Managers SOP Manual - District Manager Itineraries	PDD1503420057	PDD1503420061
PUR2754	7/1/1991	Managers SOP Manual - District Manager's Traveling Office	PDD1503420062	PDD1503420064
PUR2755	7/1/1991	Managers SOP Manual - Manager's Time Analysis Control	PDD1503420065	PDD1503420066
PUR2756	7/1/1991	Managers SOP Manual - Manager's Work-With Control	PDD1503420067	PDD1503420068
PUR2757	7/1/1991	Managers SOP Manual - Key Trade Account Personnel Record	PDD1503420069	PDD1503420070
PUR2758	7/1/1991	Managers SOP Manual - Representative Personal History Control Form	PDD1503420071	PDD1503420073
PUR2759	7/1/1991	Managers SOP Manual - Recruiting	PDD1503420074	PDD1503420076
PUR2760	1/1/1992	Managers SOP Manual - Manager's Stationary List	PDD1503420077	PDD1503420079
PUR2761	1/1/1992	Managers SOP Manual - Coaching of Representatives	PDD1503420080	PDD1503420084
PUR2762	1/1/1992	Managers SOP Manual - Counseling of Representatives	PDD1503420085	PDD1503420090
PUR2763	7/1/1991	Managers SOP Manual - Standards of Performance for Managers	PDD1503420091	PDD1503420092
PUR2764	1/1/1992	Managers SOP Manual - Representative Termination	PDD1503420093	PDD1503420109
PUR2765	1/1/1992	Managers SOP Manual - Representative Salary Review	PDD1503420110	PDD1503420113
PUR2766	1/1/1992	Managers SOP Manual - Managing Representative Development	PDD1503420114	PDD1503420151
PUR2767	12/1/1992	Managers SOP Manual - Bulletins/Newsletters	PDD1503420156	PDD1503420158
PUR2768	1/1/1992	Managers SOP Manual - Expense Reimbursement	PDD1503420159	PDD1503420167
PUR2769	1/1/1992	Managers SOP Manual - Starting a New Representative	PDD1503420168	PDD1503420190
PUR2770	2/1/1995	Managers SOP Manual - Meal Allowances; Using First Bank Visa Card	PDD1503420193	PDD1503420196
PUR2771	1/1/1994	Managers SOP Manual - Final Physical Inventory, Close Out Representative	PDD1503420197	PDD1503420198
PUR2772	7/2/1997	Managers SOP Manual - Xponent/DDD Problem Inquiries	PDD1503420202	PDD1503420203
PUR2773	2/26/1998	Managers SOP Manual - Hiring Field Sales Representatives	PDD1503420206	PDD1503420257
PUR2774	5/19/1998	Managers SOP Manual - Awards Program for Managers	PDD1503420258	PDD1503420258
PUR2775	4/9/1999	Managers SOP Manual - Travel Policy	PDD1503420259	PDD1503420262
PUR2776	1/1/2000	Purdue Managers SOP Manual - Prescription Sales Division/Awards Program	PDD1503420263	PDD1503420265
PUR2778	4/1/2001	Managers SOP Manual - Transfer of Printers in the Field	PDD1503420273	PDD1503420274
PUR2779	4/1/2001	Managers SOP Manual - Request for Sales Outlet Change	PDD1503420277	PDD1503420282
PUR2780	4/1/2001	Managers SOP Manual - Nurse Practitioner and Physician Assistant change request	PDD1503420283	PDD1503420286
PUR2781	5/21/2002	Managers SOP Manual - Sales Skills and Business Ideas Tape Rental Library	PDD1503420290	PDD1503420292
PUR2782	11/4/1991	Managers SOP Manual - Conditions of Employment	PDD1503420293	PDD1503420299
PUR2784	11/1/2002	RSOP 1.7.1, Indicators of Possible Diversion 11/2002	PDD1503450025	PDD1503450026
PUR2785	1/1/1991	Representative SOP Manual - Incentive Bonus Program	PDD1503490261	PDD1503490267

PUR2786	2/1/2000	The Purdue Frederick Company Representative SOP Manual - Purchasing Groups	PDD1503490718	PDD1503490721
PUR2787	2/1/2000	The Purdue Frederick Company Representative SOP Manual - Vendor Chargeback	PDD1503490733	PDD1503490734
PUR2788	12/1/1999	Representative SOP Manual - Proper Physician Ratings	PDD1503490838	PDD1503490838
PUR2789	5/25/2000	Purdue Pharma Sales Bulletin - Unapproved Promotional Materials	PDD1503491181	PDD1503491181
PUR2790	1/1/2000	The Purdue Frederick Company Managers SOP Manual - Incentive Bonus Program	PDD1503491345	PDD1503491349
PUR2791	1/1/2000	The Purdue Frederick Company Representative SOP Manual - Incentive Bonus Program	PDD1503491351	PDD1503491360
PUR2792	1/1/2000	The Purdue Frederick Company Representative SOP Manual - Incentive Bonus Program	PDD1503491363	PDD1503491371
PUR2793	4/24/2001	Sales Bulletin - Oxycontin 160 mg Tablets Shipment Suspension	PDD1503491661	PDD1503491661
PUR2796	4/1/2001	Representative SOP Manual - Hospital Specialty Division Incentive Bonus Program	PDD1503491738	PDD1503491758
PUR2797	1/1/2001	Managers SOP Manual - Meeting Policy Field Based	PDD1503492095	PDD1503492096
PUR2798	11/8/2002	Sales Bulletin from Russ Gasdia to Prescription Sales Division and Hospital Specialty Division, re: SOP Manual - Indicators of Possible Diversion	PDD1503492684	PDD1503492686
PUR2799	8/18/2003	Sales Bulletin from Russ Gasdia to Prescription Sales Division, re: Representative Bonus Program-SOP	PDD1503492962	PDD1503492983
PUR2801	8/22/2005	Sales Training and Development Bulletin re Reporting of Adverse Events SOP Number: MA-DSP-SOP-000001	PDD1503520499	PDD1503520500
PUR2802	6/1/2003	Purdue Health Care Law Compliance Policies (DCI 244052v1)	PDD1506090001	PDD1506090037
PUR2803	1/1/2001	Purdue Field Reference Guide	PDD1506090092	PDD1506090104
PUR2804	11/1/2001	Memorandum from Law Department (LaDonna Steiner/Paul Curtin) to Purdue Employees regarding Helathcare Law Compliance Policies	PDD1506090198	PDD1506090198
PUR2805	4/11/2003	Purdue Pharma 2003 Health Care Law Compliance Policies	PDD1506090229	PDD1506090265
PUR2806	7/3/2001	Purdue Letter to DEA about 500 OxyContin Overdose Deaths in St. Louis, MO	PDD1506250076	PDD1506250076
PUR2808	4/23/2001	Draft Letter from Stephen Seid to Trade partner on 04/30/2001 re: voluntary removal of OxyContin 160mg	PDD1507071018	PDD1507071018
PUR2809	5/1/2000	Purdue Guidelines in Rx Promotions	PDD1701000672	PDD1701000701
PUR2810	1/1/1996	1996 Promotional Plan for Oxycontin	PDD1701022585	PDD1701022644
PUR2811	12/31/2007	Sales by Product Line-1998 Forecast vs. 1997 Estimate	PDD1701024118	PDD1701024573
PUR2812	10/1/2000	Budget Presentation -Marketing and Sales-Public Affairs	PDD1701037368	PDD1701037765
PUR2813	3/20/2001	Marketing Tips for Entire Sales Force-Quest Letters	PDD1701044296	PDD1701044337
PUR2814	9/28/1994	OxyContin Launch Plan	PDD1701063328	PDD1701063376
PUR2815	11/1/1999	Purdue Pharma L.P. Presentation, Sales by Product Line 2000 Forecast vs. 1999 Estimate	PDD1701076902	PDD1701077164
PUR2816	5/25/2000	Purdue Letter to FDA regarding Letters of 5/11/2000 and 5/15/2000 discussing their advertisement of OxyContin's Proven Effective in Arthritis Pain	PDD1701143931	PDD1701143932
PUR2817	12/18/2000	OxyContin Package Insert and the Abuse/Diversion Issue	PDD1701154222	PDD1701154227
PUR2818	7/10/1997	24 Hours of Pain Control THE EASY WAY	PDD1701164942	PDD1701164962
PUR2819	11/5/1999	Expense and Budget Report for Promotional Projects, November 1999	PDD1701170142	PDD1701170203
PUR2820	3/15/2001	Promotional Projects-Expense and Budget Report	PDD1701173864	PDD1701173968
PUR2821	8/28/2000	Promotional Projects-Expense and Budget Report	PDD1701174070	PDD1701174139
PUR2822	2/26/2001	Promotional Projects-Expense and Budget Report	PDD1701175889	PDD1701176047
PUR2823	1/26/1996	Purdue Pharma OxyContin CII Training and Development Program Manual	PDD1701216003	PDD1701216240
PUR2824	12/21/2000	Purdue Market Research Budget Analysis 2000	PDD1701216619	PDD1701216621
PUR2826	5/15/2000	Letter from FDA regarding efficacy claims for OxyContin in NonCancer Patients	PDD1701339209	PDD1701339214
PUR2827	6/1/1998	R. Reeder and B. Buckley, Open Label Clinical Use Study of Controlled-Release Oxycodone Administered Orally Every 12 Hours for the Management of Pain	PDD1701412190	PDD1701412193
PUR2828	1/1/1996	OxyContin 1996 Marketing Plan Presentation	PDD1701412788	PDD1701412815
PUR2829	12/31/1996	OxyContin 1996 Marketing Plan Presentation	PDD1701420505	PDD1701420537
PUR2830	1/1/2001	American Pain Society Definitions Relating to the Use of Opioids for the Treatment of Pain	PDD1701445420	PDD1701445423
PUR2831	10/1/1998	Budget Presentation Marketing & Sales Department	PDD1701465588	PDD1701465953
PUR2832	2/1/2001	Letter from Dr. Robert F. Reder to Partners Against Pain Pharmacists	PDD1701482501	PDD1701482501
PUR2833	6/23/1993	Draft Meeting Minutes from 01/23/0993 re: Acronotin	PDD1701503232	PDD1701503245
PUR2834	6/23/1993	Purdue Frederick and FDA OxyCodone Acrocontin Project Management Meeting - RDC Site (Draft)	PDD1701505974	PDD1701505990
PUR2835	1/1/1997	Purdue Presentation: 1997 OxyContin Marketing Plan	PDD1701556509	PDD1701556568
PUR2836	1/1/1990	Robert F. Kaiko and Iwona W. Bezkowska, Purdue Pharma, L.P., Comparative Review Of Daily Dose Requirements Of OxyContin And MS Contin In Patients With Non-Malignant And Malignant Pain	PDD1701603255	PDD1701603255
PUR2837	9/14/2000	FDA Form 2253, Transmittal Of Advertisements And Promotional Labeling For Drugs And Biologics For Human Use	PDD1701638585	PDD1701638619
PUR2838	2/1/2001	Letter From Drs. Harry Lazarus and Christopher J. Neumann to Partners Against Pain Colleagues	PDD1701833815	PDD1701833816
PUR2839	2/1/2001	Purdue Presentation: "Living Our Vision" Medical Liaison Training Program	PDD1701865014	PDD1701865110
PUR2840	1/1/1990	Purdue Presentation: "A Force for the Future". OxyContin 160mg Tablet Workshop. Selling to Physicians-For Training Purposes Only	PDD1701900211	PDD1701900225
PUR2841	9/12/2000	Living Our Vision training: OxyContin Package Insert	PDD1701901157	PDD1701901235
PUR2842	4/1/2001	Living Our Vision training: The Responsibility and Role of the Purdue Representative in Reporting AEs	PDD1701901240	PDD1701901256

PUR2843	4/23/2001	Email from Phil Cramer to Tony Morello, Mike Thatcher and Debby Betz re: Top 100 Counties - abuse/diversion hot spots	PDD1704035683	PDD1704035684
PUR2844	1/1/1990	Purdue Presentation: OxyContin Training and Development Program	PDD1704082092	PDD1704082366
PUR2845	1/1/2002	Q12H Oxycontin brochure and package insert	PDD1706026549	PDD1706026568
PUR2848	4/1/2000	RSOP 4.3.2 - Customer Correspondence, January 1, 1991	PDD1706072049	PDD1706072050
PUR2849	7/1/1991	SOP Manual, Legal Guidelines for Product Promotion	PDD1706072324	PDD1706072325
PUR2851	1/1/2001	"How to Stop Drug Diversion & Protect Your Patients" Brochure	PDD1708156126	PDD1708156127
PUR2852	5/17/2006	Memorandum to File re: Law Enforcement Liaison and Education	PDD1712900941	PDD1712900947
PUR2854	5/11/2000	Letter from Spencer Salis to Beth Connelly re: NDA 20-553 OxyContin tablets, MACMIS ID# 8636	PDD1715031259	PDD1715031262
PUR2855	1/29/2003	Letter from Thomas W. Abrams to Michael Friedman re: OxyContin, NDA # 20-553, MACMIS ID# 11400	PDD1715065261	PDD1715065263
PUR2856	1/29/2003	Letter from Daniel E. Troy and Thomas W. Abrams to Richard S. Morey and Peter R. Mathers re: Warning Letter on OxyContin Professional Advertising	PDD1715065264	PDD1715065272
PUR2857	2/9/2001	Purdue Educational Materials: How To Stop Drug Diversion and Protect Your Pharmacy	PDD1715075594	PDD1715075595
PUR2859	1/28/2000	Letter from Spencer Salis to Beth Connelly re: NDA 20-553 OxyContin tablets, MACMIS ID# 8636	PDD1782044514	PDD1782044515
PUR2860	1/30/2003	Letter from J. Christopher Prue to Tom Abrams re: OxyContin, NDA # 20-553, MACMIS ID# 11400	PDD1782049751	PDD1782049753
PUR2861	5/14/2002	Sales Bulletin/Memorandum Number 116 from Jim Lang to Entire Field Force re:PhRMA Code on Interactions with Healthcare Professionals	PDD1850000061	PDD1850000061
PUR2862	1/11/1995	Email from William Mallin (at Norwalk) to Howard Udel (at PF Legal) regarding Oxycodone IR Capsule	PDD7024303221	PDD7024303257
PUR2863	9/25/1986	IND application Oxycodone Hydrochloride C-R 30 mg tablets (1 of 4)	PDD8002200001	PDD8002200018
PUR2864	9/25/1986	IND application Oxycodone Hydrochloride C-R 30 mg tablets (2 of 4)	PDD8002200019	PDD8002200041
PUR2865	9/25/1986	IND application Oxycodone Hydrochloride C-R 30 mg tablets (3 of 4)	PDD8002200042	PDD8002200125
PUR2866	9/25/1986	IND application Oxycodone Hydrochloride C-R 30 mg tablets (4 of 4)	PDD8002200126	PDD8002200193
PUR2867	3/10/1995	Letter from Lee Ann Storey to Bonnie McNeal, FDA Center for Drug Evaluation and research re: NDA #20-553 Oxycontin Controlled Release Tablets	PDD8003005789	PDD8003005885
PUR2868	2/29/1996	Regulatory Agency Contact Report regarding OxyContin	PDD8003007486	PDD8003007487
PUR2870	2/24/2003	NDA #20-553 Oxycontin -Transmittal of Advertisements and Promotional Labeling	PDD8003065762	PDD8003065786
PUR2871	8/14/2003	Letter from Brenda Marques, FDA Division of Drug Marketing to J. Christopher Prue re: NDA 20-553 Oxycontin proposed marketing materials	PDD8003183211	PDD8003183214
PUR2872	10/7/2003	Letter from Brenda Marques, FDA Division of Drug Marketing to J. Christopher Prue re: NDA 20-553 Oxycontin proposed marketing materials	PDD8003184547	PDD8003184551
PUR2873	2/12/2004	Letter from Brenda Marques, FDA Division of Drug Marketing to J. Christopher Prue re: NDA 20-553 Oxycontin proposed marketing materials	PDD8003214066	PDD8003214071
PUR2874	6/11/1996	NDA #20-553 Oxycontin -Transmittal of Advertisements and Promotional Labeling	PDD8003222740	PDD8003222765
PUR2875	11/10/2004	Oxycontin -Transmittal of Advertisements and Promotional Labeling	PDD8003256092	PDD8003256142
PUR2876	6/1/2004	Annual Report Purdue Pharma RADARS Risk Management System 2004	PDD8005021253	PDD8005021323
PUR2877	3/16/1994	Letter from Mary Ann Trout to Russell Fleischer, FDA Division of Drug Marketing re: NDA #19-516 MS Contin 200 mg	PDD8006000197	PDD8006000204
PUR2878	7/18/2001	DHCP Letter regarding Box Warning addition to the OxyContin label	PDD8013007548	PDD8013007551
PUR2880	8/28/2001	Letter from J.Christopher Prue to Dr. Cynthia McCormick	PDD8013008662	PDD8013008667
PUR2881	1/16/2002	Fax from the Division of Anesthetic, Critical Care, and Addiction Drug Products re: OxyContin Patient Package Insert Final Printed Labeling 1/16/2002	PDD8013012484	PDD8013012491
PUR2882	12/24/2002	Letter from Thomas W. Abrams, FDA, to Michael Friedman re: NDA 20-553 OxyContin Tablets - Warning Letter	PDD8013020701	PDD8013020710
PUR2883	1/31/2003	Letter from Mark W. Askine to J. Christopher Prue	PDD8013021682	PDD8013021685
PUR2884	1/17/2003	Letter from Thomas W. Abrams, FDA, to Michael Friedman re: NDA 20-553 OxyContin Tablets - Warning Letter	PDD8013021699	PDD8013021706
PUR2885	3/6/2003	Letter from J. Christopher Prue to Mark W. Askine	PDD8013023433	PDD8013023435
PUR2886	7/17/2003	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, OxyContin 10, 20, 40, 80, and 160 mg Tablets	PDD8013027660	PDD8013027693
PUR2887	6/15/2014	Letter from Brenda Marques (Regulatory Review Officer at DHHS.) to J. Christopher Prue (Purdue Pharma)	PDD8013041682	PDD8013041685
PUR2888	3/14/2005	RADARS Presentation for Kasper in KY	PDD8013047738	PDD8013047786
PUR2889	8/11/2006	2005 Annual Summary Report OxyContin Risk Management Plan	PDD8013053479	PDD8013053587
PUR2891	12/1/2003	United States General Accounting Office Report: Prescription Drugs - OxyContin Abuse and Diversion and Efforts to Address the Problem	PDD8013180635	PDD8013180697
PUR2892	4/2/2008	Communication from Purdue Pharma L.P. to the United States Food and Drug Administration	PDD8013302864	PDD8013302881
PUR2893	7/16/1987	Letter from Therese M. Ast to Dr. Paul Leber, FDA, re: MS Contin NDA #19-516 - 200 mg Supplement	PDD8023011803	PDD8023012089
PUR2894	1/4/1988	Letter from Kathleen Heffernan to Dr. Paul Leber	PDD8023012163	PDD8023012205
PUR2895	3/3/1988	Letter from Therese M. Ast to Dr. Paul Leber, FDA, re: MS Contin 60 mg Tablets - Amendment to NDA #19-516/S-001	PDD8023012224	PDD8023012249
PUR2896	1/16/1990	Letter from Dr. Carl C. Peck to Charles W. Prettyman regarding NDA	PDD8023013509	PDD8023013524
PUR2897	1/1/1990	Purdue Presentation: OxyContin Marketing Plan Overview	PDD8806076631	PDD8806076673
PUR2898	10/23/2009	Email Regarding, FDA Minutes Ad Comm OTR Advisory Committee, 2009-09-24	PDD8901052768	PDD8901052768
PUR2899	10/24/2009	Summary Minutes from Joint Meeting of the Anesthetic Life Support Drugs Advisory Committee (10/24/2009)	PDD8901052769	PDD8901052775

PUR2900	11/1/2010	Purdue Pharma Presentation: Sales & Marketing Budget Meetings	PDD8901061469	PDD8901061637
PUR2901	10/1/2008	OxyContin Risk Management Program: 2007 Annual Summary Report	PDD8901128755	PDD8901129008
PUR2902	12/17/2008	Purdue PRISMAP (Purdue Risk Information Synthesis & Minimization Action Program) Field Research Guide	PDD8901129009	PDD8901129057
PUR2903	11/6/2009	Email from Beth Connelly to Richard Fanelli Attaching Epidemiology Proposal and Cover Letter	PDD8901586164	PDD8901586164
PUR2904	11/6/2009	Letter from Craig Landau to Bob Rappaport Attaching Purdue Pharma Amendment: Provisional Proposal for Epidemiology Study re: NDA 22-272 Reformulated OxyContin Controlled-Release Tablets, Sequence 0042	PDD8901586165	PDD8901586166
PUR2905	11/6/2009	Purdue Pharma Attachment 1 - Efforts to Examine the Influence of Reformulated OxyContin on One or More Patient and Non-Patient Outcome Measures	PDD8901586167	PDD8901586169
PUR2906	6/4/2012	Purdue Pharma Presentation: 2012 Budget Proposal Executive Summary	PDD9273201415	PDD9273201528
PUR2907	11/1/2003	Purdue Pharma Presentation: Phase I Sales Representative Training: Indicators of Possible Diversion RSOP 1.7.1	PDD9316500492	PDD9316500522
PUR2908	12/11/1996	Phase IV OxyContin Tablets Team 12/10/1996 Meeting Minutes	PDD9316704043	PDD9316704044
PUR2909	7/12/1996	Phase IV OxyContin Tablets Team 7/12/1996 Extended Meeting Minutes	PDD9316705373	PDD9316705376
PUR2911	1/1/1997	Partners Against Pain: Opioid Therapy Documentation Kit	PKY180112530	PKY180112542
PUR2912	1/24/2003	Letter from Michael Friedman to Thomas Abrams in Response to FDA Letter	PKY180164850	PKY180164883
PUR2913	10/14/2003	Letter from Jeffrey Zerillo to Susan Carr regarding Request Replacement Quota for Oxycodone; Enclosing Initial Letter to the DEA	PKY180180601	PKY180180602
PUR2914	10/14/1999	Email from Stephen Seid to William Gergely	PKY180192747	PKY180192748
PUR2916	3/20/2001	Purdue Pharma Informational Document: Frequently Asked Questions About the Illegal Abuse and Diversion of OxyContin Tablets	PKY180228927	PKY180228930
PUR2917	11/2/1998	Purdue Pharma Report: 1999 Budget Submission	PKY180237582	PKY180238536
PUR2918	1/1/1991	Representative SOP Manual: RSOP 1.1. Job Description	PKY180244287	PKY180244290
PUR2919	5/27/1994	Memorandum from James Lang to Michael Friedman regarding OxyContin Agency Selection	PKY180250286	PKY180250291
PUR2920	4/2/2001	Purdue Pharma Sales Bulletin: Promotion of OxyContin	PKY180261695	PKY180261695
PUR2921	4/14/1999	Memorandum from Russell Gasdia to Sally Riddle	PKY180262025	PKY180262025
PUR2922	2/14/2001	Sales Bulletin: OxyContin Abuse and Diversion	PKY180265303	PKY180265305
PUR2923	5/24/1994	Lavey/Wolff/Swift Inc. Presentation to Purdue Frederick Company regarding OxyContin as the "Second Step" Agent of Choice for Cancer Pain	PKY180286723	PKY180286790
PUR2924	7/31/1998	Purdue Pharma Presentation: OxyContin Budget 1999	PKY180295928	PKY180295993
PUR2925	5/25/2000	Letter from Beth Connelly to Spencer Salis regarding NDA 20-553 in Response to FDA Comments on Journal Ad	PKY180364459	PKY180364460
PUR2926	3/28/2001	Purdue Pharma Sales Bulletin: Frequently Asked Questions About the Illegal Abuse and Diversion of OxyContin Tablets	PKY180375704	PKY180375707
PUR2928	5/15/2000	Letter from Spencer Salis to Beth Connelly regarding NDA 20-553 OxyContin Tablets Journal Ad	PKY180543139	PKY180543140
PUR2929	9/1/1996	R. Winston Market Research Department Report: OxyContin Primary Research 1996	PKY180544129	PKY180544655
PUR2930	7/29/1999	Scientific Communications Document Review of Purdue Pharma L.P. Speakers' Slide Kit: Pain Management with OxyContin (Oxycodone HCL controlled-release) Tablets CII	PKY180570581	PKY180570668
PUR2931	9/25/1992	Project Team Contact Report by Drs. Reder, Fitzmartin, McIntyre and Conover to Dr. Curtis Wright regarding Oxycodone Controlled-Release, IND 29,038	PKY180726279	PKY180726281
PUR2932	3/21/2001	Purdue Efforts Related to Diversion from Mexico	PKY180798632	PKY180798633
PUR2933	4/10/2001	OxyContin Tablets NDA 20-553 Pre-Meeting Package for 4/23/2001 Meeting with FDA	PKY180854555	PKY180854673
PUR2934	2/14/1997	Center for Drug Evaluation and Research Approval Package for Hydrocodone and Acetaminophen Tablets USP	PKY180965802	PKY180965816
PUR2935	6/16/1994	Groups Plus, Inc. Presentation to Purdue Frederick Company regarding Oxycodone Focus Groups: Analysis and Conclusions (Cincinnati and Dallas)	PKY181004545	PKY181004608
PUR2936	7/15/1997	Purdue Pharma Expense and Budget Report	PKY181071214	PKY181071319
PUR2938	12/18/1997	Memorandum from Mark Alfonso to Michael Friedman regarding 1998 Abbott Marketing Plan for OxyContin	PKY181076893	PKY181076894
PUR2939	1/1/1996	Purdue Pharma Marketing and Sales Presentation: Marketing Department Budget 1996	PKY181085926	PKY181086473
PUR2940	1/1/1999	Purdue Pharma Marketing and Sales Presentation: Budget 1999	PKY181087610	PKY181088019
PUR2941	1/1/1998	Purdue Pharma Presentation: 1998 Promotional Plan: OxyContin	PKY181089197	PKY181089203
PUR2942	2/26/1999	Purdue Pharma Report: OxyContin 160Mg Tablet Launch Plan	PKY181095200	PKY181095209
PUR2943	1/1/1996	Purdue Pharma Presentation: OxyContin Marketing Plan	PKY181095622	PKY181095656
PUR2944	4/23/2001	Email from Russell Gasdia to John Arent et al., regarding Training Program and "Hot Spots"	PKY181166911	PKY181166912
PUR2946	7/1/2003	Purdue Pharma Representative SOP Manual: RSOP 2.2. PSD Incentive Bonus Program	PKY181214692	PKY181214709
PUR2947	1/1/2002	Purdue Pharma Training and Development Program: OxyContin Product Training	PKY181215750	PKY181216024
PUR2948	1/1/1996	Purdue Pharma Report: 1996 Promotional Plan: OxyContin	PKY181262275	PKY181262361
PUR2949	5/21/2001	Purdue Pharma Sales Bulletin: Purdue's 10-Point Plan	PKY181266685	PKY181266685
PUR2950	10/24/2001	Memorandum from Russell Gasdia to Sales Representatives in the 100 Counties regarding 100 County Pro-Active Pain Management Initiative	PKY181291057	PKY181291058
PUR2951	3/19/2002	Sales Bulletin: Patient Confidentiality & FDA Guidelines	PKY181305333	PKY181305333
PUR2952	8/4/1995	Project Team Contact Report by Dr. Reder to Dr. Curtis Wright regarding Oxycodone Controlled-Release, NDA 20-553	PKY181380879	PKY181380880

PUR2953	9/29/1994	Groups Plus, Inc. Presentation to Purdue Frederick Company regarding Oxycodone Focus Groups: Analysis and Conclusions (Philadelphia)	PKY181386644	PKY181386713
PUR2954	1/14/2003	Letter from Richard Morey and Peter Mathers to Thomas Abrams and Daniel Troy regarding OxyContin Professional Advertising	PKY181434547	PKY181434562
PUR2955	4/1/2001	Purdue Pharma Representative SOP Manual: RSOP 2.2. PSD Incentive Bonus Program	PKY181435157	PKY181435174
PUR2956	12/13/2001	Purdue Pharma Marketing Tips: FDA Guidelines for Package Inserts	PKY181562735	PKY181562735
PUR2958	3/19/2002	Purdue Pharma Sales Bulletin: Reporting Adverse Events	PKY181683619	PKY181683624
PUR2959	5/3/2002	Letter from Ethel Gibson to Michael Moy regarding Placeboes for OxyContin Tablets	PKY181851566	PKY181851566
PUR2960	4/25/2002	Letter from Ethel Gibson to Michael Smilek regarding Placeboes for OxyContin Tablets	PKY181851567	PKY181851567
PUR2961	9/5/2002	Letter from Howard Udell to DEA Administrator Asa Hutchinson	PKY181851726	PKY181851730
PUR2962	8/19/2002	Letter from William Ammermann to DEA Investigator Michael Smilek regarding Reconsideration of Petition to Destroy Materials	PKY181851732	PKY181851733
PUR2963	6/25/2001	Letter from Howard Udell to Attorney General G. Steven Rowe regarding Abuse and Diversion of OxyContin in Maine	PKY181851873	PKY181851873
PUR2964	3/27/2002	Purdue Pharma Sales Bulletin: Prescription Sales Division Incentive Bonus Program RSOP 2.2	PKY181866008	PKY181866046
PUR2965	6/25/2001	Purdue Pharma Sales Bulletin: Physician Toll-Free Promotion Comment Number	PKY181885953	PKY181885959
PUR2966	8/4/1998	Purdue Pharma Marketing Tips: OxyContin Precise Letter Program Updates	PKY181920405	PKY181920416
PUR2967	2/4/2003	Purdue Pharma Sales Memorandum from Jim Lang to Entire Field Force regarding FDA Warning Letter	PKY181928823	PKY181928824
PUR2970	6/14/2002	Purdue Pharma Marketing Tips: OxyContin Tablets CII Patient Information Sheet	PKY182098936	PKY182098936
PUR2971	5/1/1998	Federation of State Medical Boards of the United States, Inc.: Model Guidelines for the Use of Controlled Substances for the Treatment of Pain	PKY182473781	PKY182473794
PUR2972	1/31/2002	Press Release from James Heins: Purdue Pharma's 10- Point Plan to Reduce Prescription Drug Abuse and Diversion, Without Compromising Patient Access to Proper Pain Control	PKY182476065	PKY182476067
PUR2973	1/24/2003	Purdue Pharma L.P.'s Detailed Response to Warning Letter; Enclosing 1/17/2003 Warning Letter from Thomas Abrams to Michael Friedman regarding NDA 20-553 OxyContin Tablets Journal Ads	PKY182479905	PKY182479943
PUR2974	7/19/2001	Purdue Pharma Sales Bulletin: OxyContin Package Insert Changes	PKY182634571	PKY182634572
PUR2975	1/1/2003	Purdue Pharma Presentation: OxyContin Marketing Plan Overview	PKY182684790	PKY182684832
PUR2977	2/1/2008	Purdue Pharma Retained Visual Aid: OxyContin Tablets - The New Numbers Are In ..	PKY183122315	PKY183122334
PUR2978	8/1/2003	Partners Against Pain Binder: Pain Management Kit	PKY183145184	PKY183145274
PUR2979	9/12/2000	Purdue Pharma Presentation: Manager's Meeting Workshop III: Handling Abuse, Addiction and Diversion Issues in a Selling Situation	PKY183154082	PKY183154106
PUR2980	10/1/2007	Purdue Pharma Representative SOP Manual: RSOP 2.2 Incentive Bonus Program	PKY183209456	PKY183209461
PUR2982	1/17/2003	Warning Letter from Thomas Abrams to Michael Friedman regarding NDA 20-553 OxyContin Tablets Journal Ads	PKY183262725	PKY183262737
PUR2983	5/10/2007	USA v. Michael Friedman - WDVA Plea Agreement; USA v. Paul Goldenheim - WDVA Plea Agreement; USA v. Howard Udell - WDVA Plea Agreement	PKY183308653	PKY183308673
PUR2984	1/1/1999	Purdue Pharma Presentation: 1999 Budget Plan: OxyContin Tablets Market Overview and Promotional Plan	PKY183309067	PKY183309115
PUR2985	5/1/2014	Purdue Pharma Visual Aid: An Overview of the OxyContin Labeling Regarding Abuse Deterrence Studies	PPLP003275221	PPLP003275245
PUR2986	7/1/2010	Purdue Pharma Dear Healthcare Professional Letter regarding OxyContin Tablets Reformulation Enclosing Medication Guide and Patient Information	PPLP003275277	PPLP003275281
PUR2987	8/13/2013	Purdue Pharma Dear Healthcare Professional Letter Template regarding OxyContin Updated Labeling	PPLP003275332	PPLP003275337
PUR2988	11/1/2014	Purdue Pharma Promotional Material: Introducing the Purdue Product Information Center - How does it feel to get real?	PPLP003275356	PPLP003275359
PUR2989	5/1/2013	Purdue Pharma Visual Aid: OxyContin Tablets Patient Vignettes - When determining individual treatment needs, consider ...	PPLP003275395	PPLP003275409
PUR2990	11/1/2010	Purdue Pharma Dear Healthcare Professional Letter regarding OxyContin Tablets Reformulation Enclosing Medication Guide and Patient Information	PPLP003275548	PPLP003275568
PUR2991	2/1/2011	Purdue Pharma Brochure: OxyContin - Because different patients with pain have different treatment needs	PPLP003275569	PPLP003275584
PUR2992	6/1/2011	Purdue Pharma Brochure: OxyContin - When treating patients with moderate to severe chronic pain, What is an appropriate OPTION?	PPLP003275585	PPLP003275590
PUR2993	4/1/2013	Purdue Pharma Leave Behind: Log On and Learn - Gain Instant Access to Information on OxyContin Preferred Branded Tier Formulary Coverage	PPLP003275797	PPLP003275800
PUR2994	11/1/2012	Purdue Pharma Visual Aid: Determining the Appropriate Dose for Therapy With Butrans	PPLP003276113	PPLP003276117
PUR2995	12/1/2013	Purdue Pharma Brochure: Butrans - Help patients for the week ahead	PPLP003276134	PPLP003276148
PUR2996	9/1/2014	Purdue Pharma Brochure: Did you know that Butrans (buprenorphine) Transdermal System is the only available Schedule III extended release opioid?	PPLP003276455	PPLP003276458
PUR2997	11/1/2014	Purdue Pharma Leave Behind: Hysingla ER - An Introduction for Pharmacists	PPLP003276509	PPLP003276520
PUR2999	5/1/2015	Purdue Pharma Pamphlet: Review of Abuse-Deterrent Properties and Claims in Two Extended-Release Opioid Therapies - OxyContin and Hysingla ER	PPLP003276745	PPLP003276760

PUR3000	3/1/2015	Purdue Pharma Brochure: OxyContin - A Pharmacist's Guide - because patients' chronic pain treatment needs may change over time... Reassess at every step	PPLP003277543	PPLP003277548
PUR3002	9/1/2011	Purdue Pharma Retained Visual Aid: Butrans Initiations Reference Guide	PPLP003277952	PPLP003278015
PUR3003	11/1/2013	Purdue Pharma Pamphlet: The Butrans Experience Program: Track patients' experiences	PPLP003278164	PPLP003278173
PUR3004	7/1/2014	Purdue Pharma Leave Behind: Butrans - Now Approved 7.5 mcg/hour Dosage Strength	PPLP003279220	PPLP003279240
PUR3005	1/1/2015	Purdue Leader's Guide: Hysingla ER Presentation Handbook - A New, Once-Daily Oral Hydrocodone Bitartrate Therapy	PPLP003279948	PPLP003280058
PUR3006	1/1/2011	Purdue Pharma Marketing Tips: Informational Guide OxyContin - Q1 2011 and Q3 & Q4 2010 Materials Overview	PPLP003280412	PPLP003280531
PUR3007	2/1/2008	Purdue Pharma Leave Behind: OxyContin New Tablet Strengths... for Added Flexibility - New 15 mg, 30 mg, and 60 mg tablet strengths	PPLP003280996	PPLP003280999
PUR3008	5/1/2015	Booklet: The Purdue Pharma L.P. Portfolio of Extended-Release Products	PPLP003281476	PPLP003281543
PUR3009	4/1/2013	Purdue Pharma Brochure regarding OxyContin broad nationwide formulary coverage	PPLP003281544	PPLP003281547
PUR3010	2/16/2016	Purdue Pharma Sponsored Alerts by Physicians Interactive: Preferred Formulary Status for Hysingla ER Tablets	PPLP003282068	PPLP003282068
PUR3011	11/1/2015	Purdue Pharma Dear Healthcare Professional Email Template - Conversion From IR Oxycodone to OxyContin in Appropriate Patients	PPLP003282701	PPLP003282701
PUR3012	1/8/2016	Purdue Pharma: Hysingla ER CVA Training Deck for NSM WebEx with TBM	PPLP003283640	PPLP003283675
PUR3013	10/13/2010	Purdue Pharma Interactive Promotional Program: OxyContin Attribute Map	PPLP003289371	PPLP003289438
PUR3014	8/1/2010	Purdue Pamphlet: Invitation to participate in online interactive experiences and eDetail re: OxyContin	PPLP003289670	PPLP003289672
PUR3015	12/1/2010	Purdue Pharma Leave Behind: Dear Pharmacist Letter regarding Butrans Now Approved, Available First Quarter 2011	PPLP003291182	PPLP003291199
PUR3016	3/1/2011	Purdue Pharma Pamphlet for APS room drop: One Butrans - 7 days of buprenorphine delivery	PPLP003292307	PPLP003292326
PUR3017	1/1/2011	Purdue Pharma Informational Pamphlet Direct Mail: Butrans Now Available	PPLP003292506	PPLP003292512
PUR3018	5/11/2011	Butrans CIII MCO Brochure to Marketing for final approval	PPLP003292707	PPLP003292713
PUR3019	7/1/2011	Purdue Pharma Brochure: Our Products	PPLP003293372	PPLP003293380
PUR3020	2/7/2013	Purdue Pharma Brochure: Butrans - Patient Profile 3 - David (version 3)	PPLP003298771	PPLP003298778
PUR3021	1/1/2014	Purdue Pharma Healthcasts Announcement: Dr. Jeffrey Gudin OxyContin Program Presentation - An Overview of an Extended-Release Opioid, Including a Labeling Update Review	PPLP003300701	PPLP003300702
PUR3022	3/14/2014	Purdue Pharma: The Butrans Core Visual Aid Implementation Guide	PPLP003301624	PPLP003301642
PUR3023	2/6/2015	Purdue Pharma APRIMO Submission: Hysingla ER Patient Profiles - Sonia	PPLP003304352	PPLP003304356
PUR3024	11/1/2014	Purdue Pharma: Claims-free CVA for Hysingla ER CII	PPLP003304610	PPLP003304616
PUR3025	3/8/2015	Purdue Pharma Digital Panel: Butrans - 7 Days of Buprenorphine Delivery	PPLP003305742	PPLP003305742
PUR3026	9/4/2015	Purdue Pharma PKinectMediaV14P Core Sales Aids and Full Prescribing Information for Butrans, Hysingla ER, and OxyContin	PPLP003305746	PPLP003305831
PUR3027	4/28/2015	Purdue Pharma Aprimo submission: Hysingla ER Slim Jim	PPLP003306681	PPLP003306691
PUR3028	4/16/2015	Purdue Pharma Aprimo submission: Hysingla ER Campaign Banner Ads	PPLP003307187	PPLP003307207
PUR3029	8/12/2015	Purdue Pharma Kit Holder: Track Patients' Experiences - The Hysingla ER Experience Program Prescriber's Overview	PPLP003308479	PPLP003308480
PUR3030	9/11/2015	Purdue Pharma Aprimo Submission: Butrans Patient Identification and Initiation Guide - Three Patient Profiles	PPLP003308584	PPLP003308598
PUR3031	8/23/2015	Purdue Pharma Physicians Interactive Program: Get to Know Hysingla ER (version 4)	PPLP003308737	PPLP003308775
PUR3032	12/16/2016	Purdue Pharma Patient Interactive Website: Your Guide to the Week Ahead with Butrans - Label Update	PPLP003309348	PPLP003309418
PUR3033	10/3/2017	Purdue Interactive Promotional Program: OxyContin - Virtual Insights (version 3)	PPLP003312769	PPLP003312821
PUR3034	11/1/2010	Purdue Pharma Butrans Prelaunch Prescriber Sell Sheet	PPLP003312883	PPLP003312884
PUR3035	10/20/2011	Purdue Pharma Brochure: OxyContin - When treating patients with moderate to severe chronic pain - How can you help meet their individual treatment needs?	PPLP003314171	PPLP003314178
PUR3036	12/1/2012	Purdue Sales Aid: Butrans CIII - Three Patient Profile	PPLP003314287	PPLP003314294
PUR3037	12/19/2013	Purdue OxyContin CII Conversion and Titration Guide	PPLP003315511	PPLP003315532
PUR3038	3/11/2014	Purdue OxyContin CII Conversion and Titration Guide	PPLP003315592	PPLP003315603
PUR3039	11/1/2013	Purdue Leave Behind: Butrans CIII Patient Profile - Scott	PPLP003315667	PPLP003315676
PUR3040	3/1/2015	Purdue Sales Aid: Chronic Pain Has Many Faces - OxyContin Patient Profile - Maggie	PPLP003316755	PPLP003316761
PUR3041	8/1/2014	Purdue Brochure: Butrans Initiation and Titration Guide	PPLP003316994	PPLP003317001
PUR3042	6/18/2008	Purdue Distribution: RxPATROL Update - Theft Report and Press Releases	PPLP003318459	PPLP003318460
PUR3043	9/1/2011	Purdue Pharmacist Booklet: RxPATROL - Rx Pattern Analysis Tracking Robberies & Other Losses	PPLP003318463	PPLP003318466
PUR3044	2/1/2010	Purdue Brochure: How To Protect Your Medicines At Home	PPLP003330189	PPLP003330192
PUR3045	1/11/2011	Purdue Pharma L.P. and Associated U.S. Companies Compliance Slide Deck: Information on Purdue's Compliance Program and Healthcare Laws In General As They Pertain To Field Sales	PPLP003330364	PPLP003330433
PUR3046	3/1/2006	Purdue Marketing Tips: New Information Sheets Focus on Purdue-Supported Internet Education for Healthcare Professionals	PPLP003341870	PPLP003341870
PUR3047	10/4/2007	Purdue Medical Education Bulletin: Addressing Substance Abuse Prevention (ASAP) Flyer	PPLP003342035	PPLP003342035
PUR3048	10/11/2007	Purdue Sales Training and Development Bulletin: Revision to APS Guidelines Talking Points Bulletin	PPLP003342040	PPLP003342041

PUR3050	11/2/2007	Purdue Sales Bulletin: Abuse and Diversion Detection Program	PPLP003342053	PPLP003342053
PUR3051	11/21/2007	Purdue Sales Bulletin: Revisions to the OxyContin Tablets Prescribing Information	PPLP003342067	PPLP003342069
PUR3052	2/15/2007	Purdue Sales Bulletin: Tamper-Resistant Script Pad Program - "Benefits" Visual Aid for Prescribers	PPLP003342085	PPLP003342089
PUR3053	3/9/2007	Purdue Sales Training and Development Bulletin: Suggestions for discussions with Healthcare Professionals	PPLP003342120	PPLP003342120
PUR3054	3/9/2007	Purdue Marketing Tips: Alpharma's KADIAN New 200 mg strength: FDA Approval after Alcohol Tests with No Labeling Change	PPLP003342121	PPLP003342121
PUR3055	1/15/2007	Purdue Sales Bulletin: Directions concerning the recent OxyContin Tablets Package Insert Change	PPLP003342143	PPLP003342144
PUR3056	5/10/2007	Purdue Sales Bulletin: Discussion Topics for Verbal Communication with Outside Parties	PPLP003342214	PPLP003342216
PUR3057	7/31/2007	Purdue Sales Bulletin: Promotion Monitoring Program Standard Operating Policy	PPLP003342302	PPLP003342304
PUR3058	9/28/2007	Purdue Sales Bulletin: Pharmacy Security Checklist	PPLP003342349	PPLP003342351
PUR3059	9/22/2008	Purdue Sales Training Bulletin: Physician Specialists and the Pain Types They May Treat	PPLP003342394	PPLP003342399
PUR3060	2/4/2008	Purdue Medical Services Bulletin: 2008 National Sales Meeting Follow-Up Bulletin - Revisions to the OxyContin Tablets Prescribing Information	PPLP003342502	PPLP003342506
PUR3061	3/7/2008	Purdue Marketing Tips Bulletin: Tamper-Resistant Prescription Pad Program	PPLP003342548	PPLP003342548
PUR3062	4/14/2008	Purdue Sales Training and Development Bulletin: The Value of RxPatrol	PPLP003342569	PPLP003342571
PUR3063	1/15/2008	Purdue Sales Bulletin: RxPatrol Quarterly Newsletter	PPLP003342607	PPLP003342610
PUR3064	7/30/2008	Purdue Sales Bulletin: Revised Standard Operating Policies - effective 7/31/2008	PPLP003342665	PPLP003342693
PUR3065	9/15/2010	Purdue Sales Bulletin: Update to Oxycontin Tablets Full Prescribing Information	PPLP003343270	PPLP003343272
PUR3066	9/17/2010	Purdue Sales Training and Development Bulletin: Responding to Statements Regarding OxyContin Reformulation Tablets	PPLP003343298	PPLP003343298
PUR3067	2/11/2010	Purdue Sales Training and Development Bulletin: Article on Opioids for Chronic Noncancer Pain and Overdose	PPLP003343387	PPLP003343388
PUR3068	7/23/2010	Purdue OxyContin Marketing Tips Booklet: Quick Reference Guide to OxyContin Risk Evaluation and Mitigation Strategy (REMS) and Reformulation	PPLP003343650	PPLP003343672
PUR3069	8/8/2011	Purdue Sales Training and Development Bulletin: Titrating Butrans ...Is it an Adverse Event?	PPLP003343821	PPLP003343821
PUR3070	3/7/2011	Purdue Sales Training and Development Bulletin: Initiating Butrans In Opioid-Experienced Patients	PPLP003343969	PPLP003343972
PUR3071	3/22/2011	Purdue Sales Training and Development Bulletin: Butrans Questions and Answers - Use of Supplemental Opioid Analgesics with Butrans	PPLP003343975	PPLP003343978
PUR3072	3/23/2011	Purdue Sales Training and Development Bulletin: Butrans Questions and Answers - Tapering the Patient's Current ATC Opioid Dose	PPLP003343979	PPLP003343985
PUR3073	3/29/2011	Purdue Sales Training and Development Bulletin: Butrans Questions and Answers - Mechanism of Action	PPLP003343986	PPLP003343986
PUR3074	3/28/2011	Purdue Sales Training and Development Bulletin: Butrans Questions and Answers - QTc Interval and Surgery	PPLP003343988	PPLP003343989
PUR3075	4/5/2011	Purdue Sales Training and Development Bulletin: Butrans Questions and Answers - Conversion to OxyContin Tablets	PPLP003343990	PPLP003343992
PUR3076	5/31/2011	Purdue Sales Training and Development Bulletin: A Follow Up to Bulletin #83 Issued on May 5th Regarding Urine Drug Testing and Buprenorphine	PPLP003344008	PPLP003344009
PUR3077	1/4/2011	Purdue Sales Training and Development Bulletin: Introducing the Butrans Information Kit	PPLP003344094	PPLP003344095
PUR3078	5/14/2012	Purdue Sales Bulletin: Information Regarding OxyContin Tablets and Upcoming Poster Presentations at American Pain Society Conference	PPLP003344131	PPLP003344132
PUR3079	6/28/2012	Purdue Sales Training and Development Bulletin: Butrans and OxyContin Messaging	PPLP003344224	PPLP003344225
PUR3080	8/2/2012	Purdue Sales Training and Development Bulletin: 2012 Butrans, OxyContin, and MS Contin Full Prescribing Information (FPI) Changes	PPLP003344298	PPLP003344300
PUR3081	8/8/2012	Purdue Sales Training and Development Bulletin: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit	PPLP003344315	PPLP003344316
PUR3082	5/17/2013	Purdue Sales Bulletin: OxyContin Q&A Reference Guide - Updated Version	PPLP003344638	PPLP003344645
PUR3083	7/24/2013	Purdue Sales Bulletin No. 179 (Revised): Direction Regarding the OxyContin Label Update Leave Behind	PPLP003344756	PPLP003344758
PUR3084	7/30/2013	Purdue Sales Training and Development Bulletin: Clarification on Use of the Word "Persistent" in Promotion	PPLP003344787	PPLP003344787
PUR3085	9/13/2013	Purdue Sales Bulletin: ER/LA Opioid Analgesic REMS File Card	PPLP003344829	PPLP003344831
PUR3086	2/26/2013	Purdue Sales Training and Development Bulletin: Product and Quality of Life Claims	PPLP003344977	PPLP003344977
PUR3087	11/12/2014	Purdue Sales Training Bulletin: October 2014 Butrans Article - US Pharmacist	PPLP003345124	PPLP003345124
PUR3088	11/17/2014	Purdue Sales Training Bulletin: Identifying Appropriate Patients Consistent with Recent Label Changes	PPLP003345126	PPLP003345129
PUR3089	11/18/2014	Purdue Sales Training Bulletin: Guidelines on Product Promotion	PPLP003345130	PPLP003345131
PUR3090	1/20/2014	Purdue Marketing Bulletin: Speaker Program Changes	PPLP003345171	PPLP003345171
PUR3091	2/25/2014	Purdue Sales Training and Development Bulletin: Messaging Regarding Butrans Use as "Add-On" Therapy	PPLP003345252	PPLP003345252
PUR3092	5/8/2014	Purdue Sales Training and Development Bulletin: Discussing Adverse Events During a Sales Call	PPLP003345295	PPLP003345296

PUR3093	4/29/2015	Purdue Sales Training Bulletin: Appropriate Language Regarding Abuse-Deterrent Properties	PPLP003345585	PPLP003345585
PUR3094	8/3/2015	Purdue Marketing Bulletin: We are excited to announce the launch of an unbranded website: TeamAgainstOpioidAbuse.com	PPLP003345840	PPLP003345840
PUR3095	9/24/2015	Purdue Sales Training Bulletin: Important Reminders on Various Promotional Messaging Issues	PPLP003345853	PPLP003345858
PUR3096	10/28/2015	Purdue Sales Training Bulletin: Refresher Training on Risk Mitigation Programs	PPLP003345906	PPLP003345906
PUR3097	11/10/2015	Purdue Sales Bulletin from Lisa Pilla to TBM's: Important Information Regarding the Warner Chilcott Settlement with the Department of Justice	PPLP003345909	PPLP003345909
PUR3098	6/1/2010	Purdue Pharma L.P and Associated Companies Standard Operating Procedure: GC-SOP-0001.04 Retention of Healthcare Professionals as Consultants, Advisors and Speakers	PPLP003364388	PPLP003364454
PUR3099	4/24/2014	Purdue Booklet: Update on E2E (Evolve to Excellence) Implementation	PPLP003407474	PPLP003407492
PUR3100	12/10/2012	AAPA Conference ROI: AAPA (May) Butrans, Oxycontin, Intermezzo	PPLP003407507	PPLP003407539
PUR3101	12/8/2012	AAPA Conference ROI: AAPA (Feb) Butrans, Oxycontin	PPLP003407555	PPLP003407580
PUR3102	4/30/2013	Conference ROI: ACP (April) Butrans, Oxycontin, Intermezzo	PPLP003407581	PPLP003407609
PUR3103	7/23/2014	Analysis for Oxy Decliners with Q3 target	PPLP003407610	PPLP003407629
PUR3104	4/30/2013	Conference ROI: APS (May) Butrans, Oxycontin	PPLP003407658	PPLP003407677
PUR3105	11/1/2013	Branded Products Analysis	PPLP003407678	PPLP003407688
PUR3106	2/8/2012	Conference ROI AAPM (Butrans), AAFP (Butrans), Pri-Med (Oxycontin)	PPLP003407794	PPLP003407832
PUR3107	2/4/2014	OxyContin Caremark Commercial Model and NPV	PPLP003408749	PPLP003408755
PUR3108	1/24/2012	Conference ROI: Pri-Med (Oxycontin), AAPM (Butrans), AAFP (Butrans)	PPLP003408756	PPLP003408796
PUR3109	1/26/2012	Conference ROI Pri-Med (OxyContin), AAPM (Butrans), AAFP (Butrans)	PPLP003408797	PPLP003408871
PUR3110	1/31/2012	Conference ROI Pri-Med (OxyContin), AAPM (Butrans), AAFP (Butrans)	PPLP003408913	PPLP003408952
PUR3111	2/28/2012	Conference Attendee Profile AAPM, AAFP, Pri-Med	PPLP003409075	PPLP003409094
PUR3112	12/11/2012	Conference ROI - AAPA, AAPM, ACOFP, PriMed West (Apr)	PPLP003409095	PPLP003409184
PUR3113	4/30/2013	Conference ROI - ACP APS SLEEP	PPLP003409185	PPLP003409242
PUR3114	3/18/2011	Dinner and Teleconference Program Impact: Preliminary Analysis - November and December 2010 Program	PPLP003409243	PPLP003409252
PUR3115	12/8/2014	Diminishing Return slides for OxyContin and Butrans	PPLP003409253	PPLP003409254
PUR3116	3/4/2014	Performance vs. Budget slides	PPLP003409255	PPLP003409257
PUR3117	4/6/2016	Purdue Employer Group Potential Upside Analysis, March 2016	PPLP003409258	PPLP003409266
PUR3118	2/4/2014	OxyContin ESI/Medco Commercial Model and NPV	PPLP003409267	PPLP003409279
PUR3119	1/27/2014	Graphs - Discontinued and New Prescribers Over a Year for ERO, OxyContin and Butrans	PPLP003409280	PPLP003409282
PUR3120	8/22/2012	IMS OxyContin eVoucher Program Analysis Phase II	PPLP003409457	PPLP003409515
PUR3121	7/24/2013	IMS Updated OxyContin e-Voucher and Savings Card Program ROI Analysis	PPLP003409516	PPLP003409612
PUR3122	4/2/2015	Report, FAMR LTC ,Long Term Care, Analysis, April 2, 2015	PPLP003409616	PPLP003409622
PUR3123	3/10/2014	Manage Care Plan Models and NPV for UHC and Caremark	PPLP003409645	PPLP003409699
PUR3124	2/10/2011	Dinner and Teleconference Program Impact: Preliminary Analysis - Nov 2010 data	PPLP003409715	PPLP003409722
PUR3125	2/10/2011	Purdue Pharma L.P. Presentation: NP/PA Specific Speaker Program	PPLP003409723	PPLP003409724
PUR3126	2/7/2012	Conference ROI OxyContin	PPLP003409733	PPLP003409771
PUR3127	10/31/2016	OxyContin Experience Program Analysis	PPLP003409772	PPLP003409799
PUR3128	11/24/2014	OxyContin Logistic and Marketing Mix Modeling Report	PPLP003409826	PPLP003409866
PUR3129	8/7/2012	Purdue Presentation: Rebate Program Value Assessment-OxyContin MH program	PPLP003409867	PPLP003409873
PUR3130	11/15/2016	OxyContin Marketing Mix Modeling Report	PPLP003409874	PPLP003409898
PUR3131	7/1/2012	OxyContin Marketing Mix Modeling Result	PPLP003409899	PPLP003409935
PUR3132	12/7/2014	OxyContin Promotion Response Example	PPLP003409936	PPLP003409937
PUR3133	9/25/2013	OxyContin Targeting Method	PPLP003409938	PPLP003409938
PUR3134	1/24/2014	OxyContin Abuse Deterrent Messaging Pilot Evaluation	PPLP003409939	PPLP003409950
PUR3135	7/1/2013	OxyContin Marketing Mix Presentation	PPLP003409951	PPLP003409994
PUR3136	5/4/2014	OxyContin Patient Essentials Kit (Feb 2013-May 2013 Cohorts)	PPLP003409995	PPLP003410013
PUR3137	6/6/2014	OxyContin Patient Essentials Kit (Jan 2013-Jan 2014 Cohorts)	PPLP003410014	PPLP003410039
PUR3138	10/10/2013	OxyContin PTN Program (Jan 2013-March 2013 Cohorts)	PPLP003410040	PPLP003410061
PUR3139	6/1/2014	OxyContin RM Analysis	PPLP003410062	PPLP003410120
PUR3140	6/1/2014	OxyContin RM Analysis	PPLP003410121	PPLP003410144
PUR3141	5/1/2016	OxyContin RM Analysis	PPLP003410145	PPLP003410174
PUR3142	1/31/2014	OxyContin Vignette (May 2013-Oct 2013 Cohorts)	PPLP003410175	PPLP003410189
PUR3143	5/1/2014	Pain Week Convention Program OcyContin and Butrans (September 2013)	PPLP003410190	PPLP003410215
PUR3144	11/24/2014	Portfolio Allocation with 140M Budget	PPLP003410216	PPLP003410222
PUR3146	1/17/2012	Oxycontin Pri-Med (West) Conference Impact	PPLP003410236	PPLP003410247
PUR3147	12/10/2012	Purdue Presentation: FAMR Convention ROI - PriMed West (Apr) - Butrans, OxyContin, Intermezzo,	PPLP003410248	PPLP003410277
PUR3148	9/23/2016	Purdue Campaign Measurement Results Through June 2016	PPLP003410278	PPLP003410329
PUR3149	3/1/2014	Q1 2014 OxyContin and Butrans Called on HCPs Performance	PPLP003410330	PPLP003410346
PUR3150	4/2/2015	Purdue Presentation: Impact of Moving OxyContin Primary Calls to Butrans	PPLP003410347	PPLP003410350
PUR3151	2/23/2015	Purdue Presentation: Regional Analysis of Butrans and OxyContin Prescribing Volume January 2015	PPLP003410351	PPLP003410391
PUR3152	12/2/2013	State Level Analysis - Current Market Share	PPLP003410442	PPLP003410449
PUR3153	10/30/2013	Trend Analysis of KY, WA and VT vs. Rest of Nation	PPLP003410453	PPLP003410476
PUR3154	2/2/2015	Vacant Territory and Floater Representative Concept Analysis	PPLP003410477	PPLP003410484
PUR3155	2/18/2015	Vacant Territory Upside Calculation	PPLP003410485	PPLP003410485
PUR3156	7/11/2013	The Washington Legislation, and its impact on OxyContin, Oxycodone IR, and Oxycodone APAP	PPLP003410486	PPLP003410513
PUR3157	11/18/2013	Workload Targeting: OxyContin and Butrans Coverage Review	PPLP003410521	PPLP003410608

PUR3158	5/30/2014	Nurse Practitioner & Physician Assistant Exploratory Research - An Understanding of NPs' and PAs' Authority to Prescribe CIII & CII Opioids	PPLP003413587	PPLP003413624
PUR3159	6/18/2014	Purdue Pharma L.P. Presentation: NP&PA Study with Strategic Business	PPLP003415784	PPLP003415829
PUR3160	9/30/2011	Purdue Pharma Project: Single-entity Opioid - Term Confusion Findings and Recommendations	PPLP003416023	PPLP003416049
PUR3161	9/8/2011	GfK Presentation: Clinical Message Development for Pain Module, Final Report	PPLP003416167	PPLP003416209
PUR3163	9/1/2011	Palshaw Ad Test of Three Purdue OxyContin Journal Ad Executions	PPLP003417663	PPLP003417697
PUR3164	8/25/2011	Kantar Health Presentation: OxyContin Reformulation	PPLP003417698	PPLP003417741
PUR3165	5/22/2006	OxyContin Protect and Defend Summary Report - MR 10089	PPLP003417804	PPLP003417871
PUR3166	6/27/2007	OxyContin Issues Analysis Qual Final Report - MR 10108	PPLP003417872	PPLP003417915
PUR3167	6/27/2007	OxyContin Patient Copy Study Final Report - MR 10109	PPLP003417916	PPLP003417959
PUR3168	10/10/2007	Oxycontin Positioning Qualitative - MR 10112	PPLP003417960	PPLP003418004
PUR3169	2/26/2008	OxyContin Qualitative Positioning Project #2 - MR 10113	PPLP003418005	PPLP003418050
PUR3170	2/26/2008	OxyContin New Strengths Detail Aide Qualitative - MR 10114	PPLP003418051	PPLP003418060
PUR3171	2/26/2008	OxyContin New Strengths Detail Aide Qualitative - MR 10114a	PPLP003418061	PPLP003418099
PUR3172	1/14/2009	OIC & OXN Qualitative Market Research - MR 10131	PPLP003418100	PPLP003418109
PUR3173	1/14/2009	OxyContin OTR Concept Test #2 - MR 10134	PPLP003418110	PPLP003418207
PUR3174	1/14/2009	Oxycontin OTR Tamper Language - MR 10135	PPLP003418208	PPLP003418302
PUR3175	1/14/2009	OxyContin OTR Messaging Test - MR 10136	PPLP003418303	PPLP003418362
PUR3176	10/13/2008	A Strategic Marketing Study to Aid in the Development of Compelling Messaging for OxyContin	PPLP003418363	PPLP003418430
PUR3177	10/13/2008	OxyContin Journal Ad Test	PPLP003418431	PPLP003418472
PUR3178	12/1/2013	Palshaw Ad Test Study of Four Purdue OxyContin Advertising Executions	PPLP003418473	PPLP003418513
PUR3179	10/1/2013	Qualitative Assessment: Retail Pharmacists Impressions of Recent Opioid-dispensing Policies	PPLP003418514	PPLP003418574
PUR3180	8/17/2015	OxyContin Promotional Concept Qualitative Testing	PPLP003418575	PPLP003418625
PUR3183	9/24/2015	OxyContin Message Testing Research-Final Report	PPLP003418729	PPLP003418780
PUR3184	11/5/2010	OxyContin New Formulation Qualitative Final Report	PPLP003418781	PPLP003418802
PUR3185	3/29/2011	OxyContin Concept Test: Qualitative Research	PPLP003418803	PPLP003418847
PUR3186	11/25/2013	Pain Portfolio Flat Pricing Payer Research-Final Report	PPLP003418848	PPLP003418881
PUR3188	4/1/2016	Xtampa Impact Study - Final Report	PPLP003418908	PPLP003418958
PUR3189	3/1/2014	ADT Awareness Qualitative Research-Final Report	PPLP003418959	PPLP003418984
PUR3190	1/3/2014	OxyContin Quantitative Message Testing	PPLP003418985	PPLP003419081
PUR3191	11/1/2013	OxyContin Qualitative Message Testing	PPLP003419082	PPLP003419109
PUR3192	12/19/2013	OxyContin Quantitative Message Testing: Top Line	PPLP003419110	PPLP003419159
PUR3193	11/1/2013	Patient Opioid Fulfillment Quantitative Research	PPLP003419194	PPLP003419217
PUR3194	11/8/2013	Exploring Professional Campaign Concepts for OxyContin: What Stands Out?	PPLP003419218	PPLP003419284
PUR3195	1/16/2012	Sales & Marketing: 2012 10 Year Plan Update	PPLP003419455	PPLP003419485
PUR3196	9/1/2011	Sales & Marketing: 2012 Budget	PPLP003419486	PPLP003419558
PUR3197	11/8/2013	2013 10 Year Plan Update	PPLP003419610	PPLP003419624
PUR3198	6/3/2009	2009 Marketing Plan-Oxycontin	PPLP003420164	PPLP003420209
PUR3199	8/11/2009	2010 Marketing Plan-Oxycontin	PPLP003420210	PPLP003420256
PUR3200	10/6/2013	2013 OxyContin Annual Marketing Plan	PPLP003420538	PPLP003420571
PUR3201	9/9/2014	2015 Commercial Strategy Plan OxyContin-Executive Committee Presentation	PPLP003420730	PPLP003420789
PUR3202	5/5/2015	2016 Strategy Plan OxyContin	PPLP003420790	PPLP003420812
PUR3205	11/1/2011	2012 Budget Presentations Marketing Overview	PPLP003421199	PPLP003421276
PUR3206	9/3/2008	2009 OxyContin Marketing Plan	PPLP003421761	PPLP003421918
PUR3207	10/10/2011	2012 OxyContin Annual Marketing Plan	PPLP003424814	PPLP003424832
PUR3208	3/19/2014	2014 OxyContin Annual Marketing Plan	PPLP003425040	PPLP003425074
PUR3209	3/5/2014	2014 OxyContin Budget Proposal	PPLP003429424	PPLP003429443
PUR3211	7/30/2008	Letter from Windell Fisher to Sales Force Colleagues re: revised Standard Operating Policies	PPLP003430001	PPLP003430028
PUR3212	1/30/2009	Letter from Windell Fisher to Sales Force Colleagues re: revised Standard Operating Policies	PPLP003430029	PPLP003430056
PUR3213	1/7/2011	Letter from Windell Fisher to Sales Force Colleagues re: revised Standard Operating Policies	PPLP003430057	PPLP003430092
PUR3214	1/2/2013	Letter from Windell Fisher to Sales Force Colleagues re: revised Standard Operating Policies	PPLP003430093	PPLP003430137
PUR3215	1/24/2014	Letter from Windell Fisher to Sales Force Colleagues re: revised Standard Operating Policies	PPLP003430138	PPLP003430183
PUR3216	1/1/2013	Brochure - How to Help Prevent Drug Diversion & Protect Your Pharmacy	PPLP003430194	PPLP003430195
PUR3217	1/1/2014	Purdue Presentation: Rx Patrol	PPLP003430200	PPLP003430273
PUR3220	8/1/2015	Purdue Presentation: Healthcare Law Compliance Policies	PPLP003437109	PPLP003437131
PUR3221	5/4/2011	Sales Training - Guidelines in Product Promotion 2011	PPLP003437267	PPLP003437356
PUR3222	5/4/2011	State Government Affairs Presentation: The Role of State Government & Public Affairs	PPLP003437415	PPLP003437434
PUR3223	1/1/2013	Purdue Presentation: Dedicated to Patients and Healthcare Providers	PPLP003440670	PPLP003440715
PUR3224	1/15/2014	Aligning With Your Customers: Responding to HCP's Questions and Concerns	PPLP003452443	PPLP003452447
PUR3225	1/20/2016	Purdue Presentation: Implementation Guide for the OxyContin "Experience Campaign"	PPLP003494116	PPLP003494140
PUR3226	10/24/2016	Sales Training:Phase II - Compliance Scenarios	PPLP003497744	PPLP003497762
PUR3227	10/24/2016	Email from Purdue Pharma to Healthcare Professionals re: CDC Guidelines for Prescribing Opioids for Chronic Pain	PPLP003497852	PPLP003497852
PUR3228	10/3/2016	Hysingla ER (Hydrocodone Bitartrate) Website Label Update	PPLP003502216	PPLP003502351
PUR3229	1/1/2010	Purdue Presentation: Which is more challenging, treating the patient or choosing the appropriate option?	PPLP003508725	PPLP003508730

PUR3230	3/19/2011	Butrans Patient Information Guide	PPLP003509513	PPLP003509538
PUR3231	7/1/2010	Slim Jim: OxyContin Tablet Strengths	PPLP003509967	PPLP003509977
PUR3232	4/1/2014	Butran Prescribing Information	PPLP003512812	PPLP003512830
PUR3233	1/1/2001	Purdue Brochure: Providing Relief, Preventing Abuse - A Reference Guide to Controlled Substance Prescribing Practices.	PPLP003516982	PPLP003516997
PUR3234	9/20/2016	Product Promotional Guideline: OxyContin Tablets	PPLP003517380	PPLP003517435
PUR3235	4/20/2012	Product Promotional Guideline: OxyContin Tablets	PPLP003517436	PPLP003517474
PUR3236	1/30/2013	Product Promotional Guideline - Butrans Transdermal System	PPLP003517475	PPLP003517528
PUR3237	5/3/2011	Product Promotional Guideline - Butrans Transdermal System	PPLP003517529	PPLP003517574
PUR3238	11/28/2016	Product Promotional Guideline - Hysingla ER	PPLP003517575	PPLP003517620
PUR3239	3/18/2015	Product Promotional Guideline - Hysingla ER	PPLP003517621	PPLP003517666
PUR3240	12/4/2012	Product Promotional Guideline - OxyContin Tablets	PPLP003517667	PPLP003517709
PUR3241	9/16/2013	Product Promotional Guideline - OxyContin CII	PPLP003517710	PPLP003517762
PUR3242	8/29/2014	Product Promotional Guideline - OxyContin CII	PPLP003517763	PPLP003517817
PUR3243	3/12/2013	Sales Training and Development - Guidelines on Product Promotion	PPLP003526867	PPLP003526937
PUR3244	10/6/2014	Purdue Presentation: Healthcare Law Compliance Policies Training	PPLP003540035	PPLP003540112
PUR3245	7/11/2014	Purdue Presentation: Marketing Overview of OxyContin	PPLP003541889	PPLP003541933
PUR3246	1/28/2008	Presentation: Abuse and Diversion Detection Program SOP 1.7.1	PPLP003550023	PPLP003550053
PUR3247	4/5/2013	Butrans Initiation and Titration Implementation Guide	PPLP003573769	PPLP003573786
PUR3248	4/6/2012	Purdue Presentation: Guidelines on Product Promotion	PPLP003575972	PPLP003576035
PUR3249	1/1/2016	2016 Sales Force Standard Operating Procedures Manual	PPLP003578668	PPLP003578719
PUR3250	3/31/2015	Standard Operating Policy: Sales Incentive Program FSOP 2.3	PPLP003578898	PPLP003578903
PUR3251	1/1/2013	Standard Operating Policy: Incentive Bonus Program FSOP 2.2	PPLP003578904	PPLP003578909
PUR3252	10/1/2014	Standard Operating Policy: Incentive Bonus Program MMSOP 2.2	PPLP003578910	PPLP003578912
PUR3253	1/1/2014	Standard Operating Policy: Incentive Bonus Program MCSOP 2.2	PPLP003578919	PPLP003578921
PUR3254	7/1/2013	Butran Prescribing Label	PPLP003771740	PPLP003771778
PUR3255	5/22/2007	RxPatrol Presentation: What is RxPATROL	PPLP003904089	PPLP003904178
PUR3256	10/1/2010	Purdue Presentation: When Treating Patients with Moderate to Severe Chronic Pain, What is an Appropriate Option?	PPLP003973370	PPLP003973375
PUR3257	1/1/2003	Purdue Presentation: Rx Pattern Analysis Tracking Robberies & Other Losses	PPLP004001190	PPLP004001198
PUR3258	9/13/2013	Purdue Presentation: OxyContin growth opportunities	PPLP004001344	PPLP004001475
PUR3259	5/13/2015	Sales Force Standard Operating Policies Manual	PPLP004002056	PPLP004002103
PUR3260	7/25/2012	PROP Citizen Petition	PPLP004023301	PPLP004023307
PUR3262	3/8/1995	Groups Plus, Inc. Presentation: Focus Group Research Findings & Conclusions - OxyContin for Non-Cancer Pain Management	PPLP004031668	PPLP004031734
PUR3264	1/27/2016	Working Practice Document: Ethics & Compliance Call Note Review	PPLP004035166	PPLP004035179
PUR3265	2/5/2016	Law Department Working Practice Document	PPLP004035416	PPLP004035421
PUR3266	6/1/2010	Butrans Approved Labeling	PPLP004047994	PPLP004048036
PUR3267	1/30/2013	Purdue Letter to FDA re: Prop Citizen Petition	PPLP004058394	PPLP004058402
PUR3268	6/17/2007	Email from Dr. J. David Haddox to Scott Fishman re: Responsible Opioid Prescribing	PPLP004087123	PPLP004087123
PUR3269	10/20/2007	Standard Operating Policy: Convention Planning and Attendance	PPLP004119499	PPLP004119512
PUR3270	11/30/2007	Email from Stephen Seid to Shelton Benson re: Managers Meeting Oxycontin presentation slides	PPLP004130003	PPLP004130004
PUR3271	11/28/2007	OxyContin Tablets 2008 Marketing Plans	PPLP004130005	PPLP004130055
PUR3272	6/1/2013	2013 10-Year Plan	PPLP004147654	PPLP004147711
PUR3273	6/6/2013	Purdue Presentation: Managed Care	PPLP004147712	PPLP004147734
PUR3274	5/18/2012	Email from Russell Gasdia to Tim Richards, re: Reformulated OxyContin Reduces Oral, Nonoral Abuse Potential Opioid Abusers (MPR)	PPLP004149368	PPLP004149369
PUR3275	4/16/2012	Insights and Information About the OxyContin "Individualize the Dose" - Campaign Visual Aid and PBM Leave Behind	PPLP004149407	PPLP004149441
PUR3276	3/24/2011	Purdue Presentation: Sales and Marketing Overview Wilson Leadership Team Meeting	PPLP004150361	PPLP004150371
PUR3278	4/1/2008	Purdue Pharma's Programs to Reduce Illegal Trafficking and Abuse of Prescription Medications	PPLP004159063	PPLP004159066
PUR3279	11/15/2004	Press Release: Purdue Pharma L.P. Implements Radio Frequency ID System for Drug Packaging to Deter Counterfeiting and Diversion	PPLP004159298	PPLP004159300
PUR3280	3/28/2010	Letter from Beth Connally to Mathilda Fienkeng re: NDA 22-272 Reformulated OxyContin Tablets	PPLP004183139	PPLP004183143
PUR3281	4/21/2010	Letter from Mathilda Fienkeng to Beth Connally re: NDA # 022272	PPLP004183257	PPLP004183258
PUR3282	4/1/2014	MS Contin Approved Labeling and Full Prescribing Information	PPLP004186363	PPLP004186383
PUR3283	5/1/2014	Overview of the OxyContin Labeling Regarding Abuse-Deterrence Studies	PPLP004210214	PPLP004210220
PUR3284	6/1/2016	OxyContin Lead with Experience Action Plan	PPLP004216422	PPLP004216437
PUR3285	4/21/2010	Corporate Compliance Council Meeting Minutes	PPLP004249838	PPLP004249840
PUR3286	3/9/2007	Sales Training and Development Bulletin: Suggestions for discussions with Healthcare Professionals	PPLP004256659	PPLP004256659
PUR3287	7/25/2016	RxREACTS Summary of Purdue's efforts to assist in combating prescription drug abuse and diversion	PPLP004259362	PPLP004259363
PUR3289	11/10/2011	CDC Collaboration with Pain Care Forum (PCF) Participants	PPLP004273676	PPLP004273678
PUR3290	1/14/2015	Standard Operating Procedure: Retention of Healthcare Professionals for Purposes of Consulting, Advising, Speaking, Authorship, and Market Research GC-SOP-0001.07	PPLP004342175	PPLP004342196
PUR3291	6/1/2008	Standard Operating Procedure: Material Review Process - GC-SOP-0002.02	PPLP004368428	PPLP004368461
PUR3292	11/1/2007	Standard Operating Procedure: Material Review Process - GC-SOP-0002	PPLP004368497	PPLP004368513
PUR3293	8/1/2016	Standard Operating Procedure: Material Review Process- GC-SOP-0060	PPLP004368514	PPLP004368526
PUR3295	4/10/2015	OMS Meeting Minutes	PPLP004370033	PPLP004370037
PUR3296	3/29/2016	Order Monitoring System Committee Charter Updated 2016	PPLP004371524	PPLP004371524
PUR3297	12/12/2012	OMS Meeting Minutes	PPLP004372122	PPLP004372125

PUR3298	4/11/2013	OMS Meeting Minutes	PPLP004372143	PPLP004372146
PUR3299	7/18/2013	OMS Meeting Minutes	PPLP004372147	PPLP004372149
PUR3300	10/22/2013	OMS Meeting Minutes (Draft)	PPLP004372150	PPLP004372153
PUR3301	8/28/2014	OMS Meeting Minutes	PPLP004372158	PPLP004372162
PUR3302	3/6/2014	OMS Meeting Minutes	PPLP004372166	PPLP004372169
PUR3303	1/6/2011	OMS Meeting Minutes	PPLP004376811	PPLP004376813
PUR3304	12/6/2010	OMS Meeting Minutes	PPLP004376814	PPLP004376817
PUR3305	11/9/2011	OMS Meeting Minutes	PPLP004379836	PPLP004379836
PUR3306	3/10/2011	OMS Report: Mission Pharmacy	PPLP004380003	PPLP004380007
PUR3308	2/24/2010	OMS Meeting - Draft Agenda	PPLP004381156	PPLP004381160
PUR3309	6/7/2012	OMS Meeting Minutes	PPLP004382258	PPLP004382264
PUR3310	12/10/2009	Email from Gina Limer to J. Crowley re: minutes of meeting with ABC on 08/20/2009	PPLP004383420	PPLP004383425
PUR3311	10/7/2011	OMS Notes: Mission Pharmacy	PPLP004384747	PPLP004384749
PUR3312	10/27/2010	OMS Report: Mission Pharmacy	PPLP004384823	PPLP004384825
PUR3313	4/3/2009	Standard Operating Policy: Product Labeling and Review Responsibilities -REG-SOP-0019	PPLP004385385	PPLP004385390
PUR3314	8/23/2016	Standard Operating Policy:Material Review Process-REG-SOP-0060	PPLP004385528	PPLP004385540
PUR3315	11/22/2016	Standard Operating Policy: Initial IND Submission - Regulatory -REG-SOP-0034	PPLP004390687	PPLP004390690
PUR3316	11/22/2016	Standard Operating Policy: NDA/ANDA/Regulatory Requirements - REG-SOP-005	PPLP004390691	PPLP004390695
PUR3317	2/29/2016	Standard Operating Policy: Order Monitoring Procedures GC-SOP-0007.1	PPLP004390696	PPLP004390700
PUR3318	11/22/2016	Standard Operating Procedure: Corporate Compliance Hotline Operations CC-SOP-000010 v3	PPLP004390707	PPLP004390713
PUR3319	6/17/2014	Standard Operating Procedures: Corporate Compliance Hotline Operations CC-SOP-000010	PPLP004390780	PPLP004390786
PUR3320	11/22/2016	Standard Operating Procedure : Corporate Compliance Hotline Operations CC-SOP-000010	PPLP004390787	PPLP004390792
PUR3321	11/22/2016	Standard Operating Procedure: Corporate Compliance Hotline Operations CC-SOP-000010 v4	PPLP004390793	PPLP004390796
PUR3322	2/11/2014	Working Practice Document: Corporate Compliance Attendance at District Meetings and Ride Alongs CC-WPD-000018	PPLP004390821	PPLP004390835
PUR3323	3/7/2017	Working Practice Document: Speaker Program Monitoring by Corporate Compliance CC-WPD-000022	PPLP004390869	PPLP004390878
PUR3324	2/11/2014	Working Practice Document: Ad Hoc Event Monitoring by Corporate Compliance CC-WPD-000023	PPLP004390930	PPLP004390935
PUR3325	2/11/2014	Working Practice Document: Field Contact Report Monitoring CC-WPD-000010	PPLP004390971	PPLP004390981
PUR3326	6/15/2011	Standard Operating Procedure: Corporate Compliance Hotline Operations CC-SOP-000010	PPLP004391253	PPLP004391259
PUR3327	6/20/2011	Standard Operating Procedure: Corporate Compliance Training CC-SOP-000012	PPLP004391338	PPLP004391347
PUR3328	10/2/2014	Standard Operating Procedure:Corporate Compliance Training CC-SOP-000012	PPLP004391411	PPLP004391420
PUR3329	11/22/2016	Standard Operating Policy: 2016 Whole\$um CC-SOP-000015	PPLP004391451	PPLP004391460
PUR3330	9/3/2015	Standard Operating Policy: 2015 Whole\$um CC-SOP-000015	PPLP004391461	PPLP004391470
PUR3331	8/22/2016	Working Practice Document: Corporate Compliance Call Note Review CC-WPD-000017	PPLP004391491	PPLP004391503
PUR3332	10/16/2013	Working Practice Document: Corporate Compliance Call Note Review CC-WPD-000017	PPLP004391585	PPLP004391594
PUR3333	1/27/2016	Working Practice Document: Corporate Compliance Call Note Review CC-WPD-000017	PPLP004391614	PPLP004391626
PUR3334	4/2/2013	Standard Operating Procedure: Process for Review of Free Text Notes in the Medical Science Liaison Customer Reporting System HELP-MSL-SOP-000004	PPLP004391791	PPLP004391795
PUR3335	6/24/2009	Standard Operating Procedure: Process for Review of Free Text Notes in the Medical Liaison Customer Reporting System HELP-ML-SOP-000004	PPLP004391796	PPLP004391799
PUR3336	1/3/2013	2013 Standard Operating Policies for Managed Care Personnel	PPLP004391854	PPLP004391889
PUR3337	1/7/2015	2015 Standard Operating Policies for Managed Personnel	PPLP004391890	PPLP004391928
PUR3338	4/16/2015	2015 Standard Operating Policies for the Health Care Systems Group	PPLP004391929	PPLP004391963
PUR3339	1/7/2016	2016 Standard Operating Policies for Managed Markets Account Executives	PPLP004391964	PPLP004392004
PUR3340	7/27/2009	2009 Standard Operating Policies for Sales Force Personnel	PPLP004392008	PPLP004392039
PUR3342	8/29/2017	Email from Eric Brantley to Eric Cherveny re: Q1 downstream customers of interest	PPLP004396715	PPLP004396715
PUR3343	8/29/2017	Letter from Eric Brantley to Eric Cherveny re: due diligence information on downstream customers for the purpose of DEA diversion compliance.	PPLP004396716	PPLP004396716
PUR3344	8/29/2017	Data for due diligence information on downstream customers for the purpose of DEA diversion compliance - ABC Q1	PPLP004396717	PPLP004396717
PUR3345	9/1/2017	Email from Eric Cherveny to Eric Brantley re: information on secondary customers for compliance purposes.	PPLP004396718	PPLP004396720
PUR3346	9/1/2017	Data on secondary customers for compliance purposes- ABC Oxycontin Q1 2017	PPLP004396721	PPLP004396721
PUR3347	11/29/2017	Email from Eric Brantley to Eric Cherveny re: downstream customers.	PPLP004396723	PPLP004396723
PUR3348	11/29/2017	Data on downstream customers - 3rd Quarter 2017.	PPLP004396724	PPLP004396724
PUR3349	9/12/2017	Email from D. Linden Barber to Eric Brantley re: Response to Information on Customers	PPLP004396808	PPLP004396808

PUR3350	9/12/2017	Letter from D. Linden Barber to Eric Brantley re: Purdue's request for due diligence information.	PPLP004396809	PPLP004396810
PUR3351	5/9/2017	Purdue Wholesaler/Distributor Questionnaire, completed by Cardinal Health, Inc.	PPLP004396828	PPLP004396832
PUR3352	6/27/2017	Email from Daryl Grush to Eric Brantley re: Rocky's Med Shoppe (RMS) SITE REPORT	PPLP004396962	PPLP004396962
PUR3353	4/4/2017	Purdue Wholesaler/Distributor Questionnaire, completed by Miami-Luken Inc.	PPLP004397043	PPLP004397047
PUR3354	5/8/2017	Purdue Wholesaler/Distributor Questionnaire completed by Miami-Luken Inc.	PPLP004397048	PPLP004397054
PUR3355	6/1/2017	Email from Brenda Wood to Eric Brantley re: Purdue request for information on secondary customers	PPLP004397122	PPLP004397123
PUR3356	5/22/2017	Email from Eric Brantley to Brenda Wood re: Purdue request for information on secondary customers.	PPLP004397124	PPLP004397124
PUR3357	5/22/2017	Letter from Eric Brantley to Brenda Wood re: secondary customer information for due diligence purposes.	PPLP004397125	PPLP004397125
PUR3358	5/22/2017	Spreadsheet with PBA Health secondary customer data, including dispensing location, retail location, sales data (dosage units) for PBA Q1 2017.	PPLP004397126	PPLP004397126
PUR3359	5/16/2017	Purdue Wholesaler/Distributor Questionnaire completed by Prescription Supply, Inc.	PPLP004397195	PPLP004397204
PUR3360	6/27/2017	Memorandum from Eric Brantley to File RE call with Sherri O'Donald at Value Drug reviewing 867 data.	PPLP004397359	PPLP004397360
PUR3361	5/19/2017	Email from Eric Brantley to Sherri O'Donald regarding secondary customers.	PPLP004397365	PPLP004397365
PUR3362	5/18/2017	Spreadsheet with Value Drug secondary customer data, including dispensing location, retail location, sales data (dosage units) for Value Drug Q1 2017	PPLP004397367	PPLP004397367
PUR3363	9/19/2017	AmerisourceBergen 'Statement of Work' for Purdue Pharma regarding AmerisourceBergen's The Link customer communication portal	PPLP004397424	PPLP004397424
PUR3364	4/1/2010	PRxO Generics Program Addendum to Distribution Services Agreement with AmerisourceBergen	PPLP004397425	PPLP004397437
PUR3365	10/1/2009	Drug Distribution Service Agreement Amendment between Purdue Pharma and AmerisourceBergen	PPLP004397438	PPLP004397442
PUR3366	9/29/2018	Third Amendment to Distribution Performance Agreement between Purdue Pharma and AmerisourceBergen	PPLP004397443	PPLP004397446
PUR3367	7/1/2018	First Amendment to Logistics Services Agreement between Purdue Pharma and AmerisourceBergen	PPLP004397447	PPLP004397448
PUR3368	9/30/2015	Second Amendment to Authorized Distributor Agreement between Purdue Pharma and AmerisourceBergen	PPLP004397449	PPLP004397452
PUR3369	6/12/2013	Confidential Disclosure Agreement between AmerisourceBergen Drug Corporation, Pricewaterhouse Coopers, and Purdue Pharma	PPLP004397453	PPLP004397460
PUR3370	9/30/2016	Services Agreement between Purdue Pharma and AmerisourceBergen Services Corporation regarding Butrans (buprenorphine) Transdermal System	PPLP004397461	PPLP004397463
PUR3371	2/18/2011	Purdue Products LP Application for Trade Show Participation 2011 National Healthcare Conference & Exposition Sponsored by AmerisourceBergen Drug Corporation	PPLP004397464	PPLP004397464
PUR3372	10/1/2012	Authorized Distributor Agreement between Purdue Pharma and AmerisourceBergen	PPLP004397465	PPLP004397501
PUR3373	10/1/2012	Distribution Performance Agreement between Purdue Pharma and AmerisourceBergen	PPLP004397502	PPLP004397524
PUR3375	1/8/2010	Distribution Services Agreement between AmerisourceBergen Drug Corporation and Belco Drug Corp and Rhodes Pharmaceuticals LP dated	PPLP004397548	PPLP004397562
PUR3376	8/24/2006	Drug Distribution Agreement between Purdue Pharma and AmerisourceBergen Drug Corporation	PPLP004397563	PPLP004397585
PUR3377	9/30/2014	First Amendment to Authorized Distributor Agreement between Purdue Pharma and AmerisourceBergen Drug Corporation	PPLP004397586	PPLP004397588
PUR3378	9/30/2014	First Amendment to Distribution Performance Agreement between Purdue Pharma and AmerisourceBergen Drug Corporation	PPLP004397589	PPLP004397593
PUR3379	10/2/2015	Letter from Akin Odutola to Saeed Motahari re: execution of a Logistics Services Agreement	PPLP004397594	PPLP004397595
PUR3380	4/24/2012	Letter from Stephen L. Seid to Michael Kody terminating Drug Distribution Agreement as of June 20, 2012	PPLP004397596	PPLP004397596
PUR3381	3/31/2016	Letter from Stephen Projansky to Akin Odutola re: amendment to the current (10/01/2012) Authorized Distributor Agreement	PPLP004397597	PPLP004397598
PUR3382	2/13/2015	Letter from Stephen Projansky to General Counsel, AmerisourceBergen, regarding DPA Payments as defined in the Distribution Performance Agreement.	PPLP004397599	PPLP004397600
PUR3383	11/12/2015	Logistics Services Agreement between Purdue Pharma, Integrated Commercialization Solutions, Inc and AmerisourceBergen Drug Corporation	PPLP004397601	PPLP004397611
PUR3384	10/5/2012	Letter from Russell J. Gasdia to Melissa Lattanzi re: Extension Letter Agreement of the current Drug Distribution Service Agreement	PPLP004397612	PPLP004397612
PUR3386	9/30/2015	Second Amendment to Distribution Performance Agreement between Purdue Pharma and AmerisourceBergen Drug Corporation	PPLP004397617	PPLP004397620
PUR3387	10/5/2012	Letter from Russell J. Gasdia to Michael Kody re: potential Distribution Performance Agreement	PPLP004397621	PPLP004397622
PUR3389	3/15/2012	Purdue Pharma Application for Trade Show Participation/Good Neighbor Pharmacy/ThoughtSpot 2012 sponsored by AmerisourceBergen Drug Corporation	PPLP004397625	PPLP004397627
PUR3390	11/17/2014	Letter from Purdue Pharma to Anda, Inc regarding Consent to Disclose Data sent in accordance with DPA	PPLP004397628	PPLP004397628

PUR3391	6/30/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and Anda, Inc	PPLP004397629	PPLP004397633
PUR3392	6/3/2010	Continuing Guaranty and Indemnification Agreement between Anda, Inc and Rhodes Pharmaceuticals, LP	PPLP004397634	PPLP004397637
PUR3393	6/30/2015	First Amendment to Distribution and Performance Agreement between Purdue Pharma and Burlington Drug Company	PPLP004397638	PPLP004397642
PUR3394	7/1/2012	Authorized Distributor Agreement between Purdue Pharma and Burlington Drug Company	PPLP004397643	PPLP004397677
PUR3395	11/17/2014	Letter from Purdue Pharma to Burlington Drug Company regarding Consent to Disclose Data	PPLP004397678	PPLP004397678
PUR3396	7/1/2012	Distribution Performance Agreement between Purdue Pharma and Burlington Drug Company	PPLP004397679	PPLP004397701
PUR3397	4/7/2006	Drug Distribution Service Agreement between Purdue Pharma and Burlington Drug Company	PPLP004397702	PPLP004397724
PUR3398	2/13/2015	Letter from Steven Projansky to Bob Peet re:payments and credits back to Purdue	PPLP004397725	PPLP004397726
PUR3399	4/15/2016	First Amendment To Authorized Distributor Agreement Between Purdue and Burlington Drug Company	PPLP004397727	PPLP004397728
PUR3400	7/1/2012	Authorized Distributor Agreement Between Purdue Pharma and Capital Wholesale Drug Company	PPLP004397729	PPLP004397763
PUR3401	11/17/2014	Letter from Purdue Pharma to Capital Wholesale Drug Company re: Consent to Disclose Data	PPLP004397764	PPLP004397764
PUR3402	2/13/2015	Letter fro Steven Projansky to David Franklin re: Credits and Debits Due under the Distribution Performance Agreement between Purdue Pharma and Capital Wholesale Drug Company	PPLP004397765	PPLP004397766
PUR3403	4/15/2016	First Amendment to Authorized Distributor Agreement Between Purdue Pharma and Capital Wholesale Drug Company	PPLP004397767	PPLP004397768
PUR3404	10/23/2013	Letter from Russell Gasdia to Melissa Laber re: adjustments to the metrics in the Distribution Performance Agreement between Purdue and Cardinal Health	PPLP004397769	PPLP004397769
PUR3405	3/2/2015	Amendment to Statement of Work between Cardinal Health and Purdue Pharma	PPLP004397770	PPLP004397770
PUR3406	7/1/2012	Authorized Distributor Agreement between Purdue Pharma and Cardinal Health	PPLP004397771	PPLP004397805
PUR3407	4/15/2016	Second Amendment to Authorized Distributor Agreement, Between Purdue Pharma and Cardinal Health	PPLP004397806	PPLP004397807
PUR3408	7/1/2012	Central Distribution Services Agreement between Purdue Pharma and Cardinal Health	PPLP004397808	PPLP004397818
PUR3409	8/1/2012	Distribution Performance Agreement between Purdue Pharma and Cardinal Health	PPLP004397819	PPLP004397843
PUR3410	8/8/2006	Drug Distribution Service Agreement between Purdue Pharma and Cardinal Health	PPLP004397844	PPLP004397864
PUR3411	8/31/2015	First Amendment to Authorized Distributor Agreement between Purdue Pharma and Cardinal Health	PPLP004397865	PPLP004397866
PUR3412	6/30/2015	First Amendment to Central Distribution Agreement between Purdue Pharma and Cardinal Health	PPLP004397867	PPLP004397868
PUR3413	7/31/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and Cardinal Health	PPLP004397869	PPLP004397870
PUR3414	1/1/2010	General Wholesale Service Agreement between Cardinal Health and Rhodes Pharmaceuticals	PPLP004397871	PPLP004397882
PUR3415	3/31/2016	Letter from Steven Projansky to Nicholas Rauch re: sales of Purdue prescription products to Diamond Drugs, Inc	PPLP004397883	PPLP004397883
PUR3416	8/31/2015	Second Amendment to Central Distribution Services Agreement between Purdue Pharma and Cardinal Health	PPLP004397884	PPLP004397885
PUR3418	1/27/2003	Statement of Work to Master Laboratory Services Agreement Between Cardinal Health, Inc f/k/a Magellan Laboratories Incorporated and the PF Laboratories, Inc	PPLP004397888	PPLP004397894
PUR3419	5/7/2003	Work Order To Master Laboratory Services Agreement Between Cardinal Health PTS, Inc f/k/a Magellan Laboratories Incorporated And The Purdue Pharma LP	PPLP004397895	PPLP004397902
PUR3420	1/30/2015	Statement of Work Under Authorized Distributor Agreement Dated July 1, 2012 Between Purdue Pharma and Cardinal Health	PPLP004397903	PPLP004397904
PUR3421	9/30/2015	Third Amendment to Distribution Performance Agreement between Purdue Pharma and Cardinal Health, effective September 30, 2015	PPLP004397905	PPLP004397908
PUR3422	4/1/2008	Amendment No. 1 to Drug Distribution Service Agreement between Purdue Pharma and Cardinal Health	PPLP004397909	PPLP004397911
PUR3423	8/26/2009	Cardinal Health Consumer Health Supplier Program Agreement with Purdue Pharma	PPLP004397912	PPLP004397914
PUR3424	3/28/2000	Draft Agreement between The Purdue Frederick Company International, Inc and Cesar Castillo, Inc with handwritten notes.	PPLP004397915	PPLP004397925
PUR3425	6/30/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and Cesar Castillo Inc	PPLP004397926	PPLP004397930
PUR3426	7/11/2012	Authorized Distributor Agreement between Purdue Pharma and Cesar Castillo Inc, effective July 1, 2012	PPLP004397931	PPLP004397968
PUR3427	11/17/2014	Letter from Purdue Pharma to Cesar Castillo Inc regarding Distribution Performance Agreement	PPLP004397969	PPLP004397969
PUR3428	10/1/2001	Distribution Agreement between the Purdue Frederick Company and Cesar Castillo Inc	PPLP004397970	PPLP004398002

PUR3429	7/1/2012	Distribution Performance Agreement between Purdue Pharma and Cesar Castillo Inc	PPLP004398003	PPLP004398025
PUR3430	2/9/2009	Drug Distribution Service Agreement between Purdue Pharma and Cesar Castillo Inc, DBA Drogueria Castillo	PPLP004398026	PPLP004398047
PUR3431	2/13/2015	Letter from Steven Projansky to Luis Vazquez regarding DPA Payments	PPLP004398048	PPLP004398049
PUR3432	10/1/2001	Termination, Settlement and Release Agreement between Cesar Castillo, Inc and The Purdue Frederick Company International, Inc terminating the 1971 Distribution Agreement	PPLP004398050	PPLP004398070
PUR3433	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue Pharma and Cesar Castillo Inc.	PPLP004398071	PPLP004398072
PUR3434	7/1/2012	Authorized Distributor Agreement between Purdue Pharma and Dakota Drug, Inc	PPLP004398073	PPLP004398107
PUR3435	11/17/2014	Letter from Purdue Pharma to Dakota Drug Inc. re: Consent to Disclose Data	PPLP004398108	PPLP004398108
PUR3436	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue Pharma and Dakota Drug, Inc.	PPLP004398109	PPLP004398110
PUR3437	7/1/2012	Authorized Distributor Agreement between Purdue Pharma and Drogueria Betances, Inc.	PPLP004398111	PPLP004398145
PUR3438	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue Pharma and Drogueria Betances, Inc.	PPLP004398146	PPLP004398147
PUR3439	12/16/2011	Letter of Agreement between Purdue Pharma and H.D.Smith re the renegotiation period of the Distribution Agreement in first quarter 2012.	PPLP004398148	PPLP004398148
PUR3441	7/1/2012	Authorized Distributor Agreement between Purdue Pharma and H.D.Smith Wholesale Drug Co.	PPLP004398150	PPLP004398185
PUR3442	7/1/2012	Distribution Performance Agreement between Purdue Pharma and H.D.Smith Wholesale Drug Co.	PPLP004398186	PPLP004398208
PUR3444	6/30/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and H.D.Smith	PPLP004398223	PPLP004398227
PUR3445	2/13/2015	Letter from Steven Projansky to Bob Appleby re explanation of payments to and credits from Purdue.	PPLP004398228	PPLP004398229
PUR3446	7/1/2018	Second Amendment to Distribution Performance Agreement between Purdue Pharma and H.D. Smith, LLC	PPLP004398230	PPLP004398239
PUR3447	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue Pharma and H.D.Smith Wholesale Drug Co.	PPLP004398240	PPLP004398241
PUR3448	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue and HD Smith Wholesale Drug	PPLP004398242	PPLP004398243
PUR3449	10/7/2014	Brand Rx Marketing Program Agreement between Purdue and HD Smith Wholesale	PPLP004398244	PPLP004398244
PUR3450	12/16/2011	Letter from Russell Gasdia to Brian Stalets re: renegotiating Distribution Agreements	PPLP004398245	PPLP004398245
PUR3451	7/1/2012	Authorized distributor Agreement between Purdue and HD Smith Wholesale	PPLP004398246	PPLP004398281
PUR3453	12/4/2006	Drug Distribution Service Agreement between Purdue and HD Smith Wholesale	PPLP004398305	PPLP004398318
PUR3454	10/20/2017	Services Agreement between Purdue and HD Smith	PPLP004398319	PPLP004398320
PUR3456	10/1/2009	Drug Distribution Service Agreement between Purdue and AmerisourceBergen, Bellco and JM Blanco	PPLP004398322	PPLP004398326
PUR3457	7/1/2012	Authorized Distributor Agreement between Purdue and Louisiana Wholesale Drug	PPLP004398327	PPLP004398361
PUR3458	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue and Louisiana Wholesale Drug	PPLP004398362	PPLP004398363
PUR3459	1/3/2012	First Amendment to Schedule 1A of the LoyaltyScript Program Agreement for Butrans between Purdue and McKesson	PPLP004398364	PPLP004398373
PUR3460	1/19/2012	Addendum #1 to Services Agreement between Purdue and McKesson	PPLP004398374	PPLP004398374
PUR3461	7/1/2012	Addendum #2 to Services Agreement between Purdue and McKesson	PPLP004398375	PPLP004398375
PUR3462	11/15/2001	Amendment #1 to Consultant Services Agreement between Purdue and McKesson	PPLP004398376	PPLP004398377
PUR3463	6/5/2013	Amendment #1 to Statement of Work Agreement between Purdue and McKesson	PPLP004398378	PPLP004398378
PUR3464	11/26/2007	Letter from Russell Gasdia to Greg Yonko re: amending the Distribution Agreement	PPLP004398379	PPLP004398379
PUR3465	12/16/2011	Letter from Russell Gasdia to Greg Yonko re: renegotiating Distribution Agreement	PPLP004398380	PPLP004398380
PUR3466	1/3/2012	Amendment to Services Agreement between Purdue and McKesson	PPLP004398381	PPLP004398382
PUR3467	7/1/2012	Authorized Distributor Agreement between Purdue and McKesson	PPLP004398385	PPLP004398421
PUR3468	9/21/2016	Seventh Amendment to Schedule 3A to the LoyaltyScript Program Agreement for Butrans between Purdue and McKesson	PPLP004398422	PPLP004398422
PUR3470	7/1/2012	Central Distribution Services Agreement between Purdue and McKesson	PPLP004398424	PPLP004398436
PUR3471	4/29/2002	Letter from Kristina Veaco to Purdue General Counsel re: consent to assignment of the Master Consultant Services Agreement between Purdue and McKesson	PPLP004398437	PPLP004398437
PUR3472	4/16/2001	Consultant Services Agreement between Purdue and McKesson to provide self administered questionnaires	PPLP004398438	PPLP004398447
PUR3473	10/1/2001	Consultant Services Agreement between Purdue and McKesson to provide self administered questionnaires	PPLP004398448	PPLP004398456
PUR3474	10/15/2001	Consultant Services Agreement between Purdue and McKesson to facilitate focus groups	PPLP004398457	PPLP004398466
PUR3475	1/3/2002	Consultant Services Agreement between Purdue and McKesson to conduct focus groups among physicians prescribing OxyContin	PPLP004398467	PPLP004398477

PUR3476	9/21/2000	Consultant Services Agreement between Purdue and McKesson to conduct focus groups	PPLP004398478	PPLP004398486
PUR3477	7/1/2012	Distribution Performance Agreement between Purdue and McKesson	PPLP004398487	PPLP004398510
PUR3478	10/19/2006	Drug Distribution Services Agreement between Purdue and McKesson	PPLP004398511	PPLP004398537
PUR3479	10/28/2015	Fifth Amendment to Schedule 3A of the LoyaltyScript Program Agreement for Butrans between Purdue and McKesson	PPLP004398538	PPLP004398554
PUR3480	2/18/2014	Fifth Amendment to Schedule 4A of the LoyaltyScript Intermezzo Patient Savings and TrialScript Trial Offer Agreement between Purdue and McKesson	PPLP004398555	PPLP004398556
PUR3481	8/10/2012	First Amendment to Schedule 3A of the LoyaltyScript Program Agreement for Butrans between Purdue and McKesson	PPLP004398557	PPLP004398570
PUR3482	8/10/2012	First Amendment to Schedule 4A of the LoyaltyScript Intermezzo Patient Savings, Physician Sampling Program Agreement between Purdue and McKesson	PPLP004398571	PPLP004398583
PUR3483	5/14/2015	First Amendment to Schedule 6A of the LoyaltyScript Program Agreement for Hysingla between Purdue and McKesson	PPLP004398584	PPLP004398601
PUR3484	3/17/2015	Fourth Amendment to Schedule 3A and Schedule 3B of the LoyaltyScript Program Agreement for Butrans between Purdue and McKesson	PPLP004398602	PPLP004398621
PUR3485	1/11/2013	Fourth Amendment to Schedule 4A of the LoyaltyScript Intermezzo Patient Savings and TrialScript Trial Offer Program Agreement between Purdue and McKesson	PPLP004398622	PPLP004398642
PUR3486	12/20/2013	Fourth Amendment to Services Agreement between Purdue and McKesson	PPLP004398643	PPLP004398643
PUR3487	1/3/2012	Fulfillment Services Agreement for LoyaltyScript Program (Schedule 2A) for Intermezzo between Purdue and McKesson	PPLP004398644	PPLP004398646
PUR3488	5/16/2016	Second Amendment to Schedule 6A of the LoyaltyScript Program for Hysingla between Purdue and McKesson	PPLP004398647	PPLP004398667
PUR3489	8/29/2017	Fourth Amendment to Schedule 6A of the LoyaltyScript Program for Hysingla between Purdue and McKesson	PPLP004398668	PPLP004398688
PUR3491	2/13/2015	Letter from Steven Projansky to Greg Yonko re: Distribution Performance Agreement payments	PPLP004398696	PPLP004398697
PUR3492	1/6/2011	McKesson Manufacturer Marketing Program Agreement between McKesson and Purdue Products L.P.	PPLP004398698	PPLP004398699
PUR3493	9/5/2000	Master Consultant Services Agreement between Purdue and McKesson	PPLP004398700	PPLP004398711
PUR3494	1/16/2002	Master Consultant Services Agreement between Purdue and McKesson to provide market research	PPLP004398712	PPLP004398718
PUR3495	6/22/2017	Schedule of Services for LoyaltyScript Program for Symproic (Schedule 9A) - \$15 Savings Card Program- between Purdue and McKesson	PPLP004398719	PPLP004398722
PUR3496	5/10/2016	McKesson Manufacturer Marketing Supplier Content Pass Through Agreement between Purdue and McKesson	PPLP004398723	PPLP004398729
PUR3497	3/5/2018	Amendment to 1 to Schedule 9A Schedule of Services for Loyalty Script Program for Symproic - \$15 Savings Card Program	PPLP004398730	PPLP004398731
PUR3498	6/30/2016	First Amendment to Distribution Performance Agreement between Purdue Pharma L.P. and McKesson Corporation	PPLP004398732	PPLP004398734
PUR3499	6/30/2016	First Amendment to Central Distribution Services Agreement between Purdue and McKesson	PPLP004398735	PPLP004398736
PUR3500	2/2/2017	LoyaltyScript Program for Hysingla (3d Amendment to Sched 6A)	PPLP004398737	PPLP004398754
PUR3501	9/21/2016	LoyaltyScript Program Agreement for Butrans (7th Amendment to Sched 3A)	PPLP004398755	PPLP004398756
PUR3502	9/21/2016	Sixth Amendment to Services Agreement between Purdue and McKesson	PPLP004398757	PPLP004398757
PUR3503	7/8/2016	LoyaltyScript Program Agreement for Butrans (6th Amendment to Sched 3A and 3B)	PPLP004398758	PPLP004398774
PUR3504	3/29/2017	LoyaltyScript Program Agreement for Butrans (8th Amendment to Sched 3A)	PPLP004398775	PPLP004398787
PUR3505	11/15/2010	Letter from Larry Pickett Jr to McKesson Specialty Arizona Inc. re: discussion of business relationship relating to "long acting opioid class wide REMS partnership"	PPLP004398788	PPLP004398790
PUR3506	4/2/2010	Letter from Russell Gasdia to Peggy Yelinek, general manager at McKesson Specialty Arizona Inc. re: possible business relationship relating to an analysis of Prescription Value Cards	PPLP004398791	PPLP004398793
PUR3507	3/8/2018	Seventh Amendment to Services Agreement between Purdue and Mckesson	PPLP004398794	PPLP004398794
PUR3508	10/5/2016	Schedule of Services Agreement for LoyaltyScript Program for Hysingla ER	PPLP004398795	PPLP004398807
PUR3509	6/30/2016	Distribution Performance Agreement (First Amendment) between Purdue Pharma L.P. and McKesson Corporation	PPLP004398808	PPLP004398810
PUR3510	6/30/2016	Central Distribution Services Agreement (first Amendment) between Purdue and McKesson	PPLP004398811	PPLP004398812
PUR3511	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue and McKesson	PPLP004398813	PPLP004398814
PUR3512	1/20/2006	Drug Distribution Services Agreement between Purdue and McKesson	PPLP004398815	PPLP004398833
PUR3513	11/23/2009	Drug Distribution Services Agreement between Rhodes Pharmaceuticals and McKesson	PPLP004398834	PPLP004398850
PUR3514	1/18/2012	Schedule of Services for LoyaltyScript Program Agreement for Butrans (Sched 3A)	PPLP004398851	PPLP004398865
PUR3515	3/23/2012	Schedule of Services for LoyaltyScript Program Agreement for Intermezzo Patient Savings and Physician Sampling (Sched 4A)	PPLP004398866	PPLP004398888
PUR3516	5/13/2013	Pharmacy Intervention Program for Butrans to the Master Services Agreement between McKesson and Purdue	PPLP004398889	PPLP004398892
PUR3517	3/23/2016	Schedule of Services for LoyaltyScript Program Agreement for Oxycontin (Sched 7A)	PPLP004398893	PPLP004398895
PUR3518	1/19/2011	Schedule of Services for LoyaltyScript Program Agreement for Butrans (Sched 1A)	PPLP004398896	PPLP004398911

PUR3519	1/21/2015	Schedule of Services for LoyaltyScript Program Agreement for Hysingla (Sched 6A)	PPLP004398912	PPLP004398927
PUR3520	12/18/2012	Schedule of Services for LoyaltyScript Program Agreement for Butrans (2nd Amendment to Sched 3A)	PPLP004398928	PPLP004398941
PUR3521	8/16/2012	Schedule of Services for LoyaltyScript Program Agreement for Intermezzo Patient Savings, Physician Sampling Program (2nd Amendment to Sched 4A)	PPLP004398942	PPLP004398960
PUR3522	12/18/2012	Second Amendment to Services Agreement between Purdue and McKesson	PPLP004398961	PPLP004398961
PUR3523	1/19/2011	Services Agreement between McKesson and Purdue	PPLP004398962	PPLP004398972
PUR3524	10/13/2016	McKesson Manufacturer Marketing Product Promotional Agreement	PPLP004398973	PPLP004398974
PUR3525	5/28/2013	Intermezzo Statement of Work Agreement between McKesson and Purdue	PPLP004398975	PPLP004398976
PUR3526	1/25/2002	Master Consultant Services Agreement between McKesson and Purdue (Statement of Work #1)	PPLP004398977	PPLP004398981
PUR3527	3/13/2002	Master Consultant Services Agreement between McKesson and Purdue (Statement of Work #2 - Market Research)	PPLP004398982	PPLP004398985
PUR3528	4/4/2002	Master Consultant Services Agreement between McKesson and Purdue (Statement of Work #3 - Market Research)	PPLP004398986	PPLP004398990
PUR3529	4/4/2002	Master Consultant Services Agreement between McKesson and Purdue (Statement of Work #4 - Market Research)	PPLP004398991	PPLP004398995
PUR3531	2/25/2010	Supplier Agreement, Multisource and Onestop Generics Program Agreement between McKesson and Rhodes Pharmaceuticals	PPLP004398998	PPLP004399016
PUR3532	8/26/2015	Letter from Saeed Motahari to Derek Rago re: termination of Services Agreement between Purdue and McKesson	PPLP004399017	PPLP004399017
PUR3533	12/18/2013	LoyaltyScript Program Agreement for Butrans between Purdue and McKesson (3d Amend to Sched 3A)	PPLP004399018	PPLP004399032
PUR3534	11/28/2012	LoyaltyScript Program Agreement for Intermezzo Patient Savings, Physician Sampling between Purdue and McKesson (3d Amend to Sched 4A)	PPLP004399033	PPLP004399054
PUR3535	5/3/2013	Third Amendment to Services Agreement between Purdue and McKesson	PPLP004399055	PPLP004399056
PUR3536	12/31/2011	Second Amendment to Services Agreement between Purdue and McKesson (unexecuted)	PPLP004399057	PPLP004399083
PUR3538	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue and McKesson (unexecuted)	PPLP004399086	PPLP004399087
PUR3539	10/1/2001	Consultant Services Agreement between Purdue and McKesson (unexecuted)	PPLP004399088	PPLP004399096
PUR3540	11/23/2009	Drug Distributor Services Agreement between Rhodes Pharmaceuticals and McKesson (unexecuted)	PPLP004399097	PPLP004399113
PUR3541	4/15/2016	First Amendment to Authorized Distributor Agreement between Purdue and Miami-Luken (unexecuted)	PPLP004399114	PPLP004399115
PUR3542	4/20/2012	Authorized Distributor Agreement between Purdue and Miami-Luken	PPLP004399116	PPLP004399153
PUR3543	11/17/2014	Letter from Steve Projansky to Miami-Luken re: Wholesaler consent to disclose data	PPLP004399154	PPLP004399154
PUR3544	4/20/2012	Distribution Performance Agreement between Purdue and Miami-Luken	PPLP004399155	PPLP004399177
PUR3545	4/13/2006	Drug Distribution Services Agreement between Purdue and Miami-Luken	PPLP004399178	PPLP004399200
PUR3546	2/13/2015	Letter from Steven Projansky to Barb Lanham re: distribution performance agreement payments	PPLP004399201	PPLP004399202
PUR3547	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement, btwn Purdue Pharma & Miami-Luken.	PPLP004399203	PPLP004399204
PUR3548	12/14/2012	Authorized Distributor Agreement btwn Purdue & Morris & Dickson Co., with attached Exhibits	PPLP004399205	PPLP004399241
PUR3549	11/17/2014	Consent to Disclose Data agreement btwn Purdue and Morris & Dickson.	PPLP004399242	PPLP004399242
PUR3550	9/15/2017	Services Agreement btwn Purdue Pharma and Morris & Dickson.	PPLP004399243	PPLP004399245
PUR3551	9/15/2017	Services Agreement btwn Purdue Pharma and Morris & Dickson.	PPLP004399246	PPLP004399248
PUR3552	2/9/2007	Nondisclosure Agreement between Purdue Pharma and Morris & Dickson.	PPLP004399249	PPLP004399250
PUR3553	9/26/2016	Services Agreement between Purdue Pharma and Morris & Dickson.	PPLP004399251	PPLP004399253
PUR3554	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement, between Purdue Pharma and Morris & Dickson	PPLP004399254	PPLP004399255
PUR3556	4/1/2013	(Unsigned) Data Quality Agreement between Purdue Pharma and Morris & Dickson.	PPLP004399258	PPLP004399275
PUR3557	5/2/2012	Authorized Distributor Agreement between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company, with attached Exhibits.	PPLP004399276	PPLP004399312
PUR3558	11/17/2014	Consent to Disclose Data Agreement Letter between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company.	PPLP004399313	PPLP004399313
PUR3559	5/2/2012	Distribution Performance Agreement between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company, with attached Exhibits.	PPLP004399314	PPLP004399336
PUR3560	3/27/2006	Drug Distribution Service Agreement between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company.	PPLP004399337	PPLP004399359
PUR3561	6/30/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company.	PPLP004399360	PPLP004399364
PUR3562	2/13/2015	Letter from S. Projansky (Purdue) to H. Harrison (NC Mutual Wholesale Drug Co.) re the explanation of payments to & credits from Purdue.	PPLP004399365	PPLP004399366
PUR3564	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement between Purdue Pharma and The North Carolina Mutual Wholesale Drug Company.	PPLP004399369	PPLP004399370
PUR3565	6/30/2015	First Amendment to Authorized Distributor Agreement between Purdue Pharma and Pharmacy Buying Association, with Exhibit.	PPLP004399371	PPLP004399375
PUR3566	5/2/2012	Authorized Distributor Agreement between Purdue Pharma and Pharmacy Buying Association, with Exhibits.	PPLP004399376	PPLP004399410
PUR3567	11/17/2014	Consent to Disclose Data Letter Agreement between Purdue Pharma and Pharmacy Buying Association.	PPLP004399411	PPLP004399411
PUR3568	5/2/2012	Distribution Performance Agreement between Purdue Pharma and Pharmacy Buying Association, with Exhibits.	PPLP004399412	PPLP004399436

PUR3569	2/13/2015	Letter from S. Projansky (Purdue) to N. Smock (Pharmacy Buying Assn.) re explanation of payments to and credits from Purdue.	PPLP004399437	PPLP004399438
PUR3570	12/14/2017	Services Agreement between Purdue Pharma and Pharmacy Buying Association.	PPLP004399439	PPLP004399441
PUR3571	6/1/2018	(Unsigned) Second Amendment to Distribution Performance Agreement between Purdue Pharma and Pharmacy Buying Association, with Exhibit.	PPLP004399442	PPLP004399446
PUR3572	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement between Purdue Pharma and Pharmacy Buying Association.	PPLP004399447	PPLP004399448
PUR3573	11/21/2012	Authorized Distributor Agreement between Purdue Pharma and Prescription Supply, Inc., with Exhibit.	PPLP004399449	PPLP004399483
PUR3574	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement between Purdue Pharma and Prescription Supply, Inc.,	PPLP004399484	PPLP004399485
PUR3576	4/12/2012	Authorized Distributor Agreement between Purdue Pharma and Rochester Drug Cooperative, Inc., with Exhibits.	PPLP004399488	PPLP004399525
PUR3577	11/17/2014	Consent to Disclose Data Letter Agreement between Purdue Pharma and Rochester Drug Co-Operative, Inc.,	PPLP004399526	PPLP004399526
PUR3578	4/12/2012	Distribution Performance Agreement between Purdue Pharma and Rochester Drug Co-Operative, Inc., with Exhibits.	PPLP004399527	PPLP004399549
PUR3579	4/13/2006	Drug Distribution Service Agreement between Purdue Pharma and Rochester Drug Cooperative, Inc., with Attachments	PPLP004399550	PPLP004399569
PUR3580	6/30/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and Rochester Drug Co-Operative, Inc., with Exhibit.	PPLP004399570	PPLP004399574
PUR3581	2/13/2015	Letter from S. Projansky (Purdue) to E. Kirker (Rochester Drug Co-Operative, Inc.) re explanation of payments to and credits from Purdue.	PPLP004399575	PPLP004399576
PUR3582	4/15/2016	(Unsigned) First Amendment to Authorized Distributor Agreement between Purdue Pharma and Rochester Drug Co-Operative, Inc.,	PPLP004399577	PPLP004399578
PUR3583	4/7/2006	Drug Distribution Service Agreement between Purdue Pharma and Smith Drug Company, with Attachments.	PPLP004399579	PPLP004399598
PUR3584	12/21/2017	Services Agreement between Purdue Pharma and Smith Drug Company	PPLP004399599	PPLP004399601
PUR3585	12/21/2017	Services Agreement between Purdue Pharma and Smith Drug Company.	PPLP004399602	PPLP004399604
PUR3586	8/24/2017	Invoices from Smith Drug Company to Purdue Pharma re Symproic.	PPLP004399605	PPLP004399605
PUR3587	8/22/2008	Drug Distribution Service Agreement between Purdue Pharma and Valley Wholesale Drug Company, with Attachments.	PPLP004399606	PPLP004399627
PUR3588	12/31/2015	First Amendment to Distribution Performance Agreement between Purdue Pharma and Value Drug Company, with Exhibit.	PPLP004399628	PPLP004399631
PUR3589	11/29/2012	Distribution Performance Agreement between Purdue Pharma and Value Drug Company, with Exhibits.	PPLP004399632	PPLP004399655
PUR3590	6/1/2018	Second Amendment to Distribution Performance Agreement between Purdue Pharma and Value Drug Company, with Exhibit.	PPLP004399656	PPLP004399663
PUR3591	7/11/2016	Purdue Pharma Standard Operating Procedure (Submission - Regulatory Requirements)	PPLP004404321	PPLP004404324
PUR3592	11/22/2016	Purdue SOP - Preparing and Submitting Advertising and Promotional Labeling to the FDA.	PPLP004404325	PPLP004404329
PUR3593	1/1/2001	Abuse/Diversion guidelines	PPLP004425058	PPLP004425058
PUR3594	5/16/2010	Piercefield, E, Increase in Unintentional Medication Overdose Deaths Oklahoma, 1994-2006, American Journal of Preventative Medicine, 39(4), pp. 357-363	PPLP004425059	PPLP004425065
PUR3595	6/21/2011	Purdue Corporate Compliance Audit Report 6/21/2011-7/31/2011	PPLP004429653	PPLP004429659
PUR3596	5/16/2012	Memorandum from Greg D'Onofrio to Bert Weinstein re: Speaker Bureau Program Monitoring Forms	PPLP004429660	PPLP004429661
PUR3597	5/10/2007	Plea Agreement of Paul D. Goldenheim	PPLP004429783	PPLP004429792
PUR3598	5/10/2007	Plea Agreement of Howard R. Udell	PPLP004429793	PPLP004429802
PUR3599	6/1/2009	Purdue 2009 Code of Business Ethics	PPLP004430949	PPLP004430981
PUR3600	4/1/2007	Compliance Scenarios for Sales Representatives	PPLP004431022	PPLP004431075
PUR3601	5/21/2007	Corporate Compliance Program Charter for Purdue Pharma L.P. and its Independent Associated U.S. Companies.	PPLP004431139	PPLP004431147
PUR3602	7/17/2007	Corporate Compliance Committees: structure and responsibilities of departmental compliance committees and corporate compliance council.	PPLP004431148	PPLP004431154
PUR3603	11/27/2007	SOP 000012: Corporate Compliance Training	PPLP004431155	PPLP004431164
PUR3604	5/27/2010	SOP-000006: Corporate Compliance Monitoring	PPLP004431165	PPLP004431171
PUR3605	5/21/2008	SOP-000010: Corporate Compliance Hotline operations about Administration of Purdue's ethics and compliance disclosure hotline.	PPLP004431172	PPLP004431178
PUR3606	7/17/2007	Corporate Compliance Investigations: Investigation Process for Corporate Compliance	PPLP004431179	PPLP004431185
PUR3607	7/17/2007	SOP-000008: OIG Reportable Events and Other OIG Regarding Procedure Describing the Activities of the reportable Events Committee, and Requirements to Communicate Certain Events to OIG.	PPLP004431186	PPLP004431195
PUR3608	7/17/2007	SOP-000005: Corporate Compliance Audit Program	PPLP004431196	PPLP004431203
PUR3609	2/18/2010	Purdue Pharma Working Practice Document - Promotion Monitoring Program on Monitoring of Field Sales Performance	PPLP004431206	PPLP004431214
PUR3610	2/18/2010	Purdue Working Practice Document - Monitoring of Requests for Information	PPLP004431215	PPLP004431223
PUR3611	2/18/2010	Purdue Pharma Working Practice Document - Field Contact Report Monitoring on Process for Monitoring Field Contact Reports That do not Require Compliance Detailing Review per CC-WPD-000010	PPLP004431224	PPLP004431230
PUR3612	11/21/2007	Purdue Marketing Standard Operating Procedure	PPLP004431455	PPLP004431462
PUR3613	7/26/2007	Purdue Standard Operating Procedure-Process for Medical Liaison Handling of Unsolicited, Off-Label Requests Regarding Purdue Products	PPLP004431477	PPLP004431482

PUR3614	7/6/2009	Purdue Standard Operating Procedure - Process for Field Responsibilities and Interactions by Medical Liaisons	PPLP004431483	PPLP004431490
PUR3615	7/21/2009	Purdue Standard Operating Procedure--Process for Review of Free Text Notes in the Medical Liaison Customer Reporting System	PPLP004431491	PPLP004431495
PUR3616	8/2/2007	Email from Bert Weinstein (Purdue) to Sarah Reznek (Bingham Consulting Group LLP), Re; submissions for Attorneys General with attachment of a brochure (Providing Relief, Preventing Abuse) Letter from J. David Haddox to Healthcare Professionals - Re: Brochure - Providing Relief, Preventing Abuse	PPLP004431832	PPLP004431853
PUR3617	11/28/2007	Letter with attachments from Bert I. Weinstein (vice President, Corporate Compliance) to Keisha B. Thompson regarding: Purdue Pharma's Implementation Report Under Corporate Integrity Agreement - TOC	PPLP004432012	PPLP004432028
PUR3618	10/8/2007	Report- Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 2 - VP Corp. Compliance job description	PPLP004432049	PPLP004432053
PUR3619	9/1/2007	Report - Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 3 - Code of Business Ethics	PPLP004432054	PPLP004432088
PUR3620	11/14/2007	Report- Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 6 Master Services Agreement between Purdue and Huron Consulting Services	PPLP004432256	PPLP004432276
PUR3621	11/12/2007	Report - Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Tab 8	PPLP004432279	PPLP004432300
PUR3622	11/28/2007	Report- Purdue Pharma's Implementation Report Under Corporate Integrity Agreement Legal Counsel Reviewed Document List	PPLP004432304	PPLP004432364
PUR3623	7/20/2011	Report - Standard Business Practices regarding Fourth Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 2	PPLP004432405	PPLP004432556
PUR3624	9/23/2011	Memorandum from Bert Weinstein to Mark DeWyngaert - regarding Purdue Pharma's Response to Independent Review Organization's Systems and Transactions Review Reports, Reporting Period 4.	PPLP004432959	PPLP004432970
PUR3625	8/17/2011	Letter from Mark A. DeWyngaert to Bert I. Weinstein regarding Independent Review Organization Professional Independence - Reporting Period 4.	PPLP004432971	PPLP004432972
PUR3626	1/26/2011	Standard Business Practices: Determination, Screening and Training of Relevant Covered Person and/or AG Covered Person Vendors - Annual Report of Purdue Pharma Under Corporate Integrity Agreement	PPLP004433063	PPLP004433094
PUR3627	7/29/2011	Report - List of Documents Reviewed by Legal counsel regarding Annual Report of Purdue Pharma Under Corporate Integrity Agreement	PPLP004433103	PPLP004433155
PUR3628	9/27/2010	Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 1	PPLP004434301	PPLP004434332
PUR3629	9/27/2010	Standard Business Practices - Human Resources regarding Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 2	PPLP004434333	PPLP004434453
PUR3630	9/27/2010	Memorandum from Chris Santarcangelo to Kathy Tench and Huron Consulting regarding Huron Consulting Group's report on the promotional and product services transactions engagement performed in reporting Period 3.	PPLP004434790	PPLP004434794
PUR3631	9/16/2010	Letter from Mark A.I DeWyngaert to Bert I. Weinstein regarding Independence Review Organization Professional Independence - Reporting Period 3.	PPLP004434795	PPLP004434796
PUR3632	9/27/2010	Third Reporting Period Disclosures Related to Federal Health Care Programs or FDA Requirements.	PPLP004434797	PPLP004434869
PUR3633	11/23/2009	Purdue Pharma Standard Business Practices: determination, screening and training of relevant covered person and/or AG covered person vendors for Third Annual Report	PPLP004434870	PPLP004434875
PUR3634	9/1/2010	Report - Purdue Pharma Notification to HHS Office of Inspector General pursuant to Corporate Integrity Agreement Section III. G.	PPLP004434876	PPLP004434881
PUR3635	9/27/2010	Report - List of Documents Reviewed by Legal Counsel -related to Third Annual Report of Purdue Pharma Under Corporate Integrity Agreement Tab 11	PPLP004434885	PPLP004434934
PUR3636	9/27/2012	Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement Tab 1	PPLP004434945	PPLP004434969
PUR3637	3/23/2012	SOP related to Local Exhibit Display for Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement Tab 2	PPLP004434970	PPLP004434980
PUR3638	9/27/2012	Memorandum from Bert Weinstein to Mark DeWyngaert and Tracy Mastro regarding Purdue Pharma's Response to Independent Review Organization's Report on Promotional and Product Services Transactions Engagement Reporting Period 5.	PPLP004435220	PPLP004435225
PUR3639	8/20/2012	Letter from Mark A. DeWyngaert to Bert I. Weinstein regarding Independent Review organization Professional Independence - Reporting Period 5.	PPLP004435226	PPLP004435227
PUR3640	9/27/2012	Report - Fifth Reporting Period Disclosures Related to Federal Health Care programs or FDA Requirements.	PPLP004435228	PPLP004435253
PUR3641	9/5/2012	Report - Purdue Pharma Notification to HHS Office of Inspector General Pursuant to Corporate Integrity Agreement section III.G	PPLP004435254	PPLP004435256
PUR3642	9/27/2012	Report - List of Documents Reviewed by Legal Counsel related to the Fifth Annual Report of Purdue Pharma LP Under Corporate Integrity Agreement Tab 10	PPLP004435260	PPLP004435314
PUR3643	1/4/2007	Minutes - Sales and Marketing Compliance Committee Meeting	PPLP004436083	PPLP004436084
PUR3644	3/1/2010	Meeting minutes - Sales & Marketing Compliance Committee	PPLP004436088	PPLP004436090
PUR3645	12/11/2007	Meeting minutes - Sales & Marketing Compliance Committee	PPLP004436094	PPLP004436095
PUR3646	9/9/2009	Meeting minutes and agenda - Sales & Marketing Compliance Committee	PPLP004436097	PPLP004436098
PUR3647	4/14/2006	Meeting minutes - Sales &Marketing Compliance Committee	PPLP004436101	PPLP004436102
PUR3648	9/12/2006	Meeting minutes - Sales & Marketing Compliance Committee	PPLP004436104	PPLP004436106
PUR3649	6/3/2007	Meeting minutes - Sales & Marketing Compliance Committee	PPLP004436108	PPLP004436109

PUR3650	10/3/2008	Meeting minutes - Sales & Marketing Compliance Committee	PPLP004436112	PPLP004436113
PUR3651	6/16/2009	Meeting Minutes - Sales & Marketing Compliance Committee	PPLP004436115	PPLP004436115
PUR3652	4/30/2008	Meeting Minutes - Sales & Marketing Compliance Committee	PPLP004436117	PPLP004436119
PUR3653	7/17/2006	Meeting Minutes - Sales & Marketing Compliance Committee	PPLP004436121	PPLP004436123
PUR3654	1/27/2011	Meeting Agenda - Sales and Marketing Compliance Committee	PPLP004436125	PPLP004436127
PUR3655	4/17/2007	Meeting Minutes - Sales & Marketing Compliance Committee	PPLP004436129	PPLP004436130
PUR3656	3/19/2015	Sales & Marketing Compliance Committee Meeting Minutes	PPLP004436133	PPLP004436135
PUR3657	4/2/2009	DRAFT Sales and Marketing Compliance Committee Minutes	PPLP004436140	PPLP004436143
PUR3658	3/19/2009	Meeting Minutes - Sales and Marketing Compliance Committee	PPLP004436145	PPLP004436145
PUR3659	2/8/2006	Sales and Marketing Compliance Committee (final) meeting minutes	PPLP004436148	PPLP004436150
PUR3660	5/2/2008	Sales and Marketing Compliance Committee (draft) meeting minutes for 6/16/2008	PPLP004436152	PPLP004436152
PUR3661	5/9/2012	Sales and Marketing Compliance Committee (draft) meeting minutes for 5/9/2012	PPLP004436154	PPLP004436156
PUR3662	9/12/2006	Sales and Marketing Compliance Committee (draft) meeting minutes for 11/29/2006	PPLP004436159	PPLP004436160
PUR3663	3/19/2012	Sales and Marketing Compliance Committee (draft) meeting minutes for 3/19/2012	PPLP004436163	PPLP004436167
PUR3664	12/12/2011	Agenda - Sales and Marketing Compliance Committee	PPLP004436172	PPLP004436173
PUR3665	10/29/2009	Agenda and minutes - Sales and Marketing Compliance Committee	PPLP004436174	PPLP004436176
PUR3666	10/19/2010	Email from Margaret Feltz to Purdie employees regarding draft minutes of Sales & Marketing Compliance Committee	PPLP004436177	PPLP004436180
PUR3667	7/26/2017	Agenda - Sales and Marketing Compliance Committee	PPLP004436184	PPLP004436187
PUR3668	4/8/2010	Agenda - Sales and Marketing Compliance Committee	PPLP004436208	PPLP004436208
PUR3669	1/18/2010	Meeting Minutes - Sales and Marketing Compliance Committee	PPLP004436234	PPLP004436236
PUR3670	4/4/2011	Meeting minutes - Sales and Marketing Compliance Committee	PPLP004436258	PPLP004436260
PUR3671	3/4/2011	Meeting minutes - Sales and Marketing Compliance Committee	PPLP004436270	PPLP004436271
PUR3672	12/11/2012	Agenda and Minutes - Sales and Marketing Compliance Committee	PPLP004436285	PPLP004436287
PUR3673	2/6/2013	Agenda and Minutes - Sales and Marketing Compliance Committee meeting	PPLP004436303	PPLP004436305
PUR3674	12/9/2013	Agenda and Minutes - Sales & Marketing Compliance Committee Meeting	PPLP004436311	PPLP004436314
PUR3675	3/25/2013	Meeting minutes - Sales and Marketing Compliance Committee meeting for 3/25/2013 Sunshine Act discussion	PPLP004436323	PPLP004436324
PUR3676	10/2/2013	Agenda and minutes - Sales and Marketing Compliance Committee meeting	PPLP004436331	PPLP004436333
PUR3677	8/7/2013	Agenda and minutes - Sales and Marketing Compliance Committee meeting	PPLP004436334	PPLP004436336
PUR3678	12/17/2015	Agenda - Sales & Marketing Compliance Committee Meeting	PPLP004436392	PPLP004436393
PUR3679	7/21/2010	Purdue Presentation - Order Monitoring System Presentation to Corporate Compliance Council	PPLP004436879	PPLP004436879
PUR3680	9/30/2011	Excel Spreadsheet, List of OMS Pharmacies	PPLP004437142	PPLP004437142
PUR3683	10/7/2011	PainWeek ASI-MV OxyContin ORF Poster	PPLP004437147	PPLP004437147
PUR3684	10/3/2011	Email from Jack Crowley to DEA regarding slow pharmacies	PPLP004437148	PPLP004437149
PUR3686	9/11/2014	Email from Robin Abrams to Giselle Issa re: Fwd: DEA Closeout - Wilson 09/11/2014	PPLP004437189	PPLP004437191
PUR3687	6/11/2013	Email exchange between Purdue and McKesson Pharmaceutical re compliance and regulatory matters pertaining to the NDA reformulation of OxyContin and LA-San Diego prescriber information.	PPLP004437208	PPLP004437216
PUR3688	4/20/2009	Purdue Pharma Order Monitoring System (OMS) Report	PPLP004437310	PPLP004437323
PUR3689	3/10/2011	OMS Report, Mission Pharmacy	PPLP004437324	PPLP004437328
PUR3690	3/10/2011	Memo to OMS file: Mission Pharmacy	PPLP004437329	PPLP004437363
PUR3691	9/17/2009	Accusation against Mission Pharmacy before the Board of Pharmacy Department of Consumer Affairs State of California	PPLP004437364	PPLP004437371
PUR3692	9/30/2010	St Pauls Pharmacy Report to OMS Team	PPLP004437377	PPLP004437380
PUR3693	1/26/2010	Email exchange between Purdue Pharma & AmerisourceBergen re compliance matters pertaining to Florida retail pharmacies.	PPLP004437697	PPLP004437705
PUR3694	9/1/2009	Email exchange between Purdue Pharma and H.D. Smith regarding compliance matters pertaining to South Florida & Los Angeles pharmacies.	PPLP004437712	PPLP004437718
PUR3695	8/18/2009	Email exchange between Purdue Pharma and H.D. Smith regarding compliance matters & possible diversion pertaining to St. Paul's Pharmacy (Los Angeles)	PPLP004437719	PPLP004437720
PUR3696	3/7/2014	Letter from Michael D. Reisman to Michelle Hirshman, Esq. re: Subpoena to Purdue Pharma L.P. Dated December 17, 2013	PPLP004438045	PPLP004438050
PUR3697	6/28/2010	Assured Pharmacy and Purdue Pharmaceutical Meeting Minutes	PPLP004438189	PPLP004438191
PUR3698	3/17/2010	Report of due diligence/compliance monitoring of Family Medical Pharmacy, Columbus, OH	PPLP004438209	PPLP004438211
PUR3699	10/27/2010	OMS Report for LifeFirst Pharmacy	PPLP004438238	PPLP004438239
PUR3700	9/29/2010	Report to OMS Team regarding federal indictment of physician and clinic (OH Medical and Pain Management, LLC)	PPLP004438240	PPLP004438245
PUR3701	10/28/2010	Report to OMS Team regarding V. Pacifica Pharmacy Inc	PPLP004438326	PPLP004438331
PUR3702	8/18/2011	Memo to file re Kahler Pharmacy following owner's April 2011 death	PPLP004438360	PPLP004438372
PUR3703	8/25/2011	OMS Report Olde Philly Pharmacy	PPLP004439578	PPLP004439580
PUR3704	8/19/2011	Memo to file: Olde Philly Pharmacy	PPLP004439581	PPLP004440688
PUR3705	8/25/2011	OMS Summary Report	PPLP004440689	PPLP004440715
PUR3706	8/25/2011	OMS Report Pardue's Pharmacy	PPLP004440716	PPLP004440719
PUR3707	8/18/2011	Memo to file: Pardue's Pharmacy	PPLP004440720	PPLP004440781
PUR3708	8/25/2011	OMS Report regarding The Clinic Pharmacy	PPLP004440821	PPLP004440824
PUR3709	8/25/2011	OMS Summary Report regarding Pardue's Pharmacy	PPLP004440910	PPLP004440912
PUR3710	12/15/2011	OMS Report Village Pharmacists	PPLP004440983	PPLP004440985
PUR3711	12/15/2011	OMS Report Wyatts Pharmacy Inc.	PPLP004440994	PPLP004440996
PUR3712	7/18/2011	OMS Report Northeast Pharmacy HM	PPLP004441228	PPLP004441231

PUR3713	6/29/2011	Memo to OMS file: Xpress Pharmacy formally known as Community Pharmacy III	PPLP004441266	PPLP004441376
PUR3714	6/2/2011	Memo to OMS file: Future Pharmacy	PPLP004441556	PPLP004441574
PUR3715	6/13/2011	OMS Meeting Agenda	PPLP004442535	PPLP004442535
PUR3716	5/4/2011	Memo to OMS file: Applied Pharmacy Services	PPLP004442539	PPLP004442563
PUR3717	6/13/2011	OMS Summary Report	PPLP004442716	PPLP004442733
PUR3718	6/13/2011	OMS Report The Pill Box Pharmacy	PPLP004443378	PPLP004443383
PUR3719	3/10/2011	OMS Meeting Agenda	PPLP004443493	PPLP004443493
PUR3720	5/5/2011	OMS Meeting Minutes	PPLP004443699	PPLP004443700
PUR3721	5/5/2011	OMS Report: Shaffer Pharmacy, Inc.	PPLP004443774	PPLP004443776
PUR3722	10/17/2011	OMS Report: Drug Store Pharmacy Inc.	PPLP004444088	PPLP004444091
PUR3723	2/17/2012	OMS Summary Report	PPLP004444554	PPLP004444556
PUR3724	6/7/2012	OMS Meeting Minutes	PPLP004444875	PPLP004444881
PUR3725	4/11/2013	OMS Report 07126 Walgreens	PPLP004445308	PPLP004445312
PUR3726	10/15/2013	Memo to OMS file regarding Brown's Drug	PPLP004445669	PPLP004445682
PUR3727	8/13/2014	OMS Meeting Agenda	PPLP004445905	PPLP004445905
PUR3728	8/27/2014	St Mary Pharmacy OMS Report	PPLP004445981	PPLP004445987
PUR3729	12/16/2014	OMS Report - Gulf Coast Pharmacy	PPLP004446124	PPLP004446128
PUR3730	12/8/2015	OMS Meeting Agenda	PPLP004446735	PPLP004446735
PUR3731	10/22/2015	OMS meeting minutes	PPLP004446736	PPLP004446742
PUR3732	3/18/2014	Visit tracking chart regarding OMS Pharmacy	PPLP004446790	PPLP004446790
PUR3733	4/10/2015	OMS Meeting Minutes	PPLP004447466	PPLP004447470
PUR3734	6/9/2015	OMS Meeting Minutes	PPLP004448101	PPLP004448105
PUR3735	3/30/2016	OMS Meeting Agenda	PPLP004449053	PPLP004449053
PUR3736	8/10/2016	OMS Overview from Giselle Issa	PPLP004449246	PPLP004449246
PUR3737	6/5/2012	Order Monitoring System Committee Charter	PPLP004449283	PPLP004449283
PUR3738	10/17/2011	OMS Meeting Minutes	PPLP004449814	PPLP004449816
PUR3739	12/12/2012	OMS Meeting Agenda	PPLP004449817	PPLP004449817
PUR3740	4/11/2013	OMS Meeting Agenda	PPLP004449818	PPLP004449818
PUR3741	4/4/2012	OMS Meeting Agenda	PPLP004449819	PPLP004449819
PUR3742	12/8/2015	OMS Meeting Agenda	PPLP004449821	PPLP004449821
PUR3743	12/15/2011	OMS Meeting Agenda	PPLP004449823	PPLP004449823
PUR3744	2/17/2012	OMS Meeting Agenda	PPLP004449825	PPLP004449825
PUR3745	3/6/2014	OMS Meeting Agenda	PPLP004449828	PPLP004449828
PUR3746	9/19/2012	OMS Meeting Agenda	PPLP004449834	PPLP004449834
PUR3747	10/22/2013	OMS Draft Meeting Minutes	PPLP004449835	PPLP004449838
PUR3748	10/22/2015	OMS Meeting Minutes	PPLP004449839	PPLP004449845
PUR3749	7/18/2011	OMS meeting minutes	PPLP004455092	PPLP004455097
PUR3750	8/25/2011	OMS Meeting Agenda	PPLP004455098	PPLP004455098
PUR3751	8/25/2011	OMS Summary Report	PPLP004455156	PPLP004455185
PUR3752	2/17/2012	OMS Report - Life Pharma II Inc.	PPLP004455864	PPLP004455867
PUR3753	9/5/2012	Report to OMS Team - Town Drug of Hollywood Inc.	PPLP004457783	PPLP004457784
PUR3754	12/17/2014	OMS Meeting Minutes	PPLP004458536	PPLP004458538
PUR3755	11/5/2014	OMS Meeting Minutes	PPLP004458539	PPLP004458541
PUR3756	10/17/2011	OMS Summary Report	PPLP004459610	PPLP004459637
PUR3757	4/13/2010	Meeting Agenda for Kinray and Purdue personnel	PPLP004460342	PPLP004460342
PUR3758	9/16/2010	Email from Jack Crowley to Christopher Kresnak (US DOJ) regarding OxyContin purchases in OH	PPLP004460373	PPLP004460373
PUR3759	8/27/2010	Typed notes of teleconference between Miami Luken & Purdue Pharma L.P. re "Suspicious Order Monitoring" in general and DEA expectations.	PPLP004460374	PPLP004460379
PUR3760	1/29/2009	Email from Jack Crowley to Salvadore Biondolillo, "Follow Up" regarding Moms Pharmacy and Specialty Pharmacies, Inc.	PPLP004460503	PPLP004460508
PUR3761	3/6/2008	Email from Jack Crowley to Carl Griffith regarding a follow-up Information re drug store and IMS	PPLP004460509	PPLP004460511
PUR3762	5/21/2009	Letter from Mark Geraci (Purdue Pharma) to Michael J Lewis regarding review of Lam's Pharmacy.	PPLP004460513	PPLP004460515
PUR3763	12/6/2010	Excel Spreadsheet of OMS Pharmacies	PPLP004460708	PPLP004460708
PUR3764	9/8/2008	OMS Quarterly Meeting Agenda	PPLP004460780	PPLP004460780
PUR3765	12/22/2008	OMS Quarterly Meeting Agenda	PPLP004460783	PPLP004460784
PUR3766	11/4/2009	OMS Committee Meeting	PPLP004460818	PPLP004460819
PUR3767	12/16/2009	OMS Monthly Meeting Agenda	PPLP004460826	PPLP004460826
PUR3768	8/18/2010	Email from Elizabeth Adams to Gina Limer re: Documents for OMS meeting	PPLP004460916	PPLP004460917
PUR3769	8/18/2010	OMS meeting data	PPLP004460918	PPLP004460918
PUR3770	8/18/2010	OMS meeting data	PPLP004460919	PPLP004460919
PUR3771	8/18/2010	OMS meeting data	PPLP004460920	PPLP004460920
PUR3772	8/18/2010	Email from Elizabeth Adams to Elizabeth Adams re: OMS Data for Temponeras	PPLP004460921	PPLP004460921
PUR3773	8/18/2010	OMS meeting data	PPLP004460922	PPLP004460922
PUR3774	8/18/2010	OMS meeting data	PPLP004460923	PPLP004460923
PUR3775	8/18/2010	OMS meeting data	PPLP004460924	PPLP004460924
PUR3776	8/18/2010	Email from Michael Carraturo to Elizabeth Adams re: OMS data	PPLP004460925	PPLP004460933
PUR3777	8/18/2010	OMS meeting data	PPLP004460934	PPLP004460934
PUR3778	8/18/2010	OMS meeting data	PPLP004460935	PPLP004460935
PUR3779	8/18/2010	Email from Luis Bauza to Jack Crowley, Elizabeth Adams, Robin Abrams, Mark Geraci, Stephen Seid, and Joan Zooper re: Miami-Dade Stock Sales report + OMS Database issues	PPLP004460936	PPLP004460946
PUR3780	8/18/2010	OMS Meeting Agenda	PPLP004460947	PPLP004460947
PUR3781	11/2/2010	OMS Meeting Agenda	PPLP004460999	PPLP004461000

PUR3782	12/16/2010	OMS Meeting Agenda, December 6, 2010	PPLP004461028	PPLP004461029
PUR3783	12/16/2010	OMS Slow Pharmacy data	PPLP004461030	PPLP004461030
PUR3784	1/5/2011	Slow Pharmacy 010511 "Under Watch" List	PPLP004461140	PPLP004461144
PUR3785	5/5/2009	Agenda for Meeting between McKesson and Purdue	PPLP004462126	PPLP004462126
PUR3786	9/28/2009	Report: On-Site Visits to selected retail accounts in Southeast Florida with H.D. Smith September 28-30th, 2009	PPLP004463018	PPLP004463021
PUR3787	12/6/2010	Excel Spreadsheet of OMS Pharmacy	PPLP004463297	PPLP004463297
PUR3788	12/6/2010	Excel Spread Sheet OMS Pharmacy	PPLP004463303	PPLP004463303
PUR3789	3/13/2012	Purdue Pharmaceutical Report - Order Monitoring System (OMS): Manufacturer's Perspective, Presentation for HDMA Conference	PPLP004463305	PPLP004463305
PUR3790	11/9/2011	OMS Meeting Agenda	PPLP004464370	PPLP004464370
PUR3791	11/16/2011	Purdue-ABC Meeting Agenda	PPLP004464371	PPLP004464371
PUR3792	3/16/2015	Excel Spread Sheet - OMS Pharmacy	PPLP004466415	PPLP004466415
PUR3793	9/25/2015	Excel Spread Sheet - OMS Pharmacy	PPLP004466439	PPLP004466439
PUR3794	11/4/2011	Email from S Natarajan to G Issa re OMS data with status	PPLP004466505	PPLP004466505
PUR3795	11/4/2011	OMS data with status	PPLP004466506	PPLP004466506
PUR3796	10/14/2014	Excel Spreadsheet, Open OMS cases, 2014	PPLP004466514	PPLP004466514
PUR3797	3/31/2011	Pharmacy exception report	PPLP004467456	PPLP004467456
PUR3798	3/31/2011	Prescriber exception report	PPLP004467457	PPLP004467457
PUR3799	9/29/2011	OMS Pharmacy Report	PPLP004467468	PPLP004467468
PUR3803	11/21/2012	Spreadsheet report of low Pharmacies Reported to DEA Oct 4 and 7 with Wholesalers	PPLP004467485	PPLP004467485
PUR3804	3/5/2012	Spreadsheet report of OMS pharmacies.	PPLP004467502	PPLP004467502
PUR3805	9/5/2013	OMS pharmacy report	PPLP004467856	PPLP004467856
PUR3806	6/28/2013	OMS Pharmacy report	PPLP004467868	PPLP004467868
PUR3807	10/20/2014	OMS wholesaler report	PPLP004468310	PPLP004468310
PUR3808	1/1/2000	OMS Diversion Data	PPLP004468314	PPLP004468314
PUR3809	7/27/2010	Email between Purdue and McKesson personnel regarding List of outlets pending or discussed.	PPLP004469332	PPLP004469337
PUR3810	5/4/2010	Email exchange between Purdue and G. Euson (H.D.Smith) re compliance matters pertaining to pharmacies in the Los Angeles area.	PPLP004469377	PPLP004469383
PUR3811	3/27/2009	Email exchange between Purdue Pharma and AmerisourceBergen re compliance/diversion control matters.	PPLP004469416	PPLP004469419
PUR3812	4/9/2010	Email exchange between Purdue Pharma and McKesson re CSMP-Order Monitoring.	PPLP004469436	PPLP004469436
PUR3813	6/14/2013	OMS Pharmacy report	PPLP004469751	PPLP004469751
PUR3814	2/24/2010	OMS Meeting Agenda	PPLP004470785	PPLP004470791
PUR3815	8/28/2015	Meeting Agenda Purdue and Albertsons	PPLP004471341	PPLP004471341
PUR3816	7/1/2014	Purdue-CVS Meeting agenda	PPLP004471363	PPLP004471364
PUR3817	11/4/2015	Meeting Agenda Purdue and Kroger	PPLP004471438	PPLP004471438
PUR3818	7/23/2013	Purdue - Walgreens Meeting Agenda	PPLP004471559	PPLP004471559
PUR3819	6/3/2013	Memo from S Seid to R Gasdia re: Walgreens meeting	PPLP004471589	PPLP004471590
PUR3820	8/5/2010	Email exchange between Purdue Pharma and AmerisourceBergen re compliance/monitoring pertaining to pharmacies	PPLP004472274	PPLP004472288
PUR3821	10/14/2015	Purdue-ABC Meeting Agenda	PPLP004472290	PPLP004472290
PUR3822	4/17/2014	Purdue-ABC meeting agenda	PPLP004472312	PPLP004472313
PUR3823	4/17/2014	OMS, ORF Epi Data & Patient Access, AmerisourceBergen & Purdue Presentation	PPLP004472314	PPLP004472314
PUR3824	4/8/2014	Email from S Projanksy to G Issa re: Top ABC and McKesson accounts	PPLP004472648	PPLP004472651
PUR3825	4/8/2014	Top ABC and McKesson accounts	PPLP004472652	PPLP004472652
PUR3826	7/1/2015	Meeting Agenda Purdue and Anda	PPLP004472736	PPLP004472736
PUR3827	2/22/2013	(Unsigned) Confidentiality and Restricted Use Agreement between Cardinal Health and Purdue Pharma	PPLP004472950	PPLP004472955
PUR3828	9/30/2010	OMS Meeting Minutes, September 30. 2010	PPLP004473038	PPLP004473044
PUR3829	8/6/2014	Meeting Agenda Purdue and Cardinal Health	PPLP004473054	PPLP004473054
PUR3830	11/28/2012	Purdue - Cardinal Meeting Agenda	PPLP004473076	PPLP004473076
PUR3831	7/9/2015	Purdue Meeting Agenda; Purdue and H.D. Smith	PPLP004473202	PPLP004473202
PUR3832	5/5/2014	Purdue-McKesson Meeting Agenda	PPLP004473308	PPLP004473309
PUR3833	5/5/2009	McKesson Meeting Agenda	PPLP004473314	PPLP004473314
PUR3834	11/13/2014	Purdue Meeting Agenda; Purdue and Morris and Dickson	PPLP004473343	PPLP004473343
PUR3835	10/29/2014	Purdue Meeting Agenda; North Carolina Mutual Wholesale Drug Company	PPLP004473366	PPLP004473366
PUR3836	5/2/2013	Purdue - Rochester Drug Co-Op Meeting Agenda	PPLP004473597	PPLP004473597
PUR3837	4/5/2016	Meeting Agenda Purdue and Smith Drug Company	PPLP004473601	PPLP004473601
PUR3838	6/18/2014	Email from S Projansky to G Issa re: Wholesalers reported in 867s	PPLP004473637	PPLP004473637
PUR3839	6/18/2014	Excel Spreadsheet of reported in 867s	PPLP004473638	PPLP004473638
PUR3840	1/16/2019	Excel Spreadsheet - Purdue Pharma - Lis of LELE presentations.	PPLP004473770	PPLP004473770
PUR3841	11/7/2011	Excel Spreadsheet - Purdue Pharma - OMS Pharmacies referred to DEA	PPLP004474199	PPLP004474199
PUR3842	8/23/2016	OMS Pharmacy Review - Excel Spreadsheet	PPLP004474416	PPLP004474416
PUR3843	8/16/2016	Excel Spreadsheet - OMS Pharmacy Review	PPLP004474417	PPLP004474417
PUR3844	8/16/2016	Excel Spreadsheet - OMS Pharmacy Review	PPLP004474418	PPLP004474418
PUR3845	8/16/2016	Excel Spreadsheet - OMS Pharmacy Review	PPLP004474419	PPLP004474419
PUR3846	3/30/2016	Excel Spreadsheet - OMS Pharmacy Review	PPLP004474438	PPLP004474438
PUR3847	1/29/2019	Excel Spreadsheet - OMS Notes; OMS Pharmacy Review	PPLP004474496	PPLP004474496
PUR3848	8/20/2009	Minutes - Purdue: Reportable Events Committee 7/27/09	PPLP004474811	PPLP004474812
PUR3849	10/13/2009	Minutes - Purdue: Reportable Events Committee 10/7/09	PPLP004474834	PPLP004474835
PUR3850	4/23/2010	Minutes - Purdue: Reportable Events Committee 04/20/10	PPLP004475064	PPLP004475065
PUR3851	6/9/2010	Minutes - Purdue: Reportable Events Committee	PPLP004475094	PPLP004475095
PUR3852	7/14/2010	Minutes - Purdue: Reportable Events Committee 7/27/09	PPLP004475096	PPLP004475097

PUR3853	2/1/2019	Exhibit 46: Clinical Trials for Oxycontin (Original and Reformulated	PPLP004497006	PPLP004497018
PUR3854	1/30/2019	Exhibit 47: Post-Marketing Oxycontin Epidemiology Study Program	PPLP004497019	PPLP004497025
PUR3856	1/30/2019	Exhibit 49: Boston Collaborative Drug Surveillance Program, Boston University	PPLP004497034	PPLP004497035
PUR3858	1/1/1990	Cancer pain relief and palliative care, World Health Organization, 1990	PPLP004497076	PPLP004497151
PUR3859	1/1/1990	John J. Bonica, The Management of Pain, Lea & Febiger, page 429, 1990	PPLP004497152	PPLP004497155
PUR3861	1/1/2001	National Institute on Drug Abuse Research Report: Prescription Drugs Abuse and Addiction	PPLP004497260	PPLP004497271
PUR3862	1/1/2001	Turk DC, Pain Terms and Taxonomies of Pain, Lippincott Williams & Wilkins, Bonica's Management of Pain	PPLP004497272	PPLP004497282
PUR3864	8/1/2006	Nabarun Dasgupta, Association between non-medical and Prescriptive usage of opioids, Drug and Alcohol Dependence, August 2005	PPLPC001000057517	PPLPC001000057524
PUR3865	2/24/2010	Letter from Beth Connelly to Mathilda Fienkeng (with attachment) regarding Purdue Pharma Draft Materials for DDMAC Advisory Review (Draft Sales Card submission)	PPLPC001000058826	PPLPC001000058830
PUR3866	4/1/2011	Purdue Pharma L.P. - Health Care Law Compliance Policies	PPLPC001000082678	PPLPC001000082716
PUR3867	4/12/2011	Butrans Approved Labeling - April 2011	PPLPC001000083895	PPLPC001000083938
PUR3868	8/24/2011	NADDI Card: Most Commonly Abused Pharmaceutical Drugs	PPLPC001000093313	PPLPC001000093339
PUR3869	3/15/2013	Email from Todd Baumgartner to Richard Fanelli regarding Stiles Summary and Conclusions section for LOT Report	PPLPC001000126628	PPLPC001000126628
PUR3870	5/1/2013	Highlights of Prescribing Information and Full Prescribing Information for OxyContin (oxycodone hydrochloride controlled-release) Tablets for oral use, CII	PPLPC001000130885	PPLPC001000130918
PUR3871	11/4/2013	Email from Shideh Khorasheh to Rami BenJoseph, and other board members regarding Debrief on Payer Ad Board Meeting (Sep. 26) for Oxy/ADF	PPLPC001000141285	PPLPC001000141286
PUR3872	10/6/2013	Report from Analysis Group, Inc. to Purdue Pharma L.P., re: Purdue's Payer Advisory Board Meeting on Extended Release Opioids (EROs)	PPLPC001000141287	PPLPC001000141321
PUR3873	10/10/2013	Purdue Pharma L.P. Presentation: Purdue Advisory Board Meeting on Extended-Release Opioids (EROs) Summary of Findings	PPLPC001000141322	PPLPC001000141322
PUR3874	12/3/2014	Corporate Compliance Council Meeting Minutes; 4th Quarter 2014 Meeting	PPLPC001000190067	PPLPC001000190068
PUR3875	1/14/2015	RADARS NEJM Article "Trends in Opioid Analgesic Abuse and Mortality in the US.	PPLPC001000193867	PPLPC001000193868
PUR3876	5/29/2015	Email from Paul Coplan to multiple recipients, attaching Briefing Book for OxyContin Advisory Committee	PPLPC001000207097	PPLPC001000207097
PUR3877	5/8/2017	Email from Paul Coplan to LaTatia Colbert-Reed re diversion	PPLPC001000254501	PPLPC001000254502
PUR3878	5/8/2017	Graph of Incremental costs of diversion and percentage decrease in ADF opioid diversion to achieve costs-neutrality.	PPLPC001000254503	PPLPC001000254503
PUR3879	5/8/2017	Table of Population-adjusted change in diversion after OxyContin reformulation.	PPLPC001000254504	PPLPC001000254504
PUR3880	5/9/2017	Request From Canada: OxyContin US epi overview report	PPLPC001000255293	PPLPC001000255295
PUR3881	5/15/2017	Corporate Compliance Council Meeting Minutes; May 15, 2017 meeting	PPLPC001000260094	PPLPC001000260095
PUR3882	11/9/2017	Email from Kathleen Konka to Nancy Crudele et al. re Discussion of FDA request for comments on activities the agency may undertake to address the opioid crisis.	PPLPC001000263905	PPLPC001000263906
PUR3883	2/14/2018	Email from Richa Attra re: Draft Coplan OPC Overview Paper (attaching draft Coplan OPC)Overview manuscript	PPLPC001000267088	PPLPC001000267091
PUR3884	2/2/2018	A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire	PPLPC001000267092	PPLPC001000267096
PUR3885	2/14/2018	Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication (NCT02660619)	PPLPC001000267097	PPLPC001000267101
PUR3886	2/14/2018	Study to Eval Relation Btw Doctor_Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction (NCT02667210)	PPLPC001000267102	PPLPC001000267107
PUR3887	2/14/2018	Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnaire (NCT02678507)	PPLPC001000267108	PPLPC001000267112
PUR3888	2/14/2018	A Prospective Investigation of the Risk of Opioid Misuse, Abuse, and Addiction Among Patients Treated with Extended - release/Long Acting Opioids for the treatment of Chronic Pain. (NCT02751762)	PPLPC001000267113	PPLPC001000267119
PUR3889	2/14/2018	Incidence and Predictors of Opioid Overdose and Death (NCT02662153)	PPLPC001000267120	PPLPC001000267124
PUR3890	2/14/2018	Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose (NCT02667197)	PPLPC001000267125	PPLPC001000267130
PUR3891	2/14/2018	Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term opioids for Chronic Pain (NCT02741076)	PPLPC001000267131	PPLPC001000267138
PUR3892	2/14/2018	Paul M. Coplan: Risks and Benefits of ER/LA Opioids - OPC OSW PMR Manuscript Outline	PPLPC001000267139	PPLPC001000267156
PUR3893	6/7/2013	Purdue Pharma L.P. Pamphlet: How to Help Prevent Drug Diversion & Protect Your Institution	PPLPC001000269279	PPLPC001000269280
PUR3894	9/5/2013	Working Draft-OxyContin Growth Opportunities	PPLPC002000156079	PPLPC002000156195
PUR3895	5/8/2014	Corporate Compliance Council Meeting Minutes	PPLPC002000182090	PPLPC002000182091
PUR3896	10/15/2015	Email from Richard Fanelli to Laurie Cartier re: Category IV AdCom Debrief & Next Steps	PPLPC002000225341	PPLPC002000225341
PUR3897	3/16/2016	Executive Summary: Category 4 Plans for OxyContin and Hysingla	PPLPC002000235864	PPLPC002000235864
PUR3898	12/16/2016	Letter from Sharon Hertz, FDA to Beth Connelly re sNDA for BUTRANS	PPLPC002000250257	PPLPC002000250306
PUR3899	12/16/2016	Letter from Sharon Hertz, FDA to Beth Connelly re sNDA for Hysinglar ER	PPLPC002000250357	PPLPC002000250396
PUR3900	7/16/2016	Risks of Addiction, Abuse and Misuse of Opioids	PPLPC002000251199	PPLPC002000251200
PUR3901	1/4/2017	Guideline for Prescribing Opioids for ChronicPain	PPLPC002000251201	PPLPC002000251202
PUR3902	1/20/2017	Email from Paul Coplan to Gail Cawkwell, et al., RE: OxyContin PMR's and category 4 sNDA	PPLPC002000252508	PPLPC002000252509

PUR3903	10/11/2017	Email from Marc Hart to Richard Finelli re: Butrans IB submission to FDA.	PPLPC002000274865	PPLPC002000274865
PUR3904	9/1/2014	Buprenorphine Transdermal System (BTDS) Investigator's Brochure	PPLPC002000274866	PPLPC002000274996
PUR3905	12/14/2017	Email from Richard Fanelli to Mary Guerrere attaching Purdue Open Letter regarding renewed effort to combat prescription and illicit opioid abuse crisis	PPLPC002000287249	PPLPC002000287249
PUR3906	12/14/2017	Open Letter from Purdue Pharma - "We manufacture prescription opioids. How could we not help fight the prescription and illicit opioid abuse crisis?"	PPLPC002000287250	PPLPC002000287250
PUR3907	5/8/2007	Email from Russell Gasdia to Windell Fisher and others concerning State AG Consent Judgement	PPLPC004000115134	PPLPC004000115135
PUR3908	5/15/2007	Email from Russell Gasdia regarding Purdue initiatives re prescription medicine diversion and abuse	PPLPC004000115790	PPLPC004000115791
PUR3909	10/3/2007	Email from Jack Crowley to Dan Colucci, Stephen Seid, Laura Watson, and Pat McGrath re: Follow-up on Suspicious Order Reporting	PPLPC004000132946	PPLPC004000132954
PUR3910	10/29/2008	Memorandum from Janet Koch to Entire Sales Force re: pre-call plan process	PPLPC004000179362	PPLPC004000179363
PUR3911	11/26/2008	Sales Bulletin from Russ Gasdia to Purdue Sales Force Managed Care Natl Accounts & Trade Relations re: Reminder Concerning Package Inserts	PPLPC004000182982	PPLPC004000182982
PUR3912	1/21/2009	Sales Memo from Russ Gasdia to Sales Force Managed Care Natl Accounts Managers re: OxyContin Tablets Revised Retained Visual Aid	PPLPC004000188098	PPLPC004000188099
PUR3913	4/6/2009	Email from Jack Crowley to Stephen Seid et al. re: OMS and Miami Herald news article.	PPLPC004000198309	PPLPC004000198316
PUR3914	5/29/2009	Standby Statement from Purdue Pharma Responding to Petition to Ban OxyContin Tablets	PPLPC004000202977	PPLPC004000202977
PUR3915	10/1/2009	Haddox article - "RxPatrol: A Web-based tool for combating pharmacy theft"	PPLPC004000209577	PPLPC004000209581
PUR3916	8/5/2009	Email from Stephen Seid to Jack Crowley regarding meeting with HD Smith	PPLPC004000209762	PPLPC004000209765
PUR3917	11/23/2009	Email from Jack Crowley to Robin Abrams, Stephen Seid, Mark Geraci, Luis Bauza and Joan Zooper re: South Florida	PPLPC004000220392	PPLPC004000220394
PUR3918	12/4/2006	Drug Distribution Service Agreement between Purdue Pharma and H.D.Smith.	PPLPC004000227780_001	PPLPC004000227780_014
PUR3920	9/8/2010	Announcing Updated NDC Numbers for OxyContin Tablets HUD Inside	PPLPC004000250917	PPLPC004000250936
PUR3921	10/19/2010	Inventory Data Licensing Agreement - Purdue Data Licensing Agreement 2010 (revised 062510) OAJ REVIEW	PPLPC004000254710	PPLPC004000254717
PUR3922	1/10/2011	email from Lisa miller regarding Healthcare Education and Liaison Programs Fourth Quarter Report 1-10-11	PPLPC004000264242	PPLPC004000264242
PUR3923	1/10/2011	Healthcare Education and Liaison Programs Fourth Quarter 2010 report	PPLPC004000264243	PPLPC004000264247
PUR3924	1/10/2011	Purdue Pharma Grants and Giving Summary Report	PPLPC004000264248	PPLPC004000264269
PUR3925	3/4/2011	Sales Training and Development re Planning and Delivering the RIGHT Messages for Butrans	PPLPC004000272369	PPLPC004000272369
PUR3926	10/17/2011	OMS Report for Drug Store Pharmacy	PPLPC004000298234	PPLPC004000298236
PUR3927	10/12/2011	OMS Memo for Drug Store Pharmacy, Columbus Ohio	PPLPC004000298237	PPLPC004000298243
PUR3930	2/17/2012	Email from Jack Crowley to Stephen Seid re: meeting recommendations for pharmacy reports.	PPLPC004000312845	PPLPC004000312847
PUR3932	4/5/2012	Inventory Data Licensing Agreement between Walgreen and Purdue.	PPLPC004000320062	PPLPC004000320072
PUR3933	7/1/2008	Purdue Pharma's 10 Point Plan to Reduce Illegal Trafficking	PPLPC004000338359	PPLPC004000338362
PUR3935	1/30/2013	Purdue Response to Citizen Petition by Physicians for Responsible Opioid Prescribing	PPLPC004000346195	PPLPC004000346203
PUR3936	4/16/2013	Memo from Russ Gasdia to the analgesic sales force regarding OxyContin prescribing information.	PPLPC004000354064	PPLPC004000354064
PUR3937	4/17/2013	Email from Libby Holman to Russell Gasdia regarding Final approved Q&A for NAM and AE Label Change	PPLPC004000354189	PPLPC004000354189
PUR3938	4/17/2013	NAMs and AEs OxyContin Label Change QA	PPLPC004000354190	PPLPC004000354196
PUR3939	6/1/2013	memo describing Purdue's Guidelines for Speaking to External Audiences	PPLPC004000361510	PPLPC004000361512
PUR3940	11/10/2008	Memo for employees As Speakers or Authors for Healthcare Professional Education	PPLPC004000361513	PPLPC004000361524
PUR3941	7/9/2013	Update on Order Monitoring and Retailer Due Diligence (CPPC Meeting) by Steve Seid	PPLPC004000363085	PPLPC004000363085
PUR3942	8/12/2013	Email from Russell Gasdia regarding Employee Announcement and Communications Guidance Regarding LA Times article	PPLPC004000366958	PPLPC004000366959
PUR3944	8/22/2013	Email from Micheal Cullen to Jeff Romano and Matthew Paulson attaching OxyContin Pharmacists Guide with FPI	PPLPC004000369328	PPLPC004000369328
PUR3945	7/1/2012	Pharmacist's Guide. OxyContin insert.	PPLPC004000369329	PPLPC004000369347
PUR3946	11/29/2013	Email chain between Stephen Windell, Stephen Seid, Russell Gasdia and others regarding South Miami pharmacies	PPLPC004000383393	PPLPC004000383395
PUR3947	10/18/2002	RADARS System Risk Management Plan	PPLPC005000004321	PPLPC005000004326
PUR3948	7/1/2001	NIDA Rx Drug Abuse and Addiction Research Report	PPLPC005000012210	PPLPC005000012221
PUR3949	11/12/2001	Painfully Obvious: Campaign Warns Kids About The Dangers Of Abusing Prescription Medications	PPLPC008000021624	PPLPC008000021625
PUR3950	2/1/2004	FBI-LEEDA Newsletter - RX Patrol, February 2004	PPLPC008000034324	PPLPC008000034327
PUR3951	6/19/2006	Drug Distribution Service Agreement between Purdue Pharma and McKesson Corporation.	PPLPC008000044232_001	PPLPC008000044232_018
PUR3952	8/8/2006	Purdue Drug Distribution Service Agreement (Cardinal Health)	PPLPC008000044326	PPLPC008000044346
PUR3953	7/31/2006	Purdue Drug Distribution Service Agreement (Amerisource Bergen Drug Corporation)	PPLPC008000044348	PPLPC008000044365
PUR3955	2/15/2006	Drug Distribution Service Agreement between Purdue Pharma and Kinray.	PPLPC008000057574_001	PPLPC008000057574_017
PUR3956	12/13/2006	Drug Distribution Service Agreement between Purdue Pharma and H.D.Smith	PPLPC008000057575_001	PPLPC008000057575_014
PUR3959	3/12/2001	John Burke, Director, Warren County Drug Task Force posts on "OxyContin Publicity"	PPLPC009000035051	PPLPC009000035053
PUR3960	5/10/2001	Marketing Pamphlet - Purdue Pharma's 10 Point Plan to Reduce Prescription Drug Abuse without Compromising Patient Access to Proper Pain Control.	PPLPC009000040246	PPLPC009000040247
PUR3961	2/12/2002	Transcript of Senate Hearing, Senate committee on Health, Education, Labor and Pensions.	PPLPC009000060837	PPLPC009000060861

PUR3962	1/27/2003	OxyContin State of the Brand	PPLPC009000083740	PPLPC009000083758
PUR3963	3/1/2003	OxyContin State of the Brand	PPLPC009000088163	PPLPC009000088182
PUR3964	5/21/2003	OxyContin State of the Brand	PPLPC009000089738	PPLPC009000089757
PUR3966	7/1/2003	OxyContin State of the Brand	PPLPC009000092852	PPLPC009000092871
PUR3967	12/1/2003	OxyContin State of the Brand	PPLPC009000106457	PPLPC009000106476
PUR3968	3/1/2004	OxyContin State of the Brand	PPLPC009000110585	PPLPC009000110607
PUR3969	3/25/2004	Memorandum from Windell Fisher to Mr P. Bacon, Mr. G. Boenning, Mr. K kDunleavy, Mr. M. Holt, Mr. R. Leffler, Mr. R. McBride, Ms. K. Miles, Ms. K. Millner, Mr. R. Ornelas, Mr. L. Sparks, Mr. S. Stroud, Ms. D. Zlevor: OxyContin Tablets Focus Groups	PPLPC009000110983	PPLPC009000110984
PUR3970	3/3/2008	SOP: Purdue Pharma Professional Sales Representative- Revised March 3, 2008	PPLPC010000038457	PPLPC010000038465
PUR3971	6/5/2014	Memorandum from Russ Gasdia to Purdue Sales Force, Managed Care Sales and national Account managers: Correct way to Describe Reformulated Oxycontin Tablets (Bulletin)	PPLPC010000075630	PPLPC010000075631
PUR3973	7/22/2010	FDA Presentation - "Outpatient Prescription Opioid Utilization in the U.S., Years 2000 2009	PPLPC011000043957	PPLPC011000044112
PUR3974	9/27/2016	Purdue's Medical Evaluation of the CDC Guideline for Prescribing Opioids for Chronic Pain - US, 2016	PPLPC011000121156	PPLPC011000121178
PUR3975	9/12/1997	Phase IV OxyContin Tablet Team Meeting - September 12, 1997	PPLPC012000003299	PPLPC012000003303
PUR3976	12/18/2000	Email from Russell Gasdia to Susan Moore regarding Hot Spot direction.	PPLPC012000022225	PPLPC012000022225
PUR3977	12/18/2000	Memo from Jim Lang regarding Hot Spot Direction	PPLPC012000022226	PPLPC012000022227
PUR3979	7/19/2001	OxyContin Insert Changes	PPLPC012000035604	PPLPC012000035621
PUR3980	7/19/2001	OxyContin Insert Changes	PPLPC012000035622	PPLPC012000035647
PUR3981	7/18/2001	OxyContin Insert Changes Dear HCP Letter	PPLPC012000035648	PPLPC012000035649
PUR3982	7/26/2001	Memo from Jim Lang to Entire Field Force re: FDA Website Talking Paper	PPLPC012000036182	PPLPC012000036182
PUR3983	7/25/2001	FDA Talk Paper "FDA Strengthens Warning for OxyContin"	PPLPC012000036183	PPLPC012000036184
PUR3984	7/26/2001	OxyContin Questions and Answers, U.S. Food and Drug Administration, Center for Drug Evaluation and Research	PPLPC012000036185	PPLPC012000036186
PUR3985	1/1/2004	RSOP 2.2 PSD Incentive Bonus Program	PPLPC012000068193	PPLPC012000068212
PUR3986	9/24/2004	Sales and Marketing Compliance Committee Meeting Minutes	PPLPC012000077261	PPLPC012000077261
PUR3987	12/8/2004	100 County Program Q&A	PPLPC012000078238	PPLPC012000078241
PUR3988	2/16/2005	Email from Russell Gasdia to Jane Petty re Passage of Ohio PMP program	PPLPC012000080296	PPLPC012000080297
PUR3989	5/27/2005	Cincinnati Enquirer article - "Drug Maker helps anti-crime effort" (Purdue Pharma chooses Greater Cincinnati-Northern Kentucky Crime Stoppers as its partner in a new nationwide program to combat pharmacy crime"	PPLPC012000083955	PPLPC012000083957
PUR3990	7/13/2006	Sales and Marketing Compliance Committee Meeting Minutes FINAL Minutes for June 1, 2006 Meeting	PPLPC012000111974	PPLPC012000111976
PUR3991	10/12/2006	Email from Alan Must to Lynn Nagorski re Ohio OARRS	PPLPC012000121189	PPLPC012000121189
PUR3992	3/20/2006	Ohio State Board of Pharmacy OARRS Announcement	PPLPC012000121190	PPLPC012000121190
PUR3993	3/12/2007	Memo to Ohio Sales Force re Ohio Automated Rx Reporting System Fact Sheet to be distributed to HCPs	PPLPC012000135123	PPLPC012000135123
PUR3994	3/5/2007	Fact Sheet - Ohio Automated Rx Reporting System	PPLPC012000135124	PPLPC012000135124
PUR3995	3/23/2007	Sales and Marketing Compliance Committee Meeting Minutes from February 12, 2007	PPLPC012000136463	PPLPC012000136466
PUR3996	5/30/2007	Email from Russell Gasdia regarding Audit Committee Meeting	PPLPC012000143727	PPLPC012000143728
PUR3997	11/7/2006	Audit Committee Meeting meeting powerpoint 11-7-06-DEA Related Internal Controls re:Controlled Substance Orders	PPLPC012000143729	PPLPC012000143729
PUR3998	2/8/2008	Corporate Compliance Quarterly Report to the Board 02/08/2008	PPLPC012000169617	PPLPC012000169617
PUR3999	4/23/2008	Draft Sales & Marketing Compliance Committee Meeting Minutes; New Training Position, Material Issues, Sales Force Expansion. & Ride Alongs.on March 11, 2008	PPLPC012000179721	PPLPC012000179722
PUR4000	5/6/2008	Email from Russell Gasdia to David Denning, Tammy Hayward, Damn Storhoff, Gary Maxson, Eric Perham, and Desiree Williams RE: American Pain Society Meeting attendance.	PPLPC012000181681	PPLPC012000181682
PUR4001	1/8/2009	Email from Russell Gasdia to Lori Kennedy and Lee Brickman RE: sending final version of national sales meeting presentation and remarks.	PPLPC012000208428	PPLPC012000208428
PUR4002	1/15/2009	Email from Pamela Rose to Stuart Baker, James Dolan, Russell Gasdia, Dr. Craig Landau, David Long, Edward Mahony, William Mallin, Kathleen Schady; John Stewart, Bert Weinstein re: FW: Wilson Site - DEA Inspection - Day 3	PPLPC012000209061	PPLPC012000209061
PUR4003	1/22/2009	Email from Pamela Rose to Stuart Baker, James Dolan, Russell Gasdia, Dr. Craig Landau, David Long, Edward Mahony, William Mallin, Kathleen Schady; John Stewart, Bert Weinstein re: FW: Wilson Site DEA Inspection	PPLPC012000209655	PPLPC012000209655
PUR4004	2/5/2009	Corporate Compliance Quarterly Report to the Board of Directors 4Q08	PPLPC012000211573	PPLPC012000211573
PUR4005	2/2/2009	Draft Sales & Marketing Compliance Committee Meeting Minutes; Approve Recommendations from VP's Compliance Council, Investigations, Discipline Actions, Abuse and Diversion Detection Training Program, & Labopharm on February 2, 2009	PPLPC012000211619	PPLPC012000211621
PUR4006	2/12/2009	Email from Bert Weinstein to Pamela Rose, Stuart Baker, James Dolan, Russell Gasdia, Dr. Craig Landau, David Long, Edward Mahony, William Mallin, Kathleen Schady; John Stewart re: DEA Inspection - Wilson Facility	PPLPC012000212568	PPLPC012000212569
PUR4007	3/23/2009	Email from Windell Fisher to Regional Directors RE: Compliance issue and "Rx Compliance Report"	PPLPC012000217353	PPLPC012000217354
PUR4008	7/15/2009	Draft Corporate Compliance Council Meeting Minutes; CIA Overview, Current Reporting Year IRO Review workplan, & FHCP Investigations,	PPLPC012000232908	PPLPC012000232910
PUR4009	8/26/2009	Corporate Compliance draft Presentation: Quarterly Report to Board of Directors Q2009	PPLPC012000236639	PPLPC012000236639

PUR4010	8/17/2009	Sales and Marketing Compliance Committee Meeting Agenda; Discontinuation of Materials, Material review, Update on IRO reviews, training materials, Investigations, Expense monitoring, FRC Matter, DDMAC Letter re Ryzolt, Intermezzo, Speakers Bureaus, and Webcasts	PPLPC012000237897	PPLPC012000237898
PUR4011	10/7/2009	Email from Russell Gasdia to Mark Geraci RE: Joint Meeting of FDA Advisory Committees - Corporate Security Information and sending Anti-Diversion Anti-Abuse programs overview	PPLPC012000241216	PPLPC012000241217
PUR4012	10/7/2009	Overview of Purdue Pharma Corporate Security Anti-Diversion/Anti-Abuse Programs.	PPLPC012000241218	PPLPC012000241219
PUR4013	6/17/2009	Letter from Kelly H. Rankin, United States Attorney, to Ron D'Ulisse, Senior Director, Law Enforcement Liason & Education Unit RE: Request for Abused Pharmaceutical Substances Cards	PPLPC012000241220	PPLPC012000241226
PUR4014	8/25/2009	Positive Stories regarding Purdue Pharma	PPLPC012000241227	PPLPC012000241227
PUR4015	10/19/2009	Corporate Compliance draft presentation: Quarterly Report to the Board of Directors 3Q09	PPLPC012000241976	PPLPC012000241976
PUR4016	10/14/2009	Corporate Compliance Council Meeting Minutes 10/14/09	PPLPC012000244023	PPLPC012000244025
PUR4017	12/7/2009	Sales and Marketing Compliance Committee Meeting Agenda.	PPLPC012000248128	PPLPC012000248130
PUR4018	12/16/2009	Email from Russell Gasdia to Lynn Noack RE: FDA authority in requiring sponsors to assure elements of safe use when approving new drugs.	PPLPC012000248459	PPLPC012000248461
PUR4019	12/11/2009	FDA - REMS Notification Letter regarding NDA 022272	PPLPC012000248462	PPLPC012000248465
PUR4020	2/4/2010	Corporate Compliance draft Presentation: Quarterly Report to Board of Directors 4Q09	PPLPC012000252427	PPLPC012000252427
PUR4021	2/11/2010	Email from Russell Gasdia to the Training Department RE: AAP Medicine Conflict of Interest Statement - Please read as an FYI	PPLPC012000257751	PPLPC012000257753
PUR4022	1/19/2010	Duboid, Michael, AAP Medicine Ethics Council Statement on Conclicts of Interest: Interaction b/w Physician and Industry in Pain Medicine, Pain Medicine 2010, Vol 11, pp. 257-261	PPLPC012000257754	PPLPC012000257758
PUR4023	5/6/2010	Corporate Compliance draft Presentation: Quarterly Report to Board of Directors 1Q10	PPLPC012000270901	PPLPC012000270901
PUR4024	1/4/2010	Presentation: 2010 Guidelines in Product Promotion Approved Slides for all Training Classes	PPLPC012000270911	PPLPC012000270911
PUR4025	5/17/2010	Sales and Marketing Compliance Committee Meeting Minutes; E-marketing Highlights/Programs, ORF, Investigations Update, FCR and HCP Spend Analysis, & Material Review Update	PPLPC012000274739	PPLPC012000274740
PUR4026	10/19/2010	Email from Russell Gasdia to Craig Landau RE: Help Needed regarding a question sales force training.	PPLPC012000294454	PPLPC012000294455
PUR4027	7/21/2011	Corporate Compliance draft Presentation: Quarterly Report to Board of Directors 2Q2011.	PPLPC012000335656	PPLPC012000335656
PUR4028	9/8/2011	Statement of Purdue Pharma Regarding Pain Week Data Presentation: Initial Findings on Abuse Rates and Routes of Administration Following Introduction of Reformulated OxyContin Tablets in a Sentinel Surveillance System of Patients in Substance Abuse Treatment	PPLPC012000342063	PPLPC012000342066
PUR4029	7/29/2011	Compliance Council Meeting Minutes from July 26, 2011; CIA Monitoring Update, 2011 Compliance Performance Scorecard, Butrans Speaker Programs Update, 2011 Committee Effectiveness Survey, Risk Grids, Post-CIA Compliance Program, & Third Party Committee Training & Business Owner Presentations.	PPLPC012000348897	PPLPC012000348898
PUR4030	1/19/2012	Corporate Compliance draft Presentation: Quarterly Report to Board of Directors 4Q2011	PPLPC012000363721	PPLPC012000363721
PUR4031	7/26/2012	Email from David Long to Bert Weinstein, David Lundie, John Stewart, William Malin, Russell Gasdia, Dr. Craig Landau; Philip Strassburger, Richard Silbert, James Dolan re: RE: Additional comments on Wilson Site DEA Inspection	PPLPC012000387395	PPLPC012000387400
PUR4032	8/13/2012	Compliance Council Meeting Minutes; R&D Compliance Update, Post-CIA Compliance Program Continuity, GSK \$3 Billion Settlement and CIA, Call Note Review/FCR Stats, Intermezzo/Contract Sales Force Compliance, Product Update, Business Compliance Scorecard, Review HCP Payment Caps/Utilization, & Future Areas&Focus.	PPLPC012000388861	PPLPC012000388863
PUR4033	10/28/2011	Russ Gasdia Presentation: Butrans Transdermal System	PPLPC012000392713	PPLPC012000392713
PUR4034	6/30/2011	Purdue Pharma Human Resources Standard Business Practices	PPLPC012000393158	PPLPC012000393160
PUR4035	2/1/2013	Purdue Press Release re Prop Citizen Petition	PPLPC012000410388	PPLPC012000410389
PUR4036	4/26/2013	Memorandum from McKinsey titled: Identifying Granular Growth Opportunities for OxyContin	PPLPC012000422188	PPLPC012000422190
PUR4037	5/6/2013	Memorandum from Windell Fisher to Analgesic Sales Force RE: May District Meeting Direction	PPLPC012000422235	PPLPC012000422236
PUR4038	5/14/2013	Memorandum of confirmation to John Stewart and Russ Gasdia RE: Identifying Granular Grow Opportunities for OxyContin	PPLPC012000424118	PPLPC012000424121
PUR4039	6/25/2013	Sales and Marketing Compliance Committee Meeting Minutes for June 19, 2013; Sunshine Act, OcyContin Call Notes, VPCC Members, Upcoming Training, & Compliance Scorecard.	PPLPC012000429594	PPLPC012000429596
PUR4040	9/13/2013	Memorandum from McKinsey & Company to John Stewart and Russ Gasdia: Identifying granular growth opportunities for OxyContin - 20 Specific Recommendations	PPLPC012000439476	PPLPC012000439480
PUR4041	5/28/2013	Memorandum to Ohio Sales Reps re Guidelines for Prescribing Opioids for the Treatment of Chronic Non-Terminal Pain 80 mg of a Morphine Equivalent Daily Dose (MED) "Trigger Point"	PPLPC012000446002	PPLPC012000446002
PUR4042	5/9/2013	Attachment - State Medical Board of Ohio - Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain etc.	PPLPC012000446003	PPLPC012000446004

PUR4043	1/15/2014	Email from Brianne Weingarten to Russell Gasdia: Abuse Deterrent Formulations	PPLPC012000459898	PPLPC012000459898
PUR4044	1/6/2014	Note from Brianne Weingarten: Abuse Deterrent Formulations: History, ORF and Portfolio Messaging	PPLPC012000459899	PPLPC012000459901
PUR4045	8/22/2019	Purdue Presentation: 2014 10 Year Plan Gross to Net: highlights of Major Assumptions/Trends	PPLPC012000475117	PPLPC012000475117
PUR4046	11/10/2014	PowerPoint - LELE Overview	PPLPC012000495547	PPLPC012000495547
PUR4047	1/10/1997	Phase IV OxyContin Tablet Team Meeting Minutes - January 10, 1997	PPLPC013000018285	PPLPC013000018286
PUR4048	2/21/1997	Phase IV OxyContin Tablets Team Meeting Minutes	PPLPC013000018537	PPLPC013000018539
PUR4049	4/1/1997	Phase IV OxyContin Tablets Team Meeting Minutes	PPLPC013000018856	PPLPC013000018859
PUR4050	5/21/1997	Phase IV OxyContin Tablets Team Meeting Minutes for May 9, 1997	PPLPC013000019433	PPLPC013000019436
PUR4051	5/27/1997	Phase IV OxyContin Tablets Team Meeting Minutes for May 23, 1997	PPLPC013000019524	PPLPC013000019527
PUR4052	6/16/1997	Phase IV OxyContin Tablets Team Meeting Minutes for June 13, 1997	PPLPC013000019644	PPLPC013000019647
PUR4053	7/15/1997	Phase IV OxyContin Tablets Team Meeting Minutes	PPLPC013000019966	PPLPC013000019969
PUR4054	12/23/1997	Phase IV OxyContin Tablets Team Meeting Minutes for December 12, 1997	PPLPC013000021650	PPLPC013000021654
PUR4055	1/21/1998	Phase IV OxyContin Tablets Team Meeting Minutes for January 9, 1998	PPLPC013000021845	PPLPC013000021847
PUR4056	4/6/2001	Email from Dennis Merlo regarding Purdue Anti-Diversion Campaign letter to DEA	PPLPC013000067380	PPLPC013000067381
PUR4057	8/24/2001	Email from Curtis Wright to Paul Goldenheim re: abuse potential	PPLPC013000074214	PPLPC013000074214
PUR4058	6/28/2002	Email from Mike Heinmann to Gary Norbury and Lynn Nagorski re news article on Purdue's RADARS drug diversion tracking system	PPLPC014000026214	PPLPC014000026217
PUR4059	10/15/2002	Indicators of possible diversion SOP	PPLPC014000040400	PPLPC014000040401
PUR4060	12/15/2008	Email from Kendra Prince to Barry Chudakoff, et al., re: LELE Programs at Medical Mutual Ohio	PPLPC014000084152	PPLPC014000084152
PUR4062	3/21/2012	Compliance Obligations for Field Sales Personnel Attending Speaker Programs	PPLPC014000180634	PPLPC014000180668
PUR4063	3/1/2017	Email from Donald Jureck regarding RxReacts Programming for the Toledo district 2017.	PPLPC014000356691	PPLPC014000356691
PUR4064	3/1/2017	Rx Reacts Budget Request - OH	PPLPC014000356692	PPLPC014000356695
PUR4065	1/22/2018	SalesForce SOPs , January 2018.	PPLPC014000367483	PPLPC014000367491
PUR4066	8/24/2017	Field Force Sampling Policy and Procedure Manual	PPLPC014000367515	PPLPC014000367529
PUR4067	10/30/2017	Speaker Program SOP, 2017	PPLPC014000367534	PPLPC014000367541
PUR4068	7/19/2001	Memo to entire sales force re: Oxycontin package insert changes.	PPLPC015000005844	PPLPC015000005845
PUR4069	7/14/2003	Sales training and development - SOP manual	PPLPC015000016074	PPLPC015000016078
PUR4070	7/28/2003	Sales and training and development , SOP Manual, July 28, 2003	PPLPC015000016387	PPLPC015000016393
PUR4071	6/21/2007	Purdue Presentation: Abuse and Diversion Detection Program SOP 1.7.1, June 2007	PPLPC015000030072	PPLPC015000030072
PUR4072	2/1/2008	PowerPoint - Guidelines in Product Promotion 2008	PPLPC015000032240	PPLPC015000032240
PUR4073	1/30/2008	Purdue Presentation: The Responsibility and Role of the Representative in Reporting Adverse Events (AE's), Product Complaints (PC's) and Reports of Concern (ROC's) 2008	PPLPC015000032852	PPLPC015000032852
PUR4074	4/15/2009	April 15, 2009 Letter from Windell Fisher to Sales Force attaching April 6 2009 Version of Sales Standard Operating Policies	PPLPC015000038443	PPLPC015000038473
PUR4076	10/29/2009	Purdue Compliance Training Scenario	PPLPC015000042418	PPLPC015000042418
PUR4077	1/20/2010	Email from Ritch Wagner to Andreaq Holub re: Cleveland Ohio LELE	PPLPC015000044091	PPLPC015000044093
PUR4078	1/28/2010	Email from Ritch Wanger to Andrea Holub re Cleveland OH LELE	PPLPC015000044618	PPLPC015000044620
PUR4079	7/19/2010	Abuse and Diversion detection program, SOP, 2010.	PPLPC015000074012	PPLPC015000074012
PUR4080	11/2/2012	Email from Janet Koch to Lenore Cirulli regarding the Use This As Level 100 Presentation.	PPLPC015000139623	PPLPC015000139623
PUR4081	1/25/2012	Purdue Training Presentation: Reporting Adverse Events and Product Complaints	PPLPC015000139624	PPLPC015000139624
PUR4082	6/20/2013	Memo from Russ Gasdia to the analgesic sales force regarding compliance guidance or Meals and Sunshine act.	PPLPC015000150960	PPLPC015000150967
PUR4083	3/28/2014	Sales Training and Development Bulletin re Revised Partners Against Pain Tools to Discuss and Disseminate	PPLPC015000166142	PPLPC015000166143
PUR4085	3/16/2018	Email from Eric Brantley to Dan Colucci regarding purchase order 2434	PPLPC01600000002	PPLPC01600000005
PUR4086	9/9/2011	Letter from Keshia Thompson, Senior Counsel, Office of Counsel to the Inspector General, regarding the review of potential comparative promotional claims.	PPLPC016000087686	PPLPC016000087689
PUR4087	10/26/2011	Compliance Council Meeting Minutes, October 24, 2011	PPLPC016000104626	PPLPC016000104627
PUR4088	12/12/1995	Approval Letter for NDA 20-553 from the Department of Health and Human Services.	PPLPC016000127558	PPLPC016000127586
PUR4089	9/4/2012	2013-01-10 Effects of Reformulating Oxycodone on Fatal Adverse Event Reports	PPLPC016000166094	PPLPC016000166094
PUR4090	5/6/2016	Improving Patient Knowledge and Outcomes Utilizing POEM	PPLPC016000287549	PPLPC016000287549
PUR4091	9/29/2016	Sales and Marketing Compliance Committee Meeting Minutes September 29, 2016	PPLPC016000290831	PPLPC016000290833
PUR4092	1/25/2017	Sales and Marketing Compliance Committee Meeting Minutes January 1, 2017.	PPLPC016000302348	PPLPC016000302350
PUR4093	3/8/2017	Sales and Marketing Compliance Committee Meeting Minutes March 8, 2017	PPLPC016000303730	PPLPC016000303733
PUR4094	6/20/2017	Sales and Marketing Compliance Committee Meeting Agenda June 21, 2017	PPLPC016000310728	PPLPC016000310728
PUR4095	9/6/2017	Sales and Marketing Compliance Committee Meeting Minutes September 6, 2017	PPLPC016000315900	PPLPC016000315902
PUR4096	9/21/2017	SOP 1.7.1 Abuse and Diversion Detection (ADD) Program (2017version)	PPLPC016000316429	PPLPC016000316433
PUR4097	10/12/2017	S&P Budget 2018 Proposal	PPLPC016000321828	PPLPC016000321866
PUR4098	11/1/2017	Haddox JD, Opioids with abuse-deterrent properties: A regulatory and technological overview, Journal of Opioid Management, Vol. 13, pp. 397-413 (Nov./Dec. 2017)	PPLPC016000322257	PPLPC016000322273

PUR4099	2/1/2017	Purdue Empty the Medicine Cabinet flash card: The US is in the midst of an opioid crisis	PPLPC016000324511	PPLPC016000324512
PUR4100	2/1/2017	Purdue Empty the Medicine Cabinet Poster: The Streets Aren't the Only Places Kids Find Drugs	PPLPC016000324513	PPLPC016000324513
PUR4101	2/22/2018	Board of Directors Presentation: Ethics & Compliance Update Pre-Read (March 2018)	PPLPC016000326525	PPLPC016000326538
PUR4102	5/20/2002	Email from Howard Udell to Dr. J. David Haddox, Robert Reder, Micheal Friedman, and Paul Goldenheim re: Two Postings ref OxyContin Assessment.	PPLPC018000027454	PPLPC018000027456
PUR4103	10/21/2004	Email from DEA to Jack Crowley regarding RFID system	PPLPC018000057727	PPLPC018000057728
PUR4104	12/20/2004	Purdue Presentation: OxyContin State of the Brand Presentation	PPLPC018000066708	PPLPC018000066708
PUR4105	10/12/2005	Email from Robin Abrams to Howard Udell re: FW: DEA Inspection Updat[e] Day 5	PPLPC018000069773	PPLPC018000069774
PUR4106	11/17/2005	Email from Jack Crowley to Bert Weinstein re: RE: DEA Inspection Update Day 21 - Final Day	PPLPC018000070450	PPLPC018000070452
PUR4107	4/5/2006	Presentation to the Board of Directors: Corporate Compliance April 5, 2006	PPLPC018000081432	PPLPC018000081432
PUR4108	3/1/2003	Purdue Pharma L.P. Pamphlet: How to Stop Drug Diversion & Protect Your Institution	PPLPC018000082352	PPLPC018000082353
PUR4109	1/1/2005	Purdue Pharma L.P. Pamphlet: How to Protect Your Medicines At Home	PPLPC018000082354	PPLPC018000082357
PUR4110	1/1/2001	Purdue Pharma L.P. Pamphlet: How to Stop Drug Diversion & Protect Your Pharmacy	PPLPC018000082360	PPLPC018000082361
PUR4111	1/1/2001	Purdue Pharma L.P. Pamphlet: How to Stop Drug Diversion & Protect Your Practice	PPLPC018000082362	PPLPC018000082363
PUR4112	1/1/2003	Purdue Pharma Reference Guide: Providing Relief, Preventing Abuse	PPLPC018000082364	PPLPC018000082391
PUR4113	11/1/2005	Purdue Pharma L.P. Flyer: Standard Register Tamper-Resistant Rx Pads	PPLPC018000082392	PPLPC018000082392
PUR4114	4/6/2006	Butler Tech Law Enforcement Institute Press Release: State, Local Law Officers Learn New Ways to Combat Prescription Drug Abuse in Ohio	PPLPC018000082495	PPLPC018000082496
PUR4115	4/10/2006	Email from Bruce King to DEA regarding Authorization for "After the Fact" DEA Form.	PPLPC018000083026	PPLPC018000083026
PUR4116	5/3/2006	Prismap Poster, Characterizing Opioid Analgesic Abuse: Findings from Ethnographic Field Research	PPLPC018000086595	PPLPC018000086595
PUR4117	7/27/2006	Email from Burt Rosen to Jack Crowley regarding DEA meeting which Crowley attended	PPLPC018000096871	PPLPC018000096877
PUR4118	7/13/2007	Email from DEA to Jack Crowley regarding request for information	PPLPC018000156185	PPLPC018000156187
PUR4119	12/19/2007	Email from Jack Crowley to DEA regarding OxyContin placebo program	PPLPC018000187065	PPLPC018000187066
PUR4120	2/13/2008	Sales & Marketing Compliance Committee Draft Meeting Minutes; February 8, 2008 meeting	PPLPC018000195339	PPLPC018000195340
PUR4121	5/7/2008	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 1Q08	PPLPC018000212484	PPLPC018000212484
PUR4122	7/31/2008	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 2Q08	PPLPC018000230102	PPLPC018000230102
PUR4123	9/16/2008	Email from DEA to Jack Crowley regarding weight of OxyContin tablets	PPLPC018000239104	PPLPC018000239105
PUR4125	11/17/2008	Email from Jack Crowley to DEA regarding placebo request	PPLPC018000252693	PPLPC018000252693
PUR4126	5/21/2008	Placebo request letter from DEA	PPLPC018000252694	PPLPC018000252694
PUR4127	1/13/2009	Email from Beth Evans to Jack Crowley re: FW: DEA Inspection	PPLPC018000260664	PPLPC018000260666
PUR4128	2/9/2009	Email from Jack Crowley to DEA attaching diversion audits	PPLPC018000264951	PPLPC018000264951
PUR4129	2/9/2009	Memo from DEA regarding diversion audit: VI Receiving Records (Ordering/Transfer/Receiving/Return Records)	PPLPC018000264954	PPLPC018000264957
PUR4130	2/9/2009	Memo from DEA regarding diversion audit: VII Manufacturing Process and Batch Records - Understanding the Process	PPLPC018000264958	PPLPC018000264978
PUR4131	2/9/2009	DEA Diversion Audit - WIP Inventory Spreadsheet (01/13/2009)	PPLPC018000264979	PPLPC018000264979
PUR4132	2/10/2009	Email from Jack Crowley to William Callan regarding closing conference outline for upcoming meeting	PPLPC018000265395	PPLPC018000265396
PUR4133	4/14/2009	Email from Jack Crowley to DEA regarding on-site pharmacy visits	PPLPC018000278645	PPLPC018000278647
PUR4134	4/14/2009	Outline of discussion topics for pharmacy site visits attached to Jack Crowley email to DEA	PPLPC018000278648	PPLPC018000278652
PUR4135	6/5/2009	Email from Jack Crowley to DEA regarding news article about Erie and Detroit drug busts	PPLPC018000288640	PPLPC018000288641
PUR4136	7/19/2010	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 2Q10	PPLPC018000413084	PPLPC018000413084
PUR4137	8/12/2010	Email from David Lundie to Jack Crowley re: DEA: Wilson visit	PPLPC018000421155	PPLPC018000421156
PUR4138	8/18/2010	Email from Brian Rucker to Jack Crowley re: Request for placebos	PPLPC018000423719	PPLPC018000423721
PUR4139	8/16/2010	Purdue Pharma L.P. Flyer: Updated NDC Numbers for OxyContin Tablets	PPLPC018000423722	PPLPC018000423722
PUR4140	9/20/2010	Email from Christopher A. Kresnak to Jack Crowley, re: publicly available OxyContin information	PPLPC018000433324	PPLPC018000433325
PUR4142	9/20/2010	Original and Reformulated OxyContin Tablets Infographic	PPLPC018000433327	PPLPC018000433327
PUR4144	10/20/2010	Email from Jack Crowley to S/A Marc Laing (DOJ) regarding acceptable specification for oxycodone in reformulated tablets	PPLPC018000445383	PPLPC018000445383
PUR4145	11/3/2010	Email from Jayne M. Tomko-Griffin to Jack Crowley, re: acceptable specification range	PPLPC018000449961	PPLPC018000449963
PUR4146	3/9/2011	Email from Jack Crowley to Cathy Gallagher and Barbara Boockholdt, re: Florida OxyContin numbers	PPLPC018000494860	PPLPC018000494864
PUR4147	10/5/2011	Email from Jack Crowley to Richard Boyd, Re: Number of Practitioners question	PPLPC018000580540	PPLPC018000580543
PUR4148	10/26/2011	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 3Q2011	PPLPC018000588678	PPLPC018000588678
PUR4149	11/22/2011	Email from Giselle Issa to Luis Bauza, RE: MAYFAIR PHARMACY	PPLPC018000600936	PPLPC018000600938
PUR4150	1/7/2013	Bert Weinstein, Vice President Corporate Compliance Purdue Presentation: 4Q2012 Compliance Report to the Board of Directors.	PPLPC018000766114	PPLPC018000766114

PUR4151	4/18/2013	Email from Mary Surovec to Jack Crowley, RE: OxyContin 160mg	PPLPC018000805754	PPLPC018000805755
PUR4152	4/19/2013	Purdue Pharma L.P. Pamphlet: How to Help Prevent Drug Diversion & Protect Your Practice	PPLPC018000806778	PPLPC018000806779
PUR4153	4/12/2013	Purdue Pharma; Drug Diversion & Protect Your Pharmacy poster	PPLPC018000806780	PPLPC018000806781
PUR4154	9/4/2013	Wallace LS et al., Development and Validation of the Patient Opioid Education Measure, J. of Pain Research, Vol. 6; pp. 663-681 (Sept. 4, 2013)	PPLPC018000862336	PPLPC018000862354
PUR4155	9/20/2013	Sales and Marketing Compliance Committee (SMCC) Meeting Minutes from 08/07/13	PPLPC018000869280	PPLPC018000869282
PUR4156	11/22/2013	Letter from Theodore Hester of King and Spaulding to Senators Dianne Feinstein, Charles Grassley, Charles Schumer, Tom Udall, and Edward Markey, re: Region 0 Prescribers	PPLPC018000892743	PPLPC018000892750
PUR4157	9/13/2013	Purdue Presentation: OxyContin growth opportunities - Phase II Final Report: Recommendations	PPLPC018000926329	PPLPC018000926329
PUR4158	8/7/2014	RxSafety Matters Brochure - Law Enforcement & Government	PPLPC018001083979	PPLPC018001083984
PUR4159	8/7/2014	RxSafety Matters Brochure - "Healthcare Professionals"	PPLPC018001083985	PPLPC018001083991
PUR4160	8/7/2014	RxSafety Matters Brochure - "Families & Communities"	PPLPC018001083992	PPLPC018001083999
PUR4161	6/1/2015	NADDI front and back card	PPLPC018001237881	PPLPC018001237882
PUR4162	12/6/2015	Purdue OxyContin CVA Retained visual aid: There's a lot to consider when prescribing an extended-release opioid...	PPLPC018001272326	PPLPC018001272343
PUR4163	2/3/2016	Sales and Marketing Compliance Committee (SMCC) February 3, 2016 meeting minutes	PPLPC018001286821	PPLPC018001286823
PUR4164	6/14/2016	Sales and Marketing Compliance Committee (SCMM) Meeting Minutes for June 8, 2016	PPLPC018001334447	PPLPC018001334448
PUR4165	10/6/2016	Purdue Policy Committee; Public Policies to Combat the Opioid Crisis	PPLPC018001372096	PPLPC018001372097
PUR4166	12/1/2016	Oxycontin Highlights of Prescribing Information FDA clean version	PPLPC018001400917	PPLPC018001400961
PUR4167	10/18/2017	Butrans Approved Labeling package insert	PPLPC018001494476	PPLPC018001494521
PUR4169	5/14/2003	Email from Jack Crowley to Michael Friedman re: DEA Verification of Inventory for Increase in Quota Request	PPLPC019000032872	PPLPC019000032873
PUR4170	1/29/2004	Memorandum from John C. Wargin to Marketing Department: Oxy State of the Brand report for the third quarter 2003	PPLPC019000043165	PPLPC019000043165
PUR4172	10/29/2004	Email from Jack Crowley to James Crawford regarding RFID chip press conference	PPLPC019000052326	PPLPC019000052329
PUR4174	9/30/2005	Email from Jack Crowley to Aaron Graham, Jerry Furtak, Glenn Faber re: RE: Totowa DEA Inspection	PPLPC019000067406	PPLPC019000067406
PUR4175	10/14/2005	Email from Jack Crowley to Glenn Faber regarding response to DEA questions	PPLPC019000067597	PPLPC019000067597
PUR4176	10/14/2005	Response to DEA questions, Item 20	PPLPC019000067598	PPLPC019000067610
PUR4177	10/25/2005	Email from Jack Crowley to James Cherry, et al. re: RE: DEA Inspection - Day 11	PPLPC019000067761	PPLPC019000067762
PUR4178	10/28/2005	Email from Aaron Graham to Stephen Kovary et al. re: RE: DEA Inspection Update - Day 14	PPLPC019000067848	PPLPC019000067850
PUR4179	11/4/2005	Email from Fred Sexton to James Cherry et al., re RE: DEA Inspection Update - Day 16	PPLPC019000067975	PPLPC019000067976
PUR4180	8/24/2006	Email from Linda Barefoot to Jack Crowley re; transcripts of DEA public meeting discussing electronic prescriptions for controlled substances	PPLPC019000100094	PPLPC019000100102
PUR4181	11/9/2006	Email from Jack Crowley to DEA regarding NDC file on Office of Diversion Control website	PPLPC019000111179	PPLPC019000111180
PUR4182	4/25/2007	Package Insert for MS Contin (morphine sulfate controlled-release) Tablets CII	PPLPC019000138808	PPLPC019000138829
PUR4183	5/22/2007	Purdue Pharma L.P. Presentation: Compliance Presentation to Sales Strategy Team	PPLPC019000144835	PPLPC019000144835
PUR4184	6/1/2007	Memorandum from Brian Rosen to Ohio Field Sales Force, et al. re: OHIO Automated Rx Reporting System Fact Sheet	PPLPC019000149622	PPLPC019000149622
PUR4185	10/31/2007	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors	PPLPC019000172297	PPLPC019000172297
PUR4186	2/5/2008	Email from Robin Abrams to DEA regarding reformulated OxyContin application	PPLPC019000195473	PPLPC019000195474
PUR4187	2/20/2008	Email from Barry Cole to Burt Rosen re DEA and FDA participation in Pain Care Forum	PPLPC019000198903	PPLPC019000198906
PUR4188	3/26/2003	Internal Inquiries: Procedures regarding notification of field representative concern about healthcare professional conduct	PPLPC019000213919	PPLPC019000213920
PUR4189	10/24/2008	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 3Q08	PPLPC019000239786	PPLPC019000239786
PUR4190	12/18/2008	Email from Jack Crowley to DEA regarding request for placebos	PPLPC019000250617	PPLPC019000250617
PUR4192	1/14/2009	Email from Jack Crowley to Beth Evans re: FW: Wilson Site DEA Inspection - Day 2	PPLPC019000254653	PPLPC019000254654
PUR4193	1/27/2009	Email from William Callan to Jack Crowley Attaching OXY-MFG Flow Chart	PPLPC019000256829	PPLPC019000256829
PUR4194	1/29/2007	Purdue Pharma OxyContin Manufacturing Flow Chart	PPLPC019000256830	PPLPC019000256830
PUR4195	1/26/2009	Reportable Events Committee Special Meeting Minutes - Comments regarding Purdue's Visual - December 23, 2008 (1/26/2009 Draft)	PPLPC019000257146	PPLPC019000257146
PUR4196	2/11/2009	Letter From Bert I. Weinstein/VP of corporate compliance at Purdue to Keshia Thompson/counsel at Department of Health and Human Services re: investigation and corrective actions taken with regard to the Reportable Event	PPLPC019000259351	PPLPC019000259353
PUR4197	12/23/2008	Letter from Bert I. Weinstein to Keshia Thompson, Esq.re: Reportable Event	PPLPC019000259354	PPLPC019000259357
PUR4198	4/16/2009	Email from Jack Crowley to Jayne Tomko-Griffin re: site visits rough draft outline.	PPLPC019000272291	PPLPC019000272292
PUR4199	4/16/2009	Site Visits Outline	PPLPC019000272293	PPLPC019000272297

PUR4200	4/28/2009	Email from Chad Scheuler to Jack Crowley, Follow Up on Request, regarding RFID tags	PPLPC019000274862	PPLPC019000274863
PUR4201	4/28/2009	Purdue Pharma OxyContin Wholesaler Shipment List	PPLPC019000274864	PPLPC019000274864
PUR4202	4/30/2009	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 1Q09	PPLPC019000275103	PPLPC019000275103
PUR4203	5/27/2009	Email from Jack Crowley to Mark Caverly re: FW: Question - Coincident Activities	PPLPC019000281128	PPLPC019000281131
PUR4204	6/22/2009	Email from Barbara Cvrkel to James Heins, et al., re LELE - Tiffin, OH media coverage	PPLPC019000286493	PPLPC019000286495
PUR4205	7/16/2009	Email from Jack Crowley to Julianne Dunphy, RE: Question regarding rebate coupons	PPLPC019000293157	PPLPC019000293160
PUR4206	10/12/2009	Email from Jack Crowley to Barbara Boockholdt, re: Drug Safety and Risk Management Advisory Committee Meeting	PPLPC019000320398	PPLPC019000320400
PUR4207	9/30/2009	Letter from FDA to Purdue re: date extension	PPLPC019000320401	PPLPC019000320401
PUR4208	1/27/2010	Emails from Jack Crowley to Mike Callan & Brian Fleming regarding DEA investigation	PPLPC019000346512	PPLPC019000346513
PUR4209	1/27/2010	Email from Jack Crowley to Mike Callan regarding status report	PPLPC019000346514	PPLPC019000346515
PUR4210	1/27/2010	Email from Crowley, Jack to Hazewski, Edward (AmerisourceBergen) regarding suspicious pharmacy activity. RE: Follow-up	PPLPC019000346516	PPLPC019000346519
PUR4211	5/4/2010	Email from Crowley, Jack to George Euson (HD Smith) regarding pharmacy activity. RE: L.A. Area scams - but other hot spots as well.	PPLPC019000375720	PPLPC019000375721
PUR4212	8/3/2010	OxyContin Reformulation.msg	PPLPC019000410884	PPLPC019000410884
PUR4213	8/3/2010	Email from Barbara Boockholdt to Jack Crowley, re: Stereomicrographs - OxyContin 013008	PPLPC019000410898	PPLPC019000410899
PUR4214	7/21/2010	July 21, 2010 Presentation to Ohio Prescription Drug Abuse Task Force Regulatory Work Group: State of Ohio Pharmacy and Practitioner Purchases of Oxycondone and OxyContin - January 1, 2009 - April 30, 2010 (with meeting agenda and handwritten notes)	PPLPC019000411262	PPLPC019000411276
PUR4215	8/12/2010	Email from Mark Caverly to Jack Crowley forwarding Reformulated OxyContin and Original, ORF Tablet pictures, One Page ORF NDC tab picture comparison	PPLPC019000413459	PPLPC019000413462
PUR4216	8/12/2010	Reformulated OxyContin and Original	PPLPC019000413463	PPLPC019000413463
PUR4217	8/12/2010	Original and Reformulated OxyContin Tablets Infographic	PPLPC019000413464	PPLPC019000413464
PUR4219	8/18/2010	Email from Jack Crowley to Brian Rucker, re: campaign to take down unlawful OxyContin Internet sites	PPLPC019000414982	PPLPC019000414983
PUR4220	9/20/2010	Email from Jack Crowley to Christopher Kresnak regarding first shipments of reformulated OxyContin	PPLPC019000425371	PPLPC019000425372
PUR4221	10/7/2010	Email from Crowley, Jack to Hazewski, Edward (AmerisourceBergen) regarding suspicious pharmacy activity. Mutual support.	PPLPC019000432035	PPLPC019000432037
PUR4222	10/14/2010	Email from Limer, Gina to Crowley, Jack regarding suspicious pharmacies	PPLPC019000434512	PPLPC019000434514
PUR4223	11/1/2010	Purdue Pharma L.P. Presentation: Corporate Compliance Quarterly Report to Board of Directors 3Q10	PPLPC019000448389	PPLPC019000448389
PUR4224	11/3/2010	Email from Jayne M. Tomko-Griffin to Jack Crowley, re: acceptable specification range	PPLPC019000449228	PPLPC019000449229
PUR4225	3/7/2011	Email from Jack Crowley to Scott Garriott, RE: Total Tablet Weight for OxyContin 10 mg.	PPLPC019000494239	PPLPC019000494240
PUR4226	7/8/2010	OxyContin 10mg bottle photograph	PPLPC019000494241	PPLPC019000494241
PUR4227	3/17/2010	OxyContin 10 mg tablet photograph	PPLPC019000494242	PPLPC019000494242
PUR4228	3/17/2010	Opana 10 mg tablet photograph	PPLPC019000494243	PPLPC019000494243
PUR4230	3/1/2011	REMS One Year Assessment Report for NDA 022272 (OxyContin Tablets)	PPLPC019000592376	PPLPC019000592440
PUR4231	10/6/2011	OSU - Low Literacy Opioid Project - Phase I Agreement	PPLPC019000608323	PPLPC019000608360
PUR4232	10/6/2011	OSU - Low Literacy Opioid Project - Phase II Agreement	PPLPC019000608361	PPLPC019000608400
PUR4233	11/21/2011	Email from Jack Crowley to James E. Rafalski, re: OxyContin seizure at Andy's Pharmacy in Detroit	PPLPC019000611233	PPLPC019000611235
PUR4234	11/22/2011	Email from Giselle Issa to Luis Bauza, RE: MAYFAIR PHARMACY	PPLPC019000611505	PPLPC019000611507
PUR4235	12/1/2011	Email from Jack Crowley to James Rafalski (DEA) re: Assistance - Six Mile Pharmacy (DEA #FS2233447)	PPLPC019000614755	PPLPC019000614759
PUR4236	11/1/2011	OxyContin Tablets: A Summary of the Findings of the Post-Marketing Epidemiology Study Program to Detect Changes in Patterns of Abuse and Misuse and their Consequences: Addiction, Overdose and Death (as of October 15, 2011) - November 2011	PPLPC019000621009	PPLPC019000621116
PUR4237	1/3/2012	Email from Jack Crowley to Thomas Cook, RE: Request for sham Oxycontin	PPLPC019000622312	PPLPC019000622312
PUR4238	2/6/2012	Email from Michael Wissel to Jack Crowley, Frederick Woodward and Laura Watson Re: OxyContin and 6 Mile Pharmacy	PPLPC019000637386	PPLPC019000637386
PUR4239	2/2/2012	Controlled Substances Chain of Custody	PPLPC019000637387	PPLPC019000637390
PUR4240	3/2/2012	Email from Bert Weinstein to Keshia Thompson, re: follow-up to our January 5 call.msg. Two Purdue action items (SOP for Sales Discipline Committee and OxyContin Single Entity Opioid Discussions by Representatives).	PPLPC019000645185	PPLPC019000645187
PUR4241	1/1/2001	Bonica's Management of Pain, Chapters 2, 39 & 84 Section B (3rd Ed.)	PPLPC019000706818	PPLPC019000706838
PUR4242	10/18/2012	Email from Dr. David Haddoes to Lisa Miller re: Hospital SBIRT Follow Up	PPLPC019000727394	PPLPC019000727396
PUR4243	3/29/2013	Innovative Education Grant Initiative Proposal	PPLPC019000792625	PPLPC019000792645
PUR4244	8/4/2013	Email from John Fitzgerald to Paul Coplan re: 2013 CE Subteam Grant Review Summary	PPLPC019000824727	PPLPC019000824727
PUR4245	8/4/2013	Grant Budget Comparison Document	PPLPC019000824728	PPLPC019000824728
PUR4246	8/4/2013	Grant review summary table	PPLPC019000824729	PPLPC019000824731
PUR4247	8/4/2013	REMS 2013 Grant Review Scorecard	PPLPC019000824732	PPLPC019000824732
PUR4248	7/31/2013	Grant Participation Update - Ensuring Safe and Effective Opioid Prescribing for Chronic Pain: Incorporating ER/LA Opioids REMS in Practice	PPLPC019000824733	PPLPC019000824734

PUR4249	9/10/2013	FDA response to Citizen Petition re concern about the abuse potential of OxyContin	PPLPC019000835850	PPLPC019000835863
PUR4250	10/17/2013	Email from Brian Rosen to Alan Must re OSMA Opioid Prescribing Brief and Field Memo for Yellow Sheet Approval	PPLPC019000849386	PPLPC019000849386
PUR4251	10/17/2013	Ohio State Medical Association and Opiate Action Team CME Brochure: Ohio Opioid Prescribing Guidelines	PPLPC019000849387	PPLPC019000849387
PUR4252	10/18/2013	Memorandum from Brian Rosen to Ohio Sales Force re Ohio State Medical Association Brief-Opioid Prescribing Guidelines/Opiod Prescribing Website Information Sheet	PPLPC019000849388	PPLPC019000849388
PUR4253	10/14/2013	Fact Sheet - How Can OARRS Help You	PPLPC019000850621	PPLPC019000850621
PUR4254	10/15/2013	Memo from Brian Rosen to Ohio Field Sales Force re Ohio Automated Rx Reporting System-Updated OARRS Info Sheet	PPLPC019000850622	PPLPC019000850622
PUR4255	1/7/2014	Letter from Theodore M. Hester to The Hon. Dianne Feinstein, Hon. Charles Grassley, Hon. Charles Schumer, Hon. Tom Udall and Hon. Edward Markey re: ADD program	PPLPC019000877747	PPLPC019000877748
PUR4256	11/15/2013	List of Prescribers Provided to Authorities in California	PPLPC019000877749	PPLPC019000877776
PUR4257	3/28/2014	Sales and Marketing Compliance Committee (SMCC) March 28, 2014 meeting minutes (Draft)	PPLPC019000906919	PPLPC019000906921
PUR4258	1/15/2015	Purdue Compliance Training for Speaker Presentation	PPLPC019001085230	PPLPC019001085230
PUR4260	5/13/2016	Purdue Pharma, L.P. Infographic: Order Monitoring System (OMS)	PPLPC019001275418	PPLPC019001275418
PUR4261	7/12/2017	Purdue Pharma OxyContin Tablets Investigator's Brochure (Version 17 final)	PPLPC019001441449	PPLPC019001441503
PUR4262	5/16/2003	Email from Daniel Shea to Juan Barrero, William Ammermann, re: RE: DEA Inspection	PPLPC020000027021	PPLPC020000027022
PUR4263	6/24/2003	Year-End DEA Reporting - Totowa Manufacturer Registration #PT0164587 - Report and Observations	PPLPC020000028424	PPLPC020000028431
PUR4264	3/5/2003	Year-End DEA Report for Substances Procured (2002 Amendment II)	PPLPC020000028432	PPLPC020000028433
PUR4265	2/10/2004	Email from Jack Crowley to Giselle Issa re ARCOS Reports etc	PPLPC020000034355	PPLPC020000034356
PUR4266	7/17/2001	DEA - Report of Theft or Loss of Controlled Substances Report	PPLPC020000034357	PPLPC020000034358
PUR4267	8/4/2004	Email from Dr. Richard Sackler to Robert Loewenstein, Randy Shamblen, Robert Kupper, Jack Crowley, Eckhard Muhlhauser re: RE: DEA Audit - Day 2	PPLPC020000039194	PPLPC020000039195
PUR4268	11/1/2004	Mahony Presentation: 2004 Financial Year-In-Review; 2005 Budget Proposal	PPLPC020000042737	PPLPC020000042737
PUR4269	7/30/2002	DEA Event Log - Audit Status, Questions/Concerns, and Notes from Briefing Session(s) with DEA	PPLPC020000053417	PPLPC020000053418
PUR4270	10/17/2005	Email from Bert Weinstein to James Cherry et al., re: RE: DEA Inspection Update - Day 7	PPLPC020000053554	PPLPC020000053555
PUR4271	10/21/2005	Email from Fred Sexton to James Cherry, et al., re: RE: DEA Inspection - Day 9	PPLPC020000053689	PPLPC020000053690
PUR4272	5/1/2007	Purdue Pharma Representative SOPs Manual	PPLPC020000133072	PPLPC020000133112
PUR4273	6/27/2007	Email from Jack Crowley to Kimberly Daniels, re: OxyContin information	PPLPC020000135859	PPLPC020000135861
PUR4275	1/22/2008	Email from Jack Crowley to Mark Caverly, et al., RE: Letter re: Distributor Registration Question	PPLPC020000169093	PPLPC020000169098
PUR4276	3/17/2008	Email from James Gardner to Anthony Rego, re: Receipt from City Drug Store, Needville, TX	PPLPC020000177172	PPLPC020000177172
PUR4277	3/13/2007	Two completed DEA-222 Order Forms (one for OxyContin, and one for MS Contin)	PPLPC020000177173	PPLPC020000177174
PUR4278	9/8/2008	Email from Alan Must to Robin Abrams re OH AG Communications and PMP Documents	PPLPC020000204713	PPLPC020000204713
PUR4279	3/21/2001	Letter from Michael Friedman to Betty Montgomery re: abuse of OxyContin and request for a discussion	PPLPC020000204714	PPLPC020000204714
PUR4280	5/1/2001	Letter from Alan Must to Betty Montgomery re: OxyContin abuse and diversion discussion	PPLPC020000204715	PPLPC020000204715
PUR4281	9/8/2008	Model State Prescription Monitoring Programs	PPLPC020000204716	PPLPC020000204717
PUR4282	2/15/2008	Pharmacists and Practitioners Abuse Pamphlet: Alabama PDMP	PPLPC020000204718	PPLPC020000204719
PUR4283	2/15/2008	Memo from Brian Rosen to Alabama Field Sales Force regarding the Alabama PDMP	PPLPC020000204720	PPLPC020000204720
PUR4284	2/8/2008	Memo from Colorado State Board of Pharmacy to Colorado Prescribers regarding Electronic PDMP	PPLPC020000204721	PPLPC020000204721
PUR4285	2/8/2008	Memo from Linda Barefoot to Colorado Field Sales Representatives regarding Colorado electronic PDMP	PPLPC020000204722	PPLPC020000204722
PUR4286	9/7/2007	Indiana Scheduled Prescription Electronic Collection & Tracking Fact Sheet	PPLPC020000204726	PPLPC020000204726
PUR4287	9/7/2007	Memo from Brian Rosen to Indiana Sales Force regarding Indiana PDMP	PPLPC020000204727	PPLPC020000204727
PUR4288	10/10/2007	Memo from Brian Rosen to Maine Field Sales Force regarding Maine PMP	PPLPC020000204728	PPLPC020000204728
PUR4289	10/10/2007	Maine Dept. of Health & Human Services fact sheet: Prescription Monitoring Program	PPLPC020000204729	PPLPC020000204729
PUR4290	2/4/2008	Memo from Linda Barefoot to North Dakota Sales Representatives regarding North Dakota PDMP	PPLPC020000204730	PPLPC020000204730
PUR4291	3/6/2008	North Dakota Board of Pharmacy information sheet re: North Dakota PDMP	PPLPC020000204731	PPLPC020000204731
PUR4292	9/8/2008	Ohio Automated Rx Reporting System Fact Sheet	PPLPC020000204732	PPLPC020000204732
PUR4293	3/1/2007	Memorandum from Brian Rosen to Ohio Field Sales Force, Account Executives, MLs LELEs, Field Researcher and Risk Management & Health Policy re: OHIO Automated Rx Reporting System Fact Sheet	PPLPC020000204733	PPLPC020000204733
PUR4294	12/5/2007	Memo from Brian Rosen to Tennessee Field Sales Force re: Tennessee Controlled Substance Monitoring Program	PPLPC020000204734	PPLPC020000204734
PUR4295	12/5/2007	Tennessee Dept of Agriculture & Commerce Fact Sheet: Tennessee Controlled Substance Monitoring Program	PPLPC020000204735	PPLPC020000204735
PUR4296	7/7/2008	Texas Dept. of Public Safety letter re: notification of code changes relating to PDMP	PPLPC020000204736	PPLPC020000204737

PUR4297	9/3/2008	Memo from Linda Barefoot to Texas Field Sales Representatives regarding Changes to the Texas Health and Safety Code - Texas Prescription Program	PPLPC020000204738	PPLPC020000204739
PUR4298	10/5/2007	Prescriber instruction sheet for registering for internet access to Utah's Controlled Substance DataBase Program	PPLPC020000204740	PPLPC020000204740
PUR4299	10/5/2007	Memo from Linda Barefoot to Utah Field Sales Representatives regarding Utah Controlled Substance Data Base Program	PPLPC020000204741	PPLPC020000204741
PUR4300	2/4/2008	Memo from Brian Rosen to Virginia Field Sales Force regarding Virginia PMP	PPLPC020000204742	PPLPC020000204742
PUR4301	3/6/2008	Virginia Dept. of Health Professions information sheet re: PMP	PPLPC020000204743	PPLPC020000204743
PUR4302	5/2/2008	Memo from Linda Barefoot to Wyoming Field Sales Representatives re: Wyoming PDMP	PPLPC020000204744	PPLPC020000204744
PUR4303	5/2/2008	Wyoming Board of Pharmacy information sheet re: Wyoming PDMP	PPLPC020000204745	PPLPC020000204745
PUR4304	9/5/2008	Attachment to PPLPC020000204713 - photograph of Ohio's PMP bill signing with then Governor Taft and the sponsor of the pmp bill, Rep. Tom Raga who sent Purdue copies of the photo with a handwritten note "Brian, Thanks for your work on the bill. It's a big step toward controlling illegal drug use. Tom"	PPLPC020000204746	PPLPC020000204746
PUR4305	11/18/2008	Email from Jack Crowley to John Purcell (DEA) re: New Jersey Pharmaceutical Industry Group Meeting	PPLPC020000217248	PPLPC020000217251
PUR4306	11/19/2008	New Jersey Pharmaceutical Industry Work Group Agenda	PPLPC020000217252	PPLPC020000217252
PUR4307	2/27/2008	Summary of DEA meeting with NJPIG	PPLPC020000217254	PPLPC020000217257
PUR4308	1/15/2009	Email from Jack Crowley to Jacqueline Honoway (DEA) re: placebo OxyContin	PPLPC020000223361	PPLPC020000223362
PUR4309	1/27/2009	Email from Jack Crowley to William Callan (DEA) re: security write-up for the Wilson Site	PPLPC020000224727	PPLPC020000224727
PUR4310	1/27/2009	Security write up to DEA regarding Wilson site	PPLPC020000224728	PPLPC020000224741
PUR4311	3/26/2009	Email from Jack Crowley to John Purcell (DEA) re: Oxycodone shortage	PPLPC020000235925	PPLPC020000235927
PUR4313	5/26/2009	Letter from Bert Weinstein to Keshia B.Thompson of DHHS re: OxyContin Saving Card	PPLPC020000248668	PPLPC020000248672
PUR4314	3/19/2009	Letter from Bert Weinstein to Keisha B. Thompson of DHHS re: OxyContin Savings Card.	PPLPC020000248673	PPLPC020000248675
PUR4315	7/20/2009	Email from Jack Crowley to Julianne Dunphy (DEA) re: rebate coupons	PPLPC020000294523	PPLPC020000294527
PUR4316	8/19/2009	Email from Barbara Cvrkel to Landon Gibbs, et al. re: LELE - Gallipolis, OH Media Coverage	PPLPC020000301031	PPLPC020000301034
PUR4317	4/5/2010	Email from Jack Crowley to Barbara Boockholdt (DEA) re: FDA Approval of New Formulation for OxyContin	PPLPC020000357733	PPLPC020000357734
PUR4318	6/21/2010	Email from Cathy Gallagher (DEA) to Jack Crowley re: ARCOS question	PPLPC020000383544	PPLPC020000383545
PUR4319	7/12/2010	Email from Barbara Bookholdt (DEA) to Jack Crowley re: unlawful OxyContin internet sites	PPLPC020000389965	PPLPC020000389966
PUR4320	8/5/2010	Email from Beth Evans to Marty Nealey and David Lundie re: DEA Upcoming Visit	PPLPC020000398555	PPLPC020000398555
PUR4321	8/30/2010	Letter from Bert Weinstein to Keshia Thompson of DHS re: comparative promotional claims of OxyContin and Ryzolt tablets	PPLPC020000405816	PPLPC020000405820
PUR4322	12/23/2010	Purdue SOP re: Retention of HCPs as Consultants, Advisors, and Speakers (Fee for Service)	PPLPC020000437020	PPLPC020000437086
PUR4323	3/1/2001	Draft letter from counsel for The P.F. Laboratories to Michael Smilek (DEA) re: Closing Conference - Administrative Inspection of PF Labs	PPLPC020000455260	PPLPC020000455272
PUR4325	1/12/2010	Purdue Presentation: Purdue Corporate Compliance Series-Code of Business Ethics Module	PPLPC020000464978	PPLPC020000465054
PUR4326	12/29/2009	Purdue Presentation: Purdue Corporate Compliance Series Part 1: Purdue Healthcare Law Compliance Policies Module	PPLPC020000465055	PPLPC020000465106
PUR4327	4/12/2011	Email from Robin Abrams to David Haddox re: DEA meeting	PPLPC020000468415	PPLPC020000468418
PUR4328	4/13/2011	Email from Jack Crowley to Barbara Boockholdt (DEA) re: meeting follow-up	PPLPC020000468465	PPLPC020000468466
PUR4329	6/9/2011	Email from Jack Crowley to Giselle Issa re: pharmacy OMS	PPLPC020000487409	PPLPC020000487410
PUR4330	11/4/2011	Email from Jack Crowley to James Gardner re: DEA Inspection - Cranbury Analytical Registration - Day 2 (Wrap-up)	PPLPC020000523523	PPLPC020000523527
PUR4331	12/16/2011	Email from Bert Weinstein to Allison Uzar, et al. re: Purdue Annual Report follow-up questions	PPLPC020000534495	PPLPC020000534496
PUR4332	6/6/2012	Email from Mary Johnson-Rochee to Jack Crowley re: OxyContin samples	PPLPC020000584385	PPLPC020000584386
PUR4333	8/27/2012	The Massachusetts General Hospital Handbook of Pain Management, Chapter 35 (3rd Ed.)	PPLPC020000606467	PPLPC020000606488
PUR4334	3/14/2013	Purdue Educational Piece: Steps for titrating OxyContin through the S.T.A.R.T. Principles	PPLPC020000662663	PPLPC020000662666
PUR4335	4/17/2013	Email from James Arnold (DEA) to Jack Crowley re: discontinuation of OxyContin 160mg tablets	PPLPC020000674578	PPLPC020000674578
PUR4336	1/25/2013	Letter from FBI to FDA re FBI expresses concern about generic versions of long-release opiates coming to market without tamper-resistant technology	PPLPC020000675167	PPLPC020000675167
PUR4337	8/14/2013	Memo from McKinsey & company to John Stewart & Russ Gasdia re: Identifying granular growth opportunities for OxyContin: Detail on "Turbocharging Purdue's Sales Engine"	PPLPC020000706956	PPLPC020000706960
PUR4338	6/29/2015	Email from Avni Patel to Carmen Roldan re: Fulfilling request for NADI brochures from Ohio Penitentiary	PPLPC020000922412	PPLPC020000922414
PUR4339	8/11/2015	Status of Requests Regarding Region 0 (LA Times Article)	PPLPC020000938053	PPLPC020000938053
PUR4340	4/27/2016	Sales and Marketing Compliance Committee (SMCC) Meeting Minutes April 27, 2016	PPLPC020001028266	PPLPC020001028268
PUR4341	4/4/2016	Order Monitoring Procedures, Purdue SOP No. GC-0007.1, effective 2/29/2016	PPLPC020001042161	PPLPC020001042165
PUR4342	10/11/2016	Memo from Brian Rosen to OH Territory Business Managers re: Ohio Board of Pharmacy - PMP notice	PPLPC020001061905	PPLPC020001061906
PUR4343	3/22/2001	Memo to Field Force from Jim Lang re: Promotion of OxyContin Tablets	PPLPC02100008616	PPLPC02100008616

PUR4344	11/26/2001	Email from Alan Must to Willa Ebersole re: Ohio PMP Meeting	PPLPC021000014836	PPLPC021000014837
PUR4345	5/12/2002	Email from Robin Hogen to Michael Friedman re: Painfully Obvious Launch Plan	PPLPC021000019274	PPLPC021000019274
PUR4346	5/10/2002	Painfully Obvious Launch Plan	PPLPC021000019275	PPLPC021000019296
PUR4347	3/12/2004	Email from Tom Pappas to Brian Rosen re: Rx Patrol Alert-Ohio	PPLPC021000051490	PPLPC021000051492
PUR4348	7/26/2004	PF Laboratories Presentation: Annual DEA Training	PPLPC021000058869	PPLPC021000058869
PUR4349	8/1/2002	DEA Event Log - Questions/Concerns and Notes from Briefing Session(s) with DEA - June to Sept. 2002	PPLPC021000063480	PPLPC021000063485
PUR4350	10/25/2004	Email from Jack Crowley to James Crawford (DEA) re: National Press release on RFID Chip	PPLPC021000065975	PPLPC021000065978
PUR4351	5/24/2005	Email from Bruce King to Scott Griffin re: self-audit of execution of DEA form 222	PPLPC021000080155	PPLPC021000080156
PUR4352	4/1/2005	Purdue CSA Compliance: DEA Inspection Policies for Manufacturers - April 1, 2005 (Draft)	PPLPC021000086232	PPLPC021000086273
PUR4353	1/16/2007	Email from Jack Crowley to DEA regarding physician referral	PPLPC021000130360	PPLPC021000130361
PUR4354	9/27/2007	Purdue Presentation: 2008 Marketing Plan	PPLPC021000158411	PPLPC021000158411
PUR4355	10/10/2007	Email from DEA to Jack Crowley regarding physician referral	PPLPC021000159847	PPLPC021000159851
PUR4356	3/12/2008	Email from Jack Crowley to DEA regarding placebo request	PPLPC021000176224	PPLPC021000176225
PUR4357	5/27/2004	Draft letter from DEA to Ronald D'Ulisse regarding placebo request	PPLPC021000176226	PPLPC021000176226
PUR4358	7/23/2007	OxyContin Tablets 2008 Recommendations	PPLPC021000184957	PPLPC021000184986
PUR4359	1/22/2009	Email from Gina Limer to Jack Crowley re: RE: Wilson Site DEA Inspection	PPLPC021000214416	PPLPC021000214416
PUR4360	1/29/2009	Email from Jack Crowley to DEA regarding pharmacies of interest	PPLPC021000215277	PPLPC021000215282
PUR4361	11/19/2007	Letter from Windell Fisher to Sales Force Colleagues forwarding Sales Force SOP Manual issued Nov. 2007	PPLPC021000215691	PPLPC021000215712
PUR4362	4/2/2009	Email from Jack Crowley to DEA regarding NJ Pharmaceutical Industry Group meeting	PPLPC021000223204	PPLPC021000223206
PUR4363	2/27/2008	"Medicine for Success," Pharmaceutical Industry Briefing - Feb. 27, 2008 meeting btwn DEA and NJ industry representatives	PPLPC021000223207	PPLPC021000223210
PUR4364	4/2/2009	Email from Jack Crowley to DEA regarding Year-End CSR Reports for Wilson site	PPLPC021000223219	PPLPC021000223220
PUR4365	1/8/2009	Attachment to DEA email, 2008 Year-End CSR MFG by Dispensing dates	PPLPC021000223221	PPLPC021000223221
PUR4366	1/8/2009	Attachment to DEA email, Year-End CSR Report	PPLPC021000223222	PPLPC021000223222
PUR4368	4/15/2009	Email from Jack Crowley to DEA regarding placebo request	PPLPC021000225441	PPLPC021000225442
PUR4369	5/27/2004	DEA letter to Richard Zenuch re: OxyContin placebo tablet request	PPLPC021000225443	PPLPC021000225443
PUR4370	6/2/2009	Email from DEA to Jack Crowley regarding OxyContin bottle	PPLPC021000232661	PPLPC021000232661
PUR4371	6/21/2010	Email from Jack Crowley to DEA regarding ARCOS	PPLPC021000299578	PPLPC021000299580
PUR4372	7/13/2010	Email from DEA to Jack Crowley regarding reformulated OxyContin	PPLPC021000304571	PPLPC021000304572
PUR4373	7/23/2010	OxyContin 2010 Incremental eMarketing Plan	PPLPC021000308007	PPLPC021000308007
PUR4374	8/3/2010	Email from Jack Crowley to DEA regarding request for photos	PPLPC021000310845	PPLPC021000310846
PUR4375	8/30/2010	OxyContin 60 mg bottle photo attachment to DEA	PPLPC021000310847	PPLPC021000310847
PUR4376	8/30/2010	OxyContin 20 mg bottle photo attachment to DEA	PPLPC021000310848	PPLPC021000310848
PUR4377	8/3/2010	OxyContin 15 mg bottle photo attachment to DEA	PPLPC021000310849	PPLPC021000310849
PUR4378	8/30/2010	OxyContin 30 mg bottle photo attachment to DEA	PPLPC021000310850	PPLPC021000310850
PUR4379	8/30/2010	OxyContin 40 mg bottle photo attachment to DEA	PPLPC021000310851	PPLPC021000310851
PUR4380	8/30/2010	OxyContin 80 mg bottle photo attachment to DEA	PPLPC021000310852	PPLPC021000310852
PUR4381	8/3/2010	OxyContin 10 mg bottle photo attachment to DEA	PPLPC021000310853	PPLPC021000310853
PUR4382	8/31/2010	Email from Jack Crowley to DEA regarding reformulated OxyContin	PPLPC021000318494	PPLPC021000318494
PUR4384	8/5/2010	OxyContin Tablet pictures-Original and Reformulated	PPLPC021000318496	PPLPC021000318496
PUR4385	8/5/2010	Purdue Pharma L.P. Infographic: Updated NDC Numbers for OxyContin Tablets	PPLPC021000318497	PPLPC021000318497
PUR4386	9/20/2010	Email from DEA to Jack Crowley regarding Drug Abuse Task Force presentation and OxyContin information	PPLPC021000324831	PPLPC021000324833
PUR4387	3/9/2011	Email from Jack Crowley to DEA regarding Purdue Support of Prescription Drug Monitoring Program in Florida	PPLPC021000361962	PPLPC021000361962
PUR4389	9/26/2011	Email from Jack Crowley to George Euson of HD Smith regarding pharmacy OMS	PPLPC021000408551	PPLPC021000408552
PUR4390	12/22/2011	Sales Training and Development Bulletin re Clarity on Compliance Issues	PPLPC021000457228	PPLPC021000457228
PUR4391	1/20/2014	Email from Beth Evans to John Gilbride attaching Butrans DEA correspondence	PPLPC021000624332	PPLPC021000624332
PUR4392	10/16/2012	Email from DEA to Diane O'Grady regarding ARCOS BUP clinical NDC numbers	PPLPC021000624333	PPLPC021000624337
PUR4393	5/15/2014	Quarterly Corp.Compliance Report to Board of Directors 1Q2014	PPLPC021000669224	PPLPC021000669224
PUR4394	8/4/2014	Sales and Marketing Compliance Committee meeting minutes August 4, 2014	PPLPC021000674157	PPLPC021000674159
PUR4395	4/21/2015	Quarterly Corp. Compliance Report to Board of Directors 1Q2015	PPLPC021000769400	PPLPC021000769400
PUR4396	8/29/2017	Email from Rodney Benson to DEA regarding pharmacies of interest	PPLPC021000902624	PPLPC021000902624
PUR4397	8/29/2017	"Of Interest" pharmacies reported to DEA	PPLPC021000902625	PPLPC021000902625
PUR4398	9/9/2017	Email from Rodney Benson to Eric Triana regarding pharmacies of interest referred to DEA	PPLPC021000904005	PPLPC021000904005
PUR4399	9/9/2017	"Of Interest" pharmacies reported to DEA	PPLPC021000904006	PPLPC021000904006
PUR4400	11/30/2017	Ethics and Compliance Update to the BOD, 2017	PPLPC021000914129	PPLPC021000914129
PUR4401	1/19/2018	Email from Rodney Benson to DEA regarding a suspicious order	PPLPC021000918469	PPLPC021000918469
PUR4402	3/8/2018	SOM End of Year Review: Ethics & Compliance/Legal Presentation: December 2017	PPLPC021000923153	PPLPC021000923153
PUR4403	3/8/2018	Email from Eric Brantley to Margaret Feltz RE: SOM numbers	PPLPC021000923154	PPLPC021000923155
PUR4404	3/9/2018	Suspicious Order Monitoring Committee 3/9/18	PPLPC021000923338	PPLPC021000923338
PUR4405	5/31/2018	Letter from Warren County Sheriff's Office to John Gilbride re: Placebos	PPLPC021000930107	PPLPC021000930108
PUR4406	6/12/2002	Email from Susan Merryman to Alan Must re: Draft of Ohio Strategy for "Painfully Obvious" campaign	PPLPC022000018660	PPLPC022000018660

PUR4407	5/13/2002	Draft Plan for Painfully Obvious Ohio Statewide Rollout	PPLPC022000018661	PPLPC022000018665
PUR4408	1/1/2003	Purdue Healthcare Practitioner Correction Letter Warning for OxyContin Tablets	PPLPC022000031062	PPLPC022000031063
PUR4409	2/3/2004	Memorandum from Mark Souder to Members, Subcommittee on Criminal Justice - "To Do No Harm: Strategies for Preventing Prescription Drug Abuse"	PPLPC022000044567	PPLPC022000044569
PUR4410	9/20/2004	Email from Alan Must to Pamela Bennett, et al. re: Ohio Attorney General Press Conference - Rx Patrol	PPLPC022000057551	PPLPC022000057552
PUR4411	9/20/2004	Office of Attorney General of Ohio Press Release: Attorney General Jim Petro Adds RxPatrol to Ohio Law Enforcement Gateway	PPLPC022000057553	PPLPC022000057554
PUR4413	2/8/2005	RxPATROL Pharmacy Safety and Security Slides	PPLPC022000065500	PPLPC022000065539
PUR4414	2/14/2008	Email from Jack Crowley to DEA regarding renewal process	PPLPC022000180518	PPLPC022000180519
PUR4415	4/21/2009	Email from Jack Crowley to DEA regarding site visits	PPLPC022000246958	PPLPC022000246960
PUR4416	6/15/2009	Email from Robert Loewenstein to DEA regarding Outstanding Quota Requests	PPLPC022000258003	PPLPC022000258004
PUR4417	8/25/2009	Email from Jack Crowley to DEA regarding Lam's Pharmacy	PPLPC022000274358	PPLPC022000274359
PUR4418	8/25/2009	Attachment to email to DEA (Oxycontin LAMS PHARMACY order list)	PPLPC022000274360	PPLPC022000274360
PUR4419	8/25/2009	Email from Jack Crowley to DEA re prescription records	PPLPC022000274361	PPLPC022000274363
PUR4420	2/25/2009	Attachment of prescription records sent to DEA in email from Jack Crowley	PPLPC022000274364	PPLPC022000274364
PUR4423	9/18/2009	Email from Jack Crowley to DEA regarding Rhodes Revised Aggregate Quota	PPLPC022000278385	PPLPC022000278385
PUR4424	9/1/2009	Letter from DEA regarding Rhodes Technologies Oxycodone quota	PPLPC022000278386	PPLPC022000278386
PUR4425	11/23/2009	Email from Richard Zenuch to Mark Geraci re NADDI awards Purdue LELE team annual Educator of the Year award	PPLPC022000295048	PPLPC022000295048
PUR4426	1/15/2010	Purdue Board Presentation: Purdue Pharma Corporate Security 2009 Accomplishments	PPLPC022000300674	PPLPC022000300674
PUR4427	5/11/2010	Email from Jack Crowley to DEA regarding DEA Duplicate FDA OxyContin Request #32-5	PPLPC022000329177	PPLPC022000329179
PUR4428	6/24/2010	Email from Mark Caverly (DEA) to Jack Crowley regarding ARCOM Question	PPLPC022000341054	PPLPC022000341056
PUR4429	8/3/2010	Email from Jack Crowley to DEA regarding request for photos	PPLPC022000352966	PPLPC022000352967
PUR4430	8/12/2010	Email from Jack Crowley to DEA regarding request for photos	PPLPC022000356371	PPLPC022000356375
PUR4431	8/17/2010	Email from Jack Crowley to DEA regarding updated OxyContin NDC numbers	PPLPC022000357387	PPLPC022000357387
PUR4432	8/17/2010	Updated NDC numbers for OxyContin Original & Reformulated Tablets	PPLPC022000357388	PPLPC022000357388
PUR4434	10/18/2010	Email from DEA to Jack Crowley re: pharmacy of interest	PPLPC022000378386	PPLPC022000378387
PUR4435	10/26/2010	Forwarded email from Jack Crowley to DEA regarding acceptable specification range	PPLPC022000380825	PPLPC022000380826
PUR4436	1/18/2010	Purdue Corporate Compliance Series Part 2: Purdue Healthcare Law Compliance Policies Module	PPLPC022000397899	PPLPC022000397946
PUR4437	3/9/2011	Email from Jack Crowley to DEA regarding Purdue Support of Prescription Drug Monitoring Program in Florida	PPLPC022000411236	PPLPC022000411237
PUR4438	3/9/2011	Purdue Press Release: Purdue Pharma L.P. offers \$1 million to help fund Florida's Prescription Drug Monitoring Program	PPLPC022000411238	PPLPC022000411239
PUR4439	7/26/2011	Email from Jack Crowley to DEA regarding Butrans prescription misinformation	PPLPC022000449117	PPLPC022000449118
PUR4440	5/30/2012	Email from Jack Crowley to DEA regarding report of DEA activities in Arkansas and Oklahoma	PPLPC022000534074	PPLPC022000534074
PUR4441	6/19/2012	Letter from Marysville, OH Division of Police to John Gilbride re: Placebo Request Letter	PPLPC022000539668	PPLPC022000539668
PUR4442	10/10/2012	Email from DEA to Jack Crowley regarding ARCOM NDC numbers	PPLPC022000567449	PPLPC022000567451
PUR4443	10/16/2012	Email from Jack Crowley to DEA regarding Dr. Wendell Street prescription history	PPLPC022000568777	PPLPC022000568777
PUR4444	8/8/2012	Prescription history for Dr. Wendell Street through 6-2012	PPLPC022000568778	PPLPC022000568779
PUR4445	10/11/2013	2013 Sales and Marketing Opioid Market Overview	PPLPC022000661404	PPLPC022000661404
PUR4446	5/20/2014	Sales and Marketing Compliance Committee Meeting Minutes May 20, 2014	PPLPC022000727115	PPLPC022000727117
PUR4447	9/25/2015	Email from Elizabeth Percheson to John Gilbride re LELE personnel trained through 8.21.2015 and LELE presentation through 6.5.2015	PPLPC022000884243	PPLPC022000884245
PUR4448	9/25/2015	Excel Attachment - LELE people trained 2006 through Aug. 21, 2015 - By State and by Year	PPLPC022000884246	PPLPC022000884246
PUR4449	9/25/2015	Excel Attachment - LELE Presentations from 2006 through June 5, 2015 - Old Database - By State	PPLPC022000884247	PPLPC022000884247
PUR4450	8/9/2017	Email from Rodney Benson to DEA regarding pharmacies of interest	PPLPC022001006938	PPLPC022001006938
PUR4451	8/9/2017	Pharmacies of interest reported to DEA 8-8-17	PPLPC022001006939	PPLPC022001006939
PUR4452	10/25/2017	Email from Rodney Benson to Eric Triana regarding McKesson suspicious order	PPLPC022001016920	PPLPC022001016920
PUR4453	11/30/2017	Email from Margaret Feltz to Eric Brantley regarding SOM & KYC	PPLPC022001021999	PPLPC022001022001
PUR4454	4/22/2004	Email from Brian Rosen to Alan Must re Ohio PMP Bill	PPLPC023000044083	PPLPC023000044083
PUR4456	3/22/2005	Email from John Stewart to DEA regarding export procedure	PPLPC023000061863	PPLPC023000061863
PUR4457	3/4/2005	Memo from Bob Loewenstein to Karen O'Neil regarding Oxycodone quota allocation and export procedure	PPLPC023000061865	PPLPC023000061865
PUR4458	7/22/2005	Email from Barbara Stedge to Michael Morley (ccing Jack Crowley) regarding Purdue Procurement Quota for Registration #RP0244068	PPLPC023000069634	PPLPC023000069637
PUR4459	4/17/2006	Email from Dr. Sherry Siegel to Diana Mohoreanu re Additional LELE Ohio News Coverage	PPLPC023000091278	PPLPC023000091279
PUR4460	2/22/2007	Email from Jack Crowley to DEA regarding fulfillment of request for OxyContin placebos	PPLPC023000120072	PPLPC023000120074
PUR4461	6/26/2007	Email from Jack Crowley to DEA regarding IPAP	PPLPC023000135167	PPLPC023000135168
PUR4462	9/26/2007	Email from Jack Crowley to DEA regarding maximum daily dosages of OxyContin	PPLPC023000144474	PPLPC023000144476

PUR4463	10/17/2007	Email from Jack Crowley to DEA regarding maximum daily dosage of OxyContin	PPLPC023000147474	PPLPC023000147474
PUR4464	10/17/2007	Memo regarding MAXIMUM DOSE OF OXYCONTIN	PPLPC023000147475	PPLPC023000147478
PUR4465	12/19/2007	Email from DEA to Postal Inspector General and Jack Crowley re: conversation with Jack Crowley concerning OxyContin Placebos	PPLPC023000154943	PPLPC023000154943
PUR4466	3/5/2008	Email from Jack Crowley to Gina Limer regarding New Jersey Industry Working Group	PPLPC023000163903	PPLPC023000163904
PUR4468	6/11/2008	Email from Jack Crowley to DEA regarding Distributor Registration Questions	PPLPC023000174934	PPLPC023000174937
PUR4469	4/15/2009	Email from DEA to Jack Crowley regarding On Site Pharmacy Visits	PPLPC023000212960	PPLPC023000212963
PUR4470	4/28/2009	Email from Jack Crowley to DEA regarding RFID/Follow Up on Request	PPLPC023000215085	PPLPC023000215086
PUR4471	4/28/2009	OxyContin shipment data attached to email to DEA	PPLPC023000215087	PPLPC023000215087
PUR4472	6/2/2009	Email from DEA to Jack Crowley regarding OxyContin Bottle	PPLPC023000221088	PPLPC023000221089
PUR4473	7/14/2009	Email from Jack Crowley to DEA regarding Question regarding rebate coupons	PPLPC023000229195	PPLPC023000229195
PUR4474	8/3/2009	Email from Barbara Stedge to DEA regarding Distributor Registration Questions	PPLPC023000232931	PPLPC023000232932
PUR4475	7/27/2009	Letter from DEA to Jeffrey Zerillo regarding supplier registration questions	PPLPC023000232934	PPLPC023000232945
PUR4476	8/5/2009	Email from Jack Crowley to George Euson (HD Smith) regarding suspicious accounts	PPLPC023000233576	PPLPC023000233578
PUR4477	9/1/2009	Email from George Euson (HD Smith) to Jack Crowley regarding a suspicious order in South Florida	PPLPC023000237813	PPLPC023000237819
PUR4478	9/25/2009	Email from Jack Crowley to DEA regarding Drug Safety and Risk Management Advisory Committee Meeting	PPLPC023000241829	PPLPC023000241829
PUR4479	7/13/2010	Email from Jack Crowley to DEA regarding Return Vendor Control Actions/Oxy old formula returns	PPLPC023000297909	PPLPC023000297912
PUR4480	7/15/2010	Email from DEA to Jack Crowley regarding pharmaceutical investigations	PPLPC023000299994	PPLPC023000299995
PUR4481	7/22/2010	Email from DEA to Jerry Zemble regarding Duplicate sample request	PPLPC023000301652	PPLPC023000301653
PUR4482	7/22/2010	Email from DEA to Jerry Zemble regarding Duplicate sample request	PPLPC023000301654	PPLPC023000301655
PUR4483	8/12/2010	Email from Jack Crowley to Brian Reise regarding Supplemental Information on the Wilson site	PPLPC023000308852	PPLPC023000308852
PUR4484	8/12/2010	CSA Compliance Follow up for DEA	PPLPC023000308853	PPLPC023000308863
PUR4485	8/13/2010	Email from Jack Crowley to DEA regarding reformulated OxyContin description	PPLPC023000309369	PPLPC023000309373
PUR4486	8/17/2010	Email from Jack Crowley to DEA regarding reformulated OxyContin description	PPLPC023000309975	PPLPC023000309976
PUR4487	10/5/2010	Email from Jeff Cohen to Jack Crowley re DEA Audits in 2010	PPLPC023000322697	PPLPC023000322699
PUR4488	10/15/2010	Email from DEA to Jack Crowley regarding OxyContin Shipping Question	PPLPC023000326275	PPLPC023000326277
PUR4489	3/10/2011	Email from DEA to Jack Crowley regarding Purdue Support of Prescription Drug Monitoring Program in Florida	PPLPC023000359515	PPLPC023000359516
PUR4490	8/15/2011	Email from Edward Hazewski to Jack Crowley regarding OMS mutual support request	PPLPC023000395694	PPLPC023000395697
PUR4491	6/26/2012	Email from Elizabeth Percheson to Joe Price, et al. re Non-Event Literature Distribution Submitted: For Det. Ramsey - East Liverpool PD, Ohio (LELE)	PPLPC023000478249	PPLPC023000478251
PUR4492	7/24/2012	Email from David Lundie to Jack Crowley re: DEA - Wilson Inspection Day Two	PPLPC023000485214	PPLPC023000485215
PUR4493	10/9/2012	Email from Jack Crowley to DEA regarding Rhodes Technologies waiver request	PPLPC023000502657	PPLPC023000502659
PUR4494	5/14/2012	Letter from Robert Loewenstein to John Partridge re: Rhodes Technologies synthetic process to convert oripavine to buprenorphine	PPLPC023000502660	PPLPC023000502661
PUR4495	2/26/2013	Email from Elizabeth Percheson to Joe Price, et al. re Non-Event Literature Distribution Submitted: For Det. Hosta - Brunswick PD, Ohio (LELE)	PPLPC023000532275	PPLPC023000532277
PUR4496	7/18/2013	Memorandum to Purdue Board of Directors From McKinsey & Company re: Identifying granular growth opportunities for OxyContin	PPLPC023000601147	PPLPC023000601163
PUR4497	8/21/2013	Email from Elizabeth Percheson to Joe Price, et al. re Non-Event Literature Distribution Submitted: For Det. Andrew Sperie - Maple Heights PD, Ohio (LELE)	PPLPC023000608805	PPLPC023000608807
PUR4498	9/9/2013	Email from Shannon Humeniuk to Milica Kokotovic re LELE August 2013 - Purdue's Cuyahoga drug abuse and trafficking summit	PPLPC023000613030	PPLPC023000613033
PUR4499	11/12/2013	Email from Elizabeth Percheson to Joe Price, et al. re Non-Event Literature Distribution Submitted : For Brian Worrell, State of Ohio Dept of Rehab-Youngstown, OH	PPLPC023000631296	PPLPC023000631298
PUR4500	3/3/2014	WPD-Speaker Utilization Cap 2013 (Draft No. 1) - Documentation of procedure for monitoring speaker usage	PPLPC023000659506	PPLPC023000659509
PUR4501	4/16/2015	Purdue Pharma L.P. Presentation: LELE Overview (April 16, 2015)	PPLPC023000776004	PPLPC023000776024
PUR4502	6/18/2015	Purdue Corp. Compliance Series Reporting Adverse Events and Product Complaints	PPLPC023000899674	PPLPC023000899698
PUR4503	7/31/2017	Purdue Pharma Standard Operating Procedures - Identifying, Evaluating and Reporting Suspicious Orders (CC-SOP-000017)	PPLPC023000949095	PPLPC023000949098
PUR4505	8/24/2017	Email from Rodney Benson to DEA regarding ten "of interest" pharmacies.	PPLPC023000952460	PPLPC023000952460
PUR4506	8/24/2017	Attachment to email to DEA regarding ten "of interest" pharmacies	PPLPC023000952461	PPLPC023000952461
PUR4507	11/30/2017	Email from Eric Brantley to Margaret Feltz regarding communication with DEA re suspicious orders	PPLPC023000965823	PPLPC023000965823
PUR4508	1/8/2018	Email from Rodney Benson to DEA regarding pharmacy of interest	PPLPC023000969456	PPLPC023000969456
PUR4510	1/25/2018	Working Practices Document - Compliance and Law Dept. internal procedures for implementing Abuse and Diversion Detection Programs	PPLPC023000971903	PPLPC023000971919
PUR4511	2/14/2018	Email from Eric Brantley to Margaret Feltz, et al. regarding new DEA resource to avoid the oversupplying of opioids	PPLPC023000973431	PPLPC023000973432
PUR4512	3/8/2018	Email from Rodney Benson to DEA regarding a suspicious order report	PPLPC023000975999	PPLPC023000975999

PUR4513	11/19/2001	Purdue Presentation: Painfully Obvious in Ohio - Summary of program and participant	PPLPC024000069009	PPLPC024000069009
PUR4514	6/13/2002	Sales Force Bulletin - OxyContin Tablets CII Patient Information Sheet	PPLPC024000071071	PPLPC024000071071
PUR4515	6/14/2002	Dear Pharmacist Letter re OxyContin Tablets CII Patient Information Sheet	PPLPC024000071072	PPLPC024000071072
PUR4516	3/26/2003	Email from Pamela Bennett to Helen Swalina re: Please review Ohio launch documents	PPLPC024000088139	PPLPC024000088140
PUR4517	11/20/2006	Email from Shannon Ensminger to James Heins re Purdue compilation of Good News Stories - includes story on Purdue Pharma being named Corporation of the Year by Greater Cincinnati Northern Kentucky Crime Stoppers	PPLPC024000196110	PPLPC024000196423
PUR4518	5/21/2007	Email From Burt Rosen to Brenda Becker re Pain Care forum Legislative Strategy Workgroup	PPLPC024000227398	PPLPC024000227400
PUR4519	6/15/2007	Purdue ADD SOP 1.7.1 Abuse and Diversion Detection	PPLPC024000231447	PPLPC024000231450
PUR4520	2/7/2007	Purdue Pharma Medical Educ. Dept.: ASAP - Addressing Substance Abuse Prevention notification sheet	PPLPC024000243606	PPLPC024000243606
PUR4521	10/6/2008	Purdue Products L.P. OxyContin - 2009 Marketing Plan - Draft Revised 10-6-08	PPLPC024000337290	PPLPC024000337325
PUR4522	11/12/2009	Email from Richard Widup to Mark Geraci regarding significant events in corporate security	PPLPC024000417696	PPLPC024000417697
PUR4523	6/28/2012	Purdue Sales Training and Development Memo No. 169 from Jane Koch to Analgesic Sales Force re Butrans and OxyContin Messaging	PPLPC024000640613	PPLPC024000640614
PUR4524	11/26/2012	Corporate Compliance Council Meeting Minutes - November 26, 2012	PPLPC024000701012	PPLPC024000701015
PUR4525	2/11/2013	Sales Training and Development Memo No. 40 from Janet Koch to Analgesic Sales Force re Published Study regarding Butrans	PPLPC024000702098	PPLPC024000702098
PUR4526	7/24/2014	Purdue Pharma L.P. Presentation: Improving Patient Knowledge and Outcomes Utilizing POEM (Patient Opioid Education Measure), a program developed in collaboration with researchers affiliated with Ohio State University	PPLPC024000945507	PPLPC024000945507
PUR4527	2/9/2004	Statement by Robert J. Meyer, MD (FDA) before the US House of Representatives	PPLPC025000083993	PPLPC025000084012
PUR4528	7/30/2014	Purdue Pharma L.P. Initial Distribution Strategy for Hysingla ER	PPLPC025000171067	PPLPC025000171072
PUR4529	11/9/2004	DEA Contact re: Request for Information - Manufacturing Activity at Totowa	PPLPC026000018767	PPLPC026000018770
PUR4530	11/17/2004	There Can Be Life with Relief - Retained Visual Aid	PPLPC026000018888	PPLPC026000018893
PUR4531	10/2/2005	Email from Fred Sexton to James Cherry et al., re: Totowa Inspection Day 1	PPLPC026000025312	PPLPC026000025313
PUR4532	10/26/2005	Email from Jack Crowley to Jeffrey Zerillo and James Cherry re: DEA Inspection Update for Day 12	PPLPC026000025531	PPLPC026000025532
PUR4533	4/12/2007	Email from Lynn Snyder to Mary Riordan and Keshia Thompson re Purdue requested materials from 4/12 OIG-Purdue call	PPLPC026000031091	PPLPC026000031092
PUR4534	4/20/2007	Email from Wendy Goldstein to Mary Riordan, Keshia Thompson, et al. re Purdue Pharma L.P. Draft CIA and Appendix B	PPLPC026000031246	PPLPC026000031247
PUR4535	5/7/2007	Email from Lynn Snyder to Mary Riordan and Keishia Thompson re Executed Purdue Pharma L.P. CIA and Appendices	PPLPC026000031701	PPLPC026000031701
PUR4536	6/21/2007	Sales & Marketing Compliance Committee Meeting Minutes, June 21, 2007 (7/5/2007 Draft)	PPLPC026000033335	PPLPC026000033336
PUR4537	8/22/2007	Email from Bert Weinstein to Keshia Thompson, et al. re Purdue Pharma CIA	PPLPC026000034844	PPLPC026000034844
PUR4538	8/22/2007	Notification of Government or Legal Proceedings Pursuant to Corporate Integrity Agreement section III.G from Purdue Pharma L.P. to OIG	PPLPC026000034845	PPLPC026000034849
PUR4539	1/16/2008	Email from Jack Crowley to DEA regarding request for a meeting	PPLPC026000037311	PPLPC026000037316
PUR4540	1/17/2008	Email from Jack Crowley to DEA regarding request for a meeting	PPLPC026000037317	PPLPC026000037322
PUR4541	10/1/2008	Email from Jack Crowley to DEA regarding Missing Parcel Investigation	PPLPC026000043206	PPLPC026000043207
PUR4542	10/21/2008	Email from DEA to Jack Crowley regarding settlement with Mallinckrodt and upcoming meeting	PPLPC026000043327	PPLPC026000043329
PUR4543	11/6/2008	Email from Jack Crowley to DEA regarding Meeting with DEA	PPLPC026000043484	PPLPC026000043487
PUR4544	12/15/2008	Email from DEA to Jack Crowley regarding Pain Care Forum	PPLPC026000044064	PPLPC026000044066
PUR4545	12/8/2008	Fax from Mathilda K. Fienkeng to Beth Connally, Assistant Director of U.S. Regulatory Affairs/Purdue: Enclosing Attachment to DHS OIG compliance letter concerning improper promotion video	PPLPC026000044072	PPLPC026000044077
PUR4546	12/12/2008	Letter from Anthony C. Santopolo/Purdue to Thomas W. Abrams/FDA re: DHS OIG compliance letter concerning improper promotion video	PPLPC026000044080	PPLPC026000044081
PUR4547	1/15/2009	Email from Jack Crowley to DEA regarding placebo request	PPLPC026000044420	PPLPC026000044421
PUR4548	8/3/2006	Email from Natalia Aristizabal/Purdue to Ron D'Ulisse and Peter Mendelson re police placebo request	PPLPC026000044422	PPLPC026000044428
PUR4549	2/17/2009	Email from Bert Weinstein to Keshia Thompson, et al. re Pharma L.P. - Follow up on questions from our January 29th telephone conversation	PPLPC026000045689	PPLPC026000045692
PUR4553	4/8/2009	Corporate Compliance Council Meeting Minutes April 8, 2009 (Draft)	PPLPC026000047139	PPLPC026000047142
PUR4554	4/22/2010	Email from Jack Crowley to Elizabeth Adams regarding McKesson pharmacies of interest	PPLPC026000064006	PPLPC026000064008
PUR4555	5/4/2010	Email to Jack Crowley from Elizabeth Adams regarding LA scams	PPLPC026000064594	PPLPC026000064595
PUR4556	5/4/2010	Email from Jack Crowley to George Euson at HD Smith regarding pharmacies and physicians of concern	PPLPC026000064596	PPLPC026000064599
PUR4557	5/7/2010	Letter from Sarah Reznek to Assistant AG of Ohio re Purdue Pharma Multistate Consent Judgment	PPLPC026000064681	PPLPC026000064688
PUR4558	6/9/2010	Email from Jack Crowley to Elizabeth Adams re: OMS Investigation	PPLPC026000066152	PPLPC026000066152
PUR4559	6/9/2010	OMS Investigation of Family Medical Pharmacy, Columbus Ohio	PPLPC026000066153	PPLPC026000066155
PUR4560	7/21/2010	2Q10- Corporate Compliance Council Meeting - DRAFT Minutes 07/21/2010	PPLPC026000067483	PPLPC026000067485
PUR4561	8/11/2010	Email from David Lundie to Jeff Cohen et al. re: Totowa DEA Inspection Summary fo 8/10 - 8/11/2010	PPLPC026000067903	PPLPC026000067905

PUR4562	9/1/2009	Purdue Presentation: Information on Purdue's Compliance Program and Healthcare Laws In General As They Pertain to Field Sales	PPLPC026000069597	PPLPC026000069597
PUR4563	1/18/2010	Purdue Presentation: Purdue Corporate Compliance Series - Part 2: Purdue Healthcare Law Compliance Policies Module	PPLPC026000069675	PPLPC026000069722
PUR4564	8/18/2010	Report to OMS Team regarding Pharmacy One in Miami	PPLPC026000080377	PPLPC026000080378
PUR4565	4/4/2011	Email from Jack Crowley to DEA regarding Proposed Meeting between Purdue Pharma and OD	PPLPC026000084573	PPLPC026000084574
PUR4566	4/4/2011	Draft Agenda for the Meeting between the Drug Enforcement Administration & Purdue Pharma L.P. (April 2011)	PPLPC026000084575	PPLPC026000084575
PUR4569	8/25/2011	OMS Report - Kahler Pharmacy, Toledo Ohio	PPLPC026000088249	PPLPC026000088252
PUR4570	11/30/2011	Email from Jack Crowley to DEA regarding Epidemiology Study.	PPLPC026000093063	PPLPC026000093065
PUR4571	12/1/2011	Email from Robin Abrams to DEA regarding Pharmacies and Prescribers Reported to DEA located in California	PPLPC026000093089	PPLPC026000093089
PUR4572	12/7/2011	Email from Jack Crowley to DEA regarding Epidemiology Study	PPLPC026000093267	PPLPC026000093270
PUR4573	3/20/2012	Email from Giselle Issa to Jack Crowley regarding customer of Cardinal that is a pharmacy of concern	PPLPC026000097034	PPLPC026000097038
PUR4574	9/27/2012	5th Annual Purdue Corporate Integrity Agreement (CIA) report	PPLPC026000110277	PPLPC026000110300
PUR4575	4/18/2013	Email from Jack Crowley to DEA regarding OxyContin 160mg	PPLPC026000117993	PPLPC026000117994
PUR4576	5/9/2013	OxyContin Q and A script re label change	PPLPC026000118375	PPLPC026000118381
PUR4581	3/12/2018	Brantley - Suspicious Order Monitoring System Committee (att2)	PPLPC026000160281	PPLPC026000160281
PUR4582	3/2/2001	Email from Maine Assistant AG James Cameron to James Heins regarding pending ME Narcotic Diversion bill	PPLPC027000002674	PPLPC027000002674
PUR4583	3/2/2001	Maine Narcotic Control Bill	PPLPC027000002675	PPLPC027000002679
PUR4584	12/11/2001	Email from James Heins to Robin Hogen containing the Standby Statement - "Purdue Pharma Statement on Theft of OxyContin Tablets from Mexican Licensee"	PPLPC027000007259	PPLPC027000007260
PUR4585	4/6/2006	News coverage re LELE Oho event	PPLPC027000031720	PPLPC027000031721
PUR4586	2/28/2001	Email from Ron Levine to Susan Herrmann re John Burke, Director, Warren County Drug Task Force posting on "OxyContin Medi Hysteria"	PPLPC028000029749	PPLPC028000029751
PUR4589	9/21/2001	Sales Training and Development Planning Presentation	PPLPC028000044630	PPLPC028000044630
PUR4590	11/9/2001	Email from Mark Alfonso to Sharon Franco re Painfullyobvious.com eMarketing Strategy Update	PPLPC028000048593	PPLPC028000048596
PUR4591	2/25/2002	"More Than Ever" Training Series: Postsurgical Sales Workshop	PPLPC028000054746	PPLPC028000054746
PUR4592	3/28/2002	"More Than Ever" Training Series: OxyContin Brand Positioning and Market Stretegy 2002-2003	PPLPC028000056738	PPLPC028000056738
PUR4593	2/10/2003	State of the Brand- January 2003	PPLPC028000076458	PPLPC028000076477
PUR4597	1/14/2009	Email from David Lundie to Jeffrey Zerillo re: Wilson Site DEA Inspection - Day 2	PPLPC028000237732	PPLPC028000237732
PUR4598	2/13/2009	Email from Don Kyle to Jeffrey Zerillo et al. re: DEA Inspection - Wilson Facility	PPLPC028000241132	PPLPC028000241134
PUR4599	7/29/2009	Purdue Corporate Compliance Audit Report: Audit of Field Contact Reports - Draft 07/29/2009	PPLPC028000263005	PPLPC028000263012
PUR4601	5/20/2011	Purdue Presentation: Corporate Compliance Quarterly Report to Board of Directors 1Q2011	PPLPC028000356536	PPLPC028000356536
PUR4602	10/4/2011	Email from Jack Crowley to Leonard Levin (DEA) re: list of slow pharmacies for DEA	PPLPC028000382394	PPLPC028000382395
PUR4603	1/1/2010	"Everything You Should Know About Rx medicine storage and disposal" Brochure	PPLPC028000388911	PPLPC028000388912
PUR4604	10/13/2014	Board Presentation: 2015 OxyContin Brand Budget Review	PPLPC028000579956	PPLPC028000579956
PUR4605	12/18/2000	Message from Jim Lang to Entire Field Force re OxyContin Package Insert and the Abuse/Diversion Issue	PPLPC029000030978	PPLPC029000030980
PUR4606	8/24/2001	Single Convention on Narcotic Drugs, 1961, As amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961	PPLPC029000057905	PPLPC029000057938
PUR4607	4/1/2002	Purdue promotional document for OxyContin: "IT TAKES JUST TWO Q12H OXYCONTIN®. EFFECTIVE RELIEF, JUST TWO DOSES PER DAY; IT WORKS"	PPLPC029000065200	PPLPC029000065203
PUR4608	5/9/2002	FDA Anesthetic & Life Support Drugs Advisory Committee Minutes - January 30 & 31, 2002	PPLPC029000069798	PPLPC029000069805
PUR4609	2/25/2003	OxyContin Tablets: State of the Brand- January 2003	PPLPC029000086408	PPLPC029000086426
PUR4610	3/18/2003	State of the Brand 2002-Finance Presentation	PPLPC029000087976	PPLPC029000087976
PUR4611	6/15/2010	Email from Marty Nealey to David Lundie re: DEA Inspection of Wilson Site - 15 Jun 2010	PPLPC0290000337960	PPLPC0290000337960
PUR4612	2/3/2011	Purdue Presentation: Corporate Compliance Quarterly Report to Board of Directors 4Q10-February 3, 2011	PPLPC029000428200	PPLPC029000428200
PUR4613	1/1/2015	Presentation: 2015 Net Sales Budget	PPLPC029000621344	PPLPC029000621344
PUR4614	3/28/2016	Email from Purdue to Healthcare Professional re: CDC: Guidelines for Prescribing Opioids for Chronic Pain	PPLPC029000660940	PPLPC029000660940
PUR4615	7/25/2016	Purdue HCP Services Letter re: RxREACTS Team	PPLPC029000668571	PPLPC029000668572
PUR4616	7/6/2017	Email from Eric Brantley to Steven Projansky re: due diligence on increased volume	PPLPC029000682863	PPLPC029000682866
PUR4617	12/15/2008	Email from Kendra Prince to Barry Chudakoff re: LELE programs at Medical Mutual of Ohio	PPLPC030000000506	PPLPC030000000506
PUR4618	7/18/2008	Email from Kendra Prince to Barry Chudakoff re MM of Ohio LELE Program	PPLPC030000000801	PPLPC030000000801
PUR4619	4/16/2013	FDA News Release - FDA approves abuse-deterrent labeling for reformulated OxyContin	PPLPC030000175995	PPLPC030000175996
PUR4620	5/20/2004	1970 Controlled Substances ACT - Public Law 91-513 - Oct. 27, 1970	PPLPC030000189951	PPLPC030000189955
PUR4621	6/5/2006	Drug Information Association Presentation: PRISMAP: A risk Management Program for Drugs with Abuse Potential	PPLPC030000237277	PPLPC030000237277

PUR4622	3/21/2008	RESPONSE TO FDA on PRISMAP INTERVENTIONS 2007-2008	PPLPC030000245940	PPLPC030000245943
PUR4623	2/28/2006	Purdue PRISMAP (Purdue Risk Information Synthesis & Minimization Action Program) Description	PPLPC030000251839	PPLPC030000251841
PUR4624	5/26/2005	Final Act Of The United Nations Conference For The Adoption Of A Single Convention On Narcotic Drugs	PPLPC030000254326	PPLPC030000254369
PUR4625	5/20/2002	Email from Michael Brock to Mary Kaysen regarding PMP model legislation	PPLPC030000308226	PPLPC030000308226
PUR4626	5/20/2002	Draft Model Prescription Monitoring Act December 2001	PPLPC030000308227	PPLPC030000308231
PUR4627	5/20/2002	Purdue Policy Statement: Attributes of a Model State PMP	PPLPC030000308232	PPLPC030000308235
PUR4628	5/20/2002	Tennessee House Bill 2450 - An Act to Amend Tennessee Code Annotated, Title 53, Chapter 10, relative to controlled substances and to enact the "Controlled Substance Monitoring Act of 2001"	PPLPC030000308236	PPLPC030000308245
PUR4629	5/20/2002	West Virginia PMP Senate Bill	PPLPC030000308247	PPLPC030000308247
PUR4630	12/20/2002	Purdue Presentation: Oxycontin Tablets-State of the Brand 2002	PPLPC030000315938	PPLPC030000315938
PUR4631	1/26/2004	Executive Summary for January 2004 - Ohio Rx Patrol discussion	PPLPC030000335862	PPLPC030000335863
PUR4632	6/24/2004	National Outreach Information - January 2002 to June 24, 2004	PPLPC030000344615	PPLPC030000344615
PUR4633	6/24/2004	Excel Spreadsheet: Law Enforcement Activity Summary-2004	PPLPC030000344618	PPLPC030000344618
PUR4635	6/27/2007	Email from Edward Mahony to John Stewart regarding Exec Audit Committee Meeting Minutes and Updated Presentations - June 20th Meeting	PPLPC030000397958	PPLPC030000397961
PUR4637	10/20/2009	Purdue Presentation: 2010 Budget-OxyContin Tablets P&L Review	PPLPC030000495885	PPLPC030000495885
PUR4638	2/8/2011	Memo from Janet Koch to Entire Sales Force re: Responding to Healthcare Professionals Questions Regarding the FDA Announcement on Acetaminophen (APAP) in Rx Combination Products	PPLPC030000615567	PPLPC030000615568
PUR4639	4/10/2013	Purdue Presentation: Quarterly Compliance Report to the Board of Directors 1Q2013	PPLPC030000759764	PPLPC030000759764
PUR4640	1/16/2014	Quarterly Compliance Report to the Board of Directors for 4Q2013	PPLPC030000819576	PPLPC030000819576
PUR4641	4/8/2014	Paul Coplan Presentation: Patterns of Heroin Abuse	PPLPC030000842436	PPLPC030000842436
PUR4642	1/16/2015	Quarterly Compliance Report to Board of Directors 4Q2014	PPLPC030000905983	PPLPC030000905983
PUR4643	5/17/2016	Sales Training Bulletin re Important Reminders on Promotional Messaging Issues	PPLPC030000970497	PPLPC030000970500
PUR4644	3/11/2003	Highlights of Purdue Pharma's Initiatives to Combat Abuse and Diversion of OxyContin	PPLPC030000981278	PPLPC030000981309
PUR4645	5/11/2010	Email from Robyn Miller to Jane Petty re: Pharmco Pharmacy - Potential No-Call	PPLPC031000046777	PPLPC031000046777
PUR4646	4/3/2000	Email from Ora-Anne Jarvis to Dr. J. David Haddox re: Update on Maine	PPLPC031000049684	PPLPC031000049685
PUR4647	3/20/2001	Letter from Howard Udell to Alan Slobodin and Christopher Knauer (Committee on Energy and Commerce) re Measures to alleviate diversion from Mexico	PPLPC031000058287	PPLPC031000058290
PUR4648	12/27/2001	Email from Bea Gonzalez to Alan Must regarding Draft of Model PMP legislation	PPLPC031000081186	PPLPC031000081186
PUR4650	10/9/2001	Purdue Pharma-Health Policy Position Statement: Attributes of a Model State Prescription Monitoring Program	PPLPC031000107790	PPLPC031000107793
PUR4651	12/17/2002	Letter from NADDI re Purdue Grant that supported the production of a NADDI brochure	PPLPC031000117053	PPLPC031000117054
PUR4652	2/5/2004	Email from Burt Rosen to Rodney Whitlock re Ohio PMP	PPLPC031000172852	PPLPC031000172852
PUR4653	2/5/2004	Ohio PMP Bill	PPLPC031000172853	PPLPC031000172861
PUR4654	2/20/2004	State Government Affairs Executive Summary - PMP Program in Ohio	PPLPC031000175540	PPLPC031000175541
PUR4655	2/25/2004	Email from Alan Must to Linda Barefoot re Ohio PMP Bill	PPLPC031000176241	PPLPC031000176242
PUR4657	5/25/2004	Appendix C: Purdue Initiatives to reduce abuse and diversion of OxyContin	PPLPC031000194397	PPLPC031000194402
PUR4658	2/11/2005	Email from Jack Crowley to Jaime Cepero re: Request for U/C Assistance	PPLPC031000226577	PPLPC031000226578
PUR4659	1/1/2001	DEA-Industry Communicator OxyContin Special - Article by John Burke, Commander, Warren County, Ohio Drug Task Force - "OxyContin - A Sense of Balance"	PPLPC031000252085	PPLPC031000252087
PUR4660	6/30/2005	FDA RADARS Update	PPLPC031000254834	PPLPC031000254886
PUR4661	1/10/2006	Media Advisory - Local Police Learn New Ways to Combat Prescription Drug Abuse - Drug Diversion Experts Visit Ohio to Educate Local Law Enforcement	PPLPC031000284445	PPLPC031000284445
PUR4662	2/5/2008	Email from Robin Abrams to Johanna Clifford RE: Status Update	PPLPC031000415171	PPLPC031000415172
PUR4663	3/26/2008	Email from Jack Crowley to Mark Caverly (DEA) regarding status report update	PPLPC031000426610	PPLPC031000426618
PUR4664	4/9/2010	Email from Jack Crowley to Mark Caverly re: Reformulation of OxyContin	PPLPC031000610400	PPLPC031000610401
PUR4665	4/5/2011	Email from Jack Crowley to DEA regarding Congresswoman Bono Mack Announces introduction of legislation	PPLPC031000764199	PPLPC031000764203
PUR4666	7/26/2011	Email from Jack Crowley to John Kushnir re: Butrans Transdermal System	PPLPC031000808773	PPLPC031000808774
PUR4667	7/26/2011	Butrans (buprenorphine) Transdermal System CIII prescribing information	PPLPC031000808775	PPLPC031000808777
PUR4668	6/4/2012	Email from John Gilbride to DEA regarding OxyContin for use in undercover investigations	PPLPC031000934246	PPLPC031000934247
PUR4669	1/6/2014	Purdue Slides - HealthCare Law Compliance Policies Training	PPLPC031001132990	PPLPC031001133061
PUR4670	1/1/2013	OSU - Phase III Agreement	PPLPC031001239940	PPLPC031001239956
PUR4671	1/1/2013	OSU - Phase III Agreement - Amendment to the January 1, 2013 Agreement	PPLPC031001239957	PPLPC031001239961
PUR4672	12/8/2016	MR-00801 - OXC-Conversion and Titration Guide-Digital	PPLPC031001488727	PPLPC031001488754
PUR4673	4/2/2009	GC-SOP -0007 Order Management System 3/2009	PPLPC031001491482	PPLPC031001491487
PUR4674	10/17/2017	Purdue: 2017 Healthcare Law Compliance Policies	PPLPC031001543771	PPLPC031001543792
PUR4675	4/24/2001	Overview of the Ohio Attorney General Meeting.	PPLPC032000012455	PPLPC032000012456
PUR4676	1/25/2002	OxyContin Patient Information	PPLPC032000018131	PPLPC032000018132
PUR4677	10/20/2003	Transcript of FDA Advisory Committee Meeting - 9.10.2003 Anesthetic and Life Support Drugs Advisory Committee	PPLPC032000022354	PPLPC032000022674
PUR4678	4/1/2003	SOP 066 (Standard Operating Policies) for Convention Planning: Selection of Conventions by Brand. (December 1, 2005)	PPLPC032000040358	PPLPC032000040374

PUR4679	4/1/2003	SOP 067 (Standard Operating Policies) Convention Planning: Marketing Attendance at Conventions	PPLPC032000040375	PPLPC032000040390
PUR4680	4/12/2007	Email from Wendy Goldstein (Epstein Becker & Green, P.C.) to Office of Inspector General (U.S. Health & Human Services) re draft of Purdue Pharma's proposed CIA.	PPLPC032000057073	PPLPC032000057074
PUR4681	2/1/2008	Purdue Pharma Guidelines in Product Promotion 2008 - Sales Training	PPLPC032000076505	PPLPC032000076505
PUR4682	6/12/2008	Final Report prepared for Lisa Miller, PharmD/ Purdue Pharma by Indicia (Medical Education, LLC) regarding evaluation of grant policies.	PPLPC032000084378	PPLPC032000084407
PUR4683	8/4/2008	Purdue Standard Operating Procedure: Retention of Healthcare Professionals as Consultants, Advisors and Speakers	PPLPC032000087198	PPLPC032000087208
PUR4684	3/2/2009	Sales Training and Development Bulletin re Knowing the Important Compliance Concepts	PPLPC032000097626	PPLPC032000097627
PUR4687	8/11/2010	Email from Jeff Cohen to Jack Crowley, et al. re: Totowa DEA Inspection Summary for 8/10 - 8/11/2010	PPLPC032000150052	PPLPC032000150053
PUR4688	10/13/2014	Purdue Presentation - "Office of the Inspector General On-Site Visit at Purdue"	PPLPC032000157753	PPLPC032000157753
PUR4689	11/8/2011	Communication and External Affairs Committee (CEAC) Agenda, November 8, 2011	PPLPC032000219016	PPLPC032000219020
PUR4690	7/2/2012	Sales and Marketing Compliance Committee Meeting Minutes	PPLPC032000238670	PPLPC032000238672
PUR4691	4/1/2011	Purdue Healthcare Law Compliance Policies Booklet.	PPLPC032000249866	PPLPC032000249904
PUR4692	12/6/2013	Sales and Marketing Compliance Committee, Meeting Agenda Items for Dec. 6, 2013.	PPLPC032000282831	PPLPC032000282834
PUR4693	1/24/2014	Standard Operating Procedures for all Sales Force Personnel	PPLPC032000286557	PPLPC032000286602
PUR4694	2/10/2014	Sales and Marketing Compliance Committee Meeting Minutes 2/10/14	PPLPC032000288261	PPLPC032000288263
PUR4695	9/19/2014	Sales and Marketing Compliance Committee Minutes 9/19/14	PPLPC032000330356	PPLPC032000330357
PUR4696	2/4/2015	Sales and Marketing Compliance Committee Meeting Minutes 2/4/15	PPLPC032000341191	PPLPC032000341193
PUR4697	8/20/2015	Quarterly Compliance Report to the Board 8/20/2015	PPLPC032000358636	PPLPC032000358636
PUR4698	8/19/2015	Assurance of Discontinuance - Executed Agreement between the Attorney General of the State of New York and Purdue Pharma L.P.	PPLPC032000362671	PPLPC032000362694
PUR4699	11/21/2016	RxREACTS Standard Operating Procedures Manual	PPLPC032000394070	PPLPC032000394087
PUR4700	11/1/2007	Revised Standard Operating Procedures for Sales Force	PPLPC032000395217	PPLPC032000395238
PUR4701	2/1/2017	OxyContin Core Visual Aid	PPLPC032000397039	PPLPC032000397048
PUR4702	4/26/2017	Sales and Marketing Compliance Committee Meeting Minutes	PPLPC032000398071	PPLPC032000398073
PUR4703	7/9/2008	Email from Aileen Barcia regarding Valley Wholesale, Stockton California--Suspicious Order Process	PPLPC03300001915	PPLPC03300001921
PUR4704	2/24/2010	OMS Meeting Agenda	PPLPC03300003445	PPLPC03300003451
PUR4705	9/26/2002	DEA Event Log - Questions/ Concerns and Notes from Brief Session(s) with DEA	PPLPC034000110197	PPLPC034000110197
PUR4706	8/27/2004	DEA Contact re: Controlled Substances Reconciliation - Acceptance of Offer to visit PF Labs	PPLPC034000114803	PPLPC034000114805
PUR4707	11/8/2006	Email from Jack Crowley to DEA regarding physician of concern	PPLPC034000146419	PPLPC034000146420
PUR4708	5/20/2003	Purdue Press release regarding appointment of Jack Crowley to oversee compliance for handling of controlled substances	PPLPC034000146422	PPLPC034000146422
PUR4709	1/16/2008	Email from Jack Crowley to DEA regarding Request for meeting	PPLPC034000212944	PPLPC034000212949
PUR4710	1/16/2008	Email from Jack Crowley to DEA regarding request for a meeting	PPLPC034000213194	PPLPC034000213199
PUR4711	1/17/2008	Agenda for the Meeting between the Drug Enforcement Administration & Purdue Pharma L.P.	PPLPC034000213200	PPLPC034000213201
PUR4712	9/28/2008	Email from Jack Crowley to DEA regarding Follow Up to Pain Care Forum	PPLPC034000271539	PPLPC034000271541
PUR4713	11/7/2008	Email from Jack Crowley to DEA regarding regarding Meeting with DEA	PPLPC034000277020	PPLPC034000277025
PUR4714	1/16/2009	Email from Jack Crowley to DEA regarding 1st installment	PPLPC034000287120	PPLPC034000287120
PUR4715	1/16/2009	Purdue Wilson site facility background for DEA report	PPLPC034000287121	PPLPC034000287123
PUR4716	4/16/2009	Email from Jack Crowley to DEA regarding bottle tracking	PPLPC034000299587	PPLPC034000299588
PUR4717	4/15/2009	Purdue Bottle Tracking Letter and Agreement	PPLPC034000299589	PPLPC034000299592
PUR4718	4/17/2009	Email from Jack Crowley to DEA re: quick meeting with DEA Office of Chief Counsel	PPLPC034000299601	PPLPC034000299603
PUR4720	5/22/2009	Email from DEA regarding product development	PPLPC034000304661	PPLPC034000304663
PUR4721	7/21/2009	Email from Jack Crowley to DEA regarding rebate coupons	PPLPC034000313398	PPLPC034000313402
PUR4722	4/5/2010	Email from Jack Crowley to James Gardner re: FW: DEA Inspection - Day 11	PPLPC034000376383	PPLPC034000376383
PUR4723	8/12/2010	Email from Jack Crowley to Beth Evans re: RE: DEA Visit to Wilson	PPLPC034000440926	PPLPC034000440927
PUR4724	8/18/2010	Report to OMS Team	PPLPC034000442009	PPLPC034000442011
PUR4725	12/15/2010	Robin Abrams Bottle Tracking Program Presentation to DOJ	PPLPC034000479792	PPLPC034000479792
PUR4727	5/3/2011	Email from Richard Widup to DEA regarding ENOM listing	PPLPC034000536007	PPLPC034000536007
PUR4728	5/3/2011	Websites Enforced 2010	PPLPC034000536008	PPLPC034000536008
PUR4729	9/22/2011	OxyContin Reformulation Update Teleconference scheduled with DEA and Jack Crowley	PPLPC034000581163	PPLPC034000581163
PUR4730	9/22/2011	Email between Jack Crowley and DEA regarding conference follow-up/scheduling next conference	PPLPC034000582162	PPLPC034000582166
PUR4731	10/7/2011	Email from Jack Crowley to DEA regarding slow pharmacies	PPLPC034000587170	PPLPC034000587170
PUR4732	7/26/2012	Email from Jack Crowley to DEA regarding Follow up to Purdue-DEA Meeting last December	PPLPC034000694469	PPLPC034000694472
PUR4733	7/26/2012	Theresa Cassidy, et al: Change in routes of administration for OxyContin and comparators following introduction of reformulated OxyContin among individuals assessed for substance abuse	PPLPC034000694473	PPLPC034000694473
PUR4734	7/26/2012	H. Chilcoat, et al: Impact of reformulated OxyContin on rates of abuse through oral and non-oral routes among individuals assessed in substance abuse treatment	PPLPC034000694474	PPLPC034000694474

PUR4735	7/26/2012	Paul Coplan, et al; National Changes in OxyContin, other Oxycodone, and Heroin Exposures Reported to Poison Centers with Introduction of Reformulated OxyContin	PPLPC034000694475	PPLPC034000694475
PUR4736	7/26/2012	S.G. Severtson, et al., Reduction in Oxycontin diversion cases following the introduction of reformulated OxyContin	PPLPC034000694476	PPLPC034000694476
PUR4737	7/26/2012	A. DeVeaugh-Geiss, et al: Routes of administration and frequency of abuse of OxyContin and immediate-release oxycodone in rural Kentucky county following introduction of reformulated OxyContin	PPLPC034000694477	PPLPC034000694477
PUR4738	7/26/2012	Anne Kiline, et al; Sources of opioids for nonmedical use by frequency of use in the NSDUH survey	PPLPC034000694478	PPLPC034000694478
PUR4739	7/26/2012	E. Cone, et al; In Vitro tamper testing of reformulated OxyContin: An iterative and incremental scientific approach	PPLPC034000694479	PPLPC034000694479
PUR4740	7/26/2012	Harris, Stephen et al., Effects of various tampering methods on exposure to oxycodone in healthy subjects	PPLPC034000694480	PPLPC034000694480
PUR4741	7/26/2012	Salvatore Colucci, et al: Evaluation of abuse potential of crushed and intranasally administered oxycodone tablets.	PPLPC034000694481	PPLPC034000694481
PUR4742	7/26/2012	Sellers, et al., Relative Attractiveness of reformulated OxyContin: comparative assessment of tampering potential and recreational drug user preferences for opioid formulations	PPLPC034000694482	PPLPC034000694482
PUR4743	7/26/2012	Peter Perrino, et al: Safety, tolerability, and pharmacokinetics of crushed intranasal oxycodone tamper resistant tablets and OxyContin in healthy adults.	PPLPC034000694483	PPLPC034000694483
PUR4744	10/11/2012	Presentation: What is the Bottle Tracking Program	PPLPC034000716593	PPLPC034000716593
PUR4745	4/29/2015	Purdue Presentation: Reformulated-OxyContin and Observations on Deterrence of Abuse and Misuse in the Community Setting	PPLPC034001055368	PPLPC034001055368
PUR4746	5/5/2014	Time Line on OMS Meetings/Discussions with McKesson	PPLPC034001107191	PPLPC034001107197
PUR4747	12/1/2011	Email from Robin Abrams to Michael J. Lewis (DEA) regarding Pharmacies and Prescribers Reported to DEA located in California	PPLPC034001143161	PPLPC034001143162
PUR4748	6/4/2018	Email from John Gilbride to DEA regarding Suspicious Order by Value Drug	PPLPC034001170493	PPLPC034001170516
PUR4749	6/19/2003	SOP 7.7: System to Disclose Suspicious Orders of Controlled Substances	PPLPC035000019501	PPLPC035000019503
PUR4751	9/12/2007	Purdue Sales Representative Standards of Performance	PPLPC035000057537	PPLPC035000057545
PUR4752	10/3/2013	Law Enforcement Journal-Free Professional Educational Programs Presented by Experienced Officers:Forged and Altered Prescriptions	PPLPC035000199025	PPLPC035000199025
PUR4753	4/18/2014	Presentation: Bottle Tracking Program	PPLPC035000216998	PPLPC035000216998
PUR4754	9/9/2008	FDA response to CT AG Citizen Petition	PPLPC035000255394	PPLPC035000255411
PUR4755	6/28/2016	Purdue SOP 7.19: Order Processing - OTC, Controlled III - V and Non-controlled Prescription Products	PPLPC035000265454	PPLPC035000265470
PUR4756	6/29/2016	SOP 7.8 Controlled Substance II Order Processing	PPLPC035000265471	PPLPC035000265489
PUR4757	3/12/2013	Finance and Accounting SOP Manual - System to Disclose Suspicious Orders of Controlled Substances	PPLPC035000265492	PPLPC035000265495
PUR4758	9/9/2003	Message from Michael Friedman to all Purdue US Colleagues.	PPLPC036000025806	PPLPC036000025808
PUR4759	11/15/2004	Marketing Tips No. 267 - "Revolutionary New Enhancements to Supply Chain Security - Part One Anti-Counterfeit Labels"	PPLPC036000043449	PPLPC036000043450
PUR4760	10/3/2005	Email from David Lundie to Fred Sexton re: FW: Totowa DEA Inspection Day 1	PPLPC036000062730	PPLPC036000062731
PUR4761	10/8/2005	Email from Bruce King to David Lundie, et al., re: FW: DEA Inspection Update Day 4	PPLPC036000062888	PPLPC036000062889
PUR4762	10/20/2005	Email from Bruce King to David Lundie, et al., re: FW: DEA Inspection Update - Day 8	PPLPC036000063085	PPLPC036000063086
PUR4763	10/24/2005	Email from Bruce King to David Lundie, et al., re: FW: DEA Inspection - Day 9	PPLPC036000063141	PPLPC036000063142
PUR4764	10/27/2005	Email from Bruce King to David Lundie, et al., re: FW: DEA Inspection Update Day 13	PPLPC036000063173	PPLPC036000063173
PUR4765	11/3/2005	Email from Bruce King to David Lundie re: FW: DEA Inspection Update - Day 15	PPLPC036000063377	PPLPC036000063378
PUR4766	9/1/2010	FDA REMS - Summary Minutes of the Joint Meeting of the ALSDAC and DSaRM, July 22-23, 2010	PPLPC036000159925	PPLPC036000159934
PUR4767	7/22/2010	IWG Presentation - "Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long Acting Opioid Products"	PPLPC036000159935	PPLPC036000159980
PUR4768	8/25/2018	List of Purdue Actions Taken	PPLPC036000283670	PPLPC036000283678
PUR4769	8/6/2014	OxyContin Tablets 2015 Business Plan	PPLPC037000174637	PPLPC037000174637
PUR4770	8/27/2014	Product Promotional Guideline: Butrans (buprenorphine) Transdermal System	PPLPC037000205100	PPLPC037000205156
PUR4771	3/1/2001	Letter from the State of Kentucky Medical Examiner's Office to Purdue Pharma RE: Autopsy Reports	PPLPC039000021034	PPLPC039000021034
PUR4772	6/4/2003	OxyContin Visual Aid	PPLPC039000061717	PPLPC039000061726
PUR4773	1/27/2004	OxyContin Tablets State of the Brand-3rd quarter 2003	PPLPC039000079921	PPLPC039000079941
PUR4776	2/28/2008	OxyContin Visual Aid	PPLPC039000275048	PPLPC039000275067
PUR4777	12/29/2009	Purdue Presentation: Reporting Adverse Events and Product Complaints	PPLPC041000009595	PPLPC041000009619
PUR4778	3/17/2008	Drug Distribution Service Agreement between Purdue Pharma and Anda Inc., with Exhibits.	PPLPC041000009978	PPLPC041000009999
PUR4779	7/21/2010	Robin E. Abrams Presentation: The Order Monitoring System ("OMS Program")	PPLPC041000011499	PPLPC041000011499
PUR4780	3/20/2013	GC-SOP-0001.06: Retention of HCPs for Purposes of Consulting, Advising, Speaking, Authorship and Market Research.	PPLPC041000030395	PPLPC041000030409
PUR4781	5/1/2015	2015 Sales SOPs, revised set	PPLPC041000042259	PPLPC041000042306
PUR4782	3/27/2001	Email from Michael Friedman to Udell et al RE: DEA	PPLPC04200002682	PPLPC04200002685
PUR4783	1/6/2011	OMS Meeting Minutes	PPLPC044000029683	PPLPC044000029685
PUR4784	3/10/2011	OMS Meeting Minutes	PPLPC044000030619	PPLPC044000030624

PUR4785	8/13/2004	Booklet published by DEA in partnership with Last Acts Partnership and Pain & Policy Studies Group, titled "Prescription Pain Medications: Frequently Asked Questions and Answers for Health Care Professionals and Law Enforcement Personnel"	PPLPC045000010341	PPLPC045000010358
PUR4786	10/19/2005	PowerPoint - The RADARS System: 2004 Overview by J. David Haddox	PPLPC045000011829	PPLPC045000011829
PUR4787	10/28/2010	OMS Report	PPLPC046000029830	PPLPC046000029831
PUR4788	9/10/2013	Letter from Jane Woodcock to Andrew Kolodny.	PPLPC046000054911	PPLPC046000054928
PUR4789	4/29/2013	Analysis Group, Inc.: Prescription opioid abuse and the societal impact of abuse-deterring formulations in Ohio	PPLPC047000026902	PPLPC047000026920
PUR4790	7/1/2004	Email from Howard Udell to Patti Hoffman, et al., RE: Meeting With Purdue	PPLPC049000011152	PPLPC049000011153
PUR4791	7/1/2004	Biographies for Attendees at Meeting	PPLPC049000011154	PPLPC049000011157
PUR4792	4/30/2009	Email from Jack Crowley to John Kushnir	PPLPC049000026366	PPLPC049000026368
PUR4793	10/4/2011	Email from Robin Abrams to Leonard Levin and Barbara Boockholdt.	PPLPC049000058207	PPLPC049000058207
PUR4794	10/4/2011	Copy of List of Slow Pharmacies for DEA Conference Call	PPLPC049000058208	PPLPC049000058208
PUR4795	12/1/2011	Email from Robin Abrams to Michael Lewis, RE: Pharmacies and Prescribers Reported to DEA located in California	PPLPC049000059813	PPLPC049000059814
PUR4796	4/22/2013	Email from Jack Crowley to John Kushnir regarding letter concerning discontinuation of 160 mg OxyContin tablets	PPLPC049000073348	PPLPC049000073348
PUR4797	5/11/2001	Purdue Statement Regarding Suspension of 160 mg OxyContin Tablets	PPLPC049000073349	PPLPC049000073349
PUR4798	11/1/2000	Email from James Lang to Joseph DaBronzo.	PPLPC05100001693	PPLPC05100001695
PUR4799	4/24/2001	Presentation: Action Plan to Help Reduce Abuse and Diversion of Opioid Analgesics in Ohio.	PPLPC05100002315	PPLPC05100002315
PUR4801	4/5/2007	Placebo Tablets	PPLPC051000039422	PPLPC051000039422
PUR4802	4/5/2007	Purdue Pharma Presentation: The RADARS System	PPLPC051000039424	PPLPC051000039425
PUR4803	4/5/2007	Anti Diversion Brochures	PPLPC051000039427	PPLPC051000039427
PUR4804	4/5/2007	Purdue Pharma Publication: RxPatrol	PPLPC051000039431	PPLPC051000039432
PUR4805	4/5/2007	Purdue Pharma Presentation: Reporting Suspicious Prescribers	PPLPC051000039440	PPLPC051000039441
PUR4828	6/14/2007	PowerPoint - Field Sales Standard Operating Procedures	PPLPC051000045312	PPLPC051000045312
PUR4829	5/8/2007	Stipulation for Entry of Judgment	PPLPC051000050278	PPLPC051000050313
PUR4830	12/29/2007	Letter from FBI- LEEDA to J. Aaron Graham	PPLPC051000052927	PPLPC051000052928
PUR4831	9/11/2007	Purdue Standard Operating Procedure--Retention of Healthcare Professionals as Consultants, Advisors and Speakers	PPLPC051000054972	PPLPC051000054986
PUR4832	1/7/2009	Statement of Work #1: Monitoring Methodology for Diversion, Abuse and Misconduct for Purdue Pharma, LP	PPLPC051000067672	PPLPC051000067676
PUR4833	1/22/2009	Reportable Events Committee Meeting Minutes	PPLPC051000068160	PPLPC051000068160
PUR4834	4/2/2009	Email from Jack Crowley to Michael Smilek	PPLPC051000071650	PPLPC051000071651
PUR4835	2/12/2009	Report by William Callan, Feb 12, 2009 - In Depth Investigation of a Sched II Manufacturer, Purdue	PPLPC051000071652	PPLPC051000071698
PUR4837	4/2/2009	Amount (KG) of OxyContin dispensed (WIP inventory)	PPLPC051000071700	PPLPC051000071700
PUR4838	2/12/2009	Purdue Pharma Closing Conference Outline	PPLPC051000071701	PPLPC051000071702
PUR4839	4/2/2009	OxyContin High-Level Process Flowchart Overview	PPLPC051000071703	PPLPC051000071703
PUR4841	4/13/2009	Letter from Det. Matthew Steinbrook and Chief Harold W. Gray to Richard J. Zenuch	PPLPC051000074200	PPLPC051000074201
PUR4842	3/9/2009	Purdue Corporate Compliance Audit Report	PPLPC051000079522	PPLPC051000079530
PUR4843	7/7/2009	Purdue Standard Operating Procedure--Retention of Healthcare Professionals as Consultants, Advisors and Speakers	PPLPC051000082537	PPLPC051000082597
PUR4844	10/19/2009	Corporate Compliance Quarterly Report to Board of Directors 3Q09	PPLPC051000086711	PPLPC051000086711
PUR4845	3/30/2010	Letter from Twyla Thompson, Pharm.D and Mathilda Fienkeng, Pharm.D to Beth Connally re: NDA # 22-272, OxyContin Tablets CII	PPLPC051000088461	PPLPC051000088464
PUR4847	6/22/2010	Letter from Det. Kris Kimble and Lt. Tom Brown to Richard Zenuch	PPLPC051000092938	PPLPC051000092939
PUR4848	3/19/2010	Letter from Mathilda Fienkeng, Pharm.D. to Beth Connally	PPLPC051000096732	PPLPC051000096735
PUR4849	5/23/2007	Maine v. Purdue CONSENT JUDGMENT	PPLPC051000160686	PPLPC051000160709
PUR4850	4/20/2012	Purdue Product Promotional Guideline--OxyContin	PPLPC051000163807	PPLPC051000163845
PUR4851	1/16/2013	Presentation: Purdue- Law Enforcement Bottle Tracking Program	PPLPC051000165577	PPLPC051000165577
PUR4852	9/30/2010	OMS Meeting Minutes	PPLPC051000178353	PPLPC051000178358
PUR4853	9/10/2013	Letter from Janet Woodcock (FDA) to Andrew Kolodny (PROP)	PPLPC051000249663	PPLPC051000249680
PUR4854	7/25/2012	Letter to FDA from PROP	PPLPC051000249681	PPLPC051000249688
PUR4855	1/23/2004	Petition to FDA by CT AG - re OxyContin dosing	PPLPC051000269998	PPLPC051000270056
PUR4856	6/2/2009	Email from Jack Crowley to Michael Lewis regarding Lam's Pharmacy	PPLPC051000283406	PPLPC051000283407
PUR4857	6/2/2009	Letter from F. Mark Geraci to Michael J. Lewis re summary of review of Lam's Pharmacy	PPLPC051000283409	PPLPC051000283411
PUR4858	7/22/2010	FDA CDER Joint Meeting of the ALSDAC and DSaRM transcript of Thursday meeting	PPLPC051000307903	PPLPC051000308264
PUR4859	7/23/2010	FDA CDER Joint Meeting of the ALSDAC and DSaRM transcript of Friday meeting	PPLPC051000308265	PPLPC051000308586
PUR4860	5/7/2001	PowerPoint - "Welcome to the Pilot Pro-Active Pain Management Program"	PPLPC051000308646	PPLPC051000308646
PUR4861	12/14/2016	PowerPoint - "The One Hundred County Model"	PPLPC051000308647	PPLPC051000308647
PUR4862	6/20/2003	Email from Salvatore Carino to David Haddox re Analysis of "100 Counties" Program	PPLPC051000308648	PPLPC051000308648
PUR4863	6/20/2003	Excel - Total Prescriptions for OxyContin Tablets in the 100 Counties Program Area	PPLPC051000308649	PPLPC051000308649
PUR4864	8/28/2003	OxyContin Rx's and Units in The 100 Counties Program Area	PPLPC051000308650	PPLPC051000308650
PUR4865	6/20/2003	Excel: Number of Media Reports on OxyContin Diversion Among the 100 Counties (2001-2002)	PPLPC051000308651	PPLPC051000308651
PUR4866	1/1/1998	Model Guidelines for the Use of Controlled Substances for the Treatment of Pain.	PPLPC051000319170	PPLPC051000319176
PUR4867	8/10/2001	Letter from Howard R. Udell to The Honorable Richard Blumenthal	PPLPC05300002677	PPLPC05300002678
PUR4869	9/23/2009	Email from Gina Limer to Sayee Natarajan RE: August Data	PPLPC053000036175	PPLPC053000036180

PUR4870	8/10/2010	Email from Robin Abrams to Jack Crowley et al; RE: DEA Inspection Summary for 8/10/10	PPLPC053000043158	PPLPC053000043160
PUR4871	8/16/2010	Reportable Events Committee Monthly Call Minutes	PPLPC053000043231	PPLPC053000043231
PUR4872	1/31/2011	OMS Meeting Minutes	PPLPC053000048641	PPLPC053000048645
PUR4873	4/14/2011	Emails from Jack Crowley to Gina Limer	PPLPC053000051213	PPLPC053000051217
PUR4874	12/1/2011	Email from Michael Lewis to Jack Crowley, Re: Pharmacies and Prescribers Reported to DEA located in California	PPLPC053000060143	PPLPC053000060145
PUR4875	6/7/2012	OMS Report for Food City Pharmacy	PPLPC053000066910	PPLPC053000066920
PUR4876	4/23/2012	FDA, BT Agreement	PPLPC053000083732	PPLPC053000083734
PUR4877	9/1/2015	SOP Law Department 1.7.1: Purdue Abuse and Diversion and Detection Program	PPLPC053000111796	PPLPC053000111800
PUR4878	4/12/2006	Letter from Lt. Kevin Starrett and Sheriff William Barker to Luis Bauza.	PPLPC053000113106	PPLPC053000113106
PUR4879	11/20/2008	Reportable Events Committee Meeting Minutes	PPLPC054000040955	PPLPC054000040956
PUR4880	11/29/2005	DEA Inspection at Totowa - Fall 2005 - Summary, Document Requests and What to Expect	PPLPC054000049494	PPLPC054000049507
PUR4881	5/12/2010	Reportable Events Committee Monthly Call Minutes	PPLPC054000051098	PPLPC054000051099
PUR4882	12/6/2010	OMS Meeting Minutes	PPLPC054000062907	PPLPC054000062910
PUR4883	3/5/2011	Letter from Lt. M.D. Champlin and Chief Clinton Patterson to Richard J. Zenuch	PPLPC054000065351	PPLPC054000065351
PUR4884	12/2/2013	Letter from Task Force Officer Ryan Allen and Lt. Michael Connelly to John P. Gilbride	PPLPC054000111140	PPLPC054000111141
PUR4885	1/1/2016	Sales Force Standard Operating Policies Manual	PPLPC054000128651	PPLPC054000128702
PUR4886	3/25/2005	Spreadsheet: Record of contacts with DEA in 2004	PPLPC057000005350	PPLPC057000005350
PUR4887	7/14/2015	Letter from Det. Sgt. Edwin W. Downs and Chief Deputy David Valikinburg to Luis Bauza	PPLPC057000019010	PPLPC057000019010
PUR4888	1/1/2006	Ohio Call Notes	PPLPMDL0020000001	PPLPMDL0020000001
PUR4889	12/31/2006	Ohio FCR	PPLPMDL0020000002	PPLPMDL0020000002
PUR4890	5/24/2010	Email from Joan Zooper to Charmaine Simerton et al RE: Dr. Mark Allen from Ohio	PPLPMDL0030000133	PPLPMDL0030000133
PUR4891	7/1/2014	Email from Joan Zooper to Clifford Reich et al.	PPLPMDL0030000477	PPLPMDL0030000477
PUR4892	11/9/2016	Email from Phonix-Mailer to ADD-Legal RE: Dr. Bernie, Stephen has been added to the 'No Call' List	PPLPMDL0030000850	PPLPMDL0030000850
PUR4893	6/11/2015	Email from Joan Zooper to Clifford Reich	PPLPMDL0030001151	PPLPMDL0030001151
PUR4894	11/28/2006	Email from Aileen Barcia to Barry Chudakoff, et al: re: Calvin Brown	PPLPMDL0030001298	PPLPMDL0030001299
PUR4895	1/14/2013	Email from Joan Zooper to Ashleigh Apsega et al; RE: Dr. Toni Carman from OH	PPLPMDL0030001709	PPLPMDL0030001709
PUR4896	4/7/2016	Email from Phoenix-Mailer to ADD-Legal et al.; RE should not call on Ron Celeste	PPLPMDL0030001813	PPLPMDL0030001813
PUR4897	5/10/2012	Email from Joan Zooper to Charmaine Simerton, et al re: Dr. Thomas Craig from OH.	PPLPMDL0030001884	PPLPMDL0030001884
PUR4898	3/27/2014	Akron Doctor and His Employees Indicted for Prescribing Hundreds of Thousands of Doses of Painkillers, U.S. Department of Justice	PPLPMDL0030005318	PPLPMDL0030005320
PUR4900	5/8/2012	Email from Joan Zooper to Janet Jimenez	PPLPMDL0030005322	PPLPMDL0030005324
PUR4902	5/11/2018	Dr. Adolph Harper ADD file	PPLPMDL0030005326	PPLPMDL0030005326
PUR4903	11/17/2005	Email from Donna Bartolo to Barry Chudakoff et al: RE: Dr. Adolph Harper	PPLPMDL0030005327	PPLPMDL0030005327
PUR4904	9/19/2005	Sales Force in Akron OH	PPLPMDL0030005328	PPLPMDL0030005328
PUR4905	5/11/2018	Dr. Adolph Harper OxyContin Scripts	PPLPMDL0030005329	PPLPMDL0030005333
PUR4906	9/14/2005	Call history for Dr. Adolph Harper	PPLPMDL0030005334	PPLPMDL0030005340
PUR4907	9/15/2005	Physician Details Dr. Adolph Harper	PPLPMDL0030005341	PPLPMDL0030005341
PUR4908	9/15/2005	Dr. Adolph Harper Ohio License Center	PPLPMDL0030005342	PPLPMDL0030005343
PUR4909	3/7/2013	Email from Joan Zooper to Barry Chudakoff	PPLPMDL0030005410	PPLPMDL0030005410
PUR4910	10/8/2015	Email from ADD-Legal to Katherine Laraway, re ceasing to call Dr. Juan Hernandez o Parma, OH	PPLPMDL0030005597	PPLPMDL0030005597
PUR4911	1/25/2010	Email from Jean Zooper to Christopher Roberts et al; re: instruction to cease calls on Dr. William Kerek	PPLPMDL0030006995	PPLPMDL0030006995
PUR4912	11/12/2008	Email from Joan Zooper to Brain Backiewicz, et al re: ceasing to call Drs. Kevin Lake; Terry Dragash; Patrick McGriff; and Phillip North d/b/a Columbus Southern Medical Center in Ohio	PPLPMDL0030007410	PPLPMDL0030007410
PUR4913	3/1/2004	Email from Aileen Evancho to Raji Subbarayan et al; RE: Dr. Lundeen	PPLPMDL0030007936	PPLPMDL0030007936
PUR4914	4/23/2003	Letter from Robin E. Abrams, Esq to Special Agent Boyle FBI	PPLPMDL0030008227	PPLPMDL0030008227
PUR4915	5/24/2016	Email from Phoenix-Mailer to ADD-Legal et al; RE: Dr. Rath, David	PPLPMDL0030010208	PPLPMDL0030010208
PUR4916	10/16/2008	Email from Gina Limer to Joan Zooper	PPLPMDL0030012894	PPLPMDL0030012898
PUR4917	3/1/1994	Typewritten Notes: Ohio Call Notes 1994-2005	PPLPMDL0080000001	PPLPMDL0080000001
PUR4921	11/5/2013	Order of the Ohio State Board of Pharmacy, In the Matter of Charles R. Wilson (pp. 224)	OBPM_MDL_000000092.0025	OBPM_MDL_000000092.0025
PUR4922	8/21/1990	Order of the Ohio State Board of Pharmacy, In the Matter of Dennis L. Carey	Ohio BOP 00001006	Ohio BOP 00001020
PUR4932	8/8/2005	Settlement Agreement with the State Board of Pharmacy, Right Aid Discount Pharmacies #'s 3086, 3088, 1186, 1659, 2304 (c/o Karen Mankowski) (produced document)	BOP_MDL 1st Production_011252	BOP_MDL 1st Production_011256
PUR4948	6/1/2008	Werz, "Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release," Therapeutics and Clinical Risk Management 4(5) 1035-1046, 1035	PUREX00062919	PUREX00062930
PUR4949	6/1/2012	Doogue & Polasek, "The ABCD of clinical pharmacokinetics," Therapeutic Advances in Drug Safety 4(1):5-7, 5	PUREX00062916	PUREX00062918
PUR4950	1/1/1992	William H. Oldendorf, Some Relationships Between Addiction and Drug Delivery to the Brain, National Institute on Drug Abuse Research Monograph Series (p.18).	PUREX00000073	PUREX00000344

PUR4951	11/13/1992	Harriet de Wit et al., Subjective and behavioral effects of diazepam depend on its rate of onset, Psychopharmacology 112, 324 (1993) (publicly available document)	PUREX00062902	PUREX00062908
PUR4952	8/30/1991	Harriet de Wit et al., Rate of increase of plasma drug level influences subjective response in humans, Psychopharmacology 107, 352 (1991)	PUREX00062909	PUREX00062915
PUR4955	5/9/2017	Collection of FDA Forms 2253 Submissions for OxyContin Tablets under NDA 20-553 and NDA 022272	PUREX00000413	PUREX00000418
PUR4957	1/28/2016	Daniel P. Alford Opioid Prescribing for Chronic Pain — Achieving the Right Balance through Education, , NEJM 374;4 nejm.org January 28, 2016	PPLPC011000136365	PPLPC011000136367
PUR4958	4/1/2014	Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014 Mar-Apr;17(2):E119-28.	PPLPC046000070709	PPLPC046000070718
PUR4960	12/1/2007	Edlund MJ et al. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med. 2007 Nov-Dec;8(8):647-56.	PPLP003984490	PPLP003984499
PUR4962	11/21/2016	Krashin D et al, Challenges to Treatment of Chronic Pain and Addiction During the "Opioid Crisis". Curr Pain Headache Rep. 2016 Dec;20(12):65.	PUREX00071695	PUREX71697
PUR5012	8/1/2019	Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H 54)	PUREX00058446	PUREX00058527
PUR5013	5/18/2009	Noble, M, et al., Long-term opioid management for chronic noncancer pain (Review), The Cochrane Collaboration, The Cochrane Library 2010, Issue 1, pp. 1-70	PUREX00058374	PUREX00058445
PUR5015	5/1/1979	U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, The Interagency Committee on New Therapies for Pain and Discomfort Report to the White House, May 1979	PUREX00058541	PUREX00058806
PUR5016	9/1/2015	SAMHSA Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health	PUREX00058263	PUREX00058326
PUR5017	5/8/2019	Cuyahoga County Medical Examiners's Office, Heroin/Fentanyl/Cocaine Related Deaths in Cuyahoga County, 2019 April Update, May 8, 2019	PUREX00058345	PUREX00058356
PUR5019	1/1/1990	Bonica, J., The Management of Pain, 2nd Edition, Vol I, p.429, 1990	PUREX00058327	PUREX00058330
PUR5020	1/1/1984	France, R.D., et al., Long-Term Use of Narcotic Analgesics in Chronic Pain, Soc. Sci. Med. Vol. 19, No. 12, pp. 1379-1382, 1984	PUREX00058331	PUREX00058334
PUR5021	12/31/1985	John P. Morgan MD (1985) American Opiophobia; Advances in Alcohol and Substance Abuse, 5:1-2, 163-172, DOI: 10.1300/J251v05n01_11	PUREX00058251	PUREX00058262
PUR5022	3/20/2019	2019 Cuyahoga County Community Health Implementation Strategy	PUREX00058184	PUREX00058250
PUR5025	1/4/2013	2-12-2002 Senate Hearing-Examining the Effects of the Painkiller Oxycontin	PUREX00057253	PUREX00057364
PUR5027	4/11/2011	APS_1995_Presidential_Address	PUREX00057365	PUREX00057368
PUR5028	5/16/2018	British Journal of Anesthesia - Incidence of iatrogenic opioid dependence or abuse	PUREX00057369	PUREX00057378
PUR5029	1/1/1986	Cancer Pain Relief publication	PUREX00057379	PUREX00057457
PUR5030	8/1/2013	SAMHSA CBHSQ Data Review- Associations of Nonmedical Pain Reliever Use	PUREX00057458	PUREX00057472
PUR5032	1/1/2010	Cochrane Collaboration - Long-term Opioid Management	PUREX00057489	PUREX00057491
PUR5033	10/27/1970	Controlled Substances Act - Public Law 91-513	PUREX00057492	PUREX00057552
PUR5034	10/1/2018	DEA_2018_National_Drug_Threat_Assessment	PUREX00057553	PUREX00057716
PUR5035	1/28/2008	How to Protect Your Medicines at Home	PUREX00057717	PUREX00057720
PUR5036	11/3/2007	How to stop drug diversion & protect your pharmacy	PUREX00057721	PUREX00057723
PUR5037	11/3/2007	How to stop drug diversion and protect your practice	PUREX00057724	PUREX00057726
PUR5038	8/20/2018	Key Substance Use and Mental Health Indicators	PUREX00057727	PUREX00057850
PUR5040	11/13/2003	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, OxyContin 10, 20, 40, 80 and 160 mg Tablets	PUREX00057851	PUREX00057855
PUR5041	3/27/2018	Wall M et al., Nonmedical prescription opioids and pathways of drug involvement in the US: Generational differences, Drug Alcohol Depend. 182, pp. 103-11.	PUREX00057856	PUREX00057875
PUR5043	5/9/2019	Pain Management Best Practices Inter-Agency Task Force Report	PUREX00057876	PUREX00057991
PUR5044	10/31/2013	The_International_Drug_Control_Conventions	PUREX00057992	PUREX00058159
PUR5045	2/21/2018	The_Myth_of_What's_Driving_the_Opioid_Crisis_- POLITICO_Magazine	PUREX00058160	PUREX00058167
PUR5046	7/1/2014	The_Role_of_Opioid_Prescription_in_Incident_Opioid_Abuse	PUREX00058168	PUREX00058183
PUR5048	8/27/2019	2019-11-12 FDA AdCom Meeting Docket	PUREX00058807	PUREX00058808
PUR5049	6/5/2019	Anesthetic and Analgesic Drug Products Advisory Comm. Roster for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm.	PUREX00058809	PUREX00058810
PUR5050	6/11/2019	Cicero Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00058811	PUREX00058848
PUR5051	6/11/2019	Corner Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00058849	PUREX00058885
PUR5052	6/11/2019	Darnall Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00058886	PUREX00058932
PUR5053	8/27/2019	DOCKET_FDA-2019-N-1646.csv	PUREX00058933	PUREX00058933
PUR5054	6/4/2019	Drug Safety and Risk Mgt. Advisory Comm. Roster for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. (DSaRM) and the Ane	PUREX00058934	PUREX00058935

PUR5056	6/11/2019	FDA Presentations for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00058936	PUREX00059048
PUR5057	6/11/2019	Final Agenda for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. (DSaRM) and the Anesthetic and Analgesic Drug Products	PUREX00059049	PUREX00059053
PUR5058	6/11/2019	Final Meeting Roster for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. (DSaRM) and the Anesthetic and Analgesic Drug	PUREX00059054	PUREX00059057
PUR5059	6/11/2019	Final Questions for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. (DSaRM) and the Anesthetic and Analgesic Drug Products	PUREX00059058	PUREX00059058
PUR5060	6/11/2019	Goldberger Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Produ	PUREX00059059	PUREX00059085
PUR5061	6/11/2019	June 11-12 2019 Risk Management and Analgesic Drug Products AdCom Mtg	PUREX00059086	PUREX00059094
PUR5062	6/11/2019	Kiezulas Presentation for the June 11-12, Living Lived Experience: 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Product	PUREX00059095	PUREX00059104
PUR5063	6/11/2019	Markman Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00059105	PUREX00059137
PUR5064	6/11/2019	McPherson Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00059138	PUREX00059157
PUR5065	6/11/2019	Public Comment_June 11-12 FDA Risk Management and Analgesic Drug Products Advisory Cmte mtg	PUREX00059158	PUREX00059164
PUR5066	6/11/2019	Rowbotham Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Produc	PUREX00059165	PUREX00059184
PUR5067	6/11/2019	Sandbrink Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00059185	PUREX00059217
PUR5068	6/11/2019	Surratt Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00059218	PUREX00059269
PUR5069	6/11/2019	Von Korff Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Produc	PUREX00059270	PUREX00059297
PUR5070	6/29/2019	Webcast Information for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. (DSaRM) and the Anesthetic and Analgesic Drug P	PUREX00059298	PUREX00059298
PUR5071	6/11/2019	Yarborough Presentation for the June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Mgt. Advisory Comm. and the Anesthetic and Analgesic Drug Products	PUREX00059299	PUREX00059311
PUR5072	1/7/2011	Abstral Sublingual Tablets Approval Package	PUREX00059312	PUREX00059323
PUR5073	11/12/1998	Actiq approval letter	PUREX00059324	PUREX00059329
PUR5074	10/20/2000	Anexsia approval letter	PUREX00059330	PUREX00059331
PUR5075	2/23/2018	Apadaz approval letter	PUREX00059332	PUREX00059343
PUR5076	8/20/2004	Apokyn approval letter	PUREX00059344	PUREX00059361
PUR5077	1/9/2017	Arymo approval letter	PUREX00059362	PUREX00059382
PUR5078	3/20/2002	Avinza approval letter	PUREX00059383	PUREX00059392
PUR5079	9/29/2000	Codamine approval letter	PUREX00059393	PUREX00059395
PUR5080	6/21/2004	Codeprex approval	PUREX00059396	PUREX00059419
PUR5081	11/26/2004	Combunox approval letter	PUREX00059420	PUREX00059436
PUR5082	5/18/2004	Depodur approval letter	PUREX00059437	PUREX00059441
PUR5083	8/17/2009	Embeda approval letter	PUREX00059442	PUREX00059447
PUR5084	10/25/2013	CDER Approval Package for Zohydro ER	PUREX00059448	PUREX00059465
PUR5085	9/25/2006	Fentora approval letter	PUREX00059466	PUREX00059470
PUR5086	5/14/2015	Flowtuss approval letter	PUREX00059471	PUREX00059476
PUR5087	5/21/2015	Hycocifenix approval letter	PUREX00059477	PUREX00059481
PUR5088	12/10/2007	Letter from CDER to ALZA Corp. RE: Ionsys approval letter	PUREX00059482	PUREX00059487
PUR5089	7/1/1996	Kadian 1996 Prescribing Information	PUREX00059488	PUREX00059493
PUR5090	6/30/2011	Lazanda approval letter	PUREX00059494	PUREX00059505
PUR5091	1/1/1996	Lortab launch label	PUREX00059506	PUREX00059510
PUR5092	7/16/2018	Letter from FDA approving ANDA for Mitgo (Morphine Sulphate Injection)	PUREX00059511	PUREX00059514
PUR5093	10/2/2015	Center for Drug Evaluation and Research Approval Package for Morphabond (morphine sulfate)	PUREX00059515	PUREX00059532
PUR5094	1/1/1998	Physicians' Desk Reference, 52nd Edition, 1998	PUREX00059533	PUREX00059536
PUR5095	4/6/2012	Center for Drug Evaluation and Research Approval Package for: Nucynta ER extended release oral tablets 50, 100, 150, 200, and 250 mg	PUREX00059537	PUREX00059546
PUR5096	11/14/2012	Center for Drug Evaluation and Research Approval Package for: Nucynta oral solution 20 mg/mL	PUREX00059547	PUREX00059554
PUR5097	11/14/2014	Center for Drug Evaluation and Research Approval Package for: Obredon Oral Solution, 2.5 mg, 200 mg/5mL	PUREX00059555	PUREX00059563
PUR5098	7/16/2009	FDA approval letter re Onsolis (fentanyl buccal soluble film)	PUREX00059564	PUREX00059570
PUR5099	12/9/2011	Center for Drug Evaluation and Research Approval Package for Opana, ER	PUREX00059571	PUREX00059579

PUR5100	6/28/2011	Food and Drug Administration NDA Approval Letter re Oxecta (Oxycodone HCl)	PUREX00059580	PUREX00059585
PUR5101	9/24/2004	Letter CDER to Purdue re: NDA Palladone	PUREX00059586	PUREX00059592
PUR5102	6/25/1999	Letter from Douglas Sporn to Endo re: NDA PERCOCET	PUREX00059593	PUREX00059594
PUR5103	6/8/2011	CDER Approval Package for Rezira	PUREX00059595	PUREX00059602
PUR5104	9/6/2000	Letter CDER to Roxane Labs re: NDA submission Roxicodone	PUREX00059603	PUREX00059606
PUR5105	4/20/2017	CDER Approval Package for RoxyBond	PUREX00059607	PUREX00059618
PUR5106	8/15/2012	CDER Approval Package for Subsys	PUREX00059619	PUREX00059631
PUR5107	7/23/2014	CDER Approval Package for Targiniq ER	PUREX00059632	PUREX00059649
PUR5108	12/3/2014	Letter CDER to WraSer Pharmaceuticals re: ANDA Trezix	PUREX00059650	PUREX00059652
PUR5109	8/19/2016	CDER Approval Package for Troxyca	PUREX00059653	PUREX00059672
PUR5110	9/26/2007	Letter from CDER to Mallinckrodt RE: TussiCaps	PUREX00059673	PUREX00059675
PUR5111	6/22/2015	Letter from CDER to Spiraso RE: Tuxarin ER	PUREX00059676	PUREX00059681
PUR5112	4/30/2015	CDER Approval Package for Tuzistra	PUREX00059682	PUREX00059688
PUR5113	1/17/2017	CDER Approval Package for Vantrela	PUREX00059689	PUREX00059708
PUR5114	9/23/1997	CDER Approval Package for Vicoprofen	PUREX00059709	PUREX00059714
PUR5115	2/20/2013	CDER Approval Package for Vituz	PUREX00059715	PUREX00059722
PUR5116	3/11/2014	CDER Approval Package for Xartemis	PUREX00059723	PUREX00059730
PUR5117	4/26/2016	CDER Approval Package for Xtampza	PUREX00059731	PUREX00059752
PUR5118	4/25/2018	Xtrelus NDA Approval	PUREX00059753	PUREX00059757
PUR5119	10/25/2013	CDER Approval Package for Zohydro	PUREX00059758	PUREX00059775
PUR5120	6/8/2011	CDER Approval Package for Zutripro	PUREX00059776	PUREX00059783
PUR5121	11/27/1998	Letter from CDER to Endo RE: Lortab	PUREX00059784	PUREX00059785
PUR5122	4/19/2016	Letter from CDER to Cypress Pharmaceutical RE: Zyfrel	PUREX00059786	PUREX00059787
PUR5123	8/30/2017	2016 Ohio Department of Health News Release Ohio Drug Overdose Data	PUREX00059788	PUREX00059789
PUR5124	8/30/2017	2016 Ohio Drug Overdose Report	PUREX00059790	PUREX00059799
PUR5125	12/31/2017	2017 Ohio Drug Data Demographic Summary	PUREX00059800	PUREX00059805
PUR5127	9/27/2018	2017 Ohio Drug Overdose Report	PUREX00059806	PUREX00059818
PUR5128	5/19/2010	ADAMHS 2009 Annual Report	PUREX00059819	PUREX00059842
PUR5129	8/8/2011	ADAMHS 2010 Annual Report	PUREX00059843	PUREX00059858
PUR5130	6/4/2012	ADAMHS 2011 Annual Report	PUREX00059859	PUREX00059874
PUR5131	5/17/2013	ADAMHS 2012 Annual Report	PUREX00059875	PUREX00059890
PUR5132	5/16/2014	ADAMHS 2013 Annual Report	PUREX00059891	PUREX00059906
PUR5133	5/15/2015	ADAMHS 2014 Annual Report	PUREX00059907	PUREX00059922
PUR5134	5/25/2016	ADAMHS 2015 Annual Report	PUREX00059923	PUREX00059938
PUR5135	5/24/2017	ADAMHS 2016 Annual Report	PUREX00059939	PUREX00059954
PUR5136	5/14/2018	ADAMHS 2017 Annual Report	PUREX00059955	PUREX00059970
PUR5137	5/14/2019	ADAMHS 2018 Annual Report	PUREX00059971	PUREX00059990
PUR5138	7/18/2016	CDC EpiAid Ohio: Undetermined risk factors for fentanyl-related overdose deaths, 2015	PUREX00059991	PUREX00060043
PUR5139	5/6/2005	Ohio Department of Health, 2003 Annual Report	PUREX00060044	PUREX00060055
PUR5140	4/28/2005	Ohio Department of Health, 2004 Annual Report	PUREX00060056	PUREX00060065
PUR5141	2/23/2007	Ohio Department of Health, 2005/6 Annual Report	PUREX00060066	PUREX00060081
PUR5142	7/15/2009	Ohio Department of Health, Annual Report for State Fiscal Years 2007 and 2008	PUREX00060082	PUREX00060105
PUR5143	1/5/2011	Ohio Department of Health, Combined State Fiscal Years 2009 - 2010 Annual Report	PUREX00060106	PUREX00060231
PUR5144	7/27/2011	Ohio Department of Health, State Fiscal Year 2011 Activity Report	PUREX00060232	PUREX00060257
PUR5145	8/7/2012	Ohio Department of Health, State Fiscal Year 2012 Annual Report	PUREX00060258	PUREX00060297
PUR5146	8/2/2013	Ohio Department of Health, State Fiscal Year 2013 Annual Report	PUREX00060298	PUREX00060325
PUR5147	8/1/2014	Ohio Department of Health, State Fiscal Year 2014 Annual Report	PUREX00060326	PUREX00060361
PUR5148	8/3/2015	Ohio Department of Health, State Fiscal Year 2015 Annual Report	PUREX00060362	PUREX00060406
PUR5149	8/1/2016	Ohio Department of Health, State Fiscal Year 2016 Annual Report	PUREX00060407	PUREX00060434
PUR5150	7/31/2017	Ohio Department of Health, State Fiscal Year 2017 Annual Report	PUREX00060435	PUREX00060466
PUR5151	7/31/2018	Ohio Department of Health, State Fiscal Year 2018 Annual Report	PUREX00060467	PUREX00060484
PUR5152	9/4/2014	State of Ohio Board of Pharmacy, Annual Report 2014	PUREX00060485	PUREX00060510
PUR5153	6/30/2015	OH Board of Pharmacy 2015 Annual Report	PUREX00060511	PUREX00060522
PUR5154	6/30/2016	OH Board of Pharmacy 2016 Annual Report	PUREX00060523	PUREX00060534
PUR5155	6/30/2017	OH Board of Pharmacy 2017 Annual Report	PUREX00060535	PUREX00060546
PUR5156	1/7/2019	OH Board of Pharmacy 2018 Annual Report	PUREX00060547	PUREX00060558
PUR5157	8/24/2010	OH Medical Board 2009 Report	PUREX00060559	PUREX00060581
PUR5158	12/14/2012	OH Medical Board 2012 Report	PUREX00060582	PUREX00060607
PUR5159	7/31/2013	OH Medical Board 2013 Report	PUREX00060608	PUREX00060641
PUR5160	8/1/2014	OH Medical Board 2014 Report	PUREX00060642	PUREX00060680
PUR5161	7/31/2015	OH Medical Board 2015 Report	PUREX00060681	PUREX00060696
PUR5162	3/1/2017	OH Medical Board 2016 Report	PUREX00060697	PUREX00060714
PUR5163	8/7/2017	OH Medical Board 2017 Report	PUREX00060715	PUREX00060735
PUR5164	8/1/2018	OH Medical Board 2018 Report	PUREX00060736	PUREX00060756
PUR5165	7/31/2019	OH Medical Board 2019 Report	PUREX00060757	PUREX00060778
PUR5166	4/30/2015	2013 Ohio Drug Overdose Data	PUREX00060779	PUREX00060785
PUR5167	6/2/2010	Ohio Rx Drug Abuse Task Force 2010 Report	PUREX00060786	PUREX00060805
PUR5168	4/17/2014	Ohio's Prescription Drug Overdose Epidemic: Epidemiology, Contributing Factors and Ongoing Prevention Efforts	PUREX00060806	PUREX00060870
PUR5169	3/1/2017	County of Summit Alcohol, Drug Addiction & Mental Health Services Board	PUREX00060871	PUREX00060886
PUR5170	8/3/2018	CFR-2018-title21-vol9-sec1301-71	PUREX00060887	PUREX00060889
PUR5171	8/3/2018	CFR-2018-title21-vol9-sec1301-72	PUREX00060890	PUREX00060892
PUR5172	8/3/2018	CFR-2018-title21-vol9-sec1301-73	PUREX00060893	PUREX00060894
PUR5173	8/3/2018	CFR-2018-title21-vol9-sec1301-74	PUREX00060895	PUREX00060897

PUR5174	8/3/2018	CFR-2018-title21-vol9-sec1301-75	PUREX00060898	PUREX00060898
PUR5175	8/3/2018	CFR-2018-title21-vol9-sec1301-76	PUREX00060899	PUREX00060900
PUR5176	4/1/2019	CFR-2019-title21-vol1 TITLE 21 Food and Drugs	PUREX00060901	PUREX00061494
PUR5177	8/18/2019	eCFR - Code of Federal Regulations	PUREX00061495	PUREX00061495
PUR5178	8/2/2019	Office of the Law Revision Counsel United States Code	PUREX00061496	PUREX00061496
PUR5179	8/21/2018	USCODE-2017-title21-chap13-subchapI-partA-sec801	PUREX00061497	PUREX00061505
PUR5180	8/21/2018	USCODE-2017-title21-chap13-subchapI-partA-sec802	PUREX00061506	PUREX00061517
PUR5181	8/24/2018	USCODE-2017-title21-chap13-subchapI-partA-sec832	PUREX00061518	PUREX00061519
PUR5182	8/21/2018	USCODE-2017-title21-chap13-subchapI-partC-sec823	PUREX00061520	PUREX00061529
PUR5183	8/21/2018	USCODE-2017-title21-chap13-subchapI-partC-sec824	PUREX00061530	PUREX00061532
PUR5184	8/21/2018	USCODE-2017-title21-chap13-subchapI-partE-sec871	PUREX00061533	PUREX00061533
PUR5185	9/26/2018	CFR-2018-title28-vol1 Title 28 Judicial Administration	PUREX00061534	PUREX00062786
PUR5186	9/26/2018	CFR-2018-title28-vol1-sec0-100	PUREX00062787	PUREX00062787
PUR5187; PUR4939	9/15/2015	Federal Register Vol. 80, No. 178 - Department of Justice Drug Enforcement Administration [Docket No. 13-39] Masters Pharmaceuticals, Inc.; Decision and Order	PUREX00062788	PUREX00062877
PUR5188; PUR4938	7/3/2007	DEA - Southwood Pharmaceuticals Revocation of Registration	PUREX00062878	PUREX00062901
PUR5189	11/21/2018	Various authors, Clinical Pharmacology Volume I, Pergamon Press, Chapter Assessment of the Dependence producing potentiality of narcotic analgesics (by William r. Martin), page 155 to 180, 1996	PUREX00062931	PUREX00062958
PUR5190	1/1/1990	John J. Bonica, The Management of Pain, Volume II, Lea & Febiger, 1990, page 1640 to 1675	PUREX00062959	PUREX00062996
PUR5191	4/1/2019	Janet Currie, Jonas Y. Jin, and Molly Schnell, U.S. Employment and Opioids: Is there a connection?, NBER Working Paper Series.	PUREX00062997	PUREX00063034
PUR5192	12/12/2011	INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES Presentation: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education, and Research, The national Academies Press, 2011	PUREX00063035	PUREX00063416
PUR5193	11/13/2018	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, November 13, 2018	PUREX00063417	PUREX00063418
PUR5194	2/12/2019	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, February 12, 2019	PUREX00063419	PUREX00063420
PUR5195	10/1/2013	Ohio Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain 80 mg of a Morphine Equivalent Daily Dose (MED) "Trigger Point"	PUREX00063421	PUREX00063422
PUR5196	7/1/2019	medication policy manual on extended-release opioid medication products for pain.	PUREX00063423	PUREX00063453
PUR5197	4/1/2018	Bogdan Savych, David Neumark, Randall Lea, DO OPIOIDS HELP INJURED WORKERS RECOVER AND GET BACK TO WORK?THE IMPACT OF OPIOID PRESCRIPTIONS ON DURATION OF TEMPORARY DISABILITY, NBER Working Paper Series, 2018	PUREX00063454	PUREX00063501
PUR5198	2/22/2019	For Prescribers - New Limits on Prescription Opioids for Acute Pain, State of Ohio	PUREX00063502	PUREX00063503
PUR5199	12/6/2018	Multiple Cause of Death Data	PUREX00063504	PUREX00063504
PUR5200	5/8/2015	REMS list- Extended Release and Long Acting Opioid Analgesics shared system RISK EVALUATION AND MITIGATION STRATEGY	PUREX00063505	PUREX00063508
PUR5201	8/21/2019	(130th General Assembly)(Amended Substitute House Bill Number 341), Ohio General Assembly Archives	PUREX00063509	PUREX00063526
PUR5202	8/20/2019	List of Extended-Release and Long-Acting Opioid Products Required to Have an Opioid REMS	PUREX00063527	PUREX00063529
PUR5204	5/17/2011	Fiscal Note & Local Impact Statement, Bill Sub. H.B. 93, Ohio Legislative Service Commission	PUREX00063530	PUREX00063536
PUR5205	1/10/2019	More staff, suicide prevention services pledged at Cuyahoga County Jail in newplan with MetroHealth, By Chris Anderson	PUREX00063537	PUREX00063543
PUR5206	8/20/2019	29 U.S. Code Section 1003. Coverage	PUREX00063544	PUREX00063546
PUR5207	8/2/2001	Office of the Comptroller of the Currency, 2001 Congressional Testimony	PUREX00063547	PUREX00063547
PUR5208	8/20/2019	Search results for OSU Extension: site ext miles image about does opinion crisis drop overcome data ohio sept of health pd	PUREX00063548	PUREX00063550
PUR5209	8/20/2019	Photograph of Important numbers and websites, 8/20/2019	PUREX00063551	PUREX00063554
PUR5210	1/1/2017	Cuyahoga County Summary of Benefits and Coverage: C Coverage Period: January 1, 2017– December 31, 2017	PUREX00063555	PUREX00063561
PUR5211	1/1/2017	Summary of Benefits and Coverage: What this Plan Covers & What it Costs; Coverage Period: January 1, 2017– December 31, 2017	PUREX00063562	PUREX00063568
PUR5212	1/1/2018	2018 Cuyahoga County Community Health Assessment	PUREX00063569	PUREX00063845
PUR5213	8/16/2018	2018 Cuyahoga County Employee Benefits Overview	PUREX00063846	PUREX00063854
PUR5214	1/1/2018	CUYAHOGA COUNTY 2018-2019 BIENNIAL BUDGET PLAN	PUREX00063855	PUREX00064025
PUR5215	12/10/2018	2019 Benefits Enrollment Guide, County of Cuyahoga	PUREX00064026	PUREX00064049
PUR5216	6/11/2019	FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)	PUREX00064050	PUREX00064146
PUR5217	8/20/2019	A Guide to Safe Use of Pain Medicine; published by the FDA	PUREX00064147	PUREX00064151
PUR5218	8/20/2019	Article: A look at how the opioid crisis has affected people with employer coverage	PUREX00064152	PUREX00064159
PUR5219	8/20/2019	Project TND; TND project towards no drug abuse, University of Southern California	PUREX00064160	PUREX00064160

PUR5220	4/1/2015	Abuse-Deterrent Opioids — Evaluation and Labeling: Guidance for Industry; U.S. Department of Health and Human Services Food and Drug Administration	PUREX00064161	PUREX00064189
PUR5221	11/21/2017	Standards for Commercial Support: Standards to Ensure the Independence of CME Activities; Accreditation Council for Continuing Medical Education.	PUREX00064190	PUREX00064192
PUR5222	4/5/1998	An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime; by Lawrence A. Greenfeld, U.S. Dept. of Justice	PUREX00064193	PUREX00064232
PUR5223	8/20/2019	All Stars Prevention; https://www.allstarsprevention.com/all-stars-core.html	PUREX00064233	PUREX00064234
PUR5225	12/20/2017	COMMUNITY ASSESSMENT OF THE OPIOID CRISIS IN LORAIN COUNTY, OHIO EXECUTIVE SUMMARY	PUREX00064270	PUREX00064275
PUR5226	11/14/2018	Pain News Network; AMA: Inappropriate Use of CDC Guideline Should Stop; https://www.painnewsnetwork.org/stories/2018/11/14/ama-calls-for-misapplication-of-cdc-opioid-guideline-to-end	PUREX00064276	PUREX00064278
PUR5227	11/13/2018	RESOLUTION 235 INAPPROPRIATE USE OF CDC GUIDELINES FOR PRESCRIBING OPIOIDS Passed by the AMA House of Delegates on November 13, 2018	PUREX00064279	PUREX00064279
PUR5229	10/1/2009	AMCP Drug Utilization Review	PUREX00064280	PUREX00064288
PUR5230	4/1/2016	The AMCP Format for Formulary Submissions; A Format for Submission of Clinical and Economic Evidence in Support of Formulary Consideration	PUREX00064289	PUREX00064350
PUR5231	8/20/2019	United States Census Bureau; Community Facts - Find popular facts (population, income, etc.) and frequently requested data about your community; https://factfinder.census.gov/faces/nav/jsf/pages/c-community-facts.xhtml?src=bkmk	PUREX00064351	PUREX00064351
PUR5232	11/24/2008	Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine; ASAM	PUREX00064352	PUREX00064355
PUR5233	9/17/2017	Katie Thomas and Charles Ornstein; Amid Opioid Crisis, Insurers restrict pricey, less addictive painkillers; New York times	PUREX00064356	PUREX00064363
PUR5234	12/1/2018	Analysis group; Health Care: the Opioid epidemic: Analysis Group's Work in tracking Impacts and Developing Responses	PUREX00064364	PUREX00064379
PUR5236	3/5/2018	Ohio Automated Rx Reporting System; 2017 Annual Report	PUREX00064380	PUREX00064392
PUR5237	3/15/2019	Ohio Automated Rx Reporting System; 2018 Annual Report	PUREX00064393	PUREX00064405
PUR5238	8/20/2019	Approved Risk Evaluation and mitigation Strategies (REMS); https://www.accessdata.fda.gov/scripts/cder/rems	PUREX00064406	PUREX00064410
PUR5240	11/1/2014	2014 Physician Specialty Data Book	PUREX00064411	PUREX00064452
PUR5241	10/25/2016	Report Wiley Press, re: Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy	PUREX00064453	PUREX00064462
PUR5242	8/20/2019	Cuyahoga County Dept. of Human Resources: Benefits Package	PUREX00064463	PUREX00064465
PUR5243	5/1/2013	Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets	PUREX00064466	PUREX00064467
PUR5244	8/20/2019	The County of Summit Department of Communications, Bidding Opportunities	PUREX00064468	PUREX00064471
PUR5245	8/20/2019	A live event notice, Best Practices in Combating Opioid Abuse,Misuse and Diversion: The Health Plan Perspective, October 8, 2018	PUREX00064472	PUREX00064488
PUR5246	8/20/2019	Opioid Action Council; Buckeye Health Plan; available at https://www.buckeyehealthplan.com/providers/pharmacy/OpioidActionCouncil.html	PUREX00064489	PUREX00064491
PUR5247	8/20/2019	sciencedirect topics; Butalbital - an overview; https://www.sciencedirect.com/topics/nursing-and-health-professions/butalbital	PUREX00064492	PUREX00064499
PUR5251	4/24/2019	CDC newsroom; CDC Advises Against Misapplication of the Guideline For Prescribing Opioids For Chronic Pain Some policies, practices attributed to the Guideline are inconsistent with its recommendations; available at https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html	PUREX00064594	PUREX00064595
PUR5252	12/21/2018	CDC newsroom; new data show growing complexity of drug overdose deaths in america	PUREX00064596	PUREX00064597
PUR5254	10/3/2018	CDC; U.S. Opioid Prescribing Rate Maps	PUREX00064598	PUREX00064601
PUR5255	7/29/2019	CDC WONDER; online databases	PUREX00064602	PUREX00064602
PUR5256	1/10/2019	CDC: National center for health statistics, suicide mortality by state; available at https://www.cdc.gov/nchs/pressroom/sosmap/suicide-mortality/suicide.html	PUREX00064603	PUREX00064604
PUR5257	5/1/2018	Combating Opioid Abuse through a Unified Stateand Local Response: The Ohio Governor's CabinetOpiate Action	PUREX00064605	PUREX00064613
PUR5258	10/19/2016	CDC brochure - Calculating Total Daily Dose of Opioids for Safer Dosage	PUREX00064614	PUREX00064615
PUR5259	8/21/2019	CDC; Wide-ranging Online Data for Epidemiologic Research (WONDER); available at https://healthdata.gov/dataset/wide-ranging-online-data-epidemiologic-research-wonder	PUREX00064616	PUREX00064618
PUR5260	8/13/2019	CMS.gov: Part C and D Performance Data	PUREX00064619	PUREX00064619
PUR5261	10/17/2013	Prescription Drug Addiction and Healthcare Reform Legislative Study Committee Chairman's Report, Ohio House of Representatives	PUREX00064620	PUREX00064635
PUR5262	6/1/2003	SEEP; Total Expenditures for Students with Disabilities, 1999-2000: Spending Variation by Disability	PUREX00064636	PUREX00064665
PUR5263	2/20/2018	Lab Express Scripts; Changing the way we fight the opioid epidemic	PUREX00064666	PUREX00064669

PUR5264	8/20/2019	Digest of Education Statistics; Children 3 to 21 years old served under Individuals with Disabilities Education Act (IDEA), Part B, by type of disability: Selected years, 1976-77 through 2005-06;, available at https://nces.ed.gov/programs/digest/d17/tables/dt17_204.30.asp	PUREX00064670	PUREX00064671
PUR5265	7/24/2017	Cleveland.com; Cuyahoga County includes 9 local governments and agencieson healthcare plan, after recovering from \$9.5 million shortfall; https://www.cleveland.com/cuyahoga-county/2017/07/cuyahoga_county_resumesRegional_health_insurance_program_following_shortfall.html	PUREX00064672	PUREX00064675
PUR5266	5/2/2018	Cleveland.com; Gov. John Kasich Proposes New Opioid Rules for Chronic Pain Patients	PUREX00064676	PUREX00064680
PUR5267	6/14/2018	Cleveland.com; Medicaid work requirements put 52,000 in Cuyahoga County at risk for losing healthcare coverage	PUREX00064681	PUREX00064686
PUR5269	11/2/2018	CMS.gov: CMS finalizes Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System changes for 2019	PUREX00064687	PUREX00064699
PUR5270	7/21/2018	FierceHealthcare; CMS proposes nixing pain-management questions from HCAHPS in response to opioid epidemic	PUREX00064700	PUREX00064703
PUR5271	8/20/2019	Medical Mutual; solutions to your government sector concerns	PUREX00064704	PUREX00064706
PUR5272	8/20/2019	US Dept. of Health and Human Services; Concept and History of Permanency in U.S. Child welfare	PUREX00064707	PUREX00064709
PUR5273	6/7/2001	NIDA Archives; Continuing Concern Over Imported Pharmaceuticals; https://archives.drugabuse.gov/testimonies/2001/continuing-concern-over-imported-pharmaceuticals	PUREX00064710	PUREX00064715
PUR5274	8/20/2019	Cuyahoga County Bid Solicitation	PUREX00064716	PUREX00064717
PUR5275	8/21/2019	County of Summit intranet SCENE; https://scene.summitoh.net	PUREX00064718	PUREX00064730
PUR5276	8/20/2019	Digest of Education Statistics; Current expenditures and current expenditures per pupil in public elementary and secondary schools: 1989-90 through 2027-28, available at https://nces.ed.gov/programs/digest/d17/tables/dt17_236.15.asp	PUREX00064731	PUREX00064732
PUR5277	12/31/1999	Elizabeth K. Balraj, Cuyahoga County 1999 Coroner's Statistical Report	PUREX00064733	PUREX00064970
PUR5278	9/23/2016	Article: Cuyahoga County discovers \$9.5 million health care plan shortfall; https://www.cleveland.com/cuyahoga-county/2016/09/cuyahoga_county_faces_12_million_xxx_because_of_health_care_plans.html	PUREX00064971	PUREX00064977
PUR5279	1/14/2019	cleveland.com; Cuyahoga County law director resigns; https://www.cleveland.com/metro/2019/01/cuyahoga-county-law-director-resigns.html	PUREX00064978	PUREX00064981
PUR5280	1/1/2014	Cuyahoga County Opiate Task Force Report 2014	PUREX00064982	PUREX00064997
PUR5281	8/20/2019	Cuyahoga County-Provided Shared Services	PUREX00064998	PUREX00064999
PUR5282	9/27/2018	County of Cuyahoga Presentation: FISCAL YEAR ENDED 12/31/17 ANNUAL INFORMATIONAL STATEMENT IN CONNECTION WITH OBLIGATIONS OF THE COUNTY	PUREX00065000	PUREX00065564
PUR5283	1/1/2011	Internal Audit Report of Cuyahoga County, Ohio	PUREX00065565	PUREX00065662
PUR5284	8/20/2019	Cuyahoga County Fiscal Officer; Statistics & Reports	PUREX00065663	PUREX00065664
PUR5285	8/21/2019	US Census Bureau; American FactFinder - Community Facts; https://factfinder.census.gov/faces/nav/jsf/pages/community_facts.xhtml?src=bkmk	PUREX00065665	PUREX00065665
PUR5286	8/20/2019	Cuyahoga County Opiate Taskforce web page	PUREX00065666	PUREX00065667
PUR5287	9/9/2010	Cleveland.com article; Cuyahoga County's corruption investigation: a comprehensive guide	PUREX00065668	PUREX00065670
PUR5288	1/1/2015	CVS/Caremark; Formulary Drug Removals	PUREX00065671	PUREX00065675
PUR5289	7/10/2017	Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting	PUREX00065676	PUREX00065678
PUR5290	12/19/2017	National Institute of Health Website: DailyMed, available at https://dailymed.nlm.nih.gov/dailymed/	PUREX00065679	PUREX00065680
PUR5291	6/21/2017	Effect of Abuse Deterrent formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids by Richard C. Dart, MD, PhD	PUREX00065681	PUREX00065710
PUR5292	10/1/2018	DEA 2018 National Drug Threat Assessment	PUREX00065711	PUREX00065874
PUR5293	8/20/2019	DEA Domestic Divisions List, available at https://www.dea.gov/domestic-divisions	PUREX00065875	PUREX00065876
PUR5294	8/20/2019	DEA website page - Drug Scheduling, available at https://www.dea.gov/drug-scheduling	PUREX00065877	PUREX00065878
PUR5295	8/20/2019	DEA Diversion Control Division Home Page, available at https://www.deadiversion.usdoj.gov/faq/prescriptions.htm	PUREX00065879	PUREX00065880
PUR5296	8/4/2017	DEA Proposes Reduction To Amount Of Controlled Substances To Be Manufactured In 2018 (8/4/2017), available at https://www.dea.gov/press-releases/2017/08/04/dea-proposes-reduction-amount-controlled-substances-be-manufactured-2018	PUREX00065881	PUREX00065882
PUR5298	1/1/2018	NBER Working Paper Series: Deaths of Despair or Drug Problems?	PUREX00065883	PUREX00065952
PUR5299	4/13/2015	DELFINI Evidence Tool Kit: Evidence Grading, Working Conclusions & Result Tables	PUREX00065953	PUREX00065971
PUR5300	5/30/2018	U.S. Department of Health and Human Services: Development of a Shared System REMS - Guidance for Industry	PUREX00065972	PUREX00065982
PUR5301	5/21/2018	Deloitte Insights: Strategies for stemming the opioid crisis	PUREX00065983	PUREX00066010
PUR5302	11/1/2011	U.S. Department of Health and Human Services: Guidance Medication Guides - Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)	PUREX00066011	PUREX00066022

PUR5303	5/11/2017	SAMHSA - The CBHSQ Report - A Day in the Life of Older Adults: Substance Use Facts	PUREX00066023	PUREX00066028
PUR5304	6/10/2014	SAMHSA - The CBHSQ Report - A Day in the Life of Young Adults: Substance Use Facts	PUREX00066029	PUREX00066035
PUR5305	1/29/2013	SAMHSA - The Dawn Report - Emergency Department Visits Involving Buprenorphine	PUREX00066036	PUREX00066044
PUR5306	11/5/2015	SAMHSA - The CBHSQ Report - Emergency Department Visits Involving Narcotic Pain Relievers	PUREX00066045	PUREX00066055
PUR5307	8/20/2019	Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus on Rebates	PUREX00066056	PUREX00066062
PUR5308	2/28/2019	Medicaid.gov - Drug Utilization Review	PUREX00066063	PUREX00066068
PUR5309	8/20/2019	Medicaid.gov - Drug Utilization Review Annual Report	PUREX00066069	PUREX00066071
PUR5310	8/20/2019	Drugs@FDA: FDA Approved Drug Products	PUREX00066072	PUREX00066074
PUR5311	5/8/2012	Exit Wounds by Derek McGinnis, Iraq War Veteran with Stephen R. Braun	PUREX00066075	PUREX00066179
PUR5313	1/1/2015	Express Scripts 2015 Preferred Drug List Exclusion (from website)	PUREX00066180	PUREX00066181
PUR5314	11/1/2017	Medical Mutual - Extended Use of Opioid Medication Prior Approval	PUREX00066182	PUREX00066185
PUR5315	3/1/2017	MACPAC Fact Sheet - Advising Congress on Medicaid and CHIP Policy (macpac.gov)	PUREX00066186	PUREX00066191
PUR5316	11/1/2018	Medicaid in Ohio (Henry J. Kaiser Family Foundation)	PUREX00066192	PUREX00066193
PUR5317	2/6/2019	CDC: Smoking & Tobacco Use Fast Facts	PUREX00066194	PUREX00066196
PUR5318	3/1/2018	FDA Analysis of Long-term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends	PUREX00066197	PUREX00066208
PUR5319	9/1/2018	Introduction FDA's Opioid Analgesics REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain	PUREX00066209	PUREX00066221
PUR5320	6/11/2019	Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee	PUREX00066222	PUREX00066229
PUR5321	8/20/2019	FDA Fundamentals, FDA report, 8/20/2019	PUREX00066230	PUREX00066232
PUR5322	2/6/2018	FDA in Brief: FDA finalizes new policy to encourage widespread innovation and development of new buprenorphine treatments for opioid use disorder, February 6, 2018	PUREX00066233	PUREX00066236
PUR5324	4/1/2015	Guidance Document: Abuse-Derrent Opioids - Evaluation and Labeling - April 2015	PUREX00066275	PUREX00066275
PUR5326	8/20/2019	U.S. Department of Labor Fiduciary Responsibilities (ERISA)	PUREX00066276	PUREX00066277
PUR5327	12/31/2016	The MetroHealth System (A Component Unit of Cuyahoga County) Financial Report	PUREX00066278	PUREX00066358
PUR5328	6/1/2018	Follow the Money: Pharmaceutical Manufacturer Payments and Opioid Prescribing Patterns in New York State (NYS Health Foundation)	PUREX00066359	PUREX00066388
PUR5329	10/1/2017	U.S. Department of Health and Human Services Format and Content of a REMS Document Guidance for Industry (Draft Guidance)	PUREX00066389	PUREX00066422
PUR5330	8/2/2018	Formulary Drug Exclusions on the Rise: What Health Execs Should Know	PUREX00066423	PUREX00066428
PUR5331	7/13/2019	Express Scripts Formulary Information	PUREX00066429	PUREX00066430
PUR5332	11/10/2016	Article: Cuyahoga County providing health benefits to those who shouldn't be covered	PUREX00066431	PUREX00066439
PUR5333	6/19/2008	U.S. Pharmacist: Generic-Substitution Laws	PUREX00066440	PUREX00066445
PUR5334	1/1/2017	Georgetown University Health Policy Institute, Center for Children and Families Interactive Map: The Percent of Children in Small Towns and Rural Areas Covered by Medicaid, 2015/16	PUREX00066446	PUREX00066447
PUR5335	1/1/2016	Georgetown University Health Policy Institute, Center for Children and Families: Percent of Adults Covered by Medicaid by County, 2011-2015	PUREX00066448	PUREX00066453
PUR5336	3/1/2007	NBER Working Paper Series - The Race Between Education and Technology: The Evolution of U.S. Educational Wage Differentials, 1890 to 2005	PUREX00066454	PUREX00066501
PUR5337	8/20/2019	The GRADE Working Group Homepage	PUREX00066502	PUREX00066509
PUR5338	8/20/2019	Medical Mutual Employer & Group Plans (website)	PUREX00066510	PUREX00066511
PUR5339	5/1/2009	U.S. Department of Health and Human Services: Guidance for Industry Presenting Risk Information in Prescription Drug and Medical Device Promotion (Draft Guidance)	PUREX00066512	PUREX00066538
PUR5340	4/1/2017	FSMB Guidelines for the Chronic Use of Opioid Analgesics	PUREX00066539	PUREX00066560
PUR5341	3/14/2016	CDC Guideline for Prescribing Opioids for Chronic Pain - Promoting Patient Care and Safety	PUREX00066561	PUREX00066564
PUR5342	8/10/2016	Pain doctors: Insurance companies won't cover the alternatives to opioids (Business Insider)	PUREX00066565	PUREX00066569
PUR5343	5/1/2018	Audrey J. Weiss and Kevin C. Heslin; Payers of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2010 and 2015; HCUP, 2018	PUREX00066570	PUREX00066594
PUR5344	8/20/2019	NCQA: Patient-Centered Medical Home (PCMH) Health Plan Accreditation HEDIS Measures	PUREX00066595	PUREX00066598
PUR5345	3/25/2019	CMS: Health Insurance Exchanges 2019 Open Enrollment Report	PUREX00066599	PUREX00066609
PUR5346	8/20/2019	US. Dept of Labor health plans and benefits: ERISA	PUREX00066610	PUREX00066611
PUR5347	8/20/2019	NCQA, HEDIS and Performance measurement	PUREX00066612	PUREX00066614
PUR5348	5/30/2019	HHS.gov, Pain Management Best Practices Inter-Agency Task Force; https://www.hhs.gov/ash/advisory-committees/pain/index.html	PUREX00066615	PUREX00066616
PUR5349	11/27/2017	HHS Public Access; Nonmedical prescription opioids and pathways of drug involvement in the US: Generational differences; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870126/	PUREX00066617	PUREX00066634
PUR5350	3/30/2016	HHS; HHS releases final version of national pain; https://www.aafp.org/news/government-medicine/20160330painstrategy.html	PUREX00066635	PUREX00066638

PUR5351	8/2/2018	Pharmexec; Hitting your targets: A Check-up on Data; www.pharmexec.com/print/360568?page=full	PUREX00066639	PUREX00066640
PUR5352	8/20/2019	ClinicalTrials.gov Search Page	PUREX00066641	PUREX00066642
PUR5353	2/28/2018	Cantonrep.com; Accidental Overdose or Suicide? Coroner Rulings Complicated, available at https://www.cantonrep.com/news/20180218/accidental-overdose-or-suicide-coroner-rulings-complicated	PUREX00066643	PUREX00066649
PUR5354	11/12/2018	How we build a formulary - Drug formularies are a crucial strategy for keeping prescription medications affordable, but only if they preserve access to the medications patients need to stay healthy.; lab.express-scripts.com/labinsights/drug-options/how-we-build-a-formulary-115	PUREX00066650	PUREX00066654
PUR5355	3/28/2013	Incidence and Cost of Carbon Monoxide Poisoning for All Ages, Pool and Spa Submersions for Ages 0–14, and Lead Poisoning for Ages 0–4	PUREX00066655	PUREX00066701
PUR5356	1/4/2018	Smithsonian.com: Inside the Story of America's 19th Century Opiate Addiction, (Trickey)	PUREX00066702	PUREX00066704
PUR5357	8/20/2019	IPFCC; The MetroHealth System Profile; https://www.ipfcc.org/bestpractices/profile-metrohealth.html	PUREX00066705	PUREX00066706
PUR5358	12/21/2017	Institute of Medicine: Relieving Pain in America A Blueprint for Transforming Prevention, Care, Education, and Research	PUREX00066707	PUREX00066742
PUR5359	8/10/2016	Institute of Medicine: Relieving Pain in America A Blueprint for Transforming Prevention, Care, Education, and Research	PUREX00066743	PUREX00066760
PUR5361	1/28/2019	JAMA evidence Glossary Available at: www.jamaevidence.com	PUREX00066761	PUREX00066849
PUR5362	4/16/2010	University of Massachusetts Medical School; Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain https://www.drugabuse.gov/coe	PUREX00066850	PUREX00066895
PUR5364	9/1/2018	Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health; Available at: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.html	PUREX00066896	PUREX00066996
PUR5365	8/20/2019	Time frame 2019; Number of Individuals Who Selected a Marketplace Plan Available at: http://aspe.hhs.gov/health/reports/2014/ and https://www.cms.gov/Research-Statistics-Da	PUREX00066997	PUREX00067008
PUR5366	3/1/2000	"Deep Cravings: New Research on the brain and behavior clarifies the mysteries of addiction," available at https://harvardmagazine.com/print/506?page=all	PUREX00067009	PUREX00067016
PUR5367	11/1/2017	5160:1-2-02 Medicaid: Income Guidelines, Calculations, and Exclusions Available at: codes.ohio.gov/oac/5160:1-2-02v1	PUREX00067017	PUREX00067019
PUR5368	3/22/2015	Medicaid Medical Necessity: Definitions and Principles Available at: codes.ohio.gov/oac/5160-1-01v1	PUREX00067020	PUREX00067020
PUR5369	8/20/2019	Gertie Kass' LinkedIn Page Available at: https://www.linkedin.com/in/gertie-kass-68832110/	PUREX00067021	PUREX00067023
PUR5370	7/13/2017	State and Substate Estimates of NonMedical Use of Prescription Pain Relievers Available at: http://samhsa.gov/data/ and http://www.samhsa.gov/data/population-data-nsduh	PUREX00067024	PUREX00067039
PUR5371	8/20/2019	LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Acetaminophen) Available at: https://livertox.nih.gov/Acetaminophen.htm	PUREX00067040	PUREX00067075
PUR5372	8/20/2019	LST Overview: Bolvin Lifeskills Training Available at: https://www.lifeskillstraining.com/	PUREX00067076	PUREX00067078
PUR5373	8/20/2019	Managed Care Available at: https://www.medicaid.gov/medicaid/managed-care/index.html	PUREX00067079	PUREX00067082
PUR5375	4/22/2018	Effect of Restricting the Legal Supply of Prescription Opioids on Buying Through Online Illicit Marketplaces: Interrupted Time Series Analysis Available at: https://www.bmjjournals.org/content/361/bmj.k2270	PUREX00067132	PUREX00067148
PUR5376	8/20/2019	May 2019 Medicaid & CHIP Enrollment Data Highlights (Medicaid.gov) Available at: https://www.medicaid.gov/medicaid/program-information/medicaid-and-chip-enrollment-data/report-highlights/index..html	PUREX00067149	PUREX00067176
PUR5377	8/20/2019	Molina Healthcare's Multi-Pronged Approach to Fighting Opioid Drug Abuse Available at: http://mha.ohio.gov	PUREX00067177	PUREX00067177
PUR5378	6/7/2016	MetroHealth, Medical Mutual of Ohio Seek to Cut Insurance Premiums by 15% (MedCityNews) Available at: https://medcitynews.com/2016/06/metrohealth-medical-mutual-insurance	PUREX00067178	PUREX00067186
PUR5379	10/1/2018	Medflex HMO Available at: MedMutual.com	PUREX00067187	PUREX00067192
PUR5380	12/1/2015	Medicaid Documentation for Medical Professionals Available At: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforConsumers/Report_Fraud_and_Suspected_Fraud.html	PUREX00067193	PUREX00067195
PUR5381	8/1/2014	Managed Care In Ohio Available at: http://iis.ohio.gov/OHP/bmhc/transition.stm	PUREX00067196	PUREX00067199
PUR5382	9/27/2018	Medicaid State Fact Sheets Available At: https://www.kff.org/interactive/medicaid-state-fact-sheets/	PUREX00067200	PUREX00067203
PUR5383	8/20/2019	Medical Mutual: Medical Insurance Plans Available at: https://www.medmutual.com/For-Individuals-and-Families/Plans-Products/Medical-Insurance.aspx	PUREX00067204	PUREX00067205
PUR5384	8/21/2019	Medical Mutual-Individual Health Insurance Group "Welcome Providers" Available at: https://provider.medmutual.com/default.aspx	PUREX00067206	PUREX00067206
PUR5385	1/1/2018	Medical Mutual: Pain Management Medication Program 2018 Available at: clinical_pharmacy@medmutual.com or https://provider.medmutual.com	PUREX00067207	PUREX00067209
PUR5386	9/1/2018	Medical Mutual Provider Manual 2018	PUREX00067210	PUREX00067340

PUR5387	1/1/2018	Medical Mutual Meideal Policy 201801 - Pain Management Medications	PUREX00067341	PUREX00067348
PUR5389	11/1/2011	Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)	PUREX00067349	PUREX00067360
PUR5390	3/5/2004	Harold Merskey and Nikolai Bogduk, CLASSIFICATION OF CHRONIC PAIN DESCRIPTIONS OF CHRONIC PAIN SYNDROMES AND DEFINITIONS OF PAIN TERMS Second Edition; IASP Press, 1994	PUREX00067361	PUREX00067598
PUR5391	8/20/2019	US DOJ Website: Methadone Hydrochloride Tablets USP 40 mg (Dispersible), available at https://www.deadiversion.usdoj.gov/pubs/advisories/methadone_advisory.html	PUREX00067599	PUREX00067600
PUR5392	8/20/2019	MetroHealth System Website: About Us, available at https://www.metrohealth.org/about-us	PUREX00067601	PUREX00067605
PUR5393	8/21/2019	Narconon Website: History of Heroin, available at https://www.narconon.org/drug-information/heroin-history.html	PUREX00067606	PUREX00067612
PUR5394	8/20/2019	FDA Website: National drug code directory, available at https://www.fda.gov/drugs-approvals-and-databases/national-drug-code-directory	PUREX00067613	PUREX00067619
PUR5396	8/1/2018	National Institute on Alcohol Abuse and Alcoholism (NIAAA) Website: Alcohol Facts and Statistics, available at https://www.niaaa.nih.gov/alcohol-facts-and-statistics	PUREX00067620	PUREX00067626
PUR5397	10/1/2011	National Institute on Drug Abuse, Nora D. Volkow, Prescription Drug Abuse	PUREX00067627	PUREX00067642
PUR5398	6/1/2015	National Institute on Drug Abuse Website: DrugFacts: Nationwide Trends, available at https://www.drugabuse.gov/publications/drugfacts/nationwide-trends	PUREX00067643	PUREX00067649
PUR5399	7/2/2001	National Institute of Health Website: THE MANAGEMENT OF CHRONIC PAIN, available at https://grants.nih.gov/grants/guide/pa-files/PA-01-115.html	PUREX00067650	PUREX00067661
PUR5400	6/26/2017	National Sheriffs Associate Website: National Sheriffs' Association and Purdue Pharma Announce Additional Funding for Life-Saving Opioid Overdose Initiative, available at https://www.sheriffs.org/national-sheriffs-association-and-purdue-pharma-announce-additional-funding-for-life-saving-opioid	PUREX00067662	PUREX00067667
PUR5401	1/1/2018	County of Cuyahoga; 2018 Employee Benefits Guide	PUREX00067668	PUREX00067687
PUR5402	8/29/2017	State of Ohio Communication Department; New Limits on Opiate Prescriptions for Acute Pain will Save Lives and Fight Addiction	PUREX00067688	PUREX00067688
PUR5403	5/2/2018	State of Ohio Communication Department; New Rules for Chronic Pain Prescriptions will Help Patients and Prescribers Work to Prevent Addiction	PUREX00067689	PUREX00067690
PUR5404	8/20/2019	SAMHDA Website, National Survey on Drug Use and Health (NSDUH), available at https://datafiles.samhsa.gov/study-series/national-survey-drug-use-and-health-nsduh-nid13517	PUREX00067691	PUREX00067694
PUR5405	1/18/2019	NYU Langone Health Website: New Study Shows Physician-Targeted Marketing Is Associated with Increase in Opioid Overdose Deaths, available at https://nyulangone.org/news/new-study-shows-physician-targeted-marketing-associated-increase-opioid-overdose-deaths	PUREX00067695	PUREX00067700
PUR5406	1/1/2006	Practitioner's Manual An Informational Outline of the Controlled Substances Act	PUREX00067701	PUREX00067762
PUR5407	8/20/2019	Ohio Academy of Family Physicians Website: Ohio Automated Rx Reporting System, available at https://www.ohioafp.org/public-policy/state-legislative-regulatory-issues/ohio-automated-rx-reporting-system/	PUREX00067763	PUREX00067765
PUR5408	8/20/2019	Ohio Academy of Family Physicians Website: Opioid Prescribing Guidelines, available at https://www.ohioafp.org/public-policy/state-legislative-regulatory-issues/opioid-prescribing-guidelines/	PUREX00067766	PUREX00067776
PUR5409	5/1/2019	A Longitudinal Analysis of Ohio Suicide Deaths 2008 - 2017	PUREX00067777	PUREX00067795
PUR5410	8/20/2019	Healthinsurance.org Website: Ohio and the ACA's Medicaid expansion: eligibility, enrollment and benefits, available at https://www.healthinsurance.org/ohio-medicaid/	PUREX00067796	PUREX00067806
PUR5411	8/20/2019	State of Ohio Website: Ohio Automated Rx Reporting System, available at https://www.ohiopmp.gov/About.aspx	PUREX00067807	PUREX00067808
PUR5412	8/20/2019	Sate of Ohio Website: Bureau of Workers' Compensation, available at: https://info.bwc.ohio.gov/wps/portal/bwc/site/worker/getting-medical-care/needling-a-prescription	PUREX00067809	PUREX00067811
PUR5413	4/17/2014	Ohio Department of Health: Ohio's Prescription Drug Overdose Epidemic: Epidemiology, Contributing Factors and Ongoing Prevention Efforts	PUREX00067812	PUREX00067876
PUR5414	8/20/2019	Ohio Department of Insurance Website: Health Insurance, available at https://www.insurance.ohio.gov/Consumer/Pages/Health-Insurance.aspx	PUREX00067877	PUREX00067878
PUR5415	8/20/2019	Ohio Department of Insurance Website: Ohio Heath Insurance Exchange , available at https://insurance.ohio.gov/Consumer/Pages/Exchange Overview.aspx	PUREX00067879	PUREX00067881
PUR5416	9/19/2016	Letter from John B. McCarthy to Sylvia Burwell enclosing Ohio Access Monitoring Review Plan	PUREX00067882	PUREX00068064
PUR5417	6/29/2018	Ohio Department of Medicaid Presentation: My Care Ohio Evaluation 2018	PUREX00068065	PUREX00068089
PUR5418	8/20/2019	State of Ohio Website: Drug Coverage Information, available at https://pharmacy.medicaid.ohio.gov/drug-coverage	PUREX00068090	PUREX00068090
PUR5419	8/20/2019	State of Ohio Website: Drug Utilization Review (DUR) Board, available at https://pharmacy.medicaid.ohio.gov/drug-utilization-review-board	PUREX00068091	PUREX00068092
PUR5420	8/20/2019	Ohio Department of Medicaid Website: Choosing a Managed Care Plan, available at https://medicaid.ohio.gov/FOR-OHIOANS/Programs/Managed-Care-for-Ohioans	PUREX00068093	PUREX00068093
PUR5421	2/7/2017	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, February 7, 2017	PUREX00068094	PUREX00068095

PUR5422	6/11/2014	Ohio Department of Medicaid (ODM) P&T Committee Meeting Minutes, June 11, 2014	PUREX00068096	PUREX00068280
PUR5423	5/8/2018	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, May 8, 2018	PUREX00068281	PUREX00068283
PUR5424	5/16/2017	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, May 16, 2017	PUREX00068284	PUREX00068286
PUR5425	5/17/2016	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, May 17, 2016	PUREX00068287	PUREX00068288
PUR5426	5/20/2014	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, May 20, 2014	PUREX00068289	PUREX00068290
PUR5427	11/14/2017	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, November 14, 2017	PUREX00068291	PUREX00068292
PUR5428	9/11/2018	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, September 11, 2018	PUREX00068293	PUREX00068294
PUR5429	9/16/2014	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, September 16, 2014	PUREX00068295	PUREX00068296
PUR5430	9/26/2017	Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting Minutes, September 26, 2017	PUREX00068297	PUREX00068298
PUR5432	8/20/2019	State of Ohio Website: Welcome to the Ohio Medicaid Pharmacy Program, available at: https://Pharmacy.medicaid.ohio.gov	PUREX00068299	PUREX00068299
PUR5433	6/1/2018	Ohio Department of Medicaid: Request for Rx Prior Authorization: Long-Acting or Short-Acting Opioid Medication	PUREX00068300	PUREX00068301
PUR5434	8/20/2019	Ohio Department of Mental Health and Addiction Services Website: Urban Minority Alcoholism and Drug Abuse Outreach Programs, available at: https://mha.ohio.gov/Families-Children-and-Adults/For-Teens-and-Young-Adults/Urban-Minority-Outreach/Opiate-Therapies	PUREX00068302	PUREX00068303
PUR5435	8/21/2019	Ohio Mental Health & Addiction Services Website: Opioid Prescribing Guidelines, available at: https://workforce.mha.ohio.gov/Workforce-Development/Health-Professionals/Opioid-Prescribing-Limits	PUREX00068304	PUREX00068305
PUR5436	1/1/2016	Governor's Cabinet Opiate Action Team: Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments	PUREX00068306	PUREX00068307
PUR5437	5/17/2010	Ohio Prescription Drug Abuse Task Force Presentation: Initial Report Progress & Recommendations	PUREX00068308	PUREX00068327
PUR5438; PUR4987	10/1/2010	Ohio Prescription Drug Abuse Task Force: Final Report Task Force Recommendations, published by Center for Interventions, Treatment, and Addictions Research - Unintentional Prescription Drug Poisoning Project.	PUREX00068328	PUREX00068403
PUR5439	3/22/2018	Moody's Investors Service article, republished by OMAC MuniNews: "Sales tax collections drop in 2017 with elimination of Medicaid MCO tax"	PUREX00068404	PUREX00068409
PUR5440	12/19/2018	CDC website - Opioid Data Analysis and Resources, available at https://www.cdc.gov/drugoverdose/data/analysis.html	PUREX00068410	PUREX00068414
PUR5441	9/21/2017	CVS Health website article - "Expanded Opioid Response Builds on Past Efforts"	PUREX00068415	PUREX00068417
PUR5442	12/31/2018	CVS Caremark Opioid Quantity Limits Pharmacy Reference Guide	PUREX00068418	PUREX00068418
PUR5443	3/1/2019	CMS Roadmap: Fighting the Opioid Crisis	PUREX00068419	PUREX00068422
PUR5444	5/1/2018	Federal Reserve Bank of Cleveland Working Paper 18-07: Opioids and the Labor Market	PUREX00068423	PUREX00068455
PUR5445	11/3/2015	Job Market Paper by Angela Kilby - "Opioids for the masses: Welfare tradeoffs in the regulation of narcotic pain medications"	PUREX00068456	PUREX00068548
PUR5446	6/1/2019	Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse	PUREX00068549	PUREX00068586
PUR5447	8/20/2019	Oswald Companies' Employee Benefits and Health Insurance Solutions website page, available at https://www.oswaldcompanies.com/employee-benefits/	PUREX00068587	PUREX00068596
PUR5450	10/9/2017	CIGNA website page - "Pain Management Clinic," available at https://www.cigna.com/individuals-families/health-wellness/hw/medical-topics/pain-management-clinic-tr3230	PUREX00068654	PUREX00068655
PUR5451	7/1/2016	Florida Department of Health website page - "Pain Management Clinic," available at www.floridahealth.gov/licensing-and-regulation/pain-management-clinics/index.html	PUREX00068656	PUREX00068657
PUR5452	12/1/2001	Pain: Current Understanding of Assessment, Management, and Treatments, monograph published by the National Pharmaceutical Council, Inc. and Joint Commission on Accreditation of Healthcare Organizations	PUREX00068658	PUREX00068758
PUR5453	5/6/2019	Pain Management Policies: Board-by-Board Overview, published by the Federation of State Medical Boards	PUREX00068759	PUREX00068771
PUR5454	1/1/2018	NEJM Catalyst website article - "Patient Satisfaction Surveys," available at https://catalyst.nejm.org/patient-satisfaction-surveys/	PUREX00068772	PUREX00068780
PUR5455	7/1/2014	2014-2015 Prescription Drug Benefit Cost and Plan Design Report, published by the Pharmacy Benefit Management Institute and sponsored by Takeda Pharmaceuticals U.S.A., Inc.	PUREX00068781	PUREX00068840
PUR5456	8/27/2012	CDC Expert Panel Meeting Report - Patient Review & Restriction Programs: Lessons learned from state Medicaid programs	PUREX00068841	PUREX00068858
PUR5457	8/20/2019	U.S. Department of Justice, Drug Enforcement Administration website page - "Pharmacist's Manual - Section IX-XIV," available at https://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_content.htm	PUREX00068859	PUREX00068870
PUR5458	1/1/2018	Pharmacy Quality Alliance website page - "Optimizing Health by Advancing the Quality of Medication Use," available at https://www.pqaalliance.org	PUREX00068871	PUREX00068873

PUR5459	8/20/2019	Radars System website page - "Radars System Programs: Poison Center," available at https://www.radars.org/radars-system-programs/poison-center.html	PUREX00068874	PUREX00068875
PUR5460	1/22/2004	U.S. General Accounting Office Report 04-110, "Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem," published at https://www.gao.gov/htext/d04110.html	PUREX00068876	PUREX00068921
PUR5461	1/1/2019	Medical Mutual Prescription Resources, available at https://www.medmutual.com/For-Employers/Employer-Resources/Prescription-Resources.aspx	PUREX00068922	PUREX00068923
PUR5462	8/20/2019	Medical Mutual - Individual Health Insurance, Group website page - "Medical Mutual's guide to prescription formulary, prior authorization, clinical services, pharmaceutical education, and home delivery practices," available at https://provider.medmutual.com/tools_and_resource/Care_Management/ExpressScript.s.aspx	PUREX00068924	PUREX00068924
PUR5463	1/22/2004	Article - "Purdue Pharma L.P. (Connecticut) Comments on GAO Report on OxyContin(R) Abuse and Diversion," available at https://www.biospace.com/article/releases/purdue-pharma--l-p-connecticut-comments-on-b-gao-b-report-on-oxycontin-r-abuse-and-diversion-/	PUREX00068925	PUREX00068928
PUR5464	9/6/2017	Shinogi Inc. press release - "Shinogi Inc. and Purdue Pharma L.P. to Present Data from Nalmedine Studies at PAINWeek 2017 Annual Conference," available at https://www.shinogi.com/inc-and-purdue-pharma-l-p-to-present-data-from-nalmedine-studies-at-painweek-2017-annual-conference-2/	PUREX00068929	PUREX00068933
PUR5465	5/10/2019	Website article - "Prescription of Controlled Substances: Benefits and Risks," available at https://www.ncbi.nlm.nih.gov/books/NBK537318/	PUREX00068934	PUREX00068952
PUR5466	1/1/2019	Project Alert Website: Project ALERT Adds Opioid Lesson to Core Curriculum, available at https://www.projectalert.com	PUREX00068953	PUREX00068954
PUR5467	8/20/2019	Youth.Gov Website: Project Northland, available at https://youth.gov/content/project-northland	PUREX00068955	PUREX00068962
PUR5468	10/17/2001	Joint Statement from 21 Health Organizations and the Drug Enforcement Administration, Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act	PUREX00068963	PUREX00068963
PUR5469	8/20/2019	Medicaid.Gov Website: Quality of Care, available at https://www.medicaid.gov/medicaid/quality-of-care/index.html	PUREX00068964	PUREX00068967
PUR5470	6/27/2018	Rand Corporation Website: Key Findings from RAND Health's Research on Opioid Policy, available at www.rand.org	PUREX00068968	PUREX00068971
PUR5471	1/1/2014	Lee, JM & Taylor, LO.; Discussion Papers, U.S. Census Bureau, Center for Economic Studies, CES.Papers.List@census.gov Randomized Safety Inspections and Risk Exposure on the Job: Quasi-Experimental Estimates of the Value of a Statistical Life, North Carolina State University Center for Economic Studies, CES No. 14-05, January 2014	PUREX00068972	PUREX00069022
PUR5472	1/1/2018	Regence Health Insurance, Medication Policy Manual, Extended-Release (ER) Opioid Medication Products for Pain, April 1, 2019	PUREX00069023	PUREX00069053
PUR5473	4/1/2019	FDA REMS: FDA's Application of Statutory Factors in Determining When a REMS is Necessary Guidance for Industry, Guidance for Industry, April 2019	PUREX00069054	PUREX00069066
PUR5474	10/1/2018	Kaiser Family Foundation, Employer Health Benefits, 2018 Annual Survey (Publication #9240 available at www.kff.org)	PUREX00069067	PUREX00069299
PUR5475	2/12/2018	American Academy of Pain Medicine Website: Response to Inquiries about Payments from Opioid Manufacturers, available at https://painmed.org/aapn-news/response-to-inquiries-about-payments-from-opioid-manufacturers	PUREX00069300	PUREX00069301
PUR5476	9/1/2008	McCarberg, B, Book Review of Scott Fishman's Responsible Opioid Prescribing: A Physician's Guide, Pain Medicine, Volume 9, Number 6, 2008, pp. 758-760	PUREX00069302	PUREX00069303
PUR5477	5/1/2017	RADARS Systems Presentation: Interventions in Prescription Opioid Abuse - Do (or Can) Prescription Monitoring Programs Make a Difference?	PUREX00069304	PUREX00069321
PUR5478	6/18/2010	Center for Drug Evaluation and Research, Application No. 22-272 (Purdue Pharma): Risk Assessment and Risk Mitigation Review(s)	PUREX00069322	PUREX00069374
PUR5479	5/8/2018	Statement of Robert W. Patterson, Acting Administrator, Drug Enforcement Administration, before House Judiciary Committee, U.S. House of Representatives, Hearing Entitled "Challenges and Solutions in the Opioid Abuse Crisis"	PUREX00069375	PUREX00069393
PUR5480	8/20/2019	RxList Website: Today's Top Health and Drug News, available at https://www.rxlist.com/script/main/hp.asp	PUREX00069394	PUREX00069398
PUR5481	10/18/2017	CME: Discussing Best Practices in Combating Opioid Abuse	PUREX00069399	PUREX00069403
PUR5482	12/1/1998	Article in PharmExec.com: "Sales force sizes exploded in 1998"	PUREX00069404	PUREX00069405
PUR5483	7/1/1998	Sales forces grow to record sizes	PUREX00069406	PUREX00069406
PUR5484	8/20/2019	Report from SAMHSA: "National Survey on Drug Use and Health."	PUREX00069407	PUREX00069409
PUR5485	12/1/2017	Report from SAMHSA: "Prescription Drug Monitoring Programs: A Guide for Healthcare Providers."	PUREX00069410	PUREX00069421
PUR5486	8/21/2019	Web page screen shot: www.sas.com SAS Maps Online	PUREX00069422	PUREX00069422
PUR5488	1/4/2012	Child Trends Website: Start Taking Alcohol Risks Seriously (STARS) for Families, available at https://www.childtrends.org/programs/stars-start-taking-alcohol-risks-seriously-for-families	PUREX00069423	PUREX00069427
PUR5489	1/21/2017	Joseph, Andrew & Joseph, Drew Q, CVS tightens restrictions on opioid prescriptions in bid to stanch epidemic; September 21, 2017 available at https://www.statnews.com/2017/09/21/cvs-opiod-prescriptions-limits/	PUREX00069428	PUREX00069431
PUR5490	1/11/2017	Letter from Brian Neale to Sate Medicaid Director re: Medicaid beneficiaries and the opioid crisis	PUREX00069432	PUREX00069445

PUR5491	12/23/2018	Ohio Government website: Establishing safety checkpoints on prescription opioids for long-term pain will help ensure that treatment is improving patients' quality of life without increasing the risk of opioid misuse and addiction, available at https://med.ohio.gov/Overview-Regulations-for-Chronic-and-Subacute-Opiod-Prescriptions	PUREX00069446	PUREX00069447
PUR5492	8/20/2019	Ohio Rx Reporting System website: Ohio Automated Rx Reported System available at https://www.ohiopmp.gov	PUREX00069448	PUREX00069449
PUR5493; PUR5024	1/1/2019	Ohio Automated Rx Reporting System 2018 Annual Report	PUREX00069450	PUREX00069462
PUR5494	3/27/2019	Statement from FDA Commission Scott Gottlieb, M.D. re: fentanyl products available https://www.fda.gov/news-events/press-announcements/statements-fda-commissioner-scott-gottlieb-md-new-steps-strengthen-agencys-safety-requirements	PUREX00069463	PUREX00069467
PUR5495	8/20/2019	Purdue Pharma Website: Addressing the Opioid Crisis, available at https://www.purduepharma.com/addressing-the-crisis/strong-track-record/	PUREX00069468	PUREX00069472
PUR5496	8/20/2019	Substance Abuse and Mental Health Services Administration Website: 2017 NSDUH Detailed Tables	PUREX00069473	PUREX00069474
PUR5497	8/20/2019	Healthcare.gov: Health insurance rights & protections Summary of Benefits and Coverage available at www.healthcare.gov/health-care-law-protections/summary-of-benefits-and-coverage	PUREX00069475	PUREX00069476
PUR5498	8/20/2019	U.S. Department of Labor Website: Summary of Benefits and Coverage and Uniform Glossary, available at www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordablcare-act/for-employers-and-advisers-summary-of-benefits	PUREX00069477	PUREX00069478
PUR5499	8/21/2019	Summit Department of Communications Website: Budget Information, available https://co.summitoh.net/index.php/departments/finance-a-budget/budget-information	PUREX00069479	PUREX00069481
PUR5500	8/21/2019	Summit Executive's Office Department os Communication's Website: Comprehensive Audit Reports, available at https://internalaudit.summit.net/index.php/comprehensive-audit-reports	PUREX00069482	PUREX00069483
PUR5501	8/20/2019	Summit County Addiction Help Website. Opiod & Addiction Task Force, available at https://www.summitcountyaddictionhelp.org/opiate-task-force-members.aspx	PUREX00069484	PUREX00069487
PUR5502	1/1/2016	Charter of Summit County, Ohio	PUREX00069488	PUREX00069509
PUR5503	1/12/2016	Wharton, Abby Alpert, et al., Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids, December 2016,	PUREX00069510	PUREX00069567
PUR5505	1/10/2017	Rembert, Mark, et al., Taking Measure of Ohio's Opiod Crisis, Swank Program in Rural-Urban Policy, October 2017	PUREX00069568	PUREX00069594
PUR5506	12/18/2014	Substance Abuse and Mental Health Services Administration Website, Benzodiazepines in Combination with Opiod Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes, December 18, 2014	PUREX00069595	PUREX00069600
PUR5507	10/21/2015	Journal of Managed Care Specialty Pharmacy Website; The Economic Impact of Opioid Use in the Management of Chronic Nonalignament Pain, Vol. 21, Issue 10 available at https://www.jmcp.org/doi/10.18553/jmcp.2015.21.10.891	PUREX00069601	PUREX00069611
PUR5508	1/1/2011	U.S. Department of Justice National Drug Intelligence Center: The Economic Impact of Illicit Drug Use on American Society, 2011	PUREX00069612	PUREX00069734
PUR5509	1/11/2017	The Council of Economic Advisers; The Underestimated Cost of the Opioid Crisis, 2017	PUREX00069735	PUREX00069748
PUR5510	1/18/2019	Cleveland News Website: Krouse, Peter, Three Cuyahoga County administrators indicted in corruption probe, available at www.cleveland.com/news/2019/01/three-cuyahoga-county-administraors-indicted-in-corruption-probe.html	PUREX00069749	PUREX00069756
PUR5511	2/11/2016	Presentation:Implications of Draft Guidelines on Abuse Liability Testing for Generic Opioids	PUREX00069757	PUREX00069794
PUR5512	1/3/2007	Timing and Duration of Student Participation in Special Education in the Primary Grades, National Center for Education Statistics	PUREX00069795	PUREX00069798
PUR5513	8/21/2019	Treatment Episode Data Set: Admissions (TEDS-A), Substance Abuse & Mental Health Data Archive	PUREX00069799	PUREX00069801
PUR5514	12/23/2011	Pro Publica Website: Two Leaders in Pain Treatment Have Long Ties to Drug Industry, www.propublica.org/article/two-leaders-in-pain-treatment-have-long-ties-to-drug-industry	PUREX00069802	PUREX00069806
PUR5515	1/7/2018	U.S. Department of Health & Human Services Office of Inspector General: Opioids in Ohio Medicaid: Review of Extreme Use in Prescribing	PUREX00069807	PUREX00069839
PUR5516	8/20/2019	Substance Abuse and Mental Health Services Administration (SAMHSA): Pocket Guide, Medication-Assisted Treatment of Opioid Use Disorder	PUREX00069840	PUREX00069855
PUR5517	1/1/2019	U.S. Department of Health and Human Services: Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition	PUREX00069856	PUREX00071416
PUR5519	8/20/2019	FDA Website: New Safety Measures Announced for Extended-release and Long-acting Opioids, available at https://www.fda.gov/drugs/information-drug-class/new-safety-measures-announced-extended-release-and-long-acting-opioids	PUREX00071417	PUREX00071419
PUR5520	11/21/2018	Cleveland.com Website: US Marshals: Cuyahoga County deprives inmates of food, water and Constitutional Rights amid string of seven deaths, available at: https://cleveland.com/news/errry-2018/11/9b3d3f3cc89150/us-marshals-cuyahoga-county-de.html	PUREX00071420	PUREX00071425

PUR5521	3/28/2019	US News Website: In Most States, Insurance Won't Cover Addiction Treatments, available at www.usnews.com/news/health-news/articles/2019-03-28/in-most-states-insurance-wont-cover-addiction-treatments	PUREX00071426	PUREX00071431
PUR5522	8/20/2019	FDA Website: A Guide to Safe Use of Pain Medicine, available at www.fda.gov/consumers/consumer-updates/guide-safe-use-pain-medicine	PUREX00071432	PUREX00071436
PUR5523	8/21/2019	United States Zip Codes Website: available at www.unitedstateszipcodes.org	PUREX00071437	PUREX00071441
PUR5524	8/20/2019	URAC Website: available at www.urac.org	PUREX00071442	PUREX00071444
PUR5525	1/1/2019	Medical Mutual Website: Utilization Management Program and Medical Policy Review, available at https://www.medmutual.com/For-Employers/Plans-Products/Health-and-Wellness-Programs-and-Services/Utilization-Management-and-Medical-Policy-and-Review.aspx	PUREX00071445	PUREX00071446
PUR5526	4/1/2011	Cropper, Maureen L., et al., Valuing Mortality Risk Reductions: Progress and Challenges, National Bureau of Economic Research	PUREX00071447	PUREX00071482
PUR5527	1/1/2016	Pharmaceutical Care Management Association report: PBMs: Generating Savings for Plan Sponsors and Consumers	PUREX00071483	PUREX00071504
PUR5528	8/16/2016	ZS Associates marketing: AccessMonitor and AffinityMonitor 2016 Executive Summary	PUREX00071505	PUREX00071520
PUR5529	2/15/2019	Cleveland.com article Warrant Shows Search of Cuyahoga County Executive Armond Budish's Office Related to Troubled Jail Operations, Cites Possible Extortion, available at https://www.cleveland.com/cuyahoga-county/2019/02/warrant-shows-search-of-cuyahoga-county-executive-armond-budishs-office-is-related-to-troubled-jail-operations-cites-possible-extortion.html	PUREX00071521	PUREX00071526
PUR5530	1/1/2018	Third Amendment to and Complete Restatement of Western Asbestos Settlement Trust Case Valuation Matrix	PUREX00071527	PUREX00071547
PUR5531	8/20/2019	WebMD article Stem Cell Clinics: Effective Medicine or Expensive False Hope? available at www.webmd.com	PUREX00071548	PUREX00071553
PUR5532	2/28/2017	Who are the 700,000 Ohioans receiving health insurance under Medicaid expansion - cleveland.com	PUREX00071554	PUREX00071560
PUR5534	5/14/2019	Who's who of Cuyahoga County investigation (updated) - cleveland	PUREX00071637	PUREX00071641
PUR5536	5/14/2012	Sales Bulletin 115: Information Regarding OxyContin Tablets and Upcoming Poster Presentations at American Pain Society Conference	PURCHI-000005164	PURCHI-000005165
PUR5537	9/1/2016	Sales Bulletin 138: Purdue Pride: Our Call To Action	PURCHI-000006857	PURCHI-000006860
PUR5538	2/26/2016	Marketing Bulletin 19: Update on Ordering Experience Programs and Shipping	PURCHI-000006871	PURCHI-000006895
PUR5539	1/1/2016	Marketing Spend Summary by Year 2008-2016.	PURCHI-000008315	PURCHI-000008315
PUR5540	9/4/2007	2006 Annual Summary Report for the OxyContin Risk Management Plan	PURCHI-000009755	PURCHI-000009966
PUR5541	10/1/2010	OxyContin REMS Six Month Assessment - Risk Management Program 2009-2010 Summary Report	PURCHI-000039459	PURCHI-000039521
PUR5542	10/1/2010	OxyContin REMS Six Month Assessment - Risk Management Program 2009-2010 Summary Report, Appendices	PURCHI-000039522	PURCHI-000039712
PUR5543	9/30/2010	Combined Report October 2010; OxyContin REMS 6-Month Assessment	PURCHI-000039713	PURCHI-000039714
PUR5544	8/17/2011	Letter to FDA re Proposed REMS	PURCHI-000079171	PURCHI-000079174
PUR5545	8/17/2011	NDA 020553 OxyContin REMS	PURCHI-000079198	PURCHI-000079225
PUR5546	10/1/2011	NDA 020553 Risk Management Program 2010/11 Summary Report	PURCHI-000079629	PURCHI-000079675
PUR5547	7/2/2013	Letter from Beth Connally to Bob A. Rappaport, M.D.	PURCHI-000104462	PURCHI-000104464
PUR5548	10/17/2008	RxReacts Material - How to Protect Your Medicines at Home	PURCHI-000143727	PURCHI-000143730
PUR5549	12/31/2008	RxReacts Material - Providing Relief Preventing Abuse – A reference guide to controlled substance prescribing practices	PURCHI-000143735	PURCHI-000143762
PUR5550	11/16/2009	NDA 22-272 OxyContin: Proposed Risk Evaluation and Mitigation Strategy (REMS)	PURCHI-000144440	PURCHI-000144475
PUR5551	10/1/2010	NDA 22272 OxyContin REMS Six Month Assessment and Risk Management Program 2009-2010 Summary Report	PURCHI-000154251	PURCHI-000154313
PUR5552	10/1/2010	OxyContin NDA 22272 Six Month Assessment and Risk Management Program: Appendices	PURCHI-000154314	PURCHI-000154504
PUR5553	3/1/2011	OxyContin REMS One Year Assessment Report for NDA 022272	PURCHI-000175346	PURCHI-000175410
PUR5554	3/1/2011	OxyContin REMS One Year Assessment Report for NDA 022272: Appendices	PURCHI-000175411	PURCHI-000175474
PUR5555	8/2/2011	NDA 022272 OxyContin Tablets, controlled release	PURCHI-000202240	PURCHI-000202243
PUR5556	8/10/2011	NDA 022272 OxyContin REMS	PURCHI-000202580	PURCHI-000202586
PUR5557	4/1/2012	OxyContin Tablets REMS 2-yr. Assessment Report for NDA 022272	PURCHI-000220050	PURCHI-000220413
PUR5558	7/31/2012	Purdue Law Enforcement LELE Report	PURCHI-000225508	PURCHI-000225527
PUR5559	5/28/2013	Letter from Richard Fanelli to Bob Rappaport re OxyContin Tablets NDA 022272, Sequence 0176	PURCHI-000241605	PURCHI-000241607
PUR5560	4/16/2013	Literature Review on Opioid Addiction and Risk by Craig Landau	PURCHI-000241613	PURCHI-000241667
PUR5561	12/1/2016	MS Contin - Highlights of Prescribing Information	PURCHI-000543221	PURCHI-000543247
PUR5562	6/2/1999	Regulatory Filings re: OxyContin Advertisements and Promotional Labeling	PURCHI-000550254	PURCHI-000550330
PUR5563	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mgs): Table of Contents	PURCHI-000572306	PURCHI-000572403
PUR5564	12/28/1994	OxyContin CR Tablets New Drug Application Archival and Review Copies (10, 20, 40 mg)	PURCHI-000572404	PURCHI-000572777
PUR5565	12/15/1994	OxyContin CR Tablets New Drug Application Chemistry, Manufacturing and Controls Section (10, 20, 40 mgs)	PURCHI-000572778	PURCHI-000573136
PUR5566	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 3	PURCHI-000573137	PURCHI-000573484
PUR5567	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 4	PURCHI-000573485	PURCHI-000573819
PUR5568	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 5	PURCHI-000573820	PURCHI-000574125
PUR5569	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 6	PURCHI-000574126	PURCHI-000574495
PUR5570	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 7	PURCHI-000574496	PURCHI-000574815

PUR5649	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 85	PURCHI-000603201	PURCHI-000603654
PUR5650	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 86	PURCHI-000603655	PURCHI-000604102
PUR5651	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 87	PURCHI-000604103	PURCHI-000604508
PUR5652	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 88	PURCHI-000604509	PURCHI-000604945
PUR5653	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 89	PURCHI-000604946	PURCHI-000605381
PUR5654	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 90	PURCHI-000605382	PURCHI-000605794
PUR5655	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 91	PURCHI-000605795	PURCHI-000606171
PUR5656	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 92	PURCHI-000606172	PURCHI-000606581
PUR5657	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 93	PURCHI-000606582	PURCHI-000606940
PUR5658	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 94	PURCHI-000606941	PURCHI-000607410
PUR5659	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 95	PURCHI-000607411	PURCHI-000607691
PUR5660	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 96	PURCHI-000607692	PURCHI-000608125
PUR5661	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 97	PURCHI-000608126	PURCHI-000608579
PUR5662	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 98	PURCHI-000608580	PURCHI-000608783
PUR5663	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 99	PURCHI-000608784	PURCHI-000609193
PUR5664	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 100	PURCHI-000609194	PURCHI-000609627
PUR5665	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 101	PURCHI-000609628	PURCHI-000609974
PUR5666	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 102	PURCHI-000609975	PURCHI-000610206
PUR5667	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 103	PURCHI-000610207	PURCHI-000610464
PUR5668	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 104	PURCHI-000610465	PURCHI-000610691
PUR5669	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 105	PURCHI-000610692	PURCHI-000611044
PUR5670	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 106	PURCHI-000611045	PURCHI-000611525
PUR5671	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 107	PURCHI-0006111526	PURCHI-000611949
PUR5672	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 108	PURCHI-000611950	PURCHI-000612235
PUR5673	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 109	PURCHI-000612236	PURCHI-000612456
PUR5674	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 110	PURCHI-000612457	PURCHI-000612743
PUR5675	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 111	PURCHI-000612744	PURCHI-000613094
PUR5676	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 112	PURCHI-000613095	PURCHI-000613578
PUR5677	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 113	PURCHI-000613579	PURCHI-000613851
PUR5678	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 114	PURCHI-000613852	PURCHI-000614195
PUR5679	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 115	PURCHI-000614196	PURCHI-000614473
PUR5680	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 116	PURCHI-000614474	PURCHI-000614829
PUR5681	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 117	PURCHI-000614830	PURCHI-000615206
PUR5682	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 118	PURCHI-000615207	PURCHI-000615559
PUR5683	12/28/1994	OxyContin CR Tablets New Drug Application (10, 20, 40 mg) Volume 119	PURCHI-000615560	PURCHI-000615961
PUR5684	1/25/2000	Form 2253: OxyContin Tablets	PURCHI-000620382	PURCHI-000620490
PUR5685	12/28/1994	Letter from James Conover to Robert Bedford re: NDA#20-553	PURCHI-000620750	PURCHI-000620784
PUR5686	1/31/1995	Letter from Lee Ann Storey to Robert Bedford re: Oxycodone Hydrochloride NDA #20-553	PURCHI-000620847	PURCHI-000620848
PUR5687	2/6/1995	Medical Officer Review (MOR) Integrated Summary of Efficacy Oxycodone Controlled Release	PURCHI-000620854	PURCHI-000620926
PUR5689	12/19/1995	Letter to FDA from Lee Ann Storey RE: Response to Promotional Questions	PURCHI-000621753	PURCHI-000621801
PUR5690	8/16/1995	Letter to FDA regarding revised draft package insert	PURCHI-000622498	PURCHI-000622524
PUR5691	11/13/1995	Regulatory Agency Contact Report - OxyContin NDA # 20-553	PURCHI-000622706	PURCHI-000622707
PUR5692	1/3/1996	Letter from James Conover to Robert Bedford re: Oxycodone Hydrochloride NDA #20-553	PURCHI-000622972	PURCHI-000622984
PUR5694	1/30/1996	Letter from Diane Shnitzler to James Conover and Lee Ann Storey re: OxyContin NDA #20-553	PURCHI-000623095	PURCHI-000623099
PUR5695	1/31/1996	Letter from Diane Shnitzler to James Conover re: OxyContin NDA #20-553	PURCHI-000623100	PURCHI-000623102
PUR5696	2/9/1996	Letter from Lee Ann Storey to Diane Shnitzler re: Oxycodone Hydrochloride NDA #20-553	PURCHI-000623112	PURCHI-000623167
PUR5697	2/27/1996	Letter from Diane Shnitzler to Lee Ann Storey re: OxyContin	PURCHI-000623168	PURCHI-000623172
PUR5698	3/4/1996	Memorandum from Lee Ann Storey to Diane Shnitzler re: OxyContin visual aid	PURCHI-000623173	PURCHI-000623177
PUR5699	3/6/1996	Letter from Lee Ann Storey to Robert Bedford re: OxyContin Tablets NDA #20-553	PURCHI-000623178	PURCHI-000623185
PUR5702	3/5/1996	Regulatory Agency Contact Report for OxyContin NDA #20-553	PURCHI-000623235	PURCHI-000623236
PUR5703	3/13/1996	Letter from Diane Shnitzler to Lee Ann Storey re: OxyContin NDA #20-553	PURCHI-000623238	PURCHI-000623241
PUR5704	4/16/1996	Letter from Lee Ann Storey to Diane Shnitzler re: Oxycodone Hydrochloride NDA #20-553	PURCHI-000623292	PURCHI-000623300
PUR5705	5/9/1996	Letter from Diane Shnitzler to Lee Ann Storey re: OxyContin NDA #20-553	PURCHI-000623303	PURCHI-000623307
PUR5706	5/23/1996	Memo from Lee Ann Storey to Tom Abrams re: Revised OxyContin visual aid	PURCHI-000623326	PURCHI-000623335
PUR5707	1/31/1997	Letter to Curtis Wright from Beth Kennedy re: OxyContin Controlled Release Tablets NDA #20-553/S-002	PURCHI-000623347	PURCHI-000623353
PUR5708	2/20/1997	Letter to Curtis Wright from James Conover re: OxyContin 80 mg Tablets NDA#20-553/S-002	PURCHI-000623355	PURCHI-000623377
PUR5709	3/24/1997	Letter from Stephen Sherman, FDA, to Dr. James Conover re: NDA 20-553, OxyContin 80 mg Tablets	PURCHI-000623387	PURCHI-000623392
PUR5710	4/21/1997	Letter from Lee Ann Storey to Stephen Sherman re: Oxycodone Hydrochloride NDA #20-553	PURCHI-000623439	PURCHI-000623440
PUR5711	4/21/1997	Regulatory Agency Contact Report for Oxycontin 80 mg Tablet Promotion	PURCHI-000623441	PURCHI-000623442
PUR5712	4/24/1997	Letter to Lee Ann Storey from Stephen Sherman	PURCHI-000623443	PURCHI-000623447
PUR5713	4/28/1997	Letter from Lee Ann Storey to Stephen Sherman re Oxycodone Hydrochloride NDA #20-553	PURCHI-000630870	PURCHI-000630878
PUR5714	6/20/1996	Letter from Curtis Wright from DHHS to James Conover from Purdue re: Labeling approval	PURCHI-000631782	PURCHI-000631784
PUR5715	5/9/1997	Regulatory Filings re: OxyContin Advertisements and Promotional Labeling	PURCHI-000632236	PURCHI-000632264
PUR5716	3/20/2001	Form 2253: MS Contin	PURCHI-000674082	PURCHI-000674124

PUR5717	5/16/2001	Letter to Cynthia McCormick from J. Christopher Prue	PURCHI-000674616	PURCHI-000675018
PUR5718	4/23/2001	Summary of OxyContin Meeting	PURCHI-000675080	PURCHI-000675085
PUR5719	6/7/2001	Letter to Cynthia McCormick from J. Christopher Prue	PURCHI-000675606	PURCHI-000675668
PUR5720	6/22/2001	Email to Paul Goldenheim et al from Christopher Prue	PURCHI-000678737	PURCHI-000678761
PUR5721	7/12/2001	Letter from Christopher Prue U.S. Regulatory Affairs to Cynthia McCormick FDA	PURCHI-000679174	PURCHI-000679201
PUR5722	8/3/2001	Letter from FDA to Christopher Prue regarding promotional materials	PURCHI-000679596	PURCHI-000679599
PUR5723	8/10/2001	Letter from FDA to Christopher Prue regarding promotional materials	PURCHI-000679881	PURCHI-000679885
PUR5724	1/10/2002	Letter from Christopher Prue to Cynthia McCormick Enclosing Patient Package revision.	PURCHI-000685019	PURCHI-000685025
PUR5725	3/3/1998	Form 2253: OxyContin Tablets	PURCHI-000723681	PURCHI-000723730
PUR5726	3/10/1998	Letter from James H. Conover to Minnie Baylor-Henry Enclose Purdue Advertising Reports	PURCHI-000723731	PURCHI-000723817
PUR5727	6/7/2004	Form 2253: OxyContin Tablets	PURCHI-000750868	PURCHI-000750897
PUR5728	6/23/2004	Letter from Christopher Prue to Bob A. Rappaport	PURCHI-000763168	PURCHI-000763171
PUR5729	7/20/2004	Letter to Christopher Prue from Lisa Basham-Cruz RE: Meeting Minutes	PURCHI-000764957	PURCHI-000764962
PUR5730	3/16/1999	Form 2253: OxyContin Tablets	PURCHI-000793182	PURCHI-000793206
PUR5731	9/4/2007	Letter from Beth Connally to Bob A. Rappaport	PURCHI-000822337	PURCHI-000822548
PUR5732	4/18/2014	Hysingla New Drug Application NDA#206627(cover letter)	PURCHI-000836232	PURCHI-000836242
PUR5733	11/1/2014	Hysingla ER NDA#206627 Approved Labeling	PURCHI-001845883	PURCHI-001845915
PUR5734	8/17/2011	Long-Acting and Extended-Release Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Supporting Document	PURCHI-003027032	PURCHI-003027070
PUR5735	10/16/2012	Letter from Beth Connally to Bob A. Rappaport	PURCHI-003056327	PURCHI-003056329
PUR5736	10/19/2012	Extended- Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)	PURCHI-003056343	PURCHI-003056418
PUR5737	1/4/2013	Letter from Beth Connally to Bob A Rappaport	PURCHI-003060995	PURCHI-003060997
PUR5738	12/21/2012	Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation (REMS) Program Six-Month Assessment Report	PURCHI-003060998	PURCHI-003061059
PUR5739	3/22/2013	Letter from Todd Baumgartner to Bob A. Rappaport	PURCHI-003064738	PURCHI-003064740
PUR5740	3/22/2013	Systematic Review of the Efficacy and Safety of Long-Term Opioid Therapy in the Management of Chronic Noncancer Pain	PURCHI-003065289	PURCHI-003065434
PUR5741	7/1/2012	MS Contin Highlights of Prescribing Information	PURCHI-003251592	PURCHI-003251613
PUR5742	10/10/2007	Purdue Presentation: Healthcare Law Compliance Policies	PURCHI-003283810	PURCHI-003283853
PUR5743	6/1/2009	Purdue Presentation: Healthcare Law Compliance Policies	PURCHI-003283854	PURCHI-003283897
PUR5744	4/1/2011	Purdue: Healthcare Law Compliance Policies	PURCHI-003283898	PURCHI-003283941
PUR5745	7/1/2013	Purdue Presentation: Healthcare Law Compliance Policies	PURCHI-003283942	PURCHI-003283964
PUR5746	1/1/2005	2005 OxyContin Marketing Plan	PURCHI-003286907	PURCHI-003286953
PUR5747	1/1/2006	Oxycontin Tablets Promotional Plan 2006	PURCHI-003286954	PURCHI-003286955
PUR5748	1/1/2007	OxyContin Tablets 2007 Promo Plan	PURCHI-003286956	PURCHI-003286958
PUR5749	3/1/2004	Materials request from Partners Against Pain sponsored by Purdue	PURCHI-003287355	PURCHI-003287355
PUR5750	1/1/2004	Purdue brochure about professional prescribing information	PURCHI-003287356	PURCHI-003287359
PUR5751	1/1/2004	Advertisement and request card for free copy of Purdue's Primary Care Pain Management Program	PURCHI-003287360	PURCHI-003287361
PUR5752	3/1/2004	States Receive Grades for Balancing Pain and Suffering: The War on Drugs vs. Appropriate Pain Care, Purdue's Partners Against Pain publication	PURCHI-003287362	PURCHI-003287365
PUR5753	3/1/2004	Benefits of Nursing Home Hospice, Purdue's Partners Against Pain publication	PURCHI-003287366	PURCHI-003287369
PUR5754	3/1/2004	What to see, What to find, What to expect: Pain Management Resources for Healthcare Professionals, Health Systems, Patients, and Caregivers, Purdue's Partners Against Pain publication	PURCHI-003287370	PURCHI-003287385
PUR5755	5/1/2014	Controlled Substance Patterns of Utilization Requiring Evaluation (CS-PURE) pamphlet, published by Purdue	PURCHI-003287387	PURCHI-003287387
PUR5756	6/1/2004	Correlates of Analgesic Medication Prescription in Cognitively Impaired Nursing Home Residents, Purdue's Partners Against Pain publication	PURCHI-003287388	PURCHI-003287390
PUR5757	9/1/2004	Purdue marketing pamphlet titled "When pain requires prn opioid therapy, choose OxyIR CII"	PURCHI-003287392	PURCHI-003287393
PUR5758	4/1/2004	Purdue's promotional rebate offer for one order of OxyContin through 5/19/2004	PURCHI-003287394	PURCHI-003287395
PUR5759	7/1/2004	Purdue's promotional rebate offer for two orders of OxyContin 80 mg Tablets through 9/3/2004	PURCHI-003287396	PURCHI-003287397
PUR5760	1/20/2004	Regulatory submission of Professional Sales Aid ("PSA") for OxyContin Tablets - 2004-2005 Calendar	PURCHI-003287398	PURCHI-003287407
PUR5761	3/10/2004	Regulatory submission of Professional Sales Aid ("PSA") for Oxycontin Tablets - Visual Aid for 10 mg & 20 mg	PURCHI-003287437	PURCHI-003287443
PUR5762	1/1/2005	Conversion Guide for OxyContin CII tablets, published by Purdue	PURCHI-003287444	PURCHI-003287451
PUR5763	11/1/2005	Advertising brochure for Standard Register Tamper-resistant Rx Pads from Purdue	PURCHI-003287453	PURCHI-003287453
PUR5764	4/1/2007	Purdue provider brochure "How to Stop Drug Diversion & Protect Your Patients" and patient brochure "How to Take the Medicine Your Doctor Has Prescribed"	PURCHI-003287455	PURCHI-003287456
PUR5765	1/15/2007	Information for patients on OxyContin CII (Spanish language version)	PURCHI-003287457	PURCHI-003287458
PUR5766	1/1/2005	Brochure containing professional prescribing information for Q12h OxyContin CII tablets	PURCHI-003287459	PURCHI-003287462
PUR5767	12/6/2005	Purdue advertising brochure for the launch of 20-count, bar-coded unit dose packaging for OxyContin Tablets	PURCHI-003287469	PURCHI-003287471
PUR5768	7/12/2006	\$20 Instant Savings Card Program information for OxyContin CII Tablets	PURCHI-003287472	PURCHI-003287476
PUR5769	11/1/2006	\$20 Instant Savings Card Program Overview for OxyContin CII Tablets	PURCHI-003287483	PURCHI-003287486
PUR5770	3/1/2005	Information for Vermont Prescribers of Prescription Drugs - OxyContin Tablets from Purdue	PURCHI-003287487	PURCHI-003287488

PUR5771	11/1/2007	Notice of extension of OxyContin CII \$50 Savings Card Program through 6/30/2008	PURCHI-003287489	PURCHI-003287493
PUR5772	12/1/2007	New dosage strengths for OxyContin, 15 mg 30 mg, and 60 mg.	PURCHI-003287494	PURCHI-003287495
PUR5773	5/12/2005	Convenient Conversion from Other Opioids, a guide to titration of OxyContin q12h	PURCHI-003287497	PURCHI-003287498
PUR5774	1/1/2005	Handwritten and typewritten notes re: OxyContin's 2005 media schedule	PURCHI-003287509	PURCHI-003287515
PUR5775	1/12/2004	Purdue sales memorandum from Phil Cramer and Jane Petty re: Prescription Sales Division Incentive Bonus Program RSOP 2.2	PURCHI-003288056	PURCHI-003288056
PUR5776	7/12/2004	Purdue Associated Companies' Healthcare Law Compliance Policies (Rev. 7/12/2004)	PURCHI-003288469	PURCHI-003288505
PUR5777	11/15/2004	Interoffice Memorandum from Sidney Schnoll to Medical Liaisons et al. re: RADARS System Site Visits	PURCHI-003288524	PURCHI-003288525
PUR5778	3/1/2004	Women in Pain, Pain Advocacy Community E-Newsletter Special Issue, Vol. 04-05, March, 2004	PURCHI-003288790	PURCHI-003288801
PUR5779	1/1/2010	County of Summit Capital Improvement Program 2010-2015	SUMMIT_000000001	SUMMIT_000000055
PUR5804	9/28/2016	County of Summit ADM Board Presentation: The Opiate Epidemic: Our Community Response	SUMMIT_000027215	SUMMIT_000027215
PUR5807	6/9/2016	State of Ohio Board of Pharmacy presentation: Ohio Automated Rx Reporting System (OARRS) for Law Enforcement Presentation	SUMMIT_000030045	SUMMIT_000030045
PUR5809	1/4/2006	Medical Examiner, County of Summit - File for Case No. 49140 (Robin L. Coffee)	SUMMIT_000038456	SUMMIT_000038456
PUR5810	1/27/2006	Medical Examiner, County of Summit - Report of Investigation: Robin L. Coffee (Page 1)	SUMMIT_000038457	SUMMIT_000038457
PUR5811	1/27/2006	Medical Examiner, County of Summit - Report of Investigation: Robin L. Coffee (Page 2)	SUMMIT_000038458	SUMMIT_000038458
PUR5812	2/9/2006	Medical Examiner, County of Summit - Report of Autopsy: Robin L. Coffee (Final)	SUMMIT_000038459	SUMMIT_000038470
PUR5813	1/5/2006	Ohio Department of Health, Vital Statistics - Certificate of Death: Robin Coffee	SUMMIT_000038471	SUMMIT_000038471
PUR5814	2/6/2006	Ohio Department of Health, Vital Statistics - Supplementary Medical Certification: Robin Coffee (Copy)	SUMMIT_000038472	SUMMIT_000038472
PUR5815	1/4/2006	Medical Examiner, County of Summit - Receipt for clothing of Robin Coffee	SUMMIT_000038473	SUMMIT_000038473
PUR5816	1/4/2006	Medical Examiner, County of Summit - Receipt for biological evidence gathered in death of Robin Coffee	SUMMIT_000038474	SUMMIT_000038474
PUR5817	1/4/2006	Medical Examiner, County of Summit - Medication Listing: Robin Coffee	SUMMIT_000038475	SUMMIT_000038475
PUR5818	1/4/2006	Medical Examiner, County of Summit - Property Listing of Robin Coffee	SUMMIT_000038476	SUMMIT_000038476
PUR5819	1/4/2006	Summit County Medical Examiner Valuables/Clothing Receipt: Robin Coffee	SUMMIT_000038477	SUMMIT_000038477
PUR5820	1/4/2006	Medical Examiner, County of Summit - Manila file folder for Case No. 49140 (Coffee, Robin)	SUMMIT_000038478	SUMMIT_000038478
PUR5821	6/29/2006	Medical Examiner, County of Summit - Oral and Written Telephone Communication & Content Checklist: Case No. 49140 (Robin Coffee)	SUMMIT_000038479	SUMMIT_000038479
PUR5822	6/29/2006	Ambulance Certificate of Medical Necessity for Robin Coffee on 1/4/2006 (Faxed copy)	SUMMIT+D4677_000038480	SUMMIT_000038481
PUR5823	1/4/2006	Summit County Medical Examiner's Office Fingerprint Card: Robin Coffee	SUMMIT_000038482	SUMMIT_000038482
PUR5824	1/4/2005	Summit County E.M.S. Report: Robin Coffee	SUMMIT_000038483	SUMMIT_000038484
PUR5825	1/4/2006	Offense/Incident Report, Police Division, Cuyahoga Falls, Ohio: Robin Coffee	SUMMIT_000038485	SUMMIT_000038488
PUR5826	1/4/2006	Summit County Medical Examiner's Office Record of Autopsy Completion: Robin Coffee	SUMMIT_000038489	SUMMIT_000038491
PUR5827	2/3/2006	Medical Examiner, County of Summit - Report of Autopsy: Robin L. Coffee (Draft with handwritten notes!)	SUMMIT_000038492	SUMMIT_000038511
PUR5828	1/4/2006	Autopsy Evidence Inventory Worksheet with attachments (photos, receipts, autopsy worksheet): Robin Coffee	SUMMIT_000038512	SUMMIT_000038522
PUR5829	2/15/2006	Request Form to the Cuyahoga Falls Police Dept. for Investigation Report for Case 49140 (Robin Coffee)	SUMMIT_000038523	SUMMIT_000038523
PUR5830	1/26/2009	Summit County Medical Examiner's Office Record of Autopsy Completion: Jessica Testerman	SUMMIT_000052175	SUMMIT_000052178
PUR5831	1/26/2009	Office of Medical Examiner County of Summit Autopsy Inventory Worksheet, Toxicology Order Requisition, and Autopsy Worksheets:Jessica Testerman	SUMMIT_000052219	SUMMIT_000052229
PUR5832	7/9/2009	Summit County Medical Examiner's Office Record of Autopsy Completion: Jennifer Kimberly Zinn	SUMMIT_000053771	SUMMIT_000053773
PUR5833	7/9/2009	Summit County Medical Examiner's Office Inventory Worksheet, Toxicology Order Requisition, Autopsy Worksheet and photos: Jennifer K. Zinn	SUMMIT_000053793	SUMMIT_000053803
PUR5834	7/8/2011	Office of Medical Examiner Drug & Medication Listing: Yanina Zhivotovsky	SUMMIT_000059423	SUMMIT_000059423
PUR5835	6/19/2018	Opioid Lawsuit Death Report	SUMMIT_000087427	SUMMIT_000087427
PUR5836	11/6/2011	Ohio Office of Criminal Justice Services 2010 Semi-Annual Performance Report: Summit County Drug Unit (1/1 to 12/31/2010)	SUMMIT_000109485	SUMMIT_000109492
PUR5837	12/31/2010	Ohio Office of Criminal Justice Services 2010 Semi-Annual Performance Report: Summit County Drug Unit (1/1 to 12/31/2010)	SUMMIT_000110831	SUMMIT_000110838
PUR5840	4/5/2018	Summit County Community Health Improvement Plan 2017	SUMMIT_000133661	SUMMIT_000133720
PUR5843	1/8/2018	Alkermes, Inc. Report: Ohio State Coverage and Specialty Pharmacy Guide for Vivitrol	SUMMIT_000278590	SUMMIT_000278614
PUR5846	7/5/2011	Medical records from Dr. Adolph Harper, Jr.: Yanina Zhivotovsky	SUMMIT_000360068	SUMMIT_000360072
PUR5847	7/8/2011	Summit County Medical Examiner's Office Record of Autopsy Completion: Yanina Zhivotovsky	SUMMIT_000360076	SUMMIT_000360078
PUR5848	3/3/2006	Summit County Direct Indictment Program Green Sheet: Defendant Chad Skolnik	SUMMIT_000366431	SUMMIT_000366432
PUR5849	3/2/2006	Court of Common Pleas, Summit County, Ohio Rule 9(B) Summons: Defendant Chad Skolnik	SUMMIT_000366433	SUMMIT_000366434

PUR5850	3/2/2006	Court of Common Pleas, Summit County - Indictment for Deception to Obtain a Dangerous Drug: Defendant Chad Skolnik	SUMMIT_000366435	SUMMIT_000366435
PUR5851	3/3/2006	Notice to Sheriff of Summit County of bond amount and conditions for Defendant Chad Skolnik	SUMMIT_000366436	SUMMIT_000366436
PUR5852	3/3/2006	Municipal Court of Akron -Docket, Affidavits for Arrest and Complaint, and Complaint: Defendant Chad Skolnik	SUMMIT_000366437	SUMMIT_000366439
PUR5853	3/10/2006	Court of Common Pleas, Summit County - Journal Entry for Indictment for Deception to Obtain a Dangerous Drug: Defendant Chad Skolnik	SUMMIT_000366440	SUMMIT_000366440
PUR5854	3/15/2006	Court of Common Pleas, Summit County - Journal Entry for Pretrial Continuance: Defendant Chad Skolnik	SUMMIT_000366441	SUMMIT_000366441
PUR5855	3/27/2018	Court of Common Pleas, Summit County - Journal Entry for Guilty Plea: Defendant Chad Skolnik	SUMMIT_000366442	SUMMIT_000366443
PUR5856	3/29/2006	Court of Common Pleas, Summit County - State's Demand for Discovery: Defendant Chad Skolnik	SUMMIT_000366444	SUMMIT_000366445
PUR5857	3/29/2006	Court of Common Pleas, Summit County - State's Demand for Discovery: Defendant Chad Skolnik	SUMMIT_000366446	SUMMIT_000366447
PUR5858	4/26/2006	Court of Common Pleas, Summit County - Journal Entry for Credit for Time Served: Defendant Chad Skolnik	SUMMIT_000366448	SUMMIT_000366448
PUR5859	6/26/2006	Court of Common Pleas, Summit County - Journal Entry for Motion for Judicial Release Hearing: Defendant Chad Skolnik	SUMMIT_000366449	SUMMIT_000366449
PUR5860	6/30/2006	Court of Common Pleas, Summit County - Journal Entry for Release for Further Hearing: Defendant Chad Skolnik	SUMMIT_000366450	SUMMIT_000366450
PUR5861	7/17/2006	Court of Common Pleas, Summit County - Journal Entry for Suspended Sentence: Defendant Chad Skolnik	SUMMIT_000366451	SUMMIT_000366452
PUR5862	3/28/2007	Court of Common Pleas, Summit County - Journal Entry for Violation of Community Control Sanctions: Defendant Chad Skolnik	SUMMIT_000366453	SUMMIT_000366453
PUR5863	5/12/2008	Cuyahoga Falls Municipal Court - Transcript of Criminal Docket: Defendant Brian Olson	SUMMIT_000383255	SUMMIT_000383272
PUR5864	12/7/2009	Court of Common Pleas, Summit County - Indictment for Aggravated Trafficking in Drugs, et al.: Defendants William Wingard and Kelly Wingard	SUMMIT_000416730	SUMMIT_000416738
PUR5865	8/6/2014	Court of Common Pleas, Summit County - Indictment for Aggravated Possession of Drugs et al.: Defendants Thomas L. James and Keayla M. Smith	SUMMIT_000592654	SUMMIT_000592654
PUR5866	9/21/2015	Court of Common Pleas, Summit County - Indictment for Aggravated Possession of Drugs, et al.: Defendant Larry Knox	SUMMIT_000668052	SUMMIT_000668053
PUR5867, PUR4985	9/13/2017	Ohio Department of Health Report - 2016 Ohio Drug Overdose Data: General Findings	SUMMIT_000820711	SUMMIT_000820720
PUR5871	8/18/2015	Email from Lotey Nimrit to Amy Lee, Doug Smith and Garry Thrasher re: Last meeting paper	SUMMIT_000839794	SUMMIT_000839794
PUR5878	5/19/2016	Presentation by Doug Smith on behalf of the Summit County Alcohol, Drug Addiction & Mental Health Services Board: The Opiate Epidemic in Ohio	SUMMIT_000854915	SUMMIT_000854915
PUR5891	10/3/2014	Presentation by Doug Smith, Summit County Alcohol, Drug Addiction & Mental Health Services (ADM) Board: The Opiate Epidemic	SUMMIT_000937749	SUMMIT_000937749
PUR5892	10/15/2014	Presentation by Doug Smith, Summit County Alcohol, Drug Addiction & Mental Health Services (ADM) Board: The Opiate Epidemic	SUMMIT_000938139	SUMMIT_000938139
PUR5912	2/1/2016	Drug Abuse Trends in the Akron-Canton Region, OSAM Drug Trend Report June 2015 -January 2016, pp. 25-45	SUMMIT_000951818	SUMMIT_000951838
PUR5928	8/10/2017	Email from Lori A. Baker-Stella to Summit Cty. Sheriff's Office staff re undercover office visits.	SUMMIT_001001568	SUMMIT_001001568
PUR5929	10/20/2010	Summit County Sheriff's Office Daily Bulletin, October 20, 2010	SUMMIT_001002114	SUMMIT_001002116
PUR5930	6/7/2015	Email from Matthew Paolino to Chris Rhoades (both of Summit Cty Sheriff's Office) re illicit drug use/sales	SUMMIT_001002210	SUMMIT_001002210
PUR5931	6/11/2015	Email from Matthew Paolino to Chris Rhoades re illicit drug purchases	SUMMIT_001002216	SUMMIT_001002216
PUR5932	1/6/2011	Ohio Office of Criminal Justice Services 2010 Semi-Annual Performance Report: January 1 - December 31	SUMMIT_001009736	SUMMIT_001009743
PUR5977	2/28/2018	Email from Jerry Craig to Joe Saporito re: The Myth of What's Driving the Opioid Crisis - POLITICO Magazine	SUMMIT_001100712	SUMMIT_001100712
PUR5979	4/16/2018	Drug Abuse Trends in the Akron-Canton Region, Ohio Substance Abuse Monitoring Network Drug Trend Report: January - June 2017, pp. 25-48	SUMMIT_001103531	SUMMIT_001103554
PUR6007	8/15/2017	Email from Rathe J. Yager (DEA) to local law enforcement re drug take-back day	SUMMIT_001132122	SUMMIT_001132122
PUR6008	1/1/2006	Text file - Claims Opiate Lawsuit Export	SUMMIT_001146952	SUMMIT_001146952
PUR6039	4/23/2017	National Rx Drug Abuse & Heroin Summit Panel Discussion: "Heroin" in Transition: U.S. Regional Differences and Novel Forms	SUMMIT_001286982	SUMMIT_001287082
PUR6040	6/26/2012	ADM Board - March 2012 misc articles	SUMMIT_001353461	SUMMIT_001353474
PUR6042	12/12/2011	Akron Police Department Investigation Report re: Richard Beasley, Interview of Dr. Michelle Moreno	SUMMIT_001422973	SUMMIT_001422976
PUR6051	12/20/2017	SuperMed Plus - City of Barberton Non-Bargaining 300 Plan	SUMMIT_001496028	SUMMIT_001496182
PUR6053	5/2/2018	Email from Abigail Fu to Scott Cottle et al. re: Sheriff Detective Investigations - Summit County Opioids Lawsuit	SUMMIT_001520838	SUMMIT_001520839
PUR6054	7/16/2017	Medical Mutual Presentation: 2017 Prescription Drug Formulary, HMO & PPO Plans	SUMMIT_001545793	SUMMIT_001545910
PUR6055	9/1/2018	Medical Mutual Presentation: 2018 Prescription Drug Formulary, HMO & PPO Plans	SUMMIT_001545911	SUMMIT_001546024
PUR6058	5/14/2018	Email from Medical@sheriff to Theresa Cummins	SUMMIT_001546364	SUMMIT_001546364
PUR6059	5/14/2018	Bradford Walker Records	SUMMIT_001546365	SUMMIT_001546413
PUR6062	3/20/2018	ADM Board: Summit County Quick Response Team	SUMMIT_001793050	SUMMIT_001793051
PUR6069	1/8/2018	State of Ohio Board of Pharmacy Meeting Minutes	SUMMIT_002053476	SUMMIT_002053523
PUR6070	1/1/2006	Opiod Abuse and Dependence	SUMMIT_002103953	SUMMIT_002103953

PUR6073	8/22/2017	DEA Distributor Briefing - Purdue Pharma	US-DEA-00001043	US-DEA-00001208
PUR6074	9/19/2017	DEA Memorandum from Jorge Jiminez re Distributor Initiative Briefing with Purdue Pharma	US-DEA-00001246	US-DEA-00001248
PUR6075	6/22/2013	DEA PowerPoint - "The Trafficking and Abuse of Prescription Controlled Substances, Legend Drugs and Over the Counter Products"	US-DEA-00001435	US-DEA-00001435
PUR6076	10/18/2013	DEA PowerPoint - "Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective"	US-DEA-00002435	US-DEA-00002435
PUR6077	12/12/2012	DEA PowerPoint - "New Faces of Enforcement: DEA Perspective"	US-DEA-00002436	US-DEA-00002436
PUR6078	11/1/2013	DEA PowerPoint - "Controlled Substances and Legend Drug Diversion: A Law Enforcement and Regulatory Perspective"	US-DEA-00002439	US-DEA-00002439
PUR6079	2/4/2013	DEA PowerPoint - "DEA Update - Pharmaceuticals, Methamphetamine and Synthetics"	US-DEA-00002441	US-DEA-00002441
PUR6080	6/1/2004	DEA PowerPoint - "The Diversion Control Program: Renewing and Reordering DEA's Priority"	US-DEA-00002591	US-DEA-00002591
PUR6081	9/9/2005	DEA PowerPoint - "E-Commerce Section Briefing"	US-DEA-00002933	US-DEA-00002933
PUR6082	6/1/2005	U.S. Department of Justice DEA Prescription Drug Diversion	US-DEA-00002935	US-DEA-00002961
PUR6084	3/8/2005	Synthetic Drugs Interagency Working Group Report	US-DEA-00003738	US-DEA-00003739
PUR6087	12/31/2015	National Heroin Task Force Final Report and Recommendations	US-DEA-00011297	US-DEA-00011330
PUR6088	8/19/2015	United Nations Reporting and Quota Section (ODQ) 1st Quarter Accomplishments - Fiscal Year 2015	US-DEA-00011539	US-DEA-00011546
PUR6089	2/23/2009	Email exchange between Matthew Strait (DEA) and Robert Lowenstein (Rhodes Technologies) re Statistical report for imports of narcotic raw materials	US-DEA-00013599	US-DEA-00013600
PUR6090	11/18/2008	Email exchange between Matthew Strait (DEA) and Robert Lowenstein (Rhodes Technologies)	U+D2S-DEA-00013601	US-DEA-00013602
PUR6091	2/24/2009	Email from Matthew Strait to Maria Nunes RE: Quarterly Narcotic Raw Material Report	US-DEA-00013603	US-DEA-00013606
PUR6092	2/24/2009	4Q NRM Report	US-DEA-00013607	US-DEA-00013607
PUR6093	2/24/2009	Email exchange between Matthew Strait (DEA) and Robert Lowenstein (Rhodes Technologies) re Statistical report for imports of narcotic raw materials	US-DEA-00013608	US-DEA-00013611
PUR6094	2/24/2009	Email exchange between Matthew Strait (DEA) and Robert Lowenstein (Rhodes Technologies) re Statistical report for imports of narcotic raw materials	US-DEA-00013612	US-DEA-00013614
PUR6095	2/23/2009	Email exchange between Matthew Strait (DEA) and Robert Lowenstein (Rhodes Technologies) re Statistical report for imports of narcotic raw materials	US-DEA-00013615	US-DEA-00013615
PUR6096	5/17/2016	Email exchange between Christine Sannerud (DEA) and Stacy Harper Avilla (DEA) re Action Requested: Review of FY 2018 Budget Overview and Program Descriptions	US-DEA-00014270	US-DEA-00014271
PUR6097	5/17/2016	DEA: Diversion Control Program	US-DEA-00014272	US-DEA-00014295
PUR6098	8/22/2013	Email exchange among DEA personnel re Letter from Hal Rodgers (US Congress) regarding Purdue pharma (letter itself withheld as privileged)	US-DEA-00017094	US-DEA-00017094
PUR6099	10/8/2013	Prescription Drug Abuse: Strategies to Stop the Epidemic 2013	US-DEA-00017500	US-DEA-00017563
PUR6101	3/13/2019	DEA Manual: Requirement to Report Suspicious Orders	US-DEA-00025224	US-DEA-00025224
PUR6102	12/19/2018	E&C: Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia	US-DEA-00025303	US-DEA-00025627
PUR6103	1/30/2018	Letter from David A Sierleja to Judge Polster Re: In Re: National Prescription Opiate Litigation	US-DEA-00026587	US-DEA-00026598
PUR6107	7/1/2017	The National Academies of Sciences, Engineering, and Medicine Consensus Study Report: Pain Management and the Opioid Epidemic - Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use	PPLPC001000258857	PPLPC001000258860
PUR6108	10/25/2017	House Committee on Energy and Commerce Hearing titled, 'Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives,' October 25, 2017	PPLPC006000022565	PPLPC006000022579
PUR6109	9/4/2009	Email from Brad Pine to Steve Bishop, Stephen Seid regarding Smith Drug August 2009 Inventory Sept. 2009 Forecast Report	PPLPC004000212657	PPLPC004000212657
PUR6110	9/4/2009	Smith Drug's August 2009 Inventory Sept. 2009 Forecast Report	PPLPC004000212658	PPLPC004000212658
PUR6111	11/4/2009	OMS Quarterly Meeting Agenda	PPLPC004000218650	PPLPC004000218651
PUR6112	11/16/2009	Email from Stephen Seid to Shawn Bechtold, Michael Cullen regarding Today's Order	PPLPC004000219709	PPLPC004000219711
PUR6113	6/13/2011	OMS 6/13/2011 Meeting Minutes	PPLPC004000286424	PPLPC004000286429
PUR6114	2/17/2012	OMS 2/17/2012 Meeting Minutes	PPLPC004000316917	PPLPC004000316926
PUR6115	2/10/2014	Benedict Carey, 'Prescription Painkillers Seen as a Gateway to Heroin'; and Understanding Opioid Abuse (2 letters) NYTimes.com	PPLPC019000894958	PPLPC019000894962
PUR6116	5/13/2009	Purdue and HDA 5/13/2009 Meeting Minutes regarding Customer Due Diligence and OMS	HDS_MDL_00179461	HDS_MDL_00179462
PUR6117	1/22/2009	Order Monitoring System Report - Valley Wholesale Drug, Inc., Visit - Stockton, CA	PPLPC026000046298	PPLPC026000046302
PUR6118	11/18/2010	Report to OMS Team regarding 11/17/2010 Teleconference between The Harvard Drug Group LLC & Purdue Pharma LP	PPLPC026000072717	PPLPC026000072718
PUR6119	4/4/2012	OMS 4/4/2012 Meeting Minutes	PPLPC026000098399	PPLPC026000098404
PUR6120	9/19/2012	OMS 9/19/2012 Meeting Minutes	PPLPC026000111265	PPLPC026000111271
PUR6121	8/25/2011	OMS 8/25/2011 Meeting Minutes	PPLPC004372079	PPLP004372090
PUR6122	12/15/2011	OMS 12/15/2011 Meeting Minutes	PPLPC004379823	PPLP004379828
PUR6123	1/28/2010	OMS Monthly Meeting 1/28/2010 Agenda	PPLP004381150	PPLP004381155
PUR6124	9/15/2008	AmerisourceBergen/Purdue Pharma - Business & Diversion Control Plan Discussion Agenda (redacted for privilege)	PPLP004385367	PPLP004385367

PUR6125	10/6/2009	Email from David Rosen to Mike Innaurato regarding Estimated Forecast	PPLPC031000556021	PPLPC031000556022
PUR6126	10/6/2009	Purdue Rolling 3 Month Forecast - Cardinal Health estimated purchases	PPLPC031000556023	PPLPC031000556023
PUR6127	5/12/2016	Sonia Moghe "Opioid History: From 'wonder drug' to abuse epidemic"; http://www.cnn.com/2016/05/12/health/opioid-addiction-history/index.html	PPLPC031001438992	PPLPC031001438996
PUR6128	9/30/1981	Ohio State Dental Board Disciplinary Action re: Charles G. Hatfield, DDS	OSDB_MDL_1st Production_004395	OSDB_MDL_1st Production_004398
PUR6129	11/4/2009	OMS 11/4/2009 Quarterly Meeting - Notes	PPLPC034000342258	PPLPC034000342266
PUR6130	3/31/2009	OMS Quarterly Meeting	PPLP004460793	PPLP004460793
PUR6131	8/12/2009	OMS Quarterly Meeting	PPLP004460794	PPLP004460795
PUR6132	4/5/2010	Email from Bill Mahoney to Dave Gustin et al, RE: Follow-up	PPLP004469395	PPLP004469396
PUR6133	12/2/2008	ABC/Purdue Monthly Terleconference Meeting SOMS/OMS	PPLP004472271	PPLP004472273
PUR6134	10/1/2016	Deborah Dowell et al; "Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts of Opioids Prescribed And Overdose Death Rates"; Health Affairs, October 2016, 35-10, pgs. 1876-1883.	BOP_MDL003802	BOP_MDL003810
PUR6135	1/27/2005	Ernst R. Berndt, Ph.D. "To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs"; New England Journal of Medicine, 352;4, pgs. 325-328.	PUREX00071698	PUREX00071702
PUR6136	1/28/2011	Khary K. Rigg, Samantha J. March, and James A. Inciardi; Prescription Drug Abuse & diversion: Role of the Pain Clinic; NIH Public Access; J Drug Issues; 40(3): 681-702; 2010	PUREX00071703	PUREX00071723
PUR6137	3/1/2018	United States Government Accountability Office: Report to Congressional Requesters. "Illicit Opioids, While Greater Attention Given to Combating Synthetic Opioids, Agencies Need to Better Assess their Efforts.	PUREX00071724	PUREX00071817
PUR6138	6/6/2018	Rachel Martin, NPR Radio; "In Rural Ohio, An Opioid Crisis Becomes A Meth Crisis".	PUREX00071818	PUREX00071829
PUR6139	6/6/2018	Terry DeMio, "Fentanyl deaths up 1,000% since 2013, so much so that even heroin's supply is dwarfed.", Cincinnati Enquirer; https://cin.ci/2sCeZ8q	PUREX00071830	PUREX00071834
PUR6140	7/11/2017	Cobin D. Soelberg, et al; "The US Opioid Crisis: Current Federal and State Legal Issues"; International Anesthesia Research Society, November 2017, Volume 125, Number 5, pages 1675-1681.	PUREX00071835	PUREX00071841
PUR6141	11/7/2016	Scott P. Stumbo et al, "Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement", Journal of Substance Abuse Treatment 73 (2017) 47-54.	PUREX00071842	PUREX00071849
PUR6142	5/31/2007	Email (w/attachments) from James Heins to Timothy Bannon re accomodation letters	PPLPC066000000001	PPLPC066000000003
PUR6143	3/3/2004	Letter from Det. Carrie L. Schulteiss, Butler County Sheriff's Office, to Jeannie Calcano McDonald re: success of the use of Purdue funds in the investigation of illegal sales of OxyContin	PPLPC066000000004	PPLPC066000000004
PUR6144	2/27/2004	Letter from Det. Daniel J. De Grace, Cabarrus County Sheriff's Office, to Jeannie Calcano McDonald re: investigative statistics stemming from the \$10,000 grant from Purdue	PPLPC066000000005	PPLPC066000000006
PUR6145	2/18/2004	Letter from Darrell Stephens, Chief of Police Charlotte-Mecklenburg Police Department, to Jeannie Calcano McDonald re: use of Purdue funds to investigate the illegal distribution of pharmaceuticals and other narcotics.	PPLPC066000000007	PPLPC066000000008
PUR6146	8/19/2003	Letter from Thomas H. Streicher, Jr., Police Chief Cincinnati Police Department, to J. Aaron Graham re: \$10,000 grant to the Pharmaceutical Diversion Squad	PPLPC066000000009	PPLPC066000000009
PUR6147	8/6/2004	Email from Michael Ward, Chief of Police City of Alexandria, KY, to Aaron Graham re: success of \$10,000 grant used in enforcement, education and prevention programs.	PPLPC066000000010	PPLPC066000000010
PUR6148	10/29/2003	Letter from Captain Art Norton, Fort Wayne Police Department to J. Aaron Graham re: success of \$10,000 grant used in fight against illegal distribution and use of prescription drugs	PPLPC066000000011	PPLPC066000000012
PUR6149	9/15/2004	Letter from Michael D. Sweet, Chief of Police New Haven Police Department to J. Aaron Graham re: successful use of grants for assistance in investigation, apprehension and prosecution of illegal possession and distribution of prescription and counterfeit drugs, including OxyContin.	PPLPC066000000013	PPLPC066000000014
PUR6150	2/16/2004	Letter from Craig Robison, Detective Sergeant Special Deputy United States Marshall, N.E. Indiana and the Federal Bank Robbery Task Force to J. Aaron Graham re: \$10,000 grant for New Haven Police Department for additional law enforcement funding.	PPLPC066000000015	PPLPC066000000021
PUR6151	8/30/2004	Letter from Captian Frank J. Rubino, Plantation Police Department, to J. Aaron Graham re: \$5,000 grant for use in purchasing video/audio microwave equipment to be used to obtain video and audio evidence to present for prosecution	PPLPC066000000022	PPLPC066000000022
PUR6152	2/17/2004	Letter from Larry L. Massey, Jr., Chief of Police, Plantation Police Department, to Jeannie McDonald re: appreciation for financial assistance that resulted in significant impact on the unauthorized distribution of OxyContin by otherwise legitimate sources.	PPLPC066000000023	PPLPC066000000024
PUR6153	1/1/2004	Letter from Investigator Colin Aliff, Columbia County Sheriff's Office, to J. Aaron Graham re: appreciation for support for criminal investigative efforts focusing on illegal distribution of prescription drugs and request for additional NADDI ID Cards.	PPLPC066000000025	PPLPC066000000025
PUR6154	2/18/2004	Letter from Sandra L. Buck, Commander C.A.N.E. Task Force, to Jeannie Calcano McDonald re: successful use of \$10,000 grant in three investigations	PPLPC066000000026	PPLPC066000000026
PUR6155	11/19/2003	Letter from Det. Steven Goedde, Delphos Police Department, to J. Aaron Graham re: appreciation for \$10,000 grant to help combat illegal distribution of prescription drugs	PPLPC066000000027	PPLPC066000000027

PUR6156	2/25/2004	Letter from Sergeant Mark J. Hermey, Columbus Police Department, to Jeannie Calcano McDonald re: use of \$7,500 grant in several investigations targeting the illegal sale of OxyContin.	PPLPC066000000028	PPLPC066000000029
PUR6157	11/13/2003	Letter from Wayne Wargel Commander Evansville Police Department to J. Aaron Graham re: use of funds	PPLPC066000000030	PPLPC066000000030
PUR6158	12/11/2003	Letter from Hilton C. Daniels, Chief Fort Myers Police Department to J. Aaron Graham re: use of funds related to operational plans for Rx drug investigations	PPLPC066000000031	PPLPC066000000031
PUR6159	2/10/2004	Letter from Randy Reed, Chief of Police, Fort Smith Police Department, to Jeannie Calcano McDonald re: appreciation and use of funds in investigations	PPLPC066000000032	PPLPC066000000032
PUR6160	6/9/2004	Letter from Dale Bloom & Judy Hart Elwell, Greater Fort Wayne Crime Stoppers, to J. Aaron Graham re: use of funds related to fighting illegal drug trafficking	PPLPC066000000033	PPLPC066000000033
PUR6161	1/1/2004	Letter from Paul Jarrell Chief of Police Hindman Police Dept, to J. Aaron Graham re: use of funds	PPLPC066000000034	PPLPC066000000035
PUR6162	4/2/2004	Email from Aaron Graham to Michael Friedman re email from Jim Moore, Independence, KY Police Department & successful use of grant funds	PPLPC066000000036	PPLPC066000000037
PUR6163	9/5/2003	Letter from John A. Glenn, Lake County Narcotics Agency to J. Aaron Graham re: use of funds for pharmacy diversion activities	PPLPC066000000038	PPLPC066000000038
PUR6164	1/12/2004	Letter from Logan County Commissioners to J. Aaron Graham re: use of funds to pursue prescription drug diversion	PPLPC066000000039	PPLPC066000000039
PUR6165	2/2/2004	Letter from John Mendez, Sheriff Logan County WV to Dale A. Ferrato re: request for assistance	PPLPC066000000040	PPLPC066000000040
PUR6166	6/12/2003	Letter from Officer Robert Patton Mahoning Valley Law Enforcement Task Force to J. Aaron Graham re: successful use of \$10,000 grant	PPLPC066000000041	PPLPC066000000043
PUR6167	8/21/2003	Letter from Rob L. Hunter, Chief of Police Matthews Police Department to J. Aaron Graham re: use of \$7,500 grant	PPLPC066000000044	PPLPC066000000044
PUR6168	5/24/2007	Letter from Major Doug Engel, Multi-Area Narcotics Task Force (OH) to Jeannie Calcano McDonald re: use of grant funds	PPLPC066000000045	PPLPC066000000045
PUR6169	8/27/2003	Letter from Mark E. Mulligan, Ottawa County Prosecutor to Aaron Graham re: use of grant funds	PPLPC066000000046	PPLPC066000000046
PUR6170	2/24/2004	Letter from Pat Wooton, Perry County Sheriff to Jeannie Calcano McDonald re: use of grant funds	PPLPC066000000047	PPLPC066000000048
PUR6171	3/18/2004	Letter from Det/Corporal Michael Vaughn to J. Aaron Graham re: use of grant funds	PPLPC066000000049	PPLPC066000000050
PUR6172	8/7/2003	Letter from James A. Herman, Sheriff of Allen County to J. Aaron Graham re: use of grant funds	PPLPC066000000051	PPLPC066000000051
PUR6173	2/18/2004	Letter from Todd Graham, Chief Deputy Belmont County Sheriff's Office to J. Aaron Graham re: use of grant funds	PPLPC066000000052	PPLPC066000000052
PUR6174	2/27/2004	Letter from Danny Webb, Sheriff of Letcher County, KY to Jeannie Calcano McDonald re: use of grant funds in the fight against illegal use of OxyContin	PPLPC066000000053	PPLPC066000000054
PUR6175	9/21/2004	Letter from Danny Webb, Sheriff of Letcher County, KY to J. Aaron Graham re: successful use of grant funds in the fight against illegal use of OxyContin	PPLPC066000000055	PPLPC066000000055
PUR6176	6/1/2004	Letter from Steve Knauf, Chief of Police, Taylor Mill Police Department to J. Aaron Graham re: use of grant funds	PPLPC066000000056	PPLPC066000000056
PUR6177	8/1/2003	Letter from James A. Walters, Chief of Police Town of Greenwich, CT re: use of grant funds	PPLPC066000000057	PPLPC066000000058
PUR6178	2/21/2004	Letter from Sgt. Scott Scripture, Orono Police Department to Jeannie Calcano re: successful use of grant funds	PPLPC066000000059	PPLPC066000000060
PUR6179	5/15/2003	Letter from John J. Burke, Commander Warren-Clinton Drug and Strategic Operations Task Force to J. Aaron Graham re: use of grant funds	PPLPC066000000061	PPLPC066000000061
PUR6180	5/14/2003	Letter from Chief Stephen N. Baker, Westerly Police Department to J. Aaron Graham re: use of grant funds	PPLPC066000000062	PPLPC066000000062
PUR6181	2/23/2004	Letter from William Shanafelt, LT.-Task Force Commander, Western Portage Drug Task Force to Jeannie Calcano McDonald re: successful use of grant funds	PPLPC066000000063	PPLPC066000000065
PUR6182	3/3/2004	Letter from Chief Anthony J. Rouse to Jeannie Calcano McDonald re: successful use of grant funds	PPLPC066000000066	PPLPC066000000068
PUR6183	12/17/2003	Letter from James Burke, Chief of Police Beaver Dam City Police to J. Aaron Graham re: use of grant funds	PPLPC066000000069	PPLPC066000000069
PUR6184	2/11/2004	Letter from Bruce Bennett, Bell County Sheriff to J. Aaron Graham re: successful use of grant funds	PPLPC066000000070	PPLPC066000000071
PUR6185	9/23/2003	Letter from Jeffrey L. Patterson, Chief of Police Boardman Township (OH) to J. Aaron Graham re: use of grant funds for investigation of unlawful diversion and abuse of prescription drugs	PPLPC066000000072	PPLPC066000000072
PUR6186	3/27/2003	Codrix FDA Approval Data from www.accessdata.fda.gov 500mg/30mg approved on 3/27/2003	PUREX00000067	PUREX00000068
PUR6187	2/26/2003	Codrix FDA Approval Data from www.accessdata.fda.gov 500mg/15mg approved on 2/26/2003	PUREX00000069	PUREX00000070
PUR6188	3/28/2003	Codrix FDA Approval Data from www.accessdata.fda.gov: 500mg/60mg approved on 3/28/2003	PUREX00000071	PUREX00000072
PUR6189	3/16/2018	Higgins, C., et al., Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis, British Journal of Anaesthesia, 120 (6): 1335-1344 (2018)	PUREX00058335	PUREX00058344
PUR6190	12/31/2018	State of Ohio Board of Pharmacy, Ohio Automated Rx Reporting System 2018 Annual Report (2018)	PUREX00058528	PUREX00058540

PUR6191	8/19/2019	Synthetic Drugs Will Change the Global Drug Trade Forever Drug Traffickers thrive on their ability to penetrate national borders, but a new era of toxic, man-made highs could dissolve those boundaries and transform the global drug trade, Vice News	PUREX00000345	PUREX00000350
PUR6192	8/21/2019	Advisory to Financial Institutions on Illicit Financial Schemes and Methods Related to the Trafficking of Fentanyl and Other Synthetic Opioids, FinCAN Advisory	PUREX00000351	PUREX00000368
PUR6193	7/27/2019	Border officers at risk from fentanyl exposure after drug seizures, azcentral	PUREX00000369	PUREX00000378
PUR6194	1/18/2017	Two plead guilty in case involving Akron man's fentanyl overdose death, cleveland.com	PUREX00000379	PUREX00000382
PUR6195	4/26/2017	Akron man, woman headed to federal prison in fatal fentanyl overdose, cleveland.com	PUREX00000383	PUREX00000385
PUR6196	8/21/2019	Accused Chinese fentanyl traffickers face U.S. sanctions following charges in Ohio federal court, cleveland.com	PUREX00000386	PUREX00000388
PUR6197	8/31/2017	Tracing the path of a deadly batch of heroin from China to Akron, cleveland.com	PUREX00000389	PUREX00000402
PUR6198	8/31/2019	Utah man, 29, ran 50-state opioid ring out of basement; now faces life in prison, authorities say, Foxnews.com	PUREX00000403	PUREX00000405
PUR6199	8/31/2019	Sometimes Treating Pain Is As Important As treating Disease, HuffPost	PUREX00000406	PUREX00000412
PUR6200	7/26/2019	Coast Guard unloads 26,000 pounds of cocaine seized from Pacific, NBC News.com	PUREX00000419	PUREX00000422
PUR6201	5/2/2019	United States of America v. Michale Gurry, et al. Verdict Form	PUREX00071642	PUREX00071648